PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Casili, G; Lanza, M; Campolo, M; Messina, S; Scuderi, S; Ardizzone, A; Filippone, A; Paterniti, I; Cuzzocrea, S; Esposito, E				Casili, Giovanna; Lanza, Marika; Campolo, Michela; Messina, Salvatore; Scuderi, Sarah; Ardizzone, Alessio; Filippone, Alessia; Paterniti, Irene; Cuzzocrea, Salvatore; Esposito, Emanuela			Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency	VASCULAR PHARMACOLOGY			English	Article						Chronic venous insufficiency; Natural compounds; Venous contractility; Venous tone; VEGF	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; VARICOSE-VEINS; IN-VITRO; HYPOXIA; EXPRESSION; DISEASE; VEGF; REOXYGENATION; ANGIOGENESIS	Chronic venous insufficiency (CVI) is a common disorder associated with a variety of symptoms in later disease stages; despite the high prevalence of this pathology, suitable pharmaceutical therapies have not been explored to date. In this context, it was recently reported that a chronic increase in venous wall stress or biomechanical stretch is sufficient to cause development of varicose veins. Recent evidence demonstrate that flavonoids are natural substances that convey the circulatory system functionality, playing a key role in blood flow. Particularly, troxerutin, diosmin and horse chestnut extract, appear protective for the management of vascular diseases. The aim of the present study was to evaluate the effect of a flavonoid compound, containing troxerutin, diosmin and horse chestnut extract on in vitro model on HUVECs cells, due to its production of vasculoregulatory and vasculotropic molecules, on an ex-vivo model on mesenteric vessel contraction, to regularize mesenteric microcirculation and on in vivo model of CVI-induced by saphene vein ligation. Furthermore, the flavonoid compound capacity of extensibility and compatibility with peripheral veins was investigated through a tissue block culture study. The degree of absorption, the contractile venous activity, the histological analysis, the immunoistochemical and immunofluorescence evaluation for VEGF and CD34 were performed, together with inflammatory mediators dosage. For the first time, this research revealed the therapeutic potential of a compound, enriched with flavonoids, to be a supportive treatment, suitable to reduce varicose vein pathophysiology and to regularize venous tone.	[Casili, Giovanna; Lanza, Marika; Campolo, Michela; Messina, Salvatore; Scuderi, Sarah; Ardizzone, Alessio; Filippone, Alessia; Paterniti, Irene; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO USA		Esposito, E (通讯作者)，Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	eesposito@unime.it	Lanza, Marika/AAC-3741-2022; Filippone, Alessia/AAC-3679-2022; Ardizzone, Alessio/AAC-3715-2022; Casili, Giovanna/AAC-3740-2022	Ardizzone, Alessio/0000-0002-2293-0634; Casili, Giovanna/0000-0002-0552-1396; Filippone, Alessia/0000-0002-9642-6844	Pharma Line S.r.l (Milan, Italy)	The study was supported financially by Pharma Line S.r.l (Milan, Italy). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.	Alsaigh T, 2011, MICROVASC RES, V81, P108, DOI 10.1016/j.mvr.2010.09.010; Amano H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131445; ARAUJO D, 1991, PHARMACOL RES, V24, P253, DOI 10.1016/1043-6618(91)90088-F; ARNOULD T, 1992, J CELL PHYSIOL, V152, P215, DOI 10.1002/jcp.1041520127; Babaei S, 2002, CARDIOVASC RES, V55, P190, DOI 10.1016/S0008-6363(02)00287-0; Belcaro G, 2017, INT J ANGIOL, V26, P170, DOI 10.1055/s-0036-1597756; Bergan JJ, 2005, ACTA CHIR BELG, V105, P12, DOI 10.1080/00015458.2005.11679660; Bergan J, 2007, ANN VASC SURG, V21, P260, DOI 10.1016/j.avsg.2007.03.011; Boada JN, 1999, CLIN DRUG INVEST, V18, P413, DOI 10.2165/00044011-199918060-00001; Boersma D, 2017, EUR J VASC ENDOVASC, V53, P290, DOI 10.1016/j.ejvs.2016.11.024; Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4; Bucci M, 2005, P NATL ACAD SCI USA, V102, P904, DOI 10.1073/pnas.0408906102; Budzyn M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191902; Caggiati A, 2008, EUR J VASC ENDOVASC, V35, P111, DOI 10.1016/j.ejvs.2007.08.007; Campolo M., 2020, INT J MOL SCI, V21; Carandina S, 2008, EUR J VASC ENDOVASC, V35, P230, DOI 10.1016/j.ejvs.2007.09.011; Casili G, 2016, J CROHNS COLITIS, V10, P472, DOI 10.1093/ecco-jcc/jjv231; Celik A, 2010, J PLAST RECONSTR AES, V63, P875, DOI 10.1016/j.bjps.2009.01.082; Chi JF, 2017, MED SCI MONITOR, V23, P4014, DOI 10.12659/MSM.902816; Cudmore M, 2006, BIOCHEM BIOPH RES CO, V345, P1275, DOI 10.1016/j.bbrc.2006.04.031; Eschrich J, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002405; Felixsson E, 2010, PHYTOTHER RES, V24, P1297, DOI 10.1002/ptr.3103; Frick M, 2003, ATHEROSCLEROSIS, V170, P229, DOI 10.1016/S0021-9150(03)00299-5; Frick RW, 2000, ANGIOLOGY, V51, P197, DOI 10.1177/000331970005100303; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; Gohel MS, 2009, CURR VASC PHARMACOL, V7, P303, DOI 10.2174/157016109788340758; Grudzinska E, 2014, CENT EUR J IMMUNOL, V39, P525, DOI 10.5114/ceji.2014.47740; Gschwandtner ME, 2001, VASC MED, V6, P169, DOI 10.1177/1358836X0100600308; Heeneman S, 2007, CIRC RES, V101, P441, DOI 10.1161/CIRCRESAHA.107.148338; Hollingsworth SJ, 2004, EUR J VASC ENDOVASC, V27, P259, DOI 10.1016/j.ejvs.2003.12.015; Inda AM, 2007, J EXP CLIN CANC RES, V26, P375; JANSSENS D, 1995, BIOCHEM PHARMACOL, V50, P991, DOI 10.1016/0006-2952(95)00227-Q; KANDASWAMI C, 1994, ADV EXP MED BIOL, V366, P351; KHALIL RA, 1988, J PHARMACOL EXP THER, V244, P537; Kim D, 2002, J KOREAN MED SCI, V17, P648, DOI 10.3346/jkms.2002.17.5.648; Kim HK, 1999, BIOCHEM PHARMACOL, V58, P759, DOI 10.1016/S0006-2952(99)00160-4; Kim MH, 2003, J CELL BIOCHEM, V89, P529, DOI 10.1002/jcb.10543; Koai E., 2010, WEBMEDCENTRAL, V1; Kukula-Koch W, 2015, NAT PROD RES, V29, P370, DOI 10.1080/14786419.2014.945084; Lee BB, 2016, INT ANGIOL, V35, P236; Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945; Losenkova K, 2018, BBA-MOL BASIS DIS, V1864, P1804, DOI 10.1016/j.bbadis.2018.03.001; Mansilha A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061669; Mendes-Pinto D, 2016, INT ANGIOL, V35, P599; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; MICHIELS C, 1992, J CELL PHYSIOL, V153, P53, DOI 10.1002/jcp.1041530109; Michiels C, 2002, BIOCHEM PHARMACOL, V63, P321, DOI 10.1016/S0006-2952(01)00832-2; MILHOAN KA, 1992, AM J PHYSIOL, V263, pH956, DOI 10.1152/ajpheart.1992.263.3.H956; Moyle CWA, 2015, MOL NUTR FOOD RES, V59, P401, DOI 10.1002/mnfr.201400478; Naoum JJ, 2007, VASCULAR, V15, P242, DOI 10.2310/6670.2007.00069; Ng Shiow-Fern, 2010, Pharmaceutics, V2, P209; Nicholls Stephen C, 2005, Semin Intervent Radiol, V22, P162, DOI 10.1055/s-2005-921960; Novotny K, 2019, VASA, V48, P399, DOI 10.1024/0301-1526/a000797; Olszanecki R, 2002, J PHYSIOL PHARMACOL, V53, P571; Pfisterer L, 2014, VASA, V43, P88, DOI 10.1024/0301-1526/a000335; Pittler MH, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003230.pub3; Raffetto JD, 2011, J VASC SURG, V54, P489, DOI 10.1016/j.jvs.2011.01.043; Raju S, 2009, NEW ENGL J MED, V360, P2319, DOI 10.1056/NEJMcp0802444; SAVINEAU JP, 1994, BRIT J PHARMACOL, V111, P978, DOI 10.1111/j.1476-5381.1994.tb14838.x; SCHULLERPETROVIC S, 1994, CLIN PHARMACOL THER, V56, P452, DOI 10.1038/clpt.1994.160; Somers P, 2006, ANGIOLOGY, V57, P546, DOI 10.1177/0003319706293115; Spiridon Marilena, 2017, Maedica (Bucur), V12, P59; Squadrito F, 2000, Eur Rev Med Pharmacol Sci, V4, P21; Staffa R, 2002, Bratisl Lek Listy, V103, P166; Takase S, 2000, ANN VASC SURG, V14, P427, DOI 10.1007/s100169910092; Talibov O B, 2019, Khirurgiia (Mosk), P135, DOI 10.17116/hirurgia2019031135; Tomasian D, 2000, CARDIOVASC RES, V47, P426, DOI 10.1016/S0008-6363(00)00103-6; Underland Vigdis, 2012, Glob Adv Health Med, V1, P122, DOI 10.7453/gahmj.2012.1.1.018; Valencia IC, 2001, J AM ACAD DERMATOL, V44, P401, DOI 10.1067/mjd.2001.111633; Vanscheidt W, 2002, VASA-J VASCULAR DIS, V31, P185, DOI 10.1024/0301-1526.31.3.185; WADWORTH AN, 1992, DRUGS, V44, P1013, DOI 10.2165/00003495-199244060-00009; Wang YH, 2010, ANN BIOMED ENG, V38, P729, DOI 10.1007/s10439-009-9896-6; WINDISCHBAUER A, 1994, EUR J CLIN CHEM CLIN, V32, P279; Wray S, 2005, CELL CALCIUM, V38, P397, DOI 10.1016/j.ceca.2005.06.018	74	4	4	3	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106825	10.1016/j.vph.2020.106825		MAR 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33278582				2022-04-29	WOS:000629161700004
J	Merdji, H; Kassem, M; Chomel, L; Clere-Jehl, R; Helms, J; Kurihara, K; Chaker, AB; Auger, C; Schini-Kerth, V; Toti, F; Meziani, F				Merdji, Hamid; Kassem, Mohamad; Chomel, Louise; Clere-Jehl, Raphael; Helms, Julie; Kurihara, Kei; Chaker, Ahmed Bey; Auger, Cyril; Schini-Kerth, Valerie; Toti, Florence; Meziani, Ferhat			Septic shock as a trigger of arterial stress-induced premature senescence: A new pathway involved in the post sepsis long-term cardiovascular complications	VASCULAR PHARMACOLOGY			English	Article						Septic shock; sepsis; Stress-induced premature senescence; Atherosclerosis	CELLULAR SENESCENCE; ENDOTHELIAL SENESCENCE; STEM-CELLS; LIPOPOLYSACCHARIDE; INFLAMMATION; PROMOTES; DYSFUNCTION; MECHANISMS; CLEARANCE; MORTALITY	Background: Major adverse cardiovascular events among sepsis survivors is an emerging health issue. Because endothelial senescence leads to vascular dysfunction and atherothrombosis, sepsis could be associated to vascular stress-induced premature senescence and thus with long-term cardiovascular events. Materials & methods: Adult Wistar male rats were submitted to cecal ligation and puncture, or a SHAM operation. Markers of inflammation, oxidative stress and endothelial senescence were assessed at 3, 7 and 90 days (D), and vascular reactivity was assessed in conductance and resistance vessels at D90. Expression of proteins involved in senescence and inflammation was assessed by Western blot analysis and confocal microscopy, oxidative stress by dihydroethidium probing. Results: Pro-inflammatory endothelial ICAM-1 and VCAM-1 were up-regulated by three-fold in CLP vs. SHAM at D7 and remained elevated at D90. Oxidative stress followed a similar pattern but was detected in the whole vascular wall. Sepsis accelerated premature senescence in aorta vascular tissue as shown by the significant upregulation of p53 and down-stream p21 and p16 senescent markers at D7, values peaking at D90 whereas the absence of significant variation in activated caspase-3 confirmed p53 as a prime inducer of senescence. In addition, p53 was mainly expressed in the endothelium. Sepsis-induced long-term vascular dysfunction was confirmed in aorta and main mesenteric artery, with a major alteration of the endothelial-dependent nitric oxide pathway. Conclusions: Septic shock-induced long-term vascular dysfunction is associated with endothelial and vascular senescence. Our model could prove useful for investigating senotherapies aiming at reducing long-term cardiovascular consequences of septic shock.	[Merdji, Hamid; Kassem, Mohamad; Chomel, Louise; Helms, Julie; Kurihara, Kei; Chaker, Ahmed Bey; Auger, Cyril; Schini-Kerth, Valerie; Toti, Florence; Meziani, Ferhat] Univ Strasbourg, INSERM, FMTS Federat Med Translat Starsbourg, French Natl Inst Hlth & Med Res,Regenerat Nanomed, Strasbourg, France; [Merdji, Hamid; Clere-Jehl, Raphael; Helms, Julie; Meziani, Ferhat] Hop Univ Strasbourg, Nouvel Hop Civil, Dept Intens Care, Serv Med Intens Reanimat, 1,Pl Hop, Strasbourg, France; [Kurihara, Kei] Aichi Med Univ, Fujita Hlth Univ, Dept Transplantat & Regenerat Med, Sch Med, Fujieda, Aichi, Japan		Meziani, F (通讯作者)，Hop Univ Strasbourg, Nouvel Hop Civil, Dept Intens Care, Serv Med Intens Reanimat, 1,Pl Hop, Strasbourg, France.	ferhat.meziani@chru-strasbourg.fr	Auger, Cyril/N-4702-2016		Association d'Aide aux Insuffisants Respiratoires d'Alsace-Lorraine (ADIRAL, Strasbourg, France)	This project received financial support from the << Association d'Aide aux Insuffisants Respiratoires d'Alsace-Lorraine (ADIRAL, Strasbourg, France) >>	Abbas M, 2017, CIRCULATION, V135, P280, DOI 10.1161/CIRCULATIONAHA.116.017513; Abraldes JG, 2006, AM J PHYSIOL-GASTR L, V290, pG980, DOI 10.1152/ajpgi.00336.2005; Back M, 2019, NAT REV CARDIOL, V16, P389, DOI 10.1038/s41569-019-0169-2; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Boisrame-Helms J, 2014, THROMB HAEMOSTASIS, V111, P154, DOI 10.1160/TH13-04-0313; Boisrame-Helms J, 2013, CURR VASC PHARMACOL, V11, P150; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Burger D, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.001842; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Dolmatova EV, 2021, CARDIOVASC RES, V117, P60, DOI 10.1093/cvr/cvaa070; Dookun E, 2022, CARDIOVASC DRUG THER, V36, P187, DOI 10.1007/s10557-020-07075-w; Feng XM, 2014, CELL TISSUE RES, V356, P369, DOI 10.1007/s00441-014-1799-7; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Florence JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171427; Gager GM, 2020, VASC PHARMACOL, V135, DOI 10.1016/j.vph.2020.106806; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069; Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009; Ince C, 2016, SHOCK, V45, P259, DOI 10.1097/SHK.0000000000000473; Jia GH, 2019, BBA-MOL BASIS DIS, V1865, P1802, DOI 10.1016/j.bbadis.2018.08.008; Joffre J, 2020, AM J RESP CRIT CARE, V202, P361, DOI 10.1164/rccm.201910-1911TR; Katsuumi G, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00018; Kaynar AM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0469-1; Khemais-Benkhiat S, 2016, J GERONTOL A-BIOL, V71, P1581, DOI 10.1093/gerona/glv213; Khodja NI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032039; Kim CO, 2012, ARCH GERONTOL GERIAT, V54, pE35, DOI 10.1016/j.archger.2011.07.016; Kremer H, 2011, CRIT CARE MED, V39, P1414, DOI 10.1097/CCM.0b013e318211ff6e; Kumar A, 2011, ARTERIOSCL THROM VAS, V31, P133, DOI 10.1161/ATVBAHA.110.215061; Ma YG, 2015, CARDIOVASC RES, V106, P421, DOI 10.1093/cvr/cvv128; Machado-Oliveira G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102146; Mankowski RT, 2019, INTENS CARE MED, V45, P78, DOI 10.1007/s00134-018-5173-1; Misuth S, 2021, VASC PHARMACOL, V138, DOI 10.1016/j.vph.2021.106855; Morgan RG, 2013, AM J PHYSIOL-HEART C, V305, pH251, DOI 10.1152/ajpheart.00197.2013; Oliveira NM, 2016, MOL MED, V22, P886, DOI 10.2119/molmed.2016.00225; Park KH, 2015, J KOREAN MED SCI, V30, P1213, DOI 10.3346/jkms.2015.30.9.1213; Prescott HC, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2375; Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x; Reinhart K, 2017, NEW ENGL J MED, V377, P414, DOI 10.1056/NEJMp1707170; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Rizzo AN, 2020, VASC PHARMACOL, V128, DOI 10.1016/j.vph.2020.106677; Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Ruparelia N, 2020, HEART, V106, P80, DOI 10.1136/heartjnl-2018-314230; Shankar-Hari M, 2016, CURR INFECT DIS REP, V18, DOI 10.1007/s11908-016-0544-7; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com; Verstraete S, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1972-6; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Walaszczyk A, 2019, AGING CELL, V18, DOI 10.1111/acel.12945; Warboys CM, 2014, ARTERIOSCL THROM VAS, V34, P985, DOI 10.1161/ATVBAHA.114.303415; Wolf D, 2019, CIRC RES, V124, P315, DOI 10.1161/CIRCRESAHA.118.313591; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Yu HM, 2012, NEUROIMMUNOMODULAT, V19, P131, DOI 10.1159/000330254; Zhai XZ, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/8352727; Zhao M, 2015, AM J PHYSIOL-ENDOC M, V309, pE334, DOI 10.1152/ajpendo.00601.2014	61	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106922	10.1016/j.vph.2021.106922		NOV 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34592427				2022-04-29	WOS:000756079500013
J	Alfi, E; Thairi, C; Femmino, S; Alloatti, G; Moccia, F; Brizzi, MF; Pagliaro, P; Penna, C				Alfi, Edoardo; Thairi, Cecilia; Femmino, Saveria; Alloatti, Giuseppe; Moccia, Francesco; Brizzi, Maria F.; Pagliaro, Pasquale; Penna, Claudia			Extracellular vesicles (EVs) in ischemic conditioning and angiogenesis: Focus on endothelial derived EVs	VASCULAR PHARMACOLOGY			English	Article						Endothelial cells; Cardioprotection; Biomarkers; Remote ischemic conditioning	MYOCARDIAL-INFARCTION; INDUCE ANGIOGENESIS; EXOSOMES; CELLS; INJURY; MICROVESICLES; REPERFUSION; BIOMARKERS; MICRORNA; PLASMA	During myocardial ischemia, timely reperfusion is critical to limit infarct area and the overall loss of cardiac contractile function. However, reperfusion further exacerbates the damage of the ischemic heart. This type of injury is known as ischemia-reperfusion injury (IRI). Ischemic conditioning is a procedure which consists of brief cycles of ischemia and reperfusion in order to protect the myocardium against IRI. Remote ischemic conditioning (RIC), namely transient brief episodes of ischemia at a remote site before a subsequent damaging ischemia/ reperfusion procedure of the target organ (e.g., the heart), protects against IRI. However, how the stimulus of RIC is transduced from the remote organ to the ischemic heart is still unknown. Recently, extracellular vesicles (EVs) have been proposed to have a role in the RIC procedure. The endothelium releases EVs and is also one of the tissues mostly exposed to EVs during their journey to the target organ. Moreover, EVs may have important roles in angiogenesis and, therefore, in the remodeling of post-ischemic organs. Here we analyze how EVs may contribute to the overall cardioprotective effect and the implication of the endothelium and its EVs in RIC mediated acute cardioprotection as well as in angiogenesis.	[Alfi, Edoardo; Thairi, Cecilia; Pagliaro, Pasquale; Penna, Claudia] Univ Turin, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Orbassano, TO, Italy; [Femmino, Saveria; Brizzi, Maria F.] Univ Turin, Dept Med Sci, Corso Dogliotti 14, I-10126 Turin, Italy; [Alloatti, Giuseppe] Uni Astiss, Polo Univ Rita Levi Montalcini, I-14100 Asti, Italy; [Moccia, Francesco] Univ Pavia, Dept Biol & Biotechnol, Lab Gen Physiol, I-27100 Pavia, Italy		Pagliaro, P (通讯作者)，Univ Turin, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Orbassano, TO, Italy.	pasquale.pagliaro@unito.it	Brizzi, Maria Felice/J-7882-2016		University of Turin, Torino, Italy [PAGL_RILO_19_01, PENC_RILO_19_01]; Fondi di beneficenza Intesa San Paolo [375-2019, PENC_RIC_COMP_20_01]	The authors of this work are supported by University of Turin, Torino, Italy (PAGL_RILO_19_01; PENC_RILO_19_01) and Fondi di beneficenza Intesa San Paolo No. 375-2019 to CP and MFB (PENC_RIC_COMP_20_01).	Akers JC, 2015, J NEURO-ONCOL, V123, P205, DOI 10.1007/s11060-015-1784-3; Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Balbi C, 2019, INT J CARDIOL, V287, P87, DOI 10.1016/j.ijcard.2019.04.011; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bartekova M, 2004, GEN PHYSIOL BIOPHYS, V23, P489; Barutta F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073798; Bian SY, 2014, J MOL MED, V92, P387, DOI 10.1007/s00109-013-1110-5; Casieri V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59225-7; Chen GH, 2020, THERANOSTICS, V10, P11754, DOI 10.7150/thno.43163; Chen Q, 2020, AGING-US, V12, P3682, DOI 10.18632/aging.102837; Cheow ESH, 2016, MOL CELL PROTEOMICS, V15, P2628, DOI 10.1074/mcp.M115.055731; Chiva-Blanch G, 2016, REV ESP CARDIOL, V69, P672, DOI 10.1016/j.rec.2015.12.033; Cianciaruso C, 2017, DIABETES, V66, P460, DOI 10.2337/db16-0671; Davidson SM, 2019, CARDIOVASC RES, V115, P1156, DOI 10.1093/cvr/cvy314; Davidson SM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34357-z; Davidson SM, 2018, J CELL MOL MED, V22, P141, DOI 10.1111/jcmm.13302; Deddens JC, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.01.75; Deddens JC, 2016, J CARDIOVASC TRANSL, V9, P291, DOI 10.1007/s12265-016-9705-1; Dellett M, 2017, J CELL MOL MED, V21, P3405, DOI 10.1111/jcmm.13251; Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709; Dignat-George F, 2011, ARTERIOSCL THROM VAS, V31, P27, DOI 10.1161/ATVBAHA.110.218123; Diwan V, 2008, MOL CELL BIOCHEM, V315, P195, DOI 10.1007/s11010-008-9808-3; Faris P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197406; Femmino S, 2020, VASC PHARMACOL, V135, DOI 10.1016/j.vph.2020.106790; Fujita K, 2018, INT J UROL, V25, P770, DOI 10.1111/iju.13734; Gan L, 2020, CIRCULATION, V141, P968, DOI 10.1161/CIRCULATIONAHA.119.042640; Giricz Z, 2014, J MOL CELL CARDIOL, V68, P75, DOI 10.1016/j.yjmcc.2014.01.004; Gohar A, 2018, VASC PHARMACOL, V111, P1, DOI 10.1016/j.vph.2018.05.006; Gollmann-Tepekoylu C, 2020, CARDIOVASC RES, V116, P1226, DOI 10.1093/cvr/cvz209; Herrera-Zelada N, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.636134; Huang PS, 2020, CARDIOVASC RES, V116, P353, DOI 10.1093/cvr/cvz139; Jeanneteau J, 2012, AM J PHYSIOL-HEART C, V303, pH871, DOI 10.1152/ajpheart.00102.2012; Kalluri AS, 2019, CIRCULATION, V140, P147, DOI 10.1161/CIRCULATIONAHA.118.038362; Kang T, 2016, STEM CELL TRANSL MED, V5, P440, DOI 10.5966/sctm.2015-0177; Karakoyun R, 2014, EUR J VASC ENDOVASC, V47, P172, DOI 10.1016/j.ejvs.2013.11.001; Kharbanda RK, 2001, CIRCULATION, V103, P1624, DOI 10.1161/01.CIR.103.12.1624; Kholia S, 2016, VASC PHARMACOL, V86, P64, DOI 10.1016/j.vph.2016.03.005; Kleinbongard P, 2017, PFLUG ARCH EUR J PHY, V469, P159, DOI 10.1007/s00424-016-1922-6; Lamichhane TN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14356-2; Li QJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb0202; Liu L, 2017, CELL PHYSIOL BIOCHEM, V43, P52, DOI 10.1159/000480317; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nair S, 2018, ORAL ONCOL, V84, P31, DOI 10.1016/j.oraloncology.2018.07.001; Penna C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020327; Penna C, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010013; Penna C, 2020, BRIT J PHARMACOL, V177, P5312, DOI 10.1111/bph.14993; Potz BA, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008344; PRZYKLENK K, 1993, CIRCULATION, V87, P893, DOI 10.1161/01.CIR.87.3.893; Schoemaker RG, 2000, AM J PHYSIOL-HEART C, V278, pH1571, DOI 10.1152/ajpheart.2000.278.5.H1571; Scrimgeour LA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238879; Scrimgeour LA, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012617; Silvestre JS, 2013, PHYSIOL REV, V93, P1743, DOI 10.1152/physrev.00006.2013; Spaggiari G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233619; Spannbauer A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092140; Takov K, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0785-3; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tucher C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00534; van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood-2013-02-478925; Vicencio JM, 2015, J AM COLL CARDIOL, V65, P1525, DOI 10.1016/j.jacc.2015.02.026; Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013; Wider J, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0674-1; Wilhelm EN, 2016, AM J PHYSIOL-HEART C, V311, pH1297, DOI 10.1152/ajpheart.00516.2016; Zempleni J, 2017, J NUTR, V147, P3, DOI 10.3945/jn.116.238949; Zhang Q, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860-016-0100-1; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002; Zheng X, 2021, STEM CELLS, V39, P403, DOI 10.1002/stem.3329; Zheng Y, 2017, CARDIOVASC THER, V35, DOI 10.1111/1755-5922.12257; Zhong SJ, 2021, ACTA NEUROL BELG, V121, P95, DOI 10.1007/s13760-020-01500-5	70	4	4	4	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106873	10.1016/j.vph.2021.106873		SEP 2021	7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	UW4KC	33992781	Green Published			2022-04-29	WOS:000700125900003
J	Zhang, SH; Liu, JT; Zheng, KD; Chen, LW; Sun, YP; Yao, ZZ; Sun, YR; Lin, YF; Lin, KX; Yuan, LB				Zhang, Shuhao; Liu, Jiantao; Zheng, Kaidi; Chen, Luowei; Sun, Yupeng; Yao, Zhengze; Sun, Yiruo; Lin, Yufan; Lin, Kexin; Yuan, Linbo			Exosomal miR-211 contributes to pulmonary hypertension via attenuating CaMK1/PPAR-gamma axis	VASCULAR PHARMACOLOGY			English	Article						Pulmonary hypertension; miR-211; CaMK1; PPAR-gamma; Exosome		Aim: Exsomes play a significant role in increasing pathophysiological processes by delivering their content. Recently, a variety of studies have showed exosomal microRNAs (miRNAs) are involved in pulmonary hyper tension (PH) notably. In this study, we found that exosomal miR-211 was overexpressed in hypoxia-induced PH rats but its intrinsic regulation was unclear. Therefore, our aim was to reveal the underlying mechanism which overexpressed exosomal miR-211 targeted in the development of PH. Methods: 18 male SD rats were randomly divided into normoxia and hypoxia group, housed in normal or hypoxic chamber for 3 weeks respectively. Then, mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance(PVR), right ventricular hypertrophy index(RV/(LV + S)), the percentage of medial wall area (WA%) and the percentage of medial wall thickness (WT%) were measured. Expression of miR-211 in exosomes was detected by qRT-PCR. Expression of Ca2+/calmodulin-dependent kinase1(CaMK1)and peroxisome proliferator-activated receptors-gamma(PPAR-gamma)in lung tissue were detected by Western blot(WB); After miR-211 overexpressed exosomes were injected to rats through caudal vein, mPAP, PVR, RV/(LV + S), WA% and WT% were also measured. Sequentially, hypoxia rats were injected with lentivirus riched in miR-211 inhibitor via tail vein, and PH-related indicators were measured. In vitro, after miR-211 was positively or negatively regulated in pulmonary arterial smooth muscle cell (PASMC) by plasmid transfection, proliferation of PASMC was detected by CCK8, as well as the expression of CaMK1 and PPAR gamma. Further, the relationship between CaMK1 and miR-211 was verified by Dual-Luciferase assay. And the regulatory relationship of CaMK1/PPAR gamma aixs was demonstrated in PASMC. Results: Evident increases of mPAP, PVR, RVHI, WT% and WA% were observed with hypoxia administration. And the concentration of plasma exosomes in hypoxia rats was increased and positively correlated with the above indexes. miR-211 in exosomes of PH was upregulated while the expression of CaMK1 and PPAR-gamma decreased in lung tissues. Further, injection of exosomes overexpressed with miR-211 demonstrated that exosomal miR-211 aggravated PH while inhibition of miR-211 attenuated PH in rats. In vitro, overexpression of miR-211 promoted the proliferation of PASMC and inhibited expression of CaMK1 and PPAR-gamma in PASMC. And Dual-luciferase assay demonstrated that CaMK1 was a downstream gene of miR-211. Plasmid transfection experiments indicated that CaMK1 can promote PPAR-gamma expression. Conclusion: Exosomal miR-211 promoted PH via inhibiting CaMK1/PPAR-gamma axis, promoting PASMC proliferation in rats.	[Zhang, Shuhao; Chen, Luowei; Sun, Yupeng; Yao, Zhengze; Lin, Yufan] Wenzhou Med Univ, Sch Clin Med 1, Wenzhou, Peoples R China; [Liu, Jiantao; Sun, Yiruo; Lin, Kexin] Wenzhou Med Univ, Sch Clin Med 2, Wenzhou, Peoples R China; [Zheng, Kaidi] Wenzhou Med Univ, Basic Med Sci Sch, Dept Biochem, Wenzhou, Peoples R China; [Yuan, Linbo] Wenzhou Med Univ, Basic Med Sci Sch, Dept Physiol, Wenzhou, Peoples R China		Yuan, LB (通讯作者)，Wenzhou Med Univ, Basic Med Sci Sch, Dept Physiol, Wenzhou, Peoples R China.	Yuanlb731@126.com			Science and Technology Plan Project of Wenzhou [Y20190053]; Research Development Foundation of Wenzhou Medical University [QTJ19021]; Medical Health Science and Technology Project of Zhejiang Provincial Health Commission [2021KY778]; Research Project of students in Wenzhou Medical University [wyx2019101065, wyx2018101116]; Science and Technology Innovation Plan and Xin-miao Talents of Zhejiang Province [2019R413017, 2020R413026]; National College Student Innovation and Entrepreneurship Training Program [201910343013]; National Natural Science Foundations of ChinaNational Natural Science Foundation of China (NSFC) [81701620]	This work was supported by the Science and Technology Plan Project of Wenzhou(Y20190053);the Research Development Foundation of Wenzhou Medical University (QTJ19021); the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2021KY778); the Research Project of students in Wenzhou Medical University (wyx2019101065 and wyx2018101116);the Science and Technology Innovation Plan and Xin-miao Talents of Zhejiang Province (2019R413017 and 2020R413026); National College Student Innovation and Entrepreneurship Training Program: 201910343013; The National Natural Science Foundations of China (Grant Nos. 81701620).	Aliotta JM, 2016, CARDIOVASC RES, V110, P319, DOI 10.1093/cvr/cvw054; Arenaccio C, 2017, ADV EXP MED BIOL, V998, P3, DOI 10.1007/978-981-10-4397-0_1; Bregeon J, 2009, AM J PHYSIOL-CELL PH, V297, pC1062, DOI 10.1152/ajpcell.00174.2009; Calvier L, 2017, CELL METAB, V25, P1118, DOI 10.1016/j.cmet.2017.03.011; Chen JZ, 2010, HUM MOL GENET, V19, P2524, DOI 10.1093/hmg/ddq131; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Chun HJ, 2017, AM J RESP CRIT CARE, V195, P167, DOI 10.1164/rccm.201604-0886PP; Deng L, 2015, CIRC RES, V117, P870, DOI 10.1161/CIRCRESAHA.115.306806; Ferrer E, 2018, AM J RESP CELL MOL, V59, P467, DOI 10.1165/rcmb.2017-0129OC; Garcia MP, 2006, MENOPAUSE, V13, P397, DOI 10.1097/01.gme.0000222472.08593.e4; Gu DN, 2015, EXPERT OPIN THER TAR, V19, P415, DOI 10.1517/14728222.2014.988708; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945; Hosseini M, 2017, CURR PHARM DESIGN, V23, P1705, DOI 10.2174/1381612822666161201144634; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Imoto K, 2018, PFLUG ARCH EUR J PHY, V470, P1405, DOI 10.1007/s00424-018-2158-4; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Lai YC, 2016, CIRCULATION, V133, P717, DOI 10.1161/CIRCULATIONAHA.115.018935; Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173; Legchenko E, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao0303; Li XF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12570-6; Liu HN, 2018, BIOCHEM BIOPH RES CO, V505, P1236, DOI 10.1016/j.bbrc.2018.10.052; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Meoli DF, 2009, AM J PHYSIOL-LUNG C, V297, pL706, DOI 10.1152/ajplung.90598.2008; Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029; Mizuno S, 2011, AM J PHYSIOL-LUNG C, V300, pL753, DOI 10.1152/ajplung.00286.2010; Momtazi AA, 2016, MOL DIAGN THER, V20, P335, DOI 10.1007/s40291-016-0202-7; Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002; Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152; Potus F, 2014, PULM CIRC, V4, P175, DOI 10.1086/675980; Provencher S, 2018, CIRC RES, V122, P1021, DOI 10.1161/CIRCRESAHA.117.312579; Pullamsetti SS, 2012, AM J RESP CRIT CARE, V185, P409, DOI 10.1164/rccm.201106-1093OC; Rhodes CJ, 2013, AM J RESP CRIT CARE, V187, P294, DOI 10.1164/rccm.201205-0839OC; Schneider A, 2013, CELL TISSUE RES, V352, P33, DOI 10.1007/s00441-012-1428-2; Sessa R, 2013, PULM CIRC, V3, P315, DOI 10.4103/2045-8932.114758; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Stenmark KR, 2009, AM J PHYSIOL-LUNG C, V297, pL1013, DOI 10.1152/ajplung.00217.2009; Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0897-7; Thenappan T, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5492; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Wang KF, 2017, MOL CANCER RES, V15, P448, DOI 10.1158/1541-7786.MCR-16-0288; Wang P, 2016, CELL PROLIFERAT, V49, P484, DOI 10.1111/cpr.12265; Wang XH, 2014, J MOL CELL CARDIOL, V74, P139, DOI 10.1016/j.yjmcc.2014.05.001; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yang FM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0718-4; Ye LG, 2016, TUMOR BIOL, V37, P1151, DOI 10.1007/s13277-015-3835-y; Zheng JB, 2019, J CELL BIOCHEM, V120, P4644, DOI 10.1002/jcb.27753; Zhou GF, 2015, AM J RESP CELL MOL, V52, P139, DOI 10.1165/rcmb.2014-0166TR	49	5	5	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106820	10.1016/j.vph.2020.106820		JAN 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33238205				2022-04-29	WOS:000613540200006
J	Busch, L; Stern, M; M'Pembele, R; Dannenberg, L; Mourikis, P; Grone, M; Ozaslam, G; Heinen, Y; Heiss, C; Sansone, R; Huhn, R; Kelm, M; Polzin, A				Busch, Lucas; Stern, Manuel; M'Pembele, Rene; Dannenberg, Lisa; Mourikis, Philipp; Groene, Michael; Oezaslam, Goeksen; Heinen, Yvonne; Heiss, Christian; Sansone, Roberto; Huhn, Ragnar; Kelm, Malte; Polzin, Amin			Impact of high on-treatment platelet reactivity after angioplasty in patients with critical limb ischemia	VASCULAR PHARMACOLOGY			English	Article						Bleeding; Light transmission aggregometry (LTA); Major adverse cardiac and cerebrovascular events (MACCE); Major adverse limb events (MALE); Critical limb ischemia (CLI); Vasodilator-stimulated protein; phosphorylation assay (VASP)	PERIPHERAL ARTERIAL-DISEASE; ASPIRIN; CLOPIDOGREL; RESPONSIVENESS; INHIBITION; PREVALENCE; STROKE	Objectives: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard of care in patients with peripheral artery disease (PAD) after percutaneous transluminal angioplasty (PTA). However, high on treatment platelet reactivity (HTPR) to DAPT is frequent and associated with major adverse limb events (MALE) in PAD patients. Nevertheless, association of MALE and HTPR in patients with critical limb ischemia (CLI) is not known. Moreover, comorbidities might confound response to antiplatelet medication further. Hence, in this trial we analyzed pharmacodynamic responses to DAPT and clinical events in CLI patients post PTA. Methods: In this prospective single center pilot analysis, we included 71 CLI patients. Patients received DAPT after PTA. Antiplatelet effect were measured by light transmission aggregometry (LTA) and vasodilator-stimulated protein phosphorylation assay (VASP). MALE, major adverse cardiac and cerebrovascular events (MACCE) and BARC bleeding within 12 months follow-up were assessed. Results: Mean age of patients was 73.37 +/- 7.36 years and 47 (66.2%) were male. Overall HTPR appeared in 46 patients (64.8%). MALE and MACCE showed no differences between patients with and patients without HTPR. However, bleeding was higher in patients with sufficient pharmacodynamic response to DAPT (Bleeding - HTPR: 13.4% vs. no HTPR: 36.0%; log-rank HR: 0.32; 95% CI 0.1079 to 0.9396 p = 0.0217). This finding remained robust in multivariate analysis. Conclusion: HTPR to DAPT is frequent in CLI patients. However, bleeding was higher in patients with sufficient response to DAPT. Ischemic events did not differ. Hence, CLI patients might benefit from an alternative antithrombotic approach.	[Busch, Lucas; Stern, Manuel; Dannenberg, Lisa; Mourikis, Philipp; Groene, Michael; Oezaslam, Goeksen; Heinen, Yvonne; Sansone, Roberto; Kelm, Malte; Polzin, Amin] Univ Duesseldorf, Fac Med, Cardiovasc Res Inst Dusseldorf CARID, Div Cardiol Pulmonol & Vasc Med, Dusseldorf, Germany; [M'Pembele, Rene; Huhn, Ragnar] Univ Hosp Duesseldorf, Dept Anesthesiol, Dusseldorf, Germany; [Heiss, Christian] Univ Surrey, Fac Hlth & Med Sci, Guildford, Surrey, England		Polzin, A (通讯作者)，Univ Duesseldorf, Fac Med, Div Cardiol Pulmonol & Vasc Med, Mooren Str 5, D-40225 Dusseldorf, Germany.	amin.polzin@med.uni-duesseldorf.de	Huhn, Ragnar/X-6466-2018	Huhn, Ragnar/0000-0002-3114-7190; Busch, Lucas/0000-0002-5521-1265	Forschungskommission of the Medical Faculty of the Heinrich Heine University [29-2019, 18-2019]; German Research FoundationGerman Research Foundation (DFG) [PO 2247/2-1, SFB1116]	The authors thank Ms. Brigitte Eichstadt and Ms. Micereme Izairi for calling and scheduling patients' follow up in the angiology department. This work was supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University (29-2019, to L.D., No. 18-2019 to A.P.) and by the German Research Foundation (PO 2247/2-1 to A.P. and SFB1116 to A.P.).	Baumann F, 2016, J ENDOVASC THER, V23, P468, DOI 10.1177/1526602816637621; Bonaca MP, 2020, NEW ENGL J MED, V382, P1994, DOI 10.1056/NEJMoa2000052; Breet NJ, 2010, J THROMB HAEMOST, V8, P2140, DOI 10.1111/j.1538-7836.2010.04017.x; Busch L, 2021, PLATELETS, V32, P391, DOI 10.1080/09537104.2020.1742314; Clavijo LC, 2018, CARDIOVASC REVASCULA, V19, P516, DOI 10.1016/j.carrev.2017.10.013; Dannenberg L, 2019, PHARMACOLOGY, V104, P212, DOI [10.1159/000500821, 10.1159/000503582]; Duff S, 2019, VASC HEALTH RISK MAN, V15, P187, DOI 10.2147/VHRM.S209241; Fiolaki A, 2017, J NEUROL SCI, V376, P112, DOI 10.1016/j.jns.2017.03.010; Fowkes FGR, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2016.179; Gerhard-Herman MD, 2017, VASC MED, V22, pNP1, DOI 10.1177/1358863X17701592; Gum PA, 2003, J AM COLL CARDIOL, V41, P961, DOI 10.1016/S0735-1097(02)03014-0; Gupta A, 2019, CARDIOL THER, V8, P193, DOI 10.1007/s40119-019-00153-7; Halliday A, 2018, EUR J VASC ENDOVASC, V55, P301, DOI 10.1016/j.ejvs.2018.03.004; Hartinger J, 2018, MED PRIN PRACT, V27, P356, DOI 10.1159/000489970; Iida O, 2017, CIRC-CARDIOVASC INTE, V10, DOI 10.1161/CIRCINTERVENTIONS.117.005531; Karnabatidis D, 2014, CARDIOVASC INTER RAD, V37, P631, DOI 10.1007/s00270-013-0710-3; Leunissen TC, 2016, EUR J VASC ENDOVASC, V52, P198, DOI 10.1016/j.ejvs.2016.04.019; Linnemann B, 2009, ANN HEMATOL, V88, P979, DOI 10.1007/s00277-009-0708-8; Luders F, 2016, CLIN J AM SOC NEPHRO, V11, P216, DOI 10.2215/CJN.05600515; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; Meves SH, 2014, THROMB RES, V133, P396, DOI 10.1016/j.thromres.2013.12.002; Nishikawa M, 2020, J ATHEROSCLER THROMB, V27, P13, DOI 10.5551/jat.48934; Ocak G, 2018, J THROMB HAEMOST, V16, P65, DOI 10.1111/jth.13904; Pastromas G, 2013, CARDIOVASC INTER RAD, V36, P1493, DOI 10.1007/s00270-013-0577-3; Petzold T, 2020, CIRC RES, V126, P486, DOI 10.1161/CIRCRESAHA.119.315099; Polzin A, 2016, J THROMB HAEMOST, V14, P375, DOI 10.1111/jth.13211; Polzin A, 2016, VASC PHARMACOL, V77, P54, DOI 10.1016/j.vph.2015.07.015; Polzin A, 2015, WORLD J CARDIOL, V7, P383, DOI 10.4330/wjc.v7.i7.383; Polzin A, 2015, EUR J PHARMACOL, V751, P24, DOI 10.1016/j.ejphar.2015.01.028; Polzin A, 2013, J AM COLL CARDIOL, V62, P1725, DOI 10.1016/j.jacc.2013.07.039; Rios JRR, 2018, CARDIOVASC DIAGN THE, V8, P594, DOI 10.21037/cdt.2018.05.09; Rymer JA, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012236; Saunders J, 2011, J VASC SURG, V53, P668, DOI 10.1016/j.jvs.2010.08.029; Schneider DJ, 2009, DIABETES CARE, V32, P525, DOI 10.2337/dc08-1865; Schwarz UR, 1999, THROMB HAEMOSTASIS, V82, P1145, DOI 10.1055/s-0037-1614344; Sibbing D, 2019, JACC-CARDIOVASC INTE, V12, P1521, DOI 10.1016/j.jcin.2019.03.034; Spiliopoulos S, 2015, WORLD J CARDIOL, V7, P912, DOI 10.4330/wjc.v7.i12.912; Spiliopoulos S, 2013, J AM COLL CARDIOL, V61, P2428, DOI 10.1016/j.jacc.2013.03.036; Warlo EMK, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0197-5; Wattanakit K, 2007, J AM SOC NEPHROL, V18, P629, DOI 10.1681/ASN.2005111204; Yeo KK, 2018, CATHETER CARDIO INTE, V91, P1308, DOI 10.1002/ccd.27453	41	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106925	10.1016/j.vph.2021.106925		NOV 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34619361				2022-04-29	WOS:000756079500016
J	Montinari, MR; Minelli, S; De Caterina, R				Montinari, Maria Rosa; Minelli, Sergio; De Caterina, Raffaele			Eighty years of oral anticoagulation: Learning from history	VASCULAR PHARMACOLOGY			English	Review						History of medicine; Oral anticoagulants; Vitamin K antagonists; VKAs; Non-vitamin K antagonist oral anticoagulants; NOACs; Thromboembolism	SWEET CLOVER DISEASE; VITAMIN-K; RANDOMIZED-TRIAL; HEART-DISEASE; CLINICAL-EXPERIENCE; ATRIAL-FIBRILLATION; PULMONARY EMBOLISM; HEMORRHAGIC AGENT; WARFARIN; PREVENTION	In the year 2021 we celebrate the 80th anniversary of the first clinical use of vitamin K antagonists (VKAs), the mainstay of prevention and long-term treatment of thromboembolic disease. The discovery and development of oral anticoagulants is one of the most important chapters in the history of medicine, a goal pursued by physicians trying to combat the clinical manifestations of thrombosis since ancient times. Until the last decade, VKAs were the only oral anticoagulants available and used in clinical practice. Today, their clinical use has progressively shrunk, as the non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly replacing VKAs in various conditions after the successful completion of several large randomized controlled trials. Currently, new research is tackling upstream components of the intrinsic pathway - particularly factor XI and factor XII - for the development of new, even safer anticoagulants promising to reduce bleeding without compromising efficacy. This review highlights the evolution of oral anticoagulant therapy tracing the key stages of a long and fascinating history that has unfolded from the first part of the twentieth century until today, indeed an intriguing journey where serendipity is intertwined with the tenacious work of many researchers.	[Montinari, Maria Rosa] Univ Salento, Dept Biol & Environm Sci & Technol, Chair Hist Med, Lecce, Italy; [Minelli, Sergio] ASL Lecce, DSSN 52 Cardiol, Lecce, Italy; [De Caterina, Raffaele] Univ Pisa, Univ Cardiol Div, Chair Cardiol, Azienda Osped Univ Pisana, Pisa, Italy; [De Caterina, Raffaele] Fdn VillaSerena Ric Citta Sant Angelo, Pescara, Italy		De Caterina, R (通讯作者)，Univ Pisa, Univ Hosp Pisa, Chair & Postgrad Sch Cardiol, Cardiol Div 1, Via Paradisa,2, I-56124 Pisa, Italy.	raffaele.decaterina@unipi.it	MINELLI, SERGIO/AAQ-6902-2020	MINELLI, SERGIO/0000-0002-6259-8883			Agnelli G, 2020, NEW ENGL J MED, V382, P1599, DOI 10.1056/NEJMoa1915103; Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507; Al-Horani RA, 2018, MED RES REV, V38, P1974, DOI 10.1002/med.21503; Anderson JL, 2007, CIRCULATION, V116, P2563, DOI 10.1161/CIRCULATIONAHA.107.737312; [Anonymous], 1973, JAMA-J AM MED ASSOC, V225, P724; [Anonymous], 1970, LANCET, V1, P203; [Anonymous], 1969, Br Med J, V1, P335; [Anonymous], 1994, Lancet, V343, P499; Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; Bala MM, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012169.pub3; BARRITT DW, 1960, LANCET, V1, P1309; Bassand JP, 2021, BLOOD ADV, V5, P1081, DOI 10.1182/bloodadvances.2020003560; Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903; BELL RG, 1978, FED PROC, V37, P2599; Bingham JB, 1941, AM J MED SCI, V202, P563, DOI 10.1097/00000441-194110000-00009; Buller HR, 2015, NEW ENGL J MED, V372, P232, DOI 10.1056/NEJMoa1405760; Buller HR, 2013, NEW ENGL J MED, V369, P1406, DOI 10.1056/NEJMoa1306638; BUTT H. R., 1941, PROC STAFF MEET MAYO CLINIC, V16, P388; Campbell HA, 1941, J BIOL CHEM, V138, P21; Campbell HA, 1940, J BIOL CHEM, V136, P47; Capodanno D, 2020, NAT REV CARDIOL, V17, P242, DOI 10.1038/s41569-019-0314-y; CLATANOFF DV, 1954, ARCH INTERN MED, V94, P213, DOI 10.1001/archinte.1954.00250020047003; Cohen AT, 2018, VASC PHARMACOL, V106, P9, DOI 10.1016/j.vph.2018.04.001; Cohen H, 2016, J THROMB HAEMOST, V14, P1673, DOI 10.1111/jth.13366; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Coppens M, 2012, CIRC RES, V111, P920, DOI 10.1161/CIRCRESAHA.112.264903; Daka A, 2012, ADV DRUG DELIVER REV, V64, P1508, DOI 10.1016/j.addr.2012.08.014; Dam H, 1929, BIOCHEM Z, V215, P475; Dam H, 1935, NATURE, V135, P652, DOI 10.1038/135652b0; Dam H, 1936, BIOCHEM J, V30, P897, DOI 10.1042/bj0300897; De Caterina R, 2007, EUR HEART J, V28, P880, DOI 10.1093/eurheartj/ehl492; De Caterina R, 2019, THROMB HAEMOSTASIS, V119, P14, DOI 10.1055/s-0038-1675816; De Caterina R, 2017, CLIN RES CARDIOL, V106, P565, DOI 10.1007/s00392-017-1102-5; De Caterina R, 2013, THROMB HAEMOSTASIS, V110, P1087, DOI 10.1160/TH13-06-0443; De Caterina R, 2012, J AM COLL CARDIOL, V59, P1413, DOI 10.1016/j.jacc.2012.02.008; Diener HC, 2019, NEW ENGL J MED, V380, P1906, DOI 10.1056/NEJMoa1813959; Duraes AR, 2018, DRUGS R&D, V18, P303, DOI 10.1007/s40268-018-0249-5; Duraes AR, 2021, AM J CARDIOVASC DRUG, V21, P363, DOI 10.1007/s40256-020-00449-3; Duxbury BM, 2001, CLIN APPL THROMB-HEM, V7, P269, DOI 10.1177/107602960100700403; Eikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118; Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615; ESMON CT, 1975, J BIOL CHEM, V250, P4744; FIELDS WS, 1991, HAEMOSTASIS, V21, P3; Franz F, 1903, ARCH EXP PATHOL PHAR, V49, P342, DOI 10.1007/BF01825055; Fredenburgh JC, 2021, J THROMB HAEMOST, V19, P20, DOI 10.1111/jth.15126; Friberg L, 2015, EUR HEART J, V36, P297, DOI 10.1093/eurheartj/ehu139; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Gurewich V, 2005, JAMA-J AM MED ASSOC, V293, P736, DOI 10.1001/jama.293.6.736; Ha JT, 2019, ANN INTERN MED, V171, P181, DOI 10.7326/M19-0087; Hart RG, 2018, NEW ENGL J MED, V378, P2191, DOI 10.1056/NEJMoa1802686; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; HARVEY RP, 1986, P NATL ACAD SCI USA, V83, P1084, DOI 10.1073/pnas.83.4.1084; Haycraft J.B., 1884, ARCH EXP PATHOL PHAR, V18, P209; Hippocrates E.Littre, 1839, OEUVRES COMPL ETES H; Hirsh J, 2003, J AM COLL CARDIOL, V41, P1633, DOI 10.1016/S0735-1097(03)00416-9; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HOLFORD NHG, 1986, CLIN PHARMACOKINET, V11, P483, DOI 10.2165/00003088-198611060-00005; Huebner CF, 1941, J BIOL CHEM, V138, P529; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Jacoby C. Uber Hirudin, 1904, DEUT MED WOCHENSCHR, V30, P1786; Kamali F, 2010, ANNU REV MED, V61, P63, DOI 10.1146/annurev.med.070808.170037; Karenberg A, 2012, DEUT MED WOCHENSCHR, V137, P2691, DOI 10.1055/s-0032-1327343; Karenberg A, 1997, FORTSCHR NEUROL PSYC, V65, P489, DOI 10.1055/s-2007-996355; Karenberg A, 1998, J Hist Neurosci, V7, P162; Key NS, 2014, HEMATOL-AM SOC HEMAT, P66, DOI 10.1182/asheducation-2014.1.66; Kimachi M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011373.pub2; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329; Koch AW, 2019, BLOOD, V133, P1507, DOI 10.1182/blood-2018-10-880849; Last JA, 2002, TOXICOL SCI, V66, P4, DOI 10.1093/toxsci/66.1.4; LINK KP, 1959, CIRCULATION, V19, P97, DOI 10.1161/01.CIR.19.1.97; Lu DC, 2019, NAT REV CARDIOL, V16, P661, DOI 10.1038/s41569-019-0218-x; MARCUM JA, 1990, PERSPECT BIOL MED, V33, P214; MARKWARDT F, 1956, N-S ARCH EX PATH PH, V229, P389, DOI 10.1007/BF00245864; Markwardt F, 2002, SEMIN THROMB HEMOST, V28, P405, DOI 10.1055/s-2002-35292; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MOK CK, 1985, CIRCULATION, V72, P1059, DOI 10.1161/01.CIR.72.5.1059; Montinari MR, 2019, VASC PHARMACOL, V113, P1, DOI 10.1016/j.vph.2018.10.008; Morawitz P., 1905, ERGEBNISSE PHYSL, V4, P307; MUELLER RL, 1994, CIRCULATION, V89, P432, DOI 10.1161/01.CIR.89.1.432; Mulder FI, 2020, THROMB RES, V185, P13, DOI 10.1016/j.thromres.2019.11.007; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; Nourse J, 2021, PHARMACOL THERAPEUT, V218, DOI 10.1016/j.pharmthera.2020.107676; Owen C.A., 2001, HIST BLOOD COAGULATI; Parapia LA, 2008, BRIT J HAEMATOL, V143, P490, DOI 10.1111/j.1365-2141.2008.07361.x; Pastori D, 2018, INT J CARDIOL, V264, P58, DOI 10.1016/j.ijcard.2018.01.097; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Pengo V, 2018, BLOOD, V132, P1365, DOI 10.1182/blood-2018-04-848333; PETERSEN P, 1989, LANCET, V1, P175; Pirmohamed M, 2006, BRIT J CLIN PHARMACO, V62, P509, DOI 10.1111/j.1365-2125.2006.02806.x; POLLER L, 1967, LANCET, V1, P491; Poller L., 1987, HEMATOL REV, V1, P225; POLLOCK BE, 1955, JAMA-J AM MED ASSOC, V159, P1094, DOI 10.1001/jama.1955.02960280016004; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; Quick, 1935, J BIOL CHEM, V109, P73; Raju TNK, 1999, LANCET, V353, P761, DOI 10.1016/S0140-6736(05)76139-0; RICE-WRAY E, 1964, Br Med J, V2, P837; RODERICK LEE M., 1929, JOUR AMER VET MED ASSOC, V74, P314; Roderick LM, 1931, AM J PHYSIOL, V96, P413, DOI 10.1152/ajplegacy.1931.96.2.413; Scaglione F, 2013, CLIN PHARMACOKINET, V52, P69, DOI 10.1007/s40262-012-0030-9; Schofield F., 1922, CAN VET RECORD, V3, P74; Schofield F.W., 1924, J AM VET MED ASSOC, V64, P553; SCHOFIELD FW, 1984, CAN VET J, V25, P453; Schulman S, 2013, NEW ENGL J MED, V368, P709, DOI 10.1056/NEJMoa1113697; SEVITT S, 1959, LANCET, V2, P981; SHAPIRO SHEPARD, 1953, ANGIOLOGY, V4, P380, DOI 10.1177/000331975300400410; Sihn KH, 2019, YONSEI MED J, V60, P315, DOI 10.3349/ymj.2019.60.4.315; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; Stahmann MA, 1941, J BIOL CHEM, V138, P513; Steffel J, 2021, EUROPACE, V23, P1612, DOI 10.1093/europace/euab065; Steffel J, 2018, EUR HEART J, V39, P1330, DOI 10.1093/eurheartj/ehy136; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Thalin C, 2019, ARTERIOSCL THROM VAS, V39, P1724, DOI 10.1161/ATVBAHA.119.312463; Thayer SA, 1938, SCIENCE, V88, P243, DOI 10.1126/science.88.2280.243; Tsoucalas G, 2016, CURR PHARM DESIGN, V22, P1857, DOI 10.2174/1381612822666160111124615; TURPIE AGG, 1988, LANCET, V1, P1242; Virchow R., 1871, ARCH PATHOL ANAT PHY; Wardrop D, 2008, BRIT J HAEMATOL, V141, P757, DOI 10.1111/j.1365-2141.2008.07119.x; Weitz JI, 2020, BLOOD, V135, P351, DOI 10.1182/blood.2019000919; WHITLON DS, 1978, BIOCHEMISTRY-US, V17, P1371, DOI 10.1021/bi00601a003; WHO Expert Committee on Biological Standardization, 1983, WHO TECH REP SER, V687, P1; Woodruff RS, 2017, THROMB RES, V156, P134, DOI 10.1016/j.thromres.2017.06.015; Yusuf S, 2001, NEW ENGL J MED, V345, P1716	124	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106918	10.1016/j.vph.2021.106918		NOV 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34537376				2022-04-29	WOS:000756079500009
J	Mai, V; Tan, BK; Mainbourg, S; Potus, F; Cucherat, M; Lega, JC; Provencher, S				Mai, Vicky; Tan, Boun Kim; Mainbourg, Sabine; Potus, Francois; Cucherat, Michel; Lega, Jean-Christophe; Provencher, Steeve			Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis	VASCULAR PHARMACOLOGY			English	Article						COVID-19; Venous thromboembolism; Anticoagulation; Pulmonary embolism	ILL ICU PATIENTS; IMMUNOTHROMBOSIS; COMPLICATIONS; INFECTION; RISK	Background: Many studies confirmed an association between COVID-19 and venous thromboembolism (VTE). Whether the risk of VTE significantly differed between COVID-19 cohorts and non-COVID-19 cohorts with similar disease severity remains unknown. Objectives: The aim of this systematic review with meta-analysis was to compare the rate of VTE between COVID19 and non-COVID-19 cohorts with similar disease severity. Methods: A systematic literature search (MEDLINE, Embase and Google Scholar) was conducted from January 1, 2020 to March 31, 2021 to identify studies reporting VTE in COVID-19. Relative risks (RR) were estimated for the effect measure with 95% confidence intervals. Results: Seven studies (41,768 patients) evaluated VTE in COVID-19 cohorts compared to non-COVID-19 cohorts. The overall risk of VTE (RR 1.18; 95%CI 0.79-1.77; p = 0.42; I2 = 54%), pulmonary embolism (RR 1.25; 95%CI 0.77-2.03; p = 0.36; I2 = 52%) and deep venous thrombosis (RR 0.92; 95%CI 0.52-1.65; p = 0.78; I2 = 0%) did not significantly differ between COVID-19 and non-COVID-19 cohorts. However, subgroup analyses suggested an increased risk of VTE amongst CODID-19 versus non COVID-19 cohorts when only patients hospitalized within the intensive care unit (ICU) were considered (RR 3.10; 95%CI 1.54-6.23), which was not observed in cohorts of predominantly non-ICU patients (RR 0.95; 95%CI 0.81-1.11) (Pinteraction = 0.001). Conclusion: There was no signal for a difference in VTE in COVID-19 cohorts compared to non-COVID-19 cohorts, except for the subgroup of patients hospitalized in the ICU. These results should be viewed as exploratory and further studies are needed to confirm these results.	[Mai, Vicky; Potus, Francois; Provencher, Steeve] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Res Ctr, Quebec City, PQ, Canada; [Mai, Vicky; Potus, Francois; Provencher, Steeve] Pulm Hypertens Res Grp, Quebec City, PQ, Canada; [Tan, Boun Kim] Hosp Civils Lyon, Dept Intens Care Unit, Hop Lyon Sud, F-69310 Pierre Benite, France; [Mainbourg, Sabine; Lega, Jean-Christophe] Univ Lyon, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69100 Villeurbanne, France; [Mainbourg, Sabine; Lega, Jean-Christophe] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Internal & Vasc Med, F-69310 Pierre Benite, France; [Potus, Francois; Provencher, Steeve] Univ Laval, Dept Med, Quebec City, PQ, Canada; [Cucherat, Michel] Claude Bernard Univ Lyon 1, Univ Lyon, Lab Biometrie & Biol Evolut, CNRS 5558, F-69100 Lyon, France; [Cucherat, Michel] Hosp Civils Lyon, Dept Pharmacotoxicol, F-69003 Lyon, France; [Lega, Jean-Christophe] Hosp Civils Lyon, Grp Etud Multidisciplinaire Malad Thrombot GEMMAT, Lyon, France		Provencher, S (通讯作者)，Univ Laval, Res Ctr, Inst Univ Cardiol & Pneumol Quebec, Pulm Hypertens Res Grp, 2725 Chemin Ste Foy, Quebec City, PQ G1V 4G5, Canada.	steeve.provencher@criucpq.ulaval.ca	Mainbourg, Sabine/V-1225-2019	Mainbourg, Sabine/0000-0003-4564-2931			Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; ASH, 2020, ASH GUID US ANT PAT; Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Bodilsen J., 2021, CLIN INFECT DIS; Clayton TC, 2011, INT J EPIDEMIOL, V40, P819, DOI 10.1093/ije/dyr012; Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830; Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; Frantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002; Freund Y, 2020, ACAD EMERG MED, V27, P811, DOI 10.1111/acem.14096; Gaertner F, 2016, SEMIN IMMUNOL, V28, P561, DOI 10.1016/j.smim.2016.10.010; Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hofstra JJ, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-43; Iba Toshiaki, 2015, Intensive Care Med Exp, V3, P36, DOI 10.1186/s40635-015-0072-z; Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013; Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650; Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869; Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024; Luo W, 2020, CLIN PATHOLOGY CRITI, DOI 10.13140/RG.2.2.22934.29762; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Mattioli M, 2021, J THROMB THROMBOLYS, V51, P286, DOI 10.1007/s11239-020-02243-z; Mei F, 2020, ARTERIOSCL THROM VAS, V40, P2332, DOI 10.1161/ATVBAHA.120.314779; Monreal M, CHEST; Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559; Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010; Ozolina A, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00064; Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001; Pavoni V, 2020, THROMB RES, V196, P313, DOI 10.1016/j.thromres.2020.09.013; Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430; Potus F, 2020, AM J PHYSIOL-LUNG C, V319, pL277, DOI 10.1152/ajplung.00195.2020; Ribeiro DD, 2012, J THROMB HAEMOST, V10, P1179, DOI 10.1111/j.1538-7836.2012.04732.x; Rieder M, 2020, J THROMB THROMBOLYS, V50, P558, DOI 10.1007/s11239-020-02202-8; Pellegrini JAS, 2021, J THROMB THROMBOLYS, V52, P482, DOI 10.1007/s11239-021-02395-6; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Stessel B, 2020, THROMB RES, V194, P209, DOI 10.1016/j.thromres.2020.07.038; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tan BK, 2021, THORAX, V76, P970, DOI 10.1136/thoraxjnl-2020-215383; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tritschler T, 2020, J THROMB HAEMOST, V18, P2958, DOI 10.1111/jth.15094; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343; Young E, 2008, THROMB RES, V122, P743, DOI 10.1016/j.thromres.2006.10.026; Yu YA, 2020, ANN PALLIAT MED, V9, P1257, DOI 10.21037/apm.2020.04.05	50	7	8	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106882	10.1016/j.vph.2021.106882		JUL 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34087481	Green Published, Bronze			2022-04-29	WOS:000674133600009
J	Bellos, I; Pergialiotis, V; Perrea, DN				Bellos, Ioannis; Pergialiotis, Vasilios; Perrea, Despina N.			Comparative efficacy of fixed-dose statin and antihypertensive agent combinations: A network meta-analysis of randomized controlled trials	VASCULAR PHARMACOLOGY			English	Article						Hypertension; Blood pressure; Lipid-lowering; Dyslipidemia; Fixed-dose; Polypill	IMPAIRED FASTING GLUCOSE; BLOOD-PRESSURE; HYPERTENSIVE PATIENTS; DOUBLE-BLIND; COADMINISTERED AMLODIPINE; SYSTEMATIC REVIEWS; COMBINED THERAPY; RISK-FACTORS; ROSUVASTATIN; ATORVASTATIN	Background: The concurrent administration of statins and antihypertensive agents has been associated with improved cardiovascular outcomes, although the optimal fixed-dose combination remains unclear. This meta-analysis aims to compare the blood pressure and lipid-lowering effects of various statin and antihypertensive drug combinations. Methods: PubMed, Scopus, Web of Science, CENTRAL and Clinicaltrials.gov were systematically searched from inception to 20 March 2021. Randomized controlled trials evaluating the effects of statin-antihypertensive agent combinations on systolic blood pressure or serum lipids were held eligible. A random-effects frequentist model was applied to provide estimates of mean difference of percentage change. Results: Overall, 18 studies were included, comprising 4450 patients. Compared to statin monotherapy no significant difference in the percentage change of low-density lipoprotein cholesterol was achieved by adding any antihypertensive agent. Compared to amlodipine monotherapy, the addition of moderate-intensity statin resulted in a significantly greater percentage reduction of systolic blood pressure (-2.22%, 95% confidence intervals: [-3.82 to 0.62]). Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48 to 0.89]). No significant difference of adverse effects was observed. Conclusion: The present network meta-analysis suggests that the administration of fixed-dose combinations of statins and antihypertensive agents is safe and effective in reducing blood pressure and serum lipids. The optimal dosing strategy to prevent cardiovascular events remains to be determined.	[Bellos, Ioannis; Pergialiotis, Vasilios; Perrea, Despina N.] Natl & Kapodistrian Univ Athens, Univ Athens, Sch Med, Lab Expt Surg & Surg Res NS Christeas, Athens, Greece		Bellos, I (通讯作者)，15B,Ag Thoma Str, Athens 11527, Greece.	bellosg@windowslive.com	Pergialiotis, Vasilios/H-3772-2019	Pergialiotis, Vasilios/0000-0003-4510-1633			Alghamdi J, 2020, EUR J CLIN PHARMACOL, V76, P1745, DOI 10.1007/s00228-020-02965-2; Bellos E, 2017, APPL ENERG, V205, P540, DOI 10.1016/j.apenergy.2017.07.141; Bennett A, 2016, CURR OPIN CARDIOL, V31, P381, DOI 10.1097/HCO.0000000000000293; Briasoulis A, 2013, J CLIN HYPERTENS, V15, P310, DOI 10.1111/jch.12081; Cho KI, 2019, CLIN THER, V41, P1508, DOI 10.1016/j.clinthera.2019.05.007; Choi Y, 2018, DRUG DES DEV THER, V12, P2301, DOI 10.2147/DDDT.S165171; Chung Seyong, 2020, Cardiol J, DOI 10.5603/CJ.a2020.0167; Cicero AFG, 2009, FUND CLIN PHARMACOL, V23, P583, DOI 10.1111/j.1472-8206.2009.00719.x; ClinicalTrials.gov, 2020, NCT04659070 EV EFF S; Cohn JN, 2009, AM J HYPERTENS, V22, P137, DOI 10.1038/ajh.2008.325; Curran MP, 2010, DRUGS, V70, P191, DOI 10.2165/11204420-000000000-00000; Davignon J, 2004, CIRCULATION, V109, P39, DOI 10.1161/01.CIR.0000131517.20177.5a; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Divchev D, 2008, EUR HEART J, V29, P1956, DOI 10.1093/eurheartj/ehn276; Drapala A, 2014, J RENIN-ANGIO-ALDO S, V15, P250, DOI 10.1177/1470320314531058; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fogari R, 2004, AM J HYPERTENS, V17, P823, DOI 10.1016/j.amjhyper.2004.06.005; Fogari R, 2012, EUR J GASTROEN HEPAT, V24, P164, DOI 10.1097/MEG.0b013e32834ba188; Ge CJ, 2008, HEART VESSELS, V23, P91, DOI 10.1007/s00380-007-1008-7; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; Grimm R, 2010, VASC HEALTH RISK MAN, V6, P261; Halperin RO, 2006, HYPERTENSION, V47, P45, DOI 10.1161/01.HYP.0000196306.42418.0e; Han SH, 2007, ATHEROSCLEROSIS, V190, P205, DOI 10.1016/j.atherosclerosis.2006.01.021; Haney E.M., 2007, STAT METHODS USED ME; Herttua K, 2016, J AM COLL CARDIOL, V67, P1507, DOI 10.1016/j.jacc.2016.01.044; Hong BK, 2012, AM J CARDIOVASC DRUG, V12, P189, DOI 10.2165/11597410-000000000-00000; Hong SJ, 2019, CLIN THER, V41, P233, DOI 10.1016/j.clinthera.2018.12.008; Hussein MA, 2010, AM J CARDIOVASC DRUG, V10, P193, DOI 10.2165/11530680-000000000-00000; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247; Jackson D, 2018, STAT MED, V37, P1059, DOI 10.1002/sim.7588; Jackson D, 2016, RES SYNTH METHODS, V7, P329, DOI 10.1002/jrsm.1188; Jang JY, 2015, KOREAN CIRC J, V45, P225, DOI 10.4070/kcj.2015.45.3.225; Juncos LI, 2012, AM J HYPERTENS, V25, P1140, DOI 10.1038/ajh.2012.105; Kim K, 2004, J CLIN PHARMACOL, V44, P1083, DOI 10.1177/0091270004268128; Kim SH, 2016, CLIN THER, V38, P2171, DOI 10.1016/j.clinthera.2016.09.005; Kim TS, 2019, CLIN THER, V41, P728, DOI 10.1016/j.clinthera.2019.02.013; Kim W, 2020, J CLIN HYPERTENS, V22, P261, DOI 10.1111/jch.13774; Koh KK, 2005, HYPERTENSION, V45, P1088, DOI 10.1161/01.HYP.0000166722.91714.ba; Lee HY, 2017, CLIN THER, V39, P2366, DOI 10.1016/j.clinthera.2017.10.013; Lee SI, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212484; Leibovitz E, 2003, AM J HYPERTENS, V16, P715, DOI 10.1016/S0895-7061(03)00949-X; Liberopoulos EN, 2013, J CARDIOVASC PHARM T, V18, P113, DOI 10.1177/1074248412463611; Maejima Y, 2011, CIRC J, V75, P589, DOI 10.1253/circj.CJ-10-0804; Marazzi G, 2016, INT J CARDIOL, V222, P885, DOI 10.1016/j.ijcard.2016.07.163; Mason RP, 2008, PHARM RES-DORDR, V25, P1798, DOI 10.1007/s11095-007-9491-1; Messerli F.H., 2006, J CLIN HYPERTENS GRE, V8; Milionis HJ, 2006, J HUM HYPERTENS, V20, P320, DOI 10.1038/sj.jhh.1002001; Mills KT, 2020, NAT REV NEPHROL, V16, P223, DOI 10.1038/s41581-019-0244-2; Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912; Moon SJ, 2019, DRUG DES DEV THER, V13, P2533, DOI 10.2147/DDDT.S210364; Munoz D, 2019, NEW ENGL J MED, V381, P1114, DOI 10.1056/NEJMoa1815359; Muntner P, 2014, AM J CARDIOL, V114, P826, DOI 10.1016/j.amjcard.2014.06.009; Naito R, 2017, J ATHEROSCLER THROMB, V24, P19, DOI 10.5551/jat.RV16004; Naydenov SN, 2018, ACTA CLIN CROAT, V57, P464, DOI 10.20471/acc.2018.57.03.09; Nikolakopoulou A, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003082; Nwe HH, 2016, CLIN PHARM DRUG DEV, V5, P131, DOI 10.1002/cpdd.214; Oh GC, 2018, CLIN THER, V40, P676, DOI 10.1016/j.clinthera.2018.03.010; Olsson AG, 2002, CARDIOVASC DRUG REV, V20, P303; Park JS, 2016, DRUG DES DEV THER, V10, P2599, DOI 10.2147/DDDT.S112873; Patel BV, 2008, VASC HEALTH RISK MAN, V4, P673; Preston RA, 2007, J CLIN PHARMACOL, V47, P1555, DOI 10.1177/0091270007307879; Rhee MY, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-016-0112-7; Rizos CV, 2015, ANGIOLOGY, V66, P36, DOI 10.1177/0003319713512556; Rizos CV, 2010, CLIN THER, V32, P492, DOI 10.1016/j.clinthera.2010.03.018; Roshandel G, 2019, LANCET, V394, P672, DOI 10.1016/S0140-6736(19)31791-X; Roy A, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0853-y; Rucker G, 2019, R package version 10-1; Rucker G, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0060-8; Srikanth S, 2016, CURR HYPERTENS REP, V18, DOI 10.1007/s11906-016-0683-0; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Thom S, 2013, JAMA-J AM MED ASSOC, V310, P918, DOI 10.1001/jama.2013.277064; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; U.S. Food and Drug Administration, 2011, FDA DRUG SAFETY COMM; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wang Y, 2020, CARDIOLOGY, V145, P802, DOI 10.1159/000508280; Yoon DY, 2020, DRUG DES DEV THER, V14, P661, DOI 10.2147/DDDT.S233014; Yusuf S, 2016, NEW ENGL J MED, V374, P2032, DOI 10.1056/NEJMoa1600177; Zhao BY, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01566-2; Zhou YT, 2014, THER CLIN RISK MANAG, V10, P17, DOI 10.2147/TCRM.S55512	81	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106900	10.1016/j.vph.2021.106900		NOV 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34343694				2022-04-29	WOS:000756079500003
J	Theofilis, P; Oikonomou, E; Vogiatzi, G; Antonopoulos, AS; Siasos, G; Iliopoulos, DC; Perrea, D; Tsioufis, C; Tousoulis, D				Theofilis, Panagiotis; Oikonomou, Evangelos; Vogiatzi, Georgia; Antonopoulos, Alexios S.; Siasos, Gerasimos; Iliopoulos, Dimitrios C.; Perrea, Despoina; Tsioufis, Costas; Tousoulis, Dimitris			The impact of proangiogenic microRNA modulation on blood flow recovery following hind limb ischemia. A systematic review and meta-analysis of animal studies	VASCULAR PHARMACOLOGY			English	Review						microRNA; Angiogenesis; Hind limb ischemia; Laser Doppler perfusion imaging	PERIPHERAL ARTERIAL-DISEASE; INDUCED NEOVASCULARIZATION; REGULATES ANGIOGENESIS; EXPRESSION; EXOSOMES; MIR-214	Background: Pro-angiogenic microRNA modulation is a potentially attractive approach in the management of peripheral artery disease (PAD). The aim of this systematic review and meta-analysis was to examine the impact of microRNAs involved in the process of angiogenesis on blood flow recovery following hind limb ischemia induction in animal models. Methods: A literature search was performed to identify studies testing the efficacy of microRNA treatment on animal models of hind limb ischemia. Following that, a meta-analysis of the included studies was executed with the primary outcome being the change in ischemic-to-normal hind limb perfusion ratio assessed via laser Doppler imaging. Moreover, risk of bias, sensitivity analysis and publication bias were evaluated. Results: Studies evaluation led to the inclusion of 18 studies whose meta-analysis suggested that microRNA treatment resulted in improved ischemic hind limb perfusion 7 [standardized mean difference (SMD): 0.93, 95% CI 0.49-1.38], 14 (SMD: 1.31, 95% CI 0.78-1.84), and 21 days (SMD: 1.13, 95% CI 0.59-1.66) after hind limb ischemia induction. Moderate-to-substantial heterogeneity and possible publication bias were noted. Risk of bias was unclear despite the balanced baseline animal characteristics. Conclusion: The present meta-analysis suggests that pro-angiogenic modulation of microRNAs accelerates vascular perfusion recovery in animal models of acute hind limb ischemia. Further studies on animal models with similar characteristics to that of PAD patients are warranted to translate those findings in human PAD setting.	[Theofilis, Panagiotis; Oikonomou, Evangelos; Vogiatzi, Georgia; Antonopoulos, Alexios S.; Siasos, Gerasimos; Tsioufis, Costas; Tousoulis, Dimitris] Univ Athens, Sch Med, Hippokrat Gen Hosp, Dept Cardiol 1, Athens, Greece; [Oikonomou, Evangelos; Vogiatzi, Georgia; Siasos, Gerasimos] Univ Athens, Sch Med, Sotiria Reg Hosp Chest Dis, Dept Cardiol 3, Athens, Greece; [Iliopoulos, Dimitrios C.; Perrea, Despoina] Univ Athens, Sch Med, Lab Expt Surg & Surg Res NS Christeas, Athens, Greece		Oikonomou, E (通讯作者)，Vas Sophias 114, Athens, Greece.	boikono@med.uoa.gr	Siasos, Gerasimos/AAD-7218-2019; Theofilis, Panagiotis/ABF-1450-2021	Siasos, Gerasimos/0000-0001-7601-8870; Theofilis, Panagiotis/0000-0001-9260-6306			Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095; Barc P, 2021, J CARDIOVASC TRANSL, V14, P409, DOI 10.1007/s12265-020-10066-9; Beltrami C, 2017, MOL THER, V25, P679, DOI 10.1016/j.ymthe.2016.12.022; Besnier M, 2019, MOL THER-NUCL ACIDS, V17, P49, DOI 10.1016/j.omtn.2019.05.002; Caporali A, 2011, CIRCULATION, V123, P282, DOI 10.1161/CIRCULATIONAHA.110.952325; Chen LD, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180346; Chen LD, 2017, EXP BIOL MED, V242, P1432, DOI 10.1177/1535370217716424; Cheng R, 2015, REV ENDOCR METAB DIS, V16, P67, DOI 10.1007/s11154-015-9310-7; Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014; Desjarlais M, 2019, ATHEROSCLEROSIS, V289, P73, DOI 10.1016/j.atherosclerosis.2019.08.010; Desjarlais M, 2017, ARTERIOSCL THROM VAS, V37, P900, DOI 10.1161/ATVBAHA.117.309189; Dhahri W, 2020, AGING-US, V12, P10180, DOI 10.18632/aging.103340; Dhahri W, 2017, J CELL MOL MED, V21, P2211, DOI 10.1111/jcmm.13144; Economou EK, 2015, ATHEROSCLEROSIS, V241, P624, DOI 10.1016/j.atherosclerosis.2015.06.037; Gerhardt Holger, 2008, P68, DOI 10.1007/978-0-387-78632-2_6; Hazarika S, 2013, CIRCULATION, V127, P1818, DOI 10.1161/CIRCULATIONAHA.112.000860; Heuslein JL, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00001; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Hsu PY, 2017, J CELL MOL MED, V21, P519, DOI 10.1111/jcmm.12997; Jin Y, 2015, MOL CELL BIOCHEM, V402, P111, DOI 10.1007/s11010-014-2319-5; Kesidou D, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.579892; Krishna SM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60352-4; Li XT, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1413-8; Li YY, 2021, LAB INVEST, V101, P104, DOI 10.1038/s41374-020-0450-3; Lu DC, 2019, NAT REV CARDIOL, V16, P661, DOI 10.1038/s41569-019-0218-x; Lu WJ, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00223; Luo Yu-Fang, 2020, Aging (Albany NY), V13, P1186, DOI 10.18632/aging.202257; Ma T, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3290372; Marchetti M., 2020, INT J MOL SCI, V21; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mustapha JA, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009724; Oppi S, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00046; Pan QW, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2912347; Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x; Shi YF, 2020, MOL MED REP, V22, P4890, DOI 10.3892/mmr.2020.11538; Shu XJ, 2019, MOL MED REP, V19, P5195, DOI 10.3892/mmr.2019.10196; Siasos G, 2020, HELL J CARDIOL, V61, P165, DOI 10.1016/j.hjc.2020.03.003; Siasos G, 2014, EXPERT REV CARDIOVAS, V12, P311, DOI 10.1586/14779072.2014.890516; Spinetti G, 2013, CIRC RES, V112, DOI 10.1161/CIRCRESAHA.111.300418; Sz T., REGEN MED, V15, P1761; Tang Y, 2015, FEBS J, V282, P3758, DOI 10.1111/febs.13372; Tsumaru S, 2018, J VASC SURG, V68, P1209, DOI 10.1016/j.jvs.2017.08.097; van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood-2013-02-478925; Veliceasa D, 2015, VASC CELL, V7, DOI 10.1186/s13221-015-0031-1; Vogiatzi G, 2018, CURR OPIN PHARMACOL, V39, P105, DOI 10.1016/j.coph.2018.04.001; Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747; Wu QQ, 2021, BOSNIAN J BASIC MED, V21, P71, DOI 10.17305/bjbms.2019.4493; Zhang JF, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9366; Zheng DD, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.616161	50	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106906	10.1016/j.vph.2021.106906		NOV 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34509635				2022-04-29	WOS:000756079500008
J	Wang, H; Chen, L; Wang, SX; Tian, XX; Zhang, LS; Li, HY; Li, CX; Xue, YJ; Wang, QY; Fang, LY; Yang, WJ; Sun, W; Leng, YZ; Li, MY; Gao, XM				Wang, Hong; Chen, Lu; Wang, Shaoxia; Tian, Xiaoxuan; Zhang, Lusha; Li, Huiying; Li, Chunxiao; Xue, Yuejin; Wang, Qianyi; Fang, Leyu; Yang, Wenjie; Sun, Wei; Leng, Yuze; Li, Mengyao; Gao, Xiumei			Tetrandrine promotes angiogenesis via transcriptional regulation of VEGF-A	VASCULAR PHARMACOLOGY			English	Article						Tetrandrine; Angiogenesis; VEGF-A; Ischemic diseases; A distant regulatory element	RADIX-STEPHANIAE-TETRANDRAE; FACTOR MESSENGER-RNA; THERAPEUTIC ANGIOGENESIS; CLINICAL-APPLICATIONS; HYPOXIA; GENE; APOPTOSIS; CA2+	Angiogenesis is crucial for tissue damage repair in ischemic cardiovascular diseases. Vascular endothelial growth factor A (VEGF-A) acts as a vital mediator in angiogenesis. In this study, tetrandrine (Tet) was found from 23 herbal chemicals to increase VEGF-A mRNA expression in H9c2 cells and the effect was confirmed in freshly isolated neonatal rat cardiomyocytes. The effect of Tet on VEGF-A expression and the possible mechanism were investigated. Tet treatment increased de novo VEGF-A mRNA synthesis and did not affect VEGF-A mRNA stability. The circulating chromosome conformation capture (4C) experiments indicated that Tet enhanced VEGF-A transcription by targeting a regulatory element beyond the 2.6 kb region of the translation start site. Tet augmented the angiogenic activities of endothelial cells. It also enhanced blood flow restoration and capillary vessel density following ischemic limb injury associated with an escalation of VEGF-A expression. Moreover, in myocardial infarction (MI) model Tet treatment elevated neovascularization, reduced infarction size, and improved heart function via upregulating VEGF-A levels. Our results suggested that Tet increased VEGF-A transcription through a novel mechanism that likely involves a distant regulatory element and may be useful for therapeutic angiogenesis for ischemic diseases.	[Wang, Hong; Chen, Lu; Wang, Shaoxia; Tian, Xiaoxuan; Zhang, Lusha; Li, Huiying; Li, Chunxiao; Xue, Yuejin; Wang, Qianyi; Fang, Leyu; Yang, Wenjie; Sun, Wei; Leng, Yuze; Li, Mengyao; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, State Key Lab Componentbased Chinese Med, Tianjin 301617, Peoples R China; [Wang, Hong; Chen, Lu; Wang, Shaoxia; Tian, Xiaoxuan; Zhang, Lusha; Li, Huiying; Li, Chunxiao; Xue, Yuejin; Wang, Qianyi; Fang, Leyu; Yang, Wenjie; Sun, Wei; Leng, Yuze; Li, Mengyao; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Tianjin 301617, Peoples R China; [Wang, Hong; Chen, Lu; Wang, Shaoxia; Tian, Xiaoxuan; Zhang, Lusha; Li, Huiying; Li, Chunxiao; Xue, Yuejin; Wang, Qianyi; Fang, Leyu; Yang, Wenjie; Sun, Wei; Leng, Yuze; Li, Mengyao; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Chinese Med Pharmacol, Tianjin 301617, Peoples R China; [Wang, Hong; Wang, Shaoxia; Zhang, Lusha; Xue, Yuejin; Wang, Qianyi; Fang, Leyu; Yang, Wenjie; Sun, Wei; Leng, Yuze; Li, Mengyao] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, 10 Poyanghu Rd,West Area,Tuanbo New Town, Tianjin 301617, Peoples R China; [Chen, Lu; Tian, Xiaoxuan] Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Tianjin 301617, Peoples R China		Wang, H (通讯作者)，Tianjin Univ Tradit Chinese Med, Sch Integrat Med, 10 Poyanghu Rd,West Area,Tuanbo New Town, Tianjin 301617, Peoples R China.	wanghongsys@tjutcm.edu.cn; gaoxiumei@tjutcm.edu.cn			National Key Research and Development Program of China [2018YFC1704500]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81630106]	This work was supported by the National Key Research and Development Program of China (2018YFC1704500) and National Natural Science Foundation of China (81630106).	Annex BH, 2013, NAT REV CARDIOL, V10, P387, DOI 10.1038/nrcardio.2013.70; Atluri P, 2008, BIODRUGS, V22, P209, DOI 10.2165/00063030-200822040-00001; Badimon L, 2018, CURR PHARM DESIGN, V24, P2967, DOI 10.2174/1381612824666180629162726; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cha L, 1981, Zhongguo Yao Li Xue Bao, V2, P26; CHEN NH, 1991, ACTA PHARMACOL SIN, V12, P488; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cui GZ, 2018, PHARMACOL RES, V134, P109, DOI 10.1016/j.phrs.2018.06.005; Dai CL, 2007, CANCER CHEMOTH PHARM, V60, P741, DOI 10.1007/s00280-007-0420-0; Daschil N, 2015, NEUROBIOL AGING, V36, P1333, DOI 10.1016/j.neurobiolaging.2014.12.027; FANG DC, 1986, CHINESE MED J-PEKING, V99, P638; FARNSWORTH NR, 1976, AM J PHARM, V148, P46; FELIX JP, 1992, BIOCHEMISTRY-US, V31, P11793, DOI 10.1021/bi00162a017; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Jang BC, 2004, BIOCHEM PHARMACOL, V67, P1819, DOI 10.1016/j.bcp.2004.01.018; Kobayashi S, 1999, BIOL PHARM BULL, V22, P360, DOI 10.1248/bpb.22.360; Krishna SM, 2015, INT J MOL SCI, V16, P11294, DOI 10.3390/ijms160511294; Lee JH, 2002, INT J ONCOL, V21, P1239; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7; Nishizawa T, 2010, J HYPERTENS, V28, P1515, DOI 10.1097/HJH.0b013e328339fd3a; Onesto C, 2004, J BIOL CHEM, V279, P34217, DOI 10.1074/jbc.M400219200; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577; Rao MR, 2002, ACTA PHARMACOL SIN, V23, P1075; Raskin I, 2004, CURR PHARM DESIGN, V10, P3419, DOI 10.2174/1381612043383070; Shen DF, 2010, BRIT J PHARMACOL, V159, P970, DOI 10.1111/j.1476-5381.2009.00605.x; Shen YC, 1999, BRIT J PHARMACOL, V128, P1593, DOI 10.1038/sj.bjp.0702958; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226; SUTTER MC, 1993, CARDIOVASC RES, V27, P1891, DOI 10.1093/cvr/27.11.1891; TAKEMURA H, 1995, RES COMMUN MOL PATH, V90, P59; Takemura H, 1996, CLIN EXP PHARMACOL P, V23, P751, DOI 10.1111/j.1440-1681.1996.tb01772.x; WANG G, 1994, LIFE SCI, V56, P295, DOI 10.1016/0024-3205(94)00952-X; Wang JX, 2011, NAT MED, V17, P71, DOI 10.1038/nm.2282; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Wong TM, 2000, ACTA PHARMACOL SIN, V21, P1083; Yao W X, 1995, Yao Xue Xue Bao, V30, P651; Yla-Herttuala S, 2007, J AM COLL CARDIOL, V49, P1015, DOI 10.1016/j.jacc.2006.09.053; Yla-Herttuala S, 2017, EUR HEART J, V38, P1365, DOI 10.1093/eurheartj/ehw547; Yu S L, 1986, Zhonghua Yi Xue Za Zhi, V66, P29; Yu S L, 1982, Acta Acad Med Wuhan, V2, P144; Yu XC, 2001, LIFE SCI, V68, P2863, DOI 10.1016/S0024-3205(01)01067-0; Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891	48	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106920	10.1016/j.vph.2021.106920		NOV 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34592429				2022-04-29	WOS:000756079500011
J	Song, JL; Zheng, SY; He, RL; Gui, LX; Lin, MJ; Sham, JSK				Song, Jia-Lin; Zheng, Si-Yi; He, Rui-Lan; Gui, Long-Xin; Lin, Mo-Jun; Sham, James S. K.			Serotonin and chronic hypoxic pulmonary hypertension activate a NADPH oxidase 4 and TRPM2 dependent pathway for pulmonary arterial smooth muscle cell proliferation and migration	VASCULAR PHARMACOLOGY			English	Article						NADPH oxidase 4; Chronic hypoxia; Pulmonary hypertension; Reactive oxygen species; Transient potential receptor melastatin 2&amp; nbsp; (TRPM2)	PDGF-BETA RECEPTOR; SIGNALING MECHANISMS; OXIDATIVE STRESS; NOX4 EXPRESSION; UP-REGULATION; SUBUNIT NOX4; PPAR-GAMMA; CHANNEL; TRANSPORTER; CA2+	5-Hydroxytryptamine (5-HT)-dependent signaling mediated through its transporters and receptors plays important roles in chronic hypoxic pulmonary hypertension (CHPH), which is associated with aberrant reactive oxygen species (ROS) production. NADPH oxidase 4 (NOX4) is one of the major sources of ROS in pulmonary vasculature, and has been implicated in the development of PH. NOX4 generates H2O2, which can activate the transient receptor potential melastatin 2 (TRPM2) channels, providing Ca2+ signals for cell proliferation and migration. However, the connection between 5-HT, NOX4, ROS and TRPM2 in the context of PH has not been established. Here we examined the level of 5-HT and expression of NOX4 and TRPM2, and their roles in pulmonary arterial smooth muscle cells (PASMCs) proliferation and migration. NOX4 and TRPM2 were upregulated in pulmonary arteries of CHPH rats, which were associated with elevated levels of 5-HT and ROS, and enhanced proliferation and migration in PASMCs. The increase in ROS, and the enhanced proliferation and migration of PASMCs from CHPH rats were mimicked by treating normoxic PASMCs with 5-HT. 5-HT; and CH-induced ROS production were reversed by catalase, the NOX1/NOX4 inhibitor GKT137831, and Nox4 siRNA. 5-HT and H2O2 elicited Ca2+ responses were significantly augmented in CHPH PASMCs; and the augmented Ca2+ responses were obliterated by the 2-Aminoethoxydiphenyl borate (2-APB) and Trpm2-specific siRNA. Moreover, 5-HT and CHinduced proliferation and migration were suppressed by Nox4 or Trpm2 siRNA; and simultaneous transfection of both siRNA did not cause further inhibition. These results suggest that the 5-HT and CH-induced PASMC proliferation and migration were mediated, at least in part, by TRPM2 via activation of NOX4-dependent ROS production; and revealed a novel NOX4-ROS-TRPM2 signaling pathway for the pathogenesis of CHPH.	[Song, Jia-Lin; Zheng, Si-Yi; He, Rui-Lan; Gui, Long-Xin; Lin, Mo-Jun] Fujian Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Key Lab Fujian Prov Univ Ion Channel & Signal Tra, Fuzhou, Fujian, Peoples R China; [Sham, James S. K.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA		Sham, JSK (通讯作者)，Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.; Lin, MJ (通讯作者)，Fujian Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, 1 Xueyuan Rd, Fuzhou 350108, Fujian, Peoples R China.	mjlin@mail.fjmu.edu.cn; jsks@jhmi.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC31571179]; Joint Funds for Innovation of Science and Technology, Fujian province, China [2019Y9004]	This work was supported by grants from the National Natural Science Foundation of China (NSFC31571179) and Joint Funds for Innovation of Science and Technology, Fujian province, China (2019Y9004) to MJL.	Alves-Lopes R, 2020, HYPERTENSION, V75, P139, DOI 10.1161/HYPERTENSIONAHA.119.13861; Barman SA, 2017, ADV EXP MED BIOL, V967, P1, DOI 10.1007/978-3-319-63245-2_1; Barman SA, 2014, ARTERIOSCL THROM VAS, V34, P1704, DOI 10.1161/ATVBAHA.114.303848; Bijli KM, 2015, FREE RADICAL BIO MED, V80, P111, DOI 10.1016/j.freeradbiomed.2014.12.019; Brandes RP, 2010, FREE RADICAL BIO MED, V49, P687, DOI 10.1016/j.freeradbiomed.2010.04.030; Bubolz AH, 2012, AM J PHYSIOL-HEART C, V302, pH634, DOI 10.1152/ajpheart.00717.2011; Chen SJ, 2013, AM J PHYSIOL-CELL PH, V304, pC548, DOI 10.1152/ajpcell.00069.2012; Diebold I, 2011, MOL BIOL CELL, V22, P4424, DOI 10.1091/mbc.E10-12-0971; Diebold I, 2010, MOL BIOL CELL, V21, P2087, DOI 10.1091/mbc.E09-12-1003; Dumitrascu R, 2011, EUR RESPIR J, V37, P1104, DOI 10.1183/09031936.00126010; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI200112805; Gao GF, 2014, J CLIN INVEST, V124, P4989, DOI 10.1172/JCI76042; Gu JZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep43546; Hack CT, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110518; Han XY, 2015, MICROVASC RES, V100, P17, DOI 10.1016/j.mvr.2015.04.008; Hecquet CM, 2014, CIRC RES, V114, P469, DOI 10.1161/CIRCRESAHA.114.302414; Hecquet CM, 2010, ADV EXP MED BIOL, V661, P155, DOI 10.1007/978-1-60761-500-2_10; Hecquet CM, 2009, THROMB HAEMOSTASIS, V101, P619, DOI 10.1160/TH08-10-0641; Homma N, 2007, J CARDIOVASC PHARM, V50, P697, DOI 10.1097/FJC.0b013e3181593774; Hood KY, 2017, ARTERIOSCL THROM VAS, V37, P1361, DOI 10.1161/ATVBAHA.116.308929; Hood KY, 2016, HYPERTENSION, V68, P796, DOI 10.1161/HYPERTENSIONAHA.116.07668; Huang YH, 2018, NATURE, V562, P145, DOI 10.1038/s41586-018-0558-4; Huetsch JC, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8030056; Ismail S, 2009, AM J PHYSIOL-LUNG C, V296, pL489, DOI 10.1152/ajplung.90488.2008; Jaitovich A, 2017, ADV EXP MED BIOL, V967, P71, DOI 10.1007/978-3-319-63245-2_6; Ke R, 2017, ONCOTARGET, V8, P72910, DOI 10.18632/oncotarget.20582; Kurrasch-Orbaugh DM, 2003, J PHARMACOL EXP THER, V304, P229, DOI 10.1124/jpet.102.042184; Kurrasch-Orbaugh DM, 2003, J NEUROCHEM, V86, P980, DOI 10.1046/j.1471-4159.2003.01921.x; Kylhammar D, 2017, ACTA PHYSIOL, V219, P728, DOI 10.1111/apha.12749; Lassegue B, 2012, CIRC RES, V110, P1364, DOI 10.1161/CIRCRESAHA.111.243972; Lawrie A, 2005, CIRC RES, V97, P227, DOI 10.1161/01.RES.0000176025.57706.1e; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Li FF, 2016, J CELL SCI, V129, P2016, DOI 10.1242/jcs.179796; Li Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149164; Li S, 2008, ANTIOXID REDOX SIGN, V10, P1687, DOI 10.1089/ars.2008.2035; Li X, 2019, J CELL PHYSIOL, V234, P3647, DOI 10.1002/jcp.27134; Lin M.J., AM J PHYSIOL, V292; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Liu JQ, 2005, CHEST, V128, p594S, DOI 10.1378/chest.128.6_suppl.594S; Liu JQ, 2006, AM J PHYSIOL-LUNG C, V290, pL2, DOI 10.1152/ajplung.00135.2005; Liu JQ, 2004, AM J PHYSIOL-LUNG C, V287, pL111, DOI 10.1152/ajplung.00006.2004; Liu YL, 2007, FASEB J, V21, P2725, DOI 10.1096/fj.06-8058com; Liu YL, 2011, AM J RESP CELL MOL, V44, P548, DOI 10.1165/rcmb.2010-0078OC; Lu W, 2017, SLEEP BREATH, V21, P667, DOI 10.1007/s11325-016-1449-2; Lu XH, 2013, FREE RADICAL BIO MED, V63, P151, DOI 10.1016/j.freeradbiomed.2013.05.013; Lu XH, 2010, AM J PHYSIOL-LUNG C, V299, pL559, DOI 10.1152/ajplung.00090.2010; MacLean MR, 2010, ADV EXP MED BIOL, V661, P309, DOI 10.1007/978-1-60761-500-2_20; Martinotti S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030808; Miller BA, 2019, CELL CALCIUM, V80, P8, DOI 10.1016/j.ceca.2019.03.002; Miller BA, 2016, J PHYSIOL-LONDON, V594, P4181, DOI 10.1113/JP270934; Mittal M, 2007, CIRC RES, V101, P258, DOI 10.1161/CIRCRESAHA.107.148015; Mortadza SAS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00407; Mortadza SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45032; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Ren WY, 2011, AM J PHYSIOL-LUNG C, V300, pL486, DOI 10.1152/ajplung.00237.2010; Schroder K, 2012, CIRC RES, V110, P1217, DOI 10.1161/CIRCRESAHA.112.267054; Shimoda L, 1998, AM J PHYSIOL-LUNG C, V274, pL842, DOI 10.1152/ajplung.1998.274.5.L842; Simonneau G, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01913-2018; Sita G, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7070082; Song D, 2005, ACTA PHARMACOL SIN, V26, P563, DOI 10.1111/j.1745-7254.2005.00071.x; Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005; Sumoza-Toledo A, 2011, J PHYSIOL-LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855; Takahashi N, 2011, CELL CALCIUM, V50, P279, DOI 10.1016/j.ceca.2011.04.006; Van Buul JD, 2005, ANTIOXID REDOX SIGN, V7, P308, DOI 10.1089/ars.2005.7.308; Veit F, 2013, ANTIOXID REDOX SIGN, V19, P2213, DOI 10.1089/ars.2012.4904; Wang EL, 2019, EUR J PHARMACOL, V857, DOI 10.1016/j.ejphar.2019.172459; Weissmann N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1660; Xia Y, 2014, HYPERTENSION, V63, P173, DOI 10.1161/HYPERTENSIONAHA.113.01902; Xia Y, 2013, AM J PHYSIOL-CELL PH, V305, pC704, DOI 10.1152/ajpcell.00099.2013; Yang KT, 2006, CELL DEATH DIFFER, V13, P1815, DOI 10.1038/sj.cdd.4401813; Yang XR, 2012, AM J PHYSIOL-LUNG C, V302, pL555, DOI 10.1152/ajplung.00005.2011; Yang XR, 2006, AM J PHYSIOL-LUNG C, V290, pL1267, DOI 10.1152/ajplung.00515.2005; Yin Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11733-5; You BY, 2018, CARDIOVASC RES, V114, P188, DOI 10.1093/cvr/cvx234; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912	76	1	1	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106860	10.1016/j.vph.2021.106860		MAY 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33794383	hybrid			2022-04-29	WOS:000652840900004
J	Kerage, D; Gombos, RB; Wang, SM; Brown, M; Hemmings, DG				Kerage, Daniel; Gombos, Randi B.; Wang, Shaomeng; Brown, Meagan; Hemmings, Denise G.			Sphingosine 1-phosphate-induced nitric oxide production simultaneously controls endothelial barrier function and vascular tone in resistance arteries	VASCULAR PHARMACOLOGY			English	Article						Endothelial permeability; eNOS knockout mice; Pressure myograph; Dilation; Constriction	KNOCKOUT MICE; GROWTH-FACTOR; SYNTHASE; SPHINGOSINE-1-PHOSPHATE; PERMEABILITY; ENOS; ACTIVATION; RAT; UTERINE; RESPONSES	The regulations of endothelial permeability and vascular tone by sphingosine 1-phosphate (S1P) have been wellstudied independently. Little is known about whether the effects of S1P on endothelial permeability can directly influence vascular tone in resistance arteries, which impact blood flow. The endothelium forms a partial barrier that regulates access of circulating agonists to underlying vascular smooth muscle cells (VSMCs). We hypothesized that physiological concentrations of circulating S1P simultaneously control endothelial barrier function and vascular tone through endothelial production of nitric oxide (NO). We adapted the pressure myograph system to simultaneously measure both functions in pressurized mesenteric compared to uterine resistance arteries from wild-type and eNOS KO mice. We established that: 1) S1P interacting directly with the endothelium inside pressurized arteries generates NO that limits endothelial permeability; 2) an intact endothelium forms a partial physical barrier that regulates access of intraluminal S1P to the underlying VSMCs and 3) S1P infused lumenally also generates NO through eNOS that counterbalances the constriction induced by S1P that is able to access VSMCs and this is critical to control vascular tone. We conclude that targeting the S1P signaling system, particularly the capacity to produce NO could be clinically important in the treatment of vascular diseases.	[Kerage, Daniel; Wang, Shaomeng; Brown, Meagan; Hemmings, Denise G.] Univ Alberta, Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada; [Kerage, Daniel; Gombos, Randi B.; Wang, Shaomeng; Brown, Meagan; Hemmings, Denise G.] Univ Alberta, Obstet & Gynecol, Edmonton, AB T6G 2S2, Canada; [Gombos, Randi B.] Univ Alberta, Physiol, Edmonton, AB T5G 2H7, Canada; [Kerage, Daniel; Gombos, Randi B.; Hemmings, Denise G.] Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB T6G 1C9, Canada; [Hemmings, Denise G.] Univ Alberta, Cardiovasc Res Ctr, Edmonton, AB T6G 2S2, Canada; [Hemmings, Denise G.] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB T6G 2E1, Canada		Hemmings, DG (通讯作者)，Univ Alberta, Dept Obstet & Gynecol, 227 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	denise.hemmings@ualberta.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP123488]; Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [356087-2008]; Women and Children's Health Research Institute (WCHRI) at the University of Alberta; CIHRCanadian Institutes of Health Research (CIHR) [MOP123488]; WCHRI; University of AlbertaUniversity of Alberta; Alberta Innovates-Health Solutions; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by the Canadian Institutes of Health Research (CIHR) (MOP123488) , the Natural Sciences and Engineering Research Council of Canada (NSERC) (356087-2008) and the Women and Children's Health Research Institute (WCHRI) at the University of Alberta. D. Kerage was supported by CIHR (MOP123488) . R.B. Gombos was supported by graduate studentships from NSERC, WCHRI and the University of Alberta. S. Wang was supported by two summer student-ships from Alberta Innovates-Health Solutions and WCHRI. M. Brown was supported by a summer studentship from NSERC.	Abbasi Taimur, 2013, Handb Exp Pharmacol, P201, DOI 10.1007/978-3-7091-1511-4_10; Adamson RH, 2014, AM J PHYSIOL-HEART C, V306, pH1011, DOI 10.1152/ajpheart.00829.2013; Adamson RH, 2010, CARDIOVASC RES, V88, P344, DOI 10.1093/cvr/cvq184; Arenas IA, 2006, AM J PHYSIOL-HEART C, V290, pH1259, DOI 10.1152/ajpheart.00990.2005; Argraves KM, 2008, J BIOL CHEM, V283, P25074, DOI 10.1074/jbc.M801214200; Ashina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132367; Blaho VA, 2014, J LIPID RES, V55, P1596, DOI 10.1194/jlr.R046300; Bode C, 2010, J CELL BIOCHEM, V109, P1232, DOI 10.1002/jcb.22507; BOUGHTONSMITH NK, 1993, BRIT J PHARMACOL, V110, P1189, DOI 10.1111/j.1476-5381.1993.tb13940.x; Brandes RP, 2000, HYPERTENSION, V35, P231, DOI 10.1161/01.HYP.35.1.231; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Cantalupo A, 2017, HYPERTENSION, V70, P426, DOI 10.1161/HYPERTENSIONAHA.117.09088; Celia G, 2005, J VASC RES, V42, P47, DOI 10.1159/000082976; Chakrabarti S, 2012, J LEUKOCYTE BIOL, V91, P947, DOI 10.1189/jlb.1011513; Chlopicki S, 2005, J CARDIOVASC PHARM, V46, P115, DOI 10.1097/01.fjc.0000164093.88821.00; Cui H, 2013, J ALLERGY CLIN IMMUN, V132, P1205, DOI 10.1016/j.jaci.2013.07.026; Curry FRE, 2010, CARDIOVASC RES, V87, P218, DOI 10.1093/cvr/cvq115; Di Lorenzo A, 2013, J CELL SCI, V126, P5541, DOI 10.1242/jcs.115972; Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139; Edwards RG, 1995, HUM REPROD, V10, P60, DOI 10.1093/humrep/10.suppl_2.60; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gandy K Alexa Orr, 2013, Handb Exp Pharmacol, P275, DOI 10.1007/978-3-7091-1511-4_14; Godecke A, 2000, BASIC RES CARDIOL, V95, P492, DOI 10.1007/s003950070026; Gombos RB, 2009, AM J PHYSIOL-HEART C, V296, pH937, DOI 10.1152/ajpheart.01027.2008; Gombos RB, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.099168; Gombos RB, 2010, AM J PHYSIOL-HEART C, V299, pH1124, DOI 10.1152/ajpheart.01113.2009; Hatakeyama T, 2006, J PHYSIOL-LONDON, V574, P275, DOI 10.1113/jphysiol.2006.108175; Hemmings DG, 2006, N-S ARCH PHARMACOL, V373, P18, DOI 10.1007/s00210-006-0046-5; Hemmings DG, 2005, BIOL REPROD, V72, P997, DOI 10.1095/biolreprod.104.035675; Hemmings DG, 2004, BRIT J PHARMACOL, V143, P276, DOI 10.1038/sj.bjp.0705752; Hisano Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038941; Hottinger Daniel G, 2014, J Anaesthesiol Clin Pharmacol, V30, P462, DOI 10.4103/0970-9185.142799; Jozefczuk E, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104793; Kerage D, 2014, PLACENTA, V35, pS86, DOI 10.1016/j.placenta.2013.12.006; Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833; Levkau B, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00243; Li Q, 2015, EXP PHYSIOL, V100, P95, DOI 10.1113/expphysiol.2014.082149; Li X, 2008, BLOOD, V111, P3489, DOI 10.1182/blood-2007-05-092148; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Marfia G, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013424; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Matsuki T, 2000, MICROCIRCULATION, V7, P411, DOI 10.1038/sj.mn.7300128; May JM, 2011, BIOCHEM BIOPH RES CO, V404, P701, DOI 10.1016/j.bbrc.2010.12.046; Meng W, 1996, AM J PHYSIOL-HEART C, V271, pH1145, DOI 10.1152/ajpheart.1996.271.3.H1145; Minnear FL, 2005, AM J PHYSIOL-HEART C, V289, pH840, DOI 10.1152/ajpheart.00026.2005; Moss E, 2010, J PHARMACOL TOX MET, V62, P40, DOI 10.1016/j.vascn.2010.04.008; Nakane M, 2002, INT J IMPOT RES, V14, P121, DOI 10.1038/sj.ijir.3900843; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Osol G, 2008, AM J PHYSIOL-HEART C, V294, pH1381, DOI 10.1152/ajpheart.00922.2007; Paul JJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040928; Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004; Rosen H, 2009, ANNU REV BIOCHEM, V78, P743, DOI 10.1146/annurev.biochem.78.072407.103733; Roviezzo F, 2006, FASEB J, V20, P340, DOI 10.1096/fj.05-4647fje; Saba JD, 2019, J LIPID RES, V60, P456, DOI 10.1194/jlr.S091181; Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Sladek SM, 1997, AM J PHYSIOL-REG I, V272, pR441, DOI 10.1152/ajpregu.1997.272.2.R441; Snider AJ, 2010, BIOCHIMIE, V92, P707, DOI 10.1016/j.biochi.2010.02.008; Sun XG, 2012, AM J RESP CELL MOL, V47, P628, DOI 10.1165/rcmb.2012-0048OC; Talukder MAH, 2004, J CARDIOVASC PHARM, V44, P437, DOI 10.1097/01.fjc.0000139450.64337.cd; Tolle M, 2016, BIOCHEM BIOPH RES CO, V476, P627, DOI 10.1016/j.bbrc.2016.06.009; Wilkerson BA, 2012, J BIOL CHEM, V287, P44645, DOI 10.1074/jbc.M112.423426; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Xiong YQ, 2014, CURR TOP MICROBIOL, V378, P85, DOI 10.1007/978-3-319-05879-5_4; YUAN Y, 1992, AM J PHYSIOL, V263, pH641, DOI 10.1152/ajpheart.1992.263.2.H641; Zhang GQ, 2010, AM J PHYSIOL-HEART C, V299, pH1494, DOI 10.1152/ajpheart.00462.2010; Zhang GQ, 2013, BLOOD, V122, P443, DOI 10.1182/blood-2012-11-467191	67	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106874	10.1016/j.vph.2021.106874		SEP 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	34004349				2022-04-29	WOS:000709412300008
J	de Oliveira, HT; Couto, GK; Davel, AP; Xavier, FE; Rossoni, LV				de Oliveira, Helane Tito; Couto, Gisele Kruger; Davel, Ana Paula; Xavier, Fabiano Elias; Rossoni, Luciana Venturini			Chronic cyclooxygenase-2 inhibition prevents the worsening of hypertension and endothelial dysfunction induced by ouabain in resistance arteries of spontaneously hypertensive rats	VASCULAR PHARMACOLOGY			English	Article						Ouabain; Hypertension; Cyclooxygenase-2; Thromboxane A2; Resistance arteries	K+-ATPASE ACTIVITY; NF-KAPPA-B; BLOOD-PRESSURE; NA+/K+-ATPASE; RECEPTOR; ACTIVATION; EXPRESSION; SIGNAL; NA+,K+-ATPASE; INCREASES	Aim: Previous studies raise cyclooxygenase (COX) activation as a possible mechanism involved in the pathophysiology of ouabain-induced hypertension. We hypothesized that inhibition of COX-2 activity might prevent ouabain-induced vascular dysfunction and worsening of hypertension in spontaneously hypertensive rats (SHR). Methods: SHR were exposed to ouabain or vehicle and treated or not with the selective COX-2 inhibitor nimesulide for 5 weeks. Systolic blood pressure was measured by plethysmography. Vascular reactivity by wire myograph and protein expression by Western-blot were assessed in mesenteric resistance arteries (MRA) of groups. Thromboxane A2 (TXA2) production by ELISA was evaluated in MRA supernatants of groups. Results: Noradrenaline-induced maximal contraction (Emax) was greater in MRA from SHR receiving ouabain than those of vehicle group. In situ inhibition of COX-2, TXA2 synthase, or TP receptor reduced the Emax to noradrenaline in MRA of ouabain to vehicle levels. TXA2 production was higher in ouabain than in vehicle group. Ouabain enhanced expression of cytoplasmic tyrosine kinase Src (c-Src)/ERK1/2/COX-2/TXA2 synthase/TP receptor in SHR MRA, but did not change NFkB/iKB ratio. Anticontractile effect of nitric oxide (NO) was smaller in MRA from ouabain- than vehicle-treated SHR, as well as eNOS and nNOS expression. Nimesulide co-treatment prevented the ouabain-induced worsening of hypertension and noradrenaline MRA hypercontractility in SHR. Conclusion: Ouabain worsen hypertension and induce MRA hypercontractility in SHR associated with upregulated c-Src/ERK1/2/COX-2/TXA2 synthase/TXA2/TP receptor axis. These effects were prevented by COX-2 inhibition.	[de Oliveira, Helane Tito; Couto, Gisele Kruger; Rossoni, Luciana Venturini] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Prof Lineu Prestes Av,Rm 225, BR-05508000 Sao Paulo, SP, Brazil; [Davel, Ana Paula] Univ Estadual Campinas, Dept Struct & Funct Biol, Campinas, Brazil; [Xavier, Fabiano Elias] Univ Fed Pernambuco, Biosci Ctr, Dept Physiol & Pharmacol, Recife, PE, Brazil		Rossoni, LV (通讯作者)，Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Prof Lineu Prestes Av,Rm 225, BR-05508000 Sao Paulo, SP, Brazil.	lrossoni@icb.usp.br	Rossoni, Luciana Venturini/C-7226-2012; Rossoni, Luciana Venturini/AFR-0021-2022; Xavier, Fabiano Elias/G-1253-2012	Rossoni, Luciana Venturini/0000-0002-0944-9483; Xavier, Fabiano Elias/0000-0003-2028-2562	Foundation for Research Support of the State of Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/18380-6]; National Council for Scientific and Technological Development (CNPq) from BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [308682/2019-0, 306539/2017-9]	This work was supported by Foundation for Research Support of the State of Sao Paulo (FAPESP grants 2010/18380-6) and National Council for Scientific and Technological Development (CNPq) from Brazil. HTO was supported by a PhD fellowship award from CNPq. APD and LVR are research fellows from CNPq (308682/2019-0 and 306539/2017-9).	Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15; Bereta J, 1995, FEBS LETT, V377, P21, DOI 10.1016/0014-5793(95)01301-6; Blaustein MP, 2020, CELL CALCIUM, V86, DOI 10.1016/j.ceca.2020.102159; Blaustein MP, 2012, AM J PHYSIOL-HEART C, V302, pH1031, DOI 10.1152/ajpheart.00899.2011; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; Briones AM, 2006, AM J PHYSIOL-HEART C, V291, pH193, DOI 10.1152/ajpheart.00802.2005; Briones AM, 2009, J HYPERTENS, V27, P83, DOI 10.1097/HJH.0b013e328317a7cf; Davel AP, 2014, HORM MOL BIOL CLIN I, V18, P113, DOI 10.1515/hmbci-2013-0058; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Di Filippo C, 2003, J HYPERTENS, V21, P747, DOI 10.1097/00004872-200304000-00018; dos Santos L, 2003, LIFE SCI, V74, P613, DOI 10.1016/j.lfs.2003.07.002; Drummond CA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197688; Feletou M, 2011, BRIT J PHARMACOL, V164, P894, DOI 10.1111/j.1476-5381.2011.01276.x; Ferrandi M, 2004, J BIOL CHEM, V279, P33306, DOI 10.1074/jbc.M402187200; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; Huang BS, 1999, HYPERTENSION, V34, P107, DOI 10.1161/01.HYP.34.1.107; Kawamoto EM, 2012, J NEUROSCI RES, V90, P213, DOI 10.1002/jnr.22745; Kinoshita PF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05075-9; Kinoshita PF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0218-z; Lamon BD, 2010, AM J PHYSIOL-HEART C, V299, pH613, DOI 10.1152/ajpheart.00144.2010; Lima LD, 2013, NEUROPHARMACOLOGY, V73, P327, DOI 10.1016/j.neuropharm.2013.06.006; Liu CQ, 2009, BIOCHEM PHARMACOL, V78, P374, DOI 10.1016/j.bcp.2009.04.022; Liu X, 1998, EUR J PHARMACOL, V351, P113, DOI 10.1016/S0014-2999(98)00278-7; Manunta P, 1999, HYPERTENSION, V34, P450, DOI 10.1161/01.HYP.34.3.450; MANUNTA P, 1994, J HYPERTENS, V12, P549; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Padilha AS, 2008, EUR J PHARMACOL, V600, P110, DOI 10.1016/j.ejphar.2008.10.023; Padilha AS, 2004, J CARDIOVASC PHARM, V44, P372, DOI 10.1097/01.fjc.0000138165.96364.51; Pierdomenico SD, 2001, AM J HYPERTENS, V14, P44, DOI 10.1016/S0895-7061(00)01225-5; Pulgar VM, 2013, J CARDIOVASC PHARM, V62, P174, DOI 10.1097/FJC.0b013e3182955d33; Rossoni LV, 2002, BRIT J PHARMACOL, V135, P771, DOI 10.1038/sj.bjp.0704501; Rossoni LV, 2002, AM J PHYSIOL-HEART C, V283, pH2110, DOI 10.1152/ajpheart.00454.2002; Rossoni LV, 2001, BRAZ J MED BIOL RES, V34, P1065, DOI 10.1590/S0100-879X2001000800014; Simonini M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071948; Songu-Mize E, 1995, J Basic Clin Physiol Pharmacol, V6, P309; Sun PF, 2017, EUR J PHARMACOL, V815, P298, DOI 10.1016/j.ejphar.2017.09.028; Touyz RM, 2002, J HYPERTENS, V20, P1127, DOI 10.1097/00004872-200206000-00024; Vassallo DV, 1997, BRAZ J MED BIOL RES, V30, P545; Wang H, 2000, HYPERTENS RES, V23, pS55, DOI 10.1291/hypres.23.Supplement_S55; Wenceslau CF, 2014, J HYPERTENS, V32, P542, DOI 10.1097/HJH.0000000000000059; Wenceslau CF, 2011, J VASC RES, V48, P316, DOI 10.1159/000322576; Xavier FE, 2008, BRIT J PHARMACOL, V154, P1225, DOI 10.1038/bjp.2008.200; Xavier FE, 2009, J HYPERTENS, V27, P1233, DOI 10.1097/HJH.0b013e32832a391f; Xavier FE, 2004, BRIT J PHARMACOL, V143, P794, DOI 10.1038/sj.bjp.0705994; Xavier FE, 2004, BRIT J PHARMACOL, V143, P215, DOI 10.1038/sj.bjp.0705919; Xavier FE, 2004, J HYPERTENS, V22, P949, DOI 10.1097/00004872-200405000-00017; Xie XN, 2017, CLIN EXP HYPERTENS, V39, P312, DOI 10.1080/10641963.2016.1246558; Xie Zijian, 2003, Mol Interv, V3, P157, DOI 10.1124/mi.3.3.157; Xie ZJ, 2005, FRONT BIOSCI-LANDMRK, V10, P3100, DOI 10.2741/1766; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; YUAN CM, 1993, HYPERTENSION, V22, P178, DOI 10.1161/01.HYP.22.2.178	54	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106880	10.1016/j.vph.2021.106880		JUL 2021	11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34052431				2022-04-29	WOS:000674133600001
J	Ding, Y; Li, X; Zhou, M; Cai, L; Tang, HF; Xie, TC; Shi, ZY; Fu, WG				Ding, Yong; Li, Xu; Zhou, Min; Cai, Liang; Tang, Hanfei; Xie, Tianchen; Shi, Zhenyu; Fu, Weiguo			Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation	VASCULAR PHARMACOLOGY			English	Article						Rivaroxaban; Factor Xa inhibitor; Abdominal aortic aneurysm; Aortic inflammation	COAGULATION-FACTOR XA; INTRALUMINAL THROMBUS; PLATELET ACTIVATION; PATHOGENESIS	Objective: Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban on treating cardiovascular disorders such as coronary and peripheral artery disease. However, its potential influence on abdominal aortic aneurysm (AAA) remains unclear. This study aims to investigate whether rivaroxaban treatment could attenuate experimental AAA progression and its related mechanisms. Approaches and results: In human aneurysmal aorta, FXa protein expression was significantly upregulated. Further investigations identified a positive correlation among plasma FXa level, AAA severity (the maximal aortic diameter), and intra-aneurysmal thrombus percentage. In Ang II (angiotensin II)-infused ApoE-/mice, the administration of high dose rivaroxaban (15 mg/kg/d) for 14 days significantly reduced the maximal aortic diameter, while low dose rivaroxaban (5 mg/kg/d) did not display such a protective role. Although rivaroxaban treatments reduced the incidence of AAA and thrombus formation, these differences did not reach statistical significance. Immunohistochemistry revealed a pronounced aortic remodeling including increased collagen content and enhanced elastin degradation in Ang II-induced AAAs, which was inhibited by high dose rivaroxaban treatment. Further analysis demonstrated that rivaroxaban exerted its protective effects by decreasing leukocyte infiltration, inflammatory cytokines expression, and matrix metalloproteinases (MMPs) expression in the aortic wall. The inhibitory effect of rivaroxaban on aneurysm development was also observed in calcium chloride induced AAA model. Mechanistically, in human aortic endothelial cells, FXa stimulation increased the expression of inflammatory cytokines (interleukin (IL)-1 beta, IL-6, IL-8, monocyte chemoattractant protein-1) and adhesive molecules, which were all reversed by the cotreatment of rivaroxaban. Subsequent monocyte-endothelial cell interaction was enhanced after FXa stimulation and was alleviated by rivaroxaban cotreatment. In addition, FXa induced a significantly heightened expression of MMP2 in human aortic endothelial cells, which was ameliorated by rivaroxaban coadministration. Conclusions: Rivaroxaban attenuated both angiotensin IIand calcium chloride-induced abdominal aortic aneurysm (AAA) progressions, through inhibiting aortic remodeling and inflammation. Rivaroxaban could be a promising therapeutic agent in attenuating AAA development by counteracting FXa-induced aortic wall inflammation.	[Ding, Yong; Li, Xu; Zhou, Min; Cai, Liang; Tang, Hanfei; Xie, Tianchen; Shi, Zhenyu; Fu, Weiguo] Fudan Univ, Inst Vasc Surg, Zhongshan Hosp, Dept Vasc Surg, Shanghai, Peoples R China		Shi, ZY; Fu, WG (通讯作者)，180 Fenglin Rd, Shanghai 200032, Peoples R China.	maxshizhenyu@163.com; fu.weiguo@zs-hospital.sh.cn		Ding, Yong/0000-0002-5261-0324	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81870342]	This research was sponsored by the National Natural Science Foundation of China [grant number 81870342].	Allen-Redpath K, 2019, P NATL ACAD SCI USA, V116, P8038, DOI 10.1073/pnas.1814409116; Anand SS, 2018, LANCET, V391, P219, DOI 10.1016/S0140-6736(17)32409-1; Beyer J, 2016, CLIN APPL THROMB-HEM, V22, P423, DOI 10.1177/1076029616629759; Bukowska A, 2013, EUR J PHARMACOL, V718, P114, DOI 10.1016/j.ejphar.2013.09.006; Chaikof EL, 2018, J VASC SURG, V67, P2, DOI 10.1016/j.jvs.2017.10.044; Davies RSM, 2011, J VASC SURG, V54, P865, DOI 10.1016/j.jvs.2011.04.010; Ding Y, 2020, ANN VASC SURG, V67, P254, DOI 10.1016/j.avsg.2020.02.011; Ebrahimi S, 2017, J CELL PHYSIOL, V232, P1966, DOI 10.1002/jcp.25714; Golledge J, 2017, J VASC SURG, V65, P225, DOI 10.1016/j.jvs.2016.08.003; Haller SJ, 2018, J VASC SURG, V67, P1051, DOI 10.1016/j.jvs.2017.08.069; Hara T, 2018, CIRCULATION, V138, P1706, DOI 10.1161/CIRCULATIONAHA.118.033544; Hara T, 2018, EUR J PHARMACOL, V820, P222, DOI 10.1016/j.ejphar.2017.12.037; Hara T, 2015, ATHEROSCLEROSIS, V242, P639, DOI 10.1016/j.atherosclerosis.2015.03.023; Hashikata T, 2015, INT HEART J, V56, P544, DOI 10.1536/ihj.15-112; Krupiczojc MA, 2008, INT J BIOCHEM CELL B, V40, P1228, DOI 10.1016/j.biocel.2008.02.026; Li YQ, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117659; Mahaffey KW, 2014, EUR HEART J, V35, P233, DOI 10.1093/eurheartj/eht428; Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277; Monux G, 2017, BRIT J CLIN PHARMACO, V83, P2661, DOI 10.1111/bcp.13383; Moran CS, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43079; Nordon IM, 2011, NAT REV CARDIOL, V8, P92, DOI 10.1038/nrcardio.2010.180; Oe Y, 2016, ARTERIOSCL THROM VAS, V36, P1525, DOI 10.1161/ATVBAHA.116.307883; Petzold T, 2020, CIRC RES, V126, P486, DOI 10.1161/CIRCRESAHA.119.315099; Raffort J, 2017, NAT REV CARDIOL, V14, P457, DOI 10.1038/nrcardio.2017.52; Sanada F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17508-6; Satoh K, 2009, NAT MED, V15, P649, DOI 10.1038/nm.1958; Sun J, 2007, J CLIN INVEST, V117, P3359, DOI 10.1172/JCI31311; Vorp DA, 2001, J VASC SURG, V34, P291, DOI 10.1067/mva.2001.114813; Wang YT, 2013, ATHEROSCLEROSIS, V226, P29, DOI 10.1016/j.atherosclerosis.2012.09.010; Wanhainen A, 2019, EUR J VASC ENDOVASC, V57, P8, DOI 10.1016/j.ejvs.2018.09.020; Zhou M, 2018, MOL MED REP, V17, P7089, DOI 10.3892/mmr.2018.8765; Zhu CC, 2020, RADIOLOGY, V294, P707, DOI 10.1148/radiol.2020191723	32	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106818	10.1016/j.vph.2020.106818		JAN 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33227452				2022-04-29	WOS:000613540200003
J	LaClair, HJ; Khosrodad, N; Sule, AA; Koehler, T; Krishnamoorthy, G				LaClair, Heather J.; Khosrodad, Nadia; Sule, Anupam A.; Koehler, Tracy; Krishnamoorthy, Geetha			Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients	VASCULAR PHARMACOLOGY			English	Letter						COVID-19; Angiotensin receptor antagonists; Angiotensin-converting enzyme inhibitors; Hospital mortality; Length of stay			[LaClair, Heather J.; Koehler, Tracy] Mercy Hlth Muskegon GME, 1675 Leahy St,Ste 315A, Muskegon, MI 49442 USA; [Khosrodad, Nadia; Sule, Anupam A.; Krishnamoorthy, Geetha] St Joseph Mercy Oakland, 44405 Woodward Ave, Pontiac, MI USA; [Khosrodad, Nadia] Univ Michigan, GME, 4260 Plymouth Rd, Ann Arbor, MI 48109 USA		LaClair, HJ (通讯作者)，St Joseph Mercy Oakland Hosp, Grad Med Educ, Internal Med, 44405 Woodward Ave, Pontiac, MI 48341 USA.	Heather.LaClair@mercyhealth.com; Khosrodn@med.umich.edu; anupam.a.sule@stjoeshealth.org; Tracy.Koehler@mercyhealth.com; Geetha.krishnamoorthy@stjoeshealth.org					Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]	3	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106902	10.1016/j.vph.2021.106902		NOV 2021	2	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34363963	Green Published, Bronze			2022-04-29	WOS:000756079500004
J	Ragusa, R; Basta, G; Del Turco, S; Caselli, C				Ragusa, Rosetta; Basta, Giuseppina; Del Turco, Serena; Caselli, Chiara			A possible role for ST2 as prognostic biomarker for COVID-19	VASCULAR PHARMACOLOGY			English	Review						COVID-19; Cardiovascular disease; Inflammation; Suppressor of Tumorigenicity 2; Biomarker	ANGIOTENSIN-CONVERTING ENZYME; INDUCED PULMONARY-FIBROSIS; SOLUBLE ST2; HEART-FAILURE; MYOCARDIAL-INFARCTION; CARDIAC MYOCYTES; ACE2 EXPRESSION; RECEPTOR; INFLAMMATION; CYTOKINE	COVID-19 is a pandemic illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). It has been estimated that 80% of subject infected are asymptomatic or have mild to moderate symptoms. Differently, in severe cases of COVID-19, cytokine storm, acute respiratory distress syndrome (ARDS), severe systemic inflammatory response and cardiovascular diseases were observed Even if all molecular mechanisms leading to cardiovascular dysfunction in COVID-19 patients remain to be clarified, the evaluation of biomarkers of cardiac injury, stress and inflammation proved to be an excellent tool to identify the COVID-19 patients with worse outcome. However, the number of biomarkers used to manage COVID-19 patients is expected to increase with the increasing knowledge of the pathophysiology of the disease. It is our view that soluble suppressor of tumorigenicity 2 (sST2) can be used as biomarker in COVID-19. sST2 is routinely used as prognostic biomarker in patients with HF. Moreover, high circulating levels of sST2 have also been found in subjects with ARDS, pulmonary fibrosis and sepsis. Keeping in mind these considerations, in this review the possible mechanisms through which the SARS-CoV2 infection could damage the cardiovascular system were summarized and the possible role of sST2 in COVID-19 patients with CVD was discussed.	[Ragusa, Rosetta] Scuola Super Sant Anna, Inst Life Sci, Pisa, Italy; [Ragusa, Rosetta; Basta, Giuseppina; Del Turco, Serena; Caselli, Chiara] CNR, Inst Clin Physiol, Via Moruzzi 1, Pisa, Italy; [Caselli, Chiara] Fdn Toscana G Monasterio, Pisa, Italy		Ragusa, R (通讯作者)，CNR, Inst Clin Physiol, Via Moruzzi 1, Pisa, Italy.	rosetta.ragusa@gmail.com	Del Turco, Serena/K-1972-2018; Ragusa, Rosetta/AAD-4690-2019; Basta, Giuseppina/B-8077-2015	Del Turco, Serena/0000-0003-3722-8861; Ragusa, Rosetta/0000-0002-6914-6089; Basta, Giuseppina/0000-0003-0809-4374			Abassi Z, 2020, AM J PHYSIOL-HEART C, V318, pH1080, DOI 10.1152/ajpheart.00215.2020; Adeghate EA, 2021, HEART FAIL REV, V26, P363, DOI 10.1007/s10741-020-10037-x; Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055; Amraei R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071652; [Anonymous], 2020, BIOMARKERS; ARETZ HT, 1987, HUM PATHOL, V18, P619; Atri D, 2020, JACC-BASIC TRANSL SC, V5, P518, DOI 10.1016/j.jacbts.2020.04.002; Bajwa EK, 2015, AM J CARDIOL, V115, p44B, DOI 10.1016/j.amjcard.2015.01.040; Bajwa EK, 2013, CRIT CARE MED, V41, P2521, DOI 10.1097/CCM.0b013e3182978f91; Bruins P, 1997, CIRCULATION, V96, P3542; Burian E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051514; Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114; Caselli C., 2014, INFLAMM CELL SIGNAL, V1, pE149; Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449; Chi YW, 2020, J MICROENCAPSUL, V37, P134, DOI 10.1080/02652048.2019.1705409; Del Turco S, 2020, THROMB RES, V196, P143, DOI 10.1016/j.thromres.2020.08.039; Demyanets S, 2011, ARTERIOSCL THROM VAS, V31, P2080, DOI 10.1161/ATVBAHA.111.231431; Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271; European Society of Cardiology, 2020, ESC GUID DIAGN MAN C; Felker GM, 2013, CIRC-HEART FAIL, V6, P1172, DOI 10.1161/CIRCHEARTFAILURE.113.000207; Frater JL, 2020, INT J LAB HEMATOL, V42, P11, DOI 10.1111/ijlh.13229; Gachter T, 1996, J BIOL CHEM, V271, P124; Gallagher PE, 2008, AM J PHYSIOL-HEART C, V295, pH2373, DOI 10.1152/ajpheart.00426.2008; Gao L, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01352-w; Gao QY, 2016, INT IMMUNOPHARMACOL, V30, P188, DOI 10.1016/j.intimp.2015.11.015; Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770; George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3; Guan W., 2020, N. Engl. J. Med., V382, P1708, DOI 10.1056/; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0; Hanna A, 2020, CARDIOVASC DRUG THER, V34, P849, DOI 10.1007/s10557-020-07071-0; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Henry BM, 2020, CLIN CHIM ACTA, V507, P167, DOI 10.1016/j.cca.2020.04.027; Homsak E, 2020, CLIN CHIM ACTA, V507, P75, DOI 10.1016/j.cca.2020.04.011; Hoogerwerf JJ, 2010, INTENS CARE MED, V36, P630, DOI 10.1007/s00134-010-1773-0; Hu HD, 2021, EUR HEART J, V42, P206, DOI 10.1093/eurheartj/ehaa190; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Januzzi JL, 2007, J AM COLL CARDIOL, V50, P607, DOI 10.1016/j.jacc.2007.05.014; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Kotsiou OS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02432; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518; Ky B, 2011, CIRC-HEART FAIL, V4, P180, DOI 10.1161/CIRCHEARTFAILURE.110.958223; Lala A, 2020, J AM COLL CARDIOL, V76, P533, DOI [10.1016/j.jacc.2020.06.007, 10.1101/2020.04.20.20072702]; Le Goffic R, 2011, AM J RESP CELL MOL, V45, P1125, DOI 10.1165/rcmb.2010-0516OC; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Libby P, 2020, JACC-BASIC TRANSL SC, V5, P537, DOI 10.1016/j.jacbts.2020.04.001; Lippi Giuseppe, 2020, Acta Biomed, V91, P137, DOI 10.23750/abm.v91i2.9548; Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Mikami T, 2021, J GEN INTERN MED, V36, P17, DOI 10.1007/s11606-020-05983-z; Miller AM, 2011, PHARMACOL THERAPEUT, V131, P179, DOI 10.1016/j.pharmthera.2011.02.005; Munhoz RP, 2020, ARQ NEURO-PSIQUIAT, V78, P290, DOI [10.1590/0004-282x20200051, 10.1590/0004-282X20200051]; Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x; Pascual-Figal DA, 2015, AM J CARDIOL, V115, p3B, DOI 10.1016/j.amjcard.2015.01.034; Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577; Romagnoli S, 2020, PHYSIOL REV, V100, P1455, DOI 10.1152/physrev.00020.2020; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Sanada S, 2007, J CLIN INVEST, V117, P1538, DOI 10.1172/JCI30634; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Seki K, 2009, CIRC-HEART FAIL, V2, P684, DOI 10.1161/CIRCHEARTFAILURE.109.873240; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159; Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8; Stefanini GG, 2020, HEART, V106, P1512, DOI 10.1136/heartjnl-2020-317322; Sukumaran V, 2011, INT J BIOL SCI, V7, P1077, DOI 10.7150/ijbs.7.1077; Tajima S, 2003, CHEST, V124, P1206, DOI 10.1378/chest.124.4.1206; Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871; Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Tominaga S, 1999, BIOCHEM BIOPH RES CO, V264, P14, DOI 10.1006/bbrc.1999.1469; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Watanabe M, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0872-2; Weinberg EO, 2002, CIRCULATION, V106, P2961, DOI 10.1161/01.CIR.0000038705.69871.D9; Weinberg EO, 2003, CIRCULATION, V107, P721, DOI 10.1161/01.CIR.0000047274.66749.FE; Xu H, 2017, MILITARY MED RES, V4, P1, DOI 10.1186/s40779-017-0115-8; Xu J, 2016, MOL MED REP, V14, P1704, DOI 10.3892/mmr.2016.5446; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027; Yao X H, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P411, DOI 10.3760/cma.j.cn112151-20200312-00193; Yokoyama T, 1997, CIRCULATION, V95, P1247; Yu MH, 2020, KOREAN J RADIOL, V21, P746, DOI 10.3348/kjr.2020.0215; Zeng ZK, 2020, BIOMARK MED, V14, P1619, DOI 10.2217/bmm-2020-0410; Zhao J, 2015, CRIT REV IMMUNOL, V35, P451, DOI 10.1615/CritRevImmunol.2016015865; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z; Zizzo G, 2020, LANCET RHEUMATOL, V2, pE779, DOI 10.1016/S2665-9913(20)30340-4	90	4	4	6	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106857	10.1016/j.vph.2021.106857		MAY 2021	7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33746068	Bronze, Green Published			2022-04-29	WOS:000652840900007
J	Querio, G; Antoniotti, S; Geddo, F; Tullio, F; Penna, C; Pagliaro, P; Gallo, MP				Querio, Giulia; Antoniotti, Susanna; Geddo, Federica; Tullio, Francesca; Penna, Claudia; Pagliaro, Pasquale; Gallo, Maria Pia			Ischemic heart disease and cardioprotection: Focus on estrogenic hormonal setting and microvascular health	VASCULAR PHARMACOLOGY			English	Review						Ischemic Heart Disease; Sex; Estrogens; Estrogen receptors; Cardioprotection	CYSTATHIONINE-GAMMA-LYASE; NITRIC-OXIDE SYNTHASES; RECEPTOR-ALPHA; SEX-DIFFERENCES; INSULIN-RESISTANCE; CORONARY-ARTERIES; S-NITROSYLATION; GENE-EXPRESSION; UP-REGULATION; BISPHENOL-A	Ischemic Heart Disease (IHD) is a clinical condition characterized by insufficient blood flow to the cardiac tissue, and the consequent inappropriate oxygen and nutrients supply and metabolic waste removal in the heart. In the last decade a broad scientific literature has underlined the distinct mechanism of onset and the peculiar progress of IHD between female and male patients, highlighting the estrogenic hormonal setting as a key factor of these sex-dependent divergences. In particular, estrogen-activated cardioprotective pathways exert a pivotal role for the microvascular health, and their impairment, both physiologically and pathologically driven, predispose to vascular dysfunctions. Aim of this review is to summarize the current knowledge on the estrogen receptors localization and function in the cardiovascular system, particularly focusing on sex-dependent differences in microvascular vs macrovascular dysfunction and on the experimental models that allowed the researchers to reach the current findings and sketching the leading estrogen-mediated cardioprotective mechanisms.	[Querio, Giulia; Antoniotti, Susanna; Geddo, Federica; Gallo, Maria Pia] Univ Torino, Dept Life Sci & Syst Biol, Turin, Italy; [Tullio, Francesca; Penna, Claudia; Pagliaro, Pasquale] Univ Torino, Dept Clin & Biol Sci, Turin, Italy		Gallo, MP (通讯作者)，Univ Torino, Dept Life Sci & Syst Biol, Turin, Italy.; Pagliaro, P (通讯作者)，Univ Torino, Dept Clin & Biol Sci, Turin, Italy.	pasquale.pagliaro@unito.it; mariapia.gallo@unito.it		Querio, Giulia/0000-0002-1385-561X	University of Torino [GALM_RILO_21_02]	This research received no external funding; it was supported by the local funding of the University of Torino (GALLO -Ricerca Locale 2021: GALM_RILO_21_02).	Adlanmerini M, 2014, P NATL ACAD SCI USA, V111, pE283, DOI 10.1073/pnas.1322057111; Aggarwal NR, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.117.004437; AlBadri A, 2020, ARTERIOSCL THROM VAS, V40, P3015, DOI 10.1161/ATVBAHA.120.314260; Anderson RD, 2019, J INTERV CARDIOL, V2019, DOI 10.1155/2019/7169275; Andersson S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15840; Andres-Villarreal M, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003843; Barakat R, 2016, BMB REP, V49, P488, DOI 10.5483/BMBRep.2016.49.9.141; Belcher SM, 2012, ENDOCRINOLOGY, V153, P712, DOI 10.1210/en.2011-1772; Billon-Gales A, 2011, P NATL ACAD SCI USA, V108, P13311, DOI 10.1073/pnas.1105632108; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bopassa JC, 2010, AM J PHYSIOL-HEART C, V298, pH16, DOI 10.1152/ajpheart.00588.2009; Broughton BRS, 2010, AM J PHYSIOL-HEART C, V298, pH1055, DOI 10.1152/ajpheart.00878.2009; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Christakis MK, 2020, MENOPAUSE, V27, P999, DOI 10.1097/GME.0000000000001575; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Dan P, 2003, AM J PHYSIOL-HEART C, V284, pH1295, DOI 10.1152/ajpheart.00781.2002; De Francesco EM, 2017, J CELL PHYSIOL, V232, P1640, DOI 10.1002/jcp.25585; De Francesco EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069322; De Paoli M, 2021, AM J PATHOL, V191, P1490, DOI 10.1016/j.ajpath.2021.05.011; Delbeck M, 2011, MOL MED REP, V4, P37, DOI 10.3892/mmr.2010.402; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Desai KV, 2008, AM J PHYSIOL-HEART C, V294, pH2428, DOI 10.1152/ajpheart.00860.2007; Deschamps AM, 2010, TRENDS CARDIOVAS MED, V20, P73, DOI 10.1016/j.tcm.2010.05.001; Deschamps AM, 2009, AM J PHYSIOL-HEART C, V297, pH1806, DOI 10.1152/ajpheart.00283.2009; Devanathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101900; Farah C, 2018, NAT REV CARDIOL, V15, P292, DOI 10.1038/nrcardio.2017.224; Ferguson M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52350-y; Filardo EJ, 2012, ENDOCRINOLOGY, V153, P2953, DOI 10.1210/en.2012-1061; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Fu L, 2021, J ENDOCRINOL, V249, P209, DOI 10.1530/JOE-20-0451; Fuentes N, 2019, ADV PROTEIN CHEM STR, V116, P135, DOI 10.1016/bs.apcsb.2019.01.001; Fukumoto T, 2013, EUR J PHARMACOL, V699, P74, DOI 10.1016/j.ejphar.2012.11.042; Gabel Scott A, 2005, J Mol Cell Cardiol, V38, P289, DOI 10.1016/j.yjmcc.2004.11.013; Garcia-Dorado D, 2012, J MOL CELL CARDIOL, V52, P931, DOI 10.1016/j.yjmcc.2012.01.010; Gasperi V, 2020, CARDIOVASC THER, V2020, DOI 10.1155/2020/2342837; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Geraghty L, 2021, HEART LUNG CIRC, V30, P9, DOI 10.1016/j.hlc.2020.05.108; Gohar EY, 2020, AM J PHYSIOL-RENAL, V319, pF612, DOI 10.1152/ajprenal.00045.2020; Goncalves GK, 2018, AM J PHYSIOL-CELL PH, V314, pC310, DOI 10.1152/ajpcell.00060.2017; Gourdy P, 2018, MOL METAB, V15, P56, DOI 10.1016/j.molmet.2018.05.009; Gregorio KCR, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010099; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Guo XM, 2005, J BIOL CHEM, V280, P19704, DOI 10.1074/jbc.M501244200; Gupta R, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1454-y; Gurrala R, 2021, GEROSCIENCE, V43, P433, DOI 10.1007/s11357-021-00331-3; Haas E, 2007, HYPERTENSION, V49, P1358, DOI 10.1161/HYPERTENSIONAHA.107.089995; Haas E, 2009, CIRC RES, V104, P288, DOI 10.1161/CIRCRESAHA.108.190892; Haldosen LA, 2014, MOL CELL ENDOCRINOL, V382, P665, DOI 10.1016/j.mce.2013.08.005; Hausenloy DJ, 2019, CARDIOVASC RES, V115, P1143, DOI 10.1093/cvr/cvy286; Herscovici R, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008868; HEUSCH G, 1983, CIRC RES, V53, P8, DOI 10.1161/01.RES.53.1.8; Heusch G, 2016, CIRC RES, V118, P1643, DOI 10.1161/CIRCRESAHA.116.308640; Hewitt SC, 2005, SCIENCE, V307, P1572, DOI 10.1126/science.1110345; Iorga A, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0152-8; Jazbutyte V, 2009, BIOCHEM BIOPH RES CO, V384, P450, DOI 10.1016/j.bbrc.2009.04.139; Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; Karunathilake SP, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5767864; Kawagoe J, 2007, ENDOCRINOLOGY, V148, P6092, DOI 10.1210/en.2007-0188; Khan MAB, 2020, CUREUS, V12, DOI 10.7759/cureus.9349; Kim KH, 2014, MOL CELL ENDOCRINOL, V389, P65, DOI 10.1016/j.mce.2014.02.001; King AL, 2014, P NATL ACAD SCI USA, V111, P3182, DOI 10.1073/pnas.1321871111; Klinge CM, 2020, REDOX BIOL, V31, DOI 10.1016/j.redox.2020.101435; Knowlton AA, 2012, PHARMACOL THERAPEUT, V135, P54, DOI 10.1016/j.pharmthera.2012.03.007; Lagranha CJ, 2010, CIRC RES, V106, P1681, DOI 10.1161/CIRCRESAHA.109.213645; Lee HW, 1998, J MOL CELL CARDIOL, V30, P1359, DOI 10.1006/jmcc.1998.0699; Levin ER, 2018, STEROIDS, V132, P1, DOI 10.1016/j.steroids.2017.10.014; Lin J, 2009, CIRCULATION, V120, P245, DOI 10.1161/CIRCULATIONAHA.109.868729; Lizotte E, 2009, CELL PHYSIOL BIOCHEM, V23, P75, DOI 10.1159/000204096; LOSANO G, 1994, CLIN EXP PHARMACOL P, V21, P783, DOI 10.1111/j.1440-1681.1994.tb02447.x; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Lu Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152807; Luo T, 2016, CAN J CARDIOL, V32, P1017, DOI 10.1016/j.cjca.2015.10.021; Madonna R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010098; Mao N, 2019, STEROIDS, V146, P50, DOI 10.1016/j.steroids.2019.03.006; Martensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008-0623; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; Mauvais-Jarvis F, 2013, ENDOCR REV, V34, P309, DOI 10.1210/er.2012-1055; Menazza S, 2017, J MOL CELL CARDIOL, V107, P41, DOI 10.1016/j.yjmcc.2017.04.004; Meyer MR, 2014, SCI REP-UK, V4, DOI 10.1038/srep07564; Michela P, 2015, EUR J PHARMACOL, V768, P71, DOI 10.1016/j.ejphar.2015.10.030; Molina L, 2017, EXPERT OPIN THER TAR, V21, P755, DOI 10.1080/14728222.2017.1350264; Murphy E, 2007, HEART FAIL REV, V12, P293, DOI 10.1007/s10741-007-9035-0; Naderi S, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0710-5; Nathan L, 1997, ANNU REV PHARMACOL, V37, P477, DOI 10.1146/annurev.pharmtox.37.1.477; Nikolic I, 2007, J MOL CELL CARDIOL, V42, P769, DOI 10.1016/j.yjmcc.2007.01.014; Noel Bairey Merz C., 2017, CIRCULATION, V135, P1075, DOI [10.1161/CIRCULATIONAHA.116.024534, DOI 10.1161/CIRCULATIONAHA.116.024534]; Nowbar AN, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005375; Nuedling S, 2001, FEBS LETT, V502, P103, DOI 10.1016/S0014-5793(01)02675-8; O'Lone R, 2007, MOL ENDOCRINOL, V21, P1281, DOI 10.1210/me.2006-0497; Pagliaro P., 2020, SEX GENDER DIFFERENC, P11; Paul TK, 2017, TRENDS CARDIOVAS MED, V27, P173, DOI 10.1016/j.tcm.2016.08.002; Pavon N, 2012, J STEROID BIOCHEM, V132, P135, DOI 10.1016/j.jsbmb.2012.05.003; Pelzer T, 2005, CIRCULATION, V111, P1492, DOI 10.1161/01.CIR.0000159262.18512.46; Pugach EK, 2016, MOL CELL ENDOCRINOL, V431, P62, DOI 10.1016/j.mce.2016.05.004; Raparelli V, 2020, J CARDIOVASC TRANSL, V13, P14, DOI 10.1007/s12265-018-9846-5; Recchia AG, 2011, J BIOL CHEM, V286, P10773, DOI 10.1074/jbc.M110.172247; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Ropero AB, 2006, J MOL CELL CARDIOL, V41, P496, DOI 10.1016/j.yjmcc.2006.05.022; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Russo I, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0550-6; Sabbatini AR, 2020, J AM COLL CARDIOL, V75, P1074, DOI 10.1016/j.jacc.2019.12.049; Samavat H, 2015, CANCER LETT, V356, P231, DOI 10.1016/j.canlet.2014.04.018; Sandoo A, 2010, OPEN CARDIOVASC MED, V4, P302, DOI 10.2174/1874192401004010302; Sara JD, 2015, JACC-CARDIOVASC INTE, V8, P1445, DOI 10.1016/j.jcin.2015.06.017; Schultz JG, 2016, CARDIOL YOUNG, V26, P451, DOI 10.1017/S1047951115000402; Schwartz BG, 2012, J MOL CELL CARDIOL, V52, P873, DOI 10.1016/j.yjmcc.2011.06.009; Scotland RS, 2005, P NATL ACAD SCI USA, V102, P14452, DOI 10.1073/pnas.0504961102; Sezer M, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009949; Shankar A, 2012, ENVIRON HEALTH PERSP, V120, P1297, DOI 10.1289/ehp.1104114; Shao Q, 2016, AM J PHYSIOL-HEART C, V310, pH505, DOI 10.1152/ajpheart.00681.2015; Sharma G, 2013, ENDOCRINOLOGY, V154, P4136, DOI 10.1210/en.2013-1357; Shen YQ, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/925167; Sheridan FM, 1996, CIRCULATION, V93, P1784, DOI 10.1161/01.CIR.93.10.1784; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Srivastava RAK, 1997, J BIOL CHEM, V272, P33360, DOI 10.1074/jbc.272.52.33360; Sun JH, 2006, CIRC RES, V98, P403, DOI 10.1161/01.RES.0000202707.79018.0a; Sun JH, 2013, FREE RADICAL BIO MED, V54, P105, DOI 10.1016/j.freeradbiomed.2012.09.005; Tiano JP, 2011, J CLIN INVEST, V121, P3331, DOI 10.1172/JCI44564; Tribulova N, 2005, PHYSIOL RES, V54, P705; Tsutsui M, 2010, PHARMACOL THERAPEUT, V128, P499, DOI 10.1016/j.pharmthera.2010.08.010; Ueda K, 2013, ARTERIOSCL THROM VAS, V33, P1837, DOI 10.1161/ATVBAHA.112.300752; Vogel H, 2013, HORM METAB RES, V45, P430, DOI 10.1055/s-0032-1331700; Waheed N, 2020, CARDIOVASC RES, V116, P829, DOI 10.1093/cvr/cvaa001; Wang H, 2017, BBA-MOL BASIS DIS, V1863, P1870, DOI 10.1016/j.bbadis.2016.10.003; Wang L, 2020, NAT CELL BIOL, V22, P108, DOI 10.1038/s41556-019-0446-7; Wang L, 2015, ENDOCRINOLOGY, V156, P2124, DOI 10.1210/en.2014-1362; Wang MJ, 2006, AM J PHYSIOL-HEART C, V290, pH2204, DOI 10.1152/ajpheart.01219.2005; Wang ZY, 2015, MOL CELL ENDOCRINOL, V418, P193, DOI 10.1016/j.mce.2015.04.017; Wehbe Z, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-1022-z; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wilkins E., 2017, EUROPEAN CARDIOVASCU; Yan SJ, 2013, FOOD CHEM TOXICOL, V56, P75, DOI 10.1016/j.fct.2013.02.011; Yan SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025455; Yang SF, 2020, TOXICOLOGY, V432, DOI 10.1016/j.tox.2020.152380; Zhu XY, 2013, MENOPAUSE, V20, P1084, DOI [10.1097/gme.0b013e3182874732, 10.1097/GME.0b013e3182874732]	139	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106921	10.1016/j.vph.2021.106921		NOV 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34592428				2022-04-29	WOS:000756079500012
J	Li, B; Luo, YR; Zhang, Q; Fu, SH; Chen, YD; Tian, JW; Guo, Y				Li, Bo; Luo, Yan Rong; Zhang, Qian; Fu, Shi Hui; Chen, Yun Dai; Tian, Jing Wen; Guo, Yi			Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice	VASCULAR PHARMACOLOGY			English	Article						Sitagliptin; Dipeptidyl peptidase-4 inhibitor; Glucagon-like peptide-1; Atherosclerosis; Apoptosis; Wnt signaling pathway	GLUCAGON-LIKE PEPTIDE-1; MICROVASCULAR ENDOTHELIAL-CELLS; DPP-4 INHIBITION; ACTIVATION; PROTECTS; INJURY	Sitagliptin, a dipeptidyl peptidase-4(DPP-4) Inhibitor, has been found to have an anti-atherosclerotic effect. Since apoptosis of vascular smooth muscle cells (VSMCs) contributes to the occurrence of diabetic atherosclerosis. This study aimed to examine whether sitagliptin suppresses the atherosclerosis progression to hyperglycemia in a low-dose streptozotocin (STZ)-induced diabetic mouse model, and then investigated the effect of sitagliptin on VSMCs apoptosis and its underlying mechanism. In vivo studies, eight-week-old low-dose STZ-induced diabetic apolipoprotein E (apoE)-deficient (apoE-/-) mice fed a high-fat diet were administered a DPP-4 inhibitor, sitagliptin, 200 mg/kg/day, or Lantus insulin by daily subcutaneous injection of 1 unit/mouse over a period of 12 weeks. Aortic atherosclerosis and apoptosis in the plaque were determined using dUTP-biotin nick end labeling (TUNEL) staining and immunohistochemistry. In vitro studies utilized the VSMCs for determination of glucagon-like peptide 1 receptor (GLP-1R) and DPP-4 expression and flow cytometry and Western blotting were used to determine apoptosis and protein expression, respectively. Sitagliptin significantly reduced atherosclerotic lesion area (7.00 +/- 0.13 vs. 12.80 +/- 2.7%, p = 0.003) and suppressed vascular smooth muscle cell apoptosis (2.30 +/- 1.34 vs. 4.8 +/- 1.93%, p = 0.003) compared with vehicle treatment. In addition, sitagliptin significantly increased the expression of beta-catenin in the aortic tissue(0.56 +/- 0.13 vs.0.17 +/- 0.02, p = 0.008)compared with vehicle treatment. In cultured mouse VSMCs, sitagliptin enhanced GLP-1 activity significantly retarded oxidative stress (H2O2)-induced apoptosis compared with GLP-1 or sitagliptin alone. Sitagliptin increased GLP-1-induced cytosolic levels of beta-catenin compared with GLP-1 alone, resulted in increasing the expression of survivin, and suppressed proinflammatory cytokines, i.e., interleukin-6(IL-6) and tumor necrosis factor-alpha(TNF-alpha), production in response to H2O2. In conclusion, these results indicated that the anti-atherosclerotic effect of sitagliptin is mediated, at least in part, by its inhibition of VSMCs apoptosis.	[Li, Bo; Fu, Shi Hui; Tian, Jing Wen; Guo, Yi] Peoples Liberat Army Gen Hosp, Chinese Hainan Hosp, Dept Cardiol, Sanya, Hainan, Peoples R China; [Luo, Yan Rong] Peoples Liberat Army Gen Hosp, Hainan Hosp, Dept Radiat Oncol, Sanya, Hainan, Peoples R China; [Zhang, Qian] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Endocrinol, Beijing, Peoples R China; [Chen, Yun Dai] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China		Chen, YD (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China.	chenyundai@plagh.cn		Fu, Shihui/0000-0001-6707-9049	Chinese PLA General Hospital [2017FC-TSYS-3039]; Chinese Cardiovascular Association [2017-CCA-VG-027]	This study was supported by clinical support fund grant number 2017FC-TSYS-3039 from the Chinese PLA General Hospital. In addition, this work was also supported by Chinese Cardiovascular Association-V.G fund (2017-CCA-VG-027) .	Bennett MR, 2016, CIRC RES, V118, P692, DOI 10.1161/CIRCRESAHA.115.306361; Blankesteijn WM, 2015, EUR J PHARMACOL, V763, P122, DOI 10.1016/j.ejphar.2015.05.023; Brocardo M, 2008, TRENDS CELL BIOL, V18, P587, DOI 10.1016/j.tcb.2008.09.002; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Christman MA, 2008, AM J PHYSIOL-HEART C, V294, pH2864, DOI 10.1152/ajpheart.00982.2007; Connelly KA, 2016, J DIABETES, V8, P63, DOI 10.1111/1753-0407.12258; Deacon CF, 2008, FRONT BIOSCI-LANDMRK, V13, P1780, DOI 10.2741/2799; Drucker DJ, 2010, DIABETES CARE, V33, P428, DOI 10.2337/dc09-1499; Fadini GP, 2011, VASC PHARMACOL, V55, P10, DOI 10.1016/j.vph.2011.05.001; Ge GH, 2015, ASIAN PAC J TROP MED, V8, P73, DOI 10.1016/S1995-7645(14)60191-7; Geng YJ, 2001, CELL RES, V11, P253, DOI 10.1038/sj.cr.7290094; Hu LN, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.117.005886; Kavurma MM, 2005, J THROMB HAEMOST, V3, P465, DOI 10.1111/j.1538-7836.2005.01120.x; Kubota A, 2016, J MOL CELL CARDIOL, V91, P72, DOI 10.1016/j.yjmcc.2015.12.026; Lei YN, 2017, INT J CARDIOL, V243, P413, DOI 10.1016/j.ijcard.2017.05.062; Li F, 2006, HISTOL HISTOPATHOL, V21, P103, DOI 10.14670/HH-21.103; Liu R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160212; Liu ZY, 2008, J BIOL CHEM, V283, P8723, DOI 10.1074/jbc.M706105200; Matsubara J, 2012, J AM COLL CARDIOL, V59, P265, DOI 10.1016/j.jacc.2011.07.053; Mill C, 2014, ARTERIOSCL THROM VAS, V34, P2449, DOI 10.1161/ATVBAHA.114.303922; Mita T, 2016, DIABETES CARE, V39, P139, DOI 10.2337/dc15-0781; Reinhold D, 2009, CLIN CHEM LAB MED, V47, P268, DOI 10.1515/CCLM.2009.062; Salim HM, 2016, VASC PHARMACOL, V79, P16, DOI 10.1016/j.vph.2015.08.011; Scott LJ, 2017, DRUGS, V77, P209, DOI 10.1007/s40265-016-0686-9; Shao WJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE1263, DOI 10.1152/ajpendo.00600.2012; Vittone F, 2012, DIABETOLOGIA, V55, P2267, DOI 10.1007/s00125-012-2582-5; Wang DJ, 2013, DIABETES, V62, P1697, DOI 10.2337/db12-1025; Wang RH, 2015, J CARDIOVASC PHARM, V66, P135, DOI 10.1097/FJC.0000000000000255; Wessely R, 2010, J AM COLL CARDIOL, V55, P2269, DOI 10.1016/j.jacc.2010.02.017; Yang G, 2017, ATHEROSCLEROSIS, V264, P1, DOI 10.1016/j.atherosclerosis.2017.07.014; Yeo W, 2004, DEV BIOL, V274, P233, DOI 10.1016/j.ydbio.2004.07.026; Zeng YM, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-32; Zhang Y, 2016, FREE RADICAL BIO MED, V95, P278, DOI 10.1016/j.freeradbiomed.2016.03.035	33	1	1	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106854	10.1016/j.vph.2021.106854		SEP 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33781961				2022-04-29	WOS:000709412300002
J	Li, SS; Chen, Y; Zhang, YY; Qiu, F; Zeng, FX; Shi, LJ				Li, Shanshan; Chen, Yu; Zhang, Yanyan; Qiu, Fang; Zeng, Fanxing; Shi, Lijun			Prenatal exercise reprograms the development of hypertension progress and improves vascular health in SHR offspring	VASCULAR PHARMACOLOGY			English	Article						Exercise during pregnancy; Hypertension; Offspring; CaV1; 2 channel; DNA methylation	BKCA CHANNEL ACTIVITY; BLOOD-PRESSURE; PHYSICAL-ACTIVITY; EPIGENETIC MODIFICATIONS; MATERNAL EXERCISE; CALCIUM-CHANNELS; DNA METHYLATION; PREGNANCY; DYSFUNCTION; FETAL	Background: Upregulation of L-type voltage-gated Ca2+ (CaV1.2) channel in the arterial myocytes is a hallmark feature of hypertension. However, whether maternal exercise during pregnancy has a sustained beneficial effect on the offspring of spontaneously hypertensive rats (SHRs) through epigenetic regulation of CaV1.2 channel is largely unknown. Methods: Pregnant SHRs and Wistar-Kyoto rats were subjected to swimming and the vascular molecular and functional properties of male offspring were evaluated at embryonic (E) 20.5 day, 3 months (3 M), and 6 months (6 M). Results: Exercise during pregnancy significantly decreased the resting blood pressure at 3 M but not 6 M in the offspring of SHR. Prenatal exercise significantly reduced the cardiovascular reactivity, the contribution of CaV1.2 channel to the vascular tone, and the whole-cell current density of CaV1.2 channel in both 3 M and 6 M offspring of SHR. Moreover, maternal exercise triggered hypermethylation of the promoter region of the CaV1.2 alpha 1C gene (CACNA1C), with a concomitant decrease in its protein and mRNA expressions in SHR offspring at E20.5, 3 M, and 6 M. Tissue culture experiments further confirmed that 5-Aza-2 '-deoxycytidine increased the structure and functional expression of CaV1.2 channel by inhibiting the DNA methylation of CACNA1C. However, the improvement of prenatal exercise on the blood pressure, function, and expression of CaV1.2 channel was attenuated in the offspring of SHRs at 6 M compared to the 3 M readout. Conclusions: These data suggest that prenatal exercise improves the vascular function by the hypermethylation of CACNA1C in the arterial myocytes and delays the development of hypertension in the offspring of SHRs. However, these effects fade out with age.	[Li, Shanshan; Chen, Yu; Zhang, Yanyan; Qiu, Fang; Zeng, Fanxing; Shi, Lijun] Beijing Sport Univ, Dept Exercise Physiol, Beijing 100084, Peoples R China; [Shi, Lijun] Beijing Sport Univ, Key Lab Phys Fitness & Exercise, Minist Educ, Beijing, Peoples R China; [Li, Shanshan] Shandong Sport Univ, Dept Sports & Hlth, Jinan 250102, Peoples R China		Shi, LJ (通讯作者)，Beijing Sport Univ, Dept Exercise Physiol, Beijing 100084, Peoples R China.	shilj@bsu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32071174, 31771312]; Beijing Natural Science FoundationBeijing Natural Science Foundation [5172023]; Chinese Universities Scientific Fund [2020049]	This work was supported by the National Natural Science Foundation of China [32071174, 31771312] , the Beijing Natural Science Foundation [5172023] , and the Chinese Universities Scientific Fund [2020049] .	Barakat R, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.11.039; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Botting KJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb1929; Brunet A, 2014, J GERONTOL A-BIOL, V69, pS17, DOI 10.1093/gerona/glu042; Bunt JC, 2005, J CLIN ENDOCR METAB, V90, P3225, DOI 10.1210/jc.2005-0007; Catterall WA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003947; Chalk TEW, 2014, EPIGENOMICS-UK, V6, P469, DOI [10.2217/EPI.14.38, 10.2217/epi.14.38]; Chamiot-Clerc P, 2001, HYPERTENSION, V37, P313, DOI 10.1161/01.HYP.37.2.313; Chen M, 2015, HYPERTENSION, V66, P44, DOI 10.1161/HYPERTENSIONAHA.115.05299; Chen M, 2014, HYPERTENSION, V64, P610, DOI 10.1161/HYPERTENSIONAHA.114.03407; Chen Y, 2015, HYPERTENS RES, V38, P656, DOI 10.1038/hr.2015.56; Cheng HM, 2017, INT J CARDIOL, V230, P209, DOI 10.1016/j.ijcard.2016.12.170; Clapp JF, 2003, EUR J OBSTET GYN R B, V110, pS80, DOI 10.1016/S0301-2115(03)00176-3; Clapp JF, 2000, AM J OBSTET GYNECOL, V182, P300, DOI 10.1016/S0002-9378(00)70215-8; Clapp JF, 2000, CLIN SPORT MED, V19, P273, DOI 10.1016/S0278-5919(05)70203-9; Clapp JF, 1998, AM J OBSTET GYNECOL, V178, P594, DOI 10.1016/S0002-9378(98)70444-2; COX RH, 1995, HYPERTENSION, V26, P1060, DOI 10.1161/01.HYP.26.6.1060; Alves JLD, 2014, BRIT J NUTR, V111, P606, DOI 10.1017/S0007114513002833; Abate DTDES, 2012, FETAL PEDIATR PATHOL, V31, P423, DOI 10.3109/15513815.2012.659535; Dempsey JC, 2004, DIABETES RES CLIN PR, V66, P203, DOI 10.1016/j.diabres.2004.03.010; Eclarinal JD, 2016, FASEB J, V30, P2541, DOI 10.1096/fj.201500018R; Feng XQ, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201900022; Gilbert JS, 2012, HYPERTENSION, V60, P1545, DOI 10.1161/HYPERTENSIONAHA.112.202275; Giussani DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031017; Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102; Grigore D, 2008, GENDER MED, V5, pS121, DOI 10.1016/j.genm.2008.03.012; Haugen AC, 2015, J DEV ORIG HLTH DIS, V6, P55, DOI 10.1017/S2040174414000580; Hill MA, 2009, TRENDS PHARMACOL SCI, V30, P363, DOI 10.1016/j.tips.2009.04.008; Kane AD, 2013, CIRC J, V77, P2604, DOI 10.1253/circj.CJ-13-0311; Kurtz TW, 2015, HYPERTENSION, V65, P932, DOI 10.1161/HYPERTENSIONAHA.114.05092; Laker RC, 2014, DIABETES, V63, P1605, DOI [10.2337/db13-1614, 10.2337/db14-0135]; LangleyEvans SC, 1996, COMP BIOCHEM PHYS A, V114, P327, DOI 10.1016/0300-9629(96)00018-7; Li N, 2015, SCI REP-UK, V5, DOI 10.1038/srep13225; Maruyama K, 2015, LIFE SCI, V136, P42, DOI 10.1016/j.lfs.2015.06.023; May LE, 2010, EARLY HUM DEV, V86, P213, DOI 10.1016/j.earlhumdev.2010.03.002; Morris RC, 2016, CIRCULATION, V133, P881, DOI 10.1161/CIRCULATIONAHA.115.017923; Mourtakos SP, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0498-z; Mudd LM, 2013, MED SCI SPORT EXER, V45, P268, DOI 10.1249/MSS.0b013e31826cebcb; Niu YG, 2018, HYPERTENSION, V72, P971, DOI 10.1161/HYPERTENSIONAHA.118.11363; Ohya S, 2016, PHARMACOL THERAPEUT, V160, P11, DOI 10.1016/j.pharmthera.2016.02.001; Ohya Y, 1998, HYPERTENSION, V31, P1125, DOI 10.1161/01.HYP.31.5.1125; Patel J, 2010, PLACENTA, V31, P951, DOI 10.1016/j.placenta.2010.08.008; Pausova Z, 2003, KIDNEY INT, V64, P829, DOI 10.1046/j.1523-1755.2003.00172.x; Peracoli J C, 2001, Sao Paulo Med J, V119, P54, DOI 10.1590/S1516-31802001000200003; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Rocha R, 2014, ACTA CIR BRAS, V29, P553, DOI 10.1590/S0102-8650201400150002; Ronn T, 2013, EPIGENOMICS-UK, V5, P603, DOI 10.2217/epi.13.61; Santos JM, 2014, MED HYPOTHESES, V82, P748, DOI 10.1016/j.mehy.2014.03.018; Schmieder RE, 2010, DTSCH ARZTEBL INT, V107, P866, DOI 10.3238/arztebl.2010.0866; Sehgel NL, 2015, HYPERTENSION, V65, P370, DOI 10.1161/HYPERTENSIONAHA.114.04456; Shi LJ, 2012, EUR J APPL PHYSIOL, V112, P3667, DOI 10.1007/s00421-012-2344-6; Small HY, 2016, HYPERTENSION, V68, P1298, DOI 10.1161/HYPERTENSIONAHA.116.07933; Sonkusare S, 2006, VASC PHARMACOL, V44, P131, DOI 10.1016/j.vph.2005.10.005; Soubry A, 2015, INT J OBESITY, V39, P650, DOI 10.1038/ijo.2013.193; Tain YL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010023; Tang JQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep09723; Vieira JO, 2018, PSYCHONEUROENDOCRINO, V97, P111, DOI 10.1016/j.psyneuen.2018.07.014; Wang J, 2016, SCI REP-UK, V6, DOI 10.1038/srep39469; Zhang YY, 2020, J HYPERTENS, V38, P1763, DOI 10.1097/HJH.0000000000002457; Zhang YY, 2018, HYPERTENS RES, V41, P96, DOI 10.1038/hr.2017.96; Zhao Q, 2015, NEUROBIOL DIS, V82, P54, DOI 10.1016/j.nbd.2015.05.014	61	0	0	3	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106885	10.1016/j.vph.2021.106885		JUL 2021	14	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34116258				2022-04-29	WOS:000674133600004
J	Liu, Y; Hu, R; Zhu, JQ; Nie, XW; Jiang, YJ; Hu, PP; Liu, Y; Sun, ZX				Liu, Yun; Hu, Rong; Zhu, Jinquan; Nie, Xiaowei; Jiang, Yanjiao; Hu, Panpan; Liu, Yi; Sun, Zengxian			The lncRNA PAHRF functions as a competing endogenous RNA to regulate MST1 expression by sponging miR-23a-3p in pulmonary arterial hypertension	VASCULAR PHARMACOLOGY			English	Article						lncRNA PAHRF; Pulmonary arterial hypertension; Proliferation; Pulmonary smooth muscle cells	SMOOTH-MUSCLE-CELLS; PROLIFERATION; APOPTOSIS; MIGRATION	Background: Emerging evidence has shown that long non-coding RNA (lncRNA) plays important roles in the development of pulmonary arterial hypertension (PAH). However, some new lncRNAs in patients with PAH are still lacking research. Herein, we examined the expression and role of lncRNA (pulmonary arterial hypertension related factor, PAHRF) in PAH. Methods: LncRNA PAHRF expression and localization were analyzed by realtime PCR and fluorescence in situ hybridization. Proliferation and apoptosis were detected by MTT, CCK-8, EDU staining, JC-1 assay, flow cytometry and western blotting. Luciferase activity assay was used to identify PAHRF/ miR-23a-3p/serine/ threonine kinase 4 (STK4/MST1) interaction. Results: LncRNA PAHRF was down-regulated in both the PAs of PAH patients and hypoxic human pulmonary artery smooth muscle cells (PASMCs). The overexpression of PAHRF inhibited the proliferation and promoted the apoptosis of PASMCs. Similarly, we also found PAHRF overexpression decreased the proliferation under hypoxia condition. Knockdown of PAHRF exerted the opposite effects. Luciferase activity assay proved molecular binding between PAHRF and hsa-miR-23a-3p. Moreover, MST1 was confirmed to be the putative target gene and regulated by PAHRF/miR-23a-3p. In addition, we explored the molecular mechanism regulating the expression of miR-23a-3p, and found that lncRNA PAHRF acted as an endogenous sponge for miR-23a-3p, and silencing lncRNA PAHRF could up-regulate the expression of miR-23a-3p. On the contrary, PAHRF-overexpressing plasmid inhibited the expression of miR-23a-3p in hypoxia. Conclusions: Our present study reveals a novel PAH regulating model that is composed of PAHRF, miR-23a-3p, and MST1. The aim of this study is probably going to provide a new explanation and give a further understanding of the occurrence of vascular remodeling in PAH from the perspective competing endogenous RNA hypothesis.	[Liu, Yun; Hu, Rong; Zhu, Jinquan; Jiang, Yanjiao; Hu, Panpan; Liu, Yi; Sun, Zengxian] First Peoples Hosp Lianyungang, Dept Pharm, 6 Zhen Hua Rd, Lianyungang 222061, Peoples R China; [Liu, Yun; Jiang, Yanjiao; Hu, Panpan; Liu, Yi; Sun, Zengxian] Xuzhou Med Univ, Peoples Hosp Lianyungang 1, Affiliated Lianyungang Hosp, Dept Pharm, Lianyungang 222061, Peoples R China; [Hu, Rong] First Peoples Hosp Lianyungang, Dept Resp & Crit Care Med, Lianyungang 222061, Peoples R China; [Nie, Xiaowei] Shenzhen Third Peoples Hosp, Natl Clin Res Ctr Infect Dis, Inst Hepatol, Shenzhen 518112, Guangdong, Peoples R China; [Nie, Xiaowei] Nanjing Med Univ, Wuxi Peoples Hosp, Lung Transplant Grp, Wuxi 214023, Jiangsu, Peoples R China		Liu, Y (通讯作者)，First Peoples Hosp Lianyungang, Dept Pharm, 6 Zhen Hua Rd, Lianyungang 222061, Peoples R China.	yunliu211315@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31871155]; project of Jiangsu Provincial Commission of Health and Family Planning [QNRC2016505]; Six big talent peak C projects [YY-110]	This work was supported by National Natural Science Foundation of China (31871155) , project of Jiangsu Provincial Commission of Health and Family Planning (QNRC2016505) , Six big talent peak C projects (YY110) .	Ardestani A, 2016, DIABETOLOGIA, V59, P1843, DOI 10.1007/s00125-016-3892-9; Cai TZ, 2019, J CELL MOL MED, V23, P7289, DOI 10.1111/jcmm.14575; Chen JD, 2018, AM J RESP CELL MOL, V58, P181, DOI 10.1165/rcmb.2017-0111OC; Dong WD, 2018, STEM CELLS, V36, P1863, DOI 10.1002/stem.2904; Gao YR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.311; Khyzha N, 2019, P NATL ACAD SCI USA, V116, P16410, DOI 10.1073/pnas.1904108116; Leisegang MS, 2017, CIRCULATION, V136, P65, DOI 10.1161/CIRCULATIONAHA.116.026991; Li SS, 2013, BIOCHEM J, V452, P281, DOI 10.1042/BJ20120680; Liu BY, 2018, MOL THER-NUCL ACIDS, V13, P472, DOI 10.1016/j.omtn.2018.09.026; Liu Y, 2018, J CELL PHYSIOL, V233, P4801, DOI 10.1002/jcp.26279; Liu Y, 2016, INT J BIOCHEM CELL B, V77, P141, DOI 10.1016/j.biocel.2016.06.006; Ono H, 2005, ARTERIOSCL THROM VAS, V25, P1871, DOI 10.1161/01.ATV.0000174588.50971.1a; Peng GY, 2017, CYTOTECHNOLOGY, V69, P831, DOI 10.1007/s10616-017-0081-8; Rabinovitch M, 2012, J CLIN INVEST, V122, P4306, DOI 10.1172/JCI60658; Sarrion I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/792846; Simion V, 2019, VASC PHARMACOL, V114, P145, DOI 10.1016/j.vph.2018.01.003; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Su H, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0956-z; Sun ZX, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108933; Sun ZX, 2017, CELL PHYSIOL BIOCHEM, V42, P2569, DOI 10.1159/000480218; Thenappan T, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5492; Thompson BJ, 2015, J CELL BIOL, V210, P871, DOI 10.1083/jcb.201507005; Turunen SP, 2019, CELL DEATH DIFFER, V26, P2577, DOI 10.1038/s41418-019-0321-x; Wang DP, 2019, INT J MOL MED, V44, P871, DOI 10.3892/ijmm.2019.4256; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang K, 2014, CIRC RES, V114, P1377, DOI 10.1161/CIRCRESAHA.114.302476; Wang S, 2019, CAN J CARDIOL, V35, P1534, DOI 10.1016/j.cjca.2019.07.630; Xing Y, 2019, MOL THER, V27, P2166, DOI 10.1016/j.ymthe.2019.07.022; Yan L, 2017, ONCOL LETT, V13, P89, DOI 10.3892/ol.2016.5440; Yang L, 2019, LIFE SCI, V237, DOI 10.1016/j.lfs.2019.116769; Zhang HY, 2019, CARDIOVASC RES, V115, P647, DOI 10.1093/cvr/cvy250; Zhang L, 2014, J CELL PHYSIOL, V229, P245, DOI 10.1002/jcp.24443; Zhang YW, 2018, BIOMED PHARMACOTHER, V103, P1279, DOI 10.1016/j.biopha.2018.04.172; Zhao X, 2020, AUTOPHAGY, V16, P70, DOI 10.1080/15548627.2019.1598750; Zhou XH, 2020, CELL CYCLE, V19, P1363, DOI 10.1080/15384101.2020.1750257; Zhuang X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1850-4	36	1	1	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106886	10.1016/j.vph.2021.106886		JUL 2021	15	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34126237				2022-04-29	WOS:000674133600003
J	Zhao, J; Liu, ZY; Chang, ZH				Zhao, Jian; Liu, Zhaoyu; Chang, Zhihui			Osteogenic differentiation and calcification of human aortic smooth muscle cells is induced by the RCN2/STAT3/miR-155-5p feedback loop	VASCULAR PHARMACOLOGY			English	Article						Vascular calcification; RCN2; STAT3; miR-155-5p; Vascular smooth muscle cells		Background: Vascular calcification (VC) is associated with the high morbidity and mortality of cardiovascular diseases in dialysis patients and is a process in which vascular smooth muscle cells (VSMCs) actively differentiate into osteoblast-like cells. Reticulocalbin-2 (RCN2) is involved in the process of osteogenic differentiation under diabetic conditions, but its regulatory role under hyperphosphatemic conditions and the related mechanisms remain unclear. In this study, the importance of the interactions among RCN2, STAT3 and miR-155-5p during the osteogenic differentiation and calcification of human aortic VSMCs (HASMCs) were investigated. Methods: RCN2 was measured in femoropopliteal artery plaque specimens from 6 peripheral arterial disease (PAD) patients with chronic kidney disease (CKD) and 6 PAD patients without CKD. RCN2 protein and mRNA expression were assessed in the high phosphate-induced aortic rings culture ex vivo model. In vitro calcification assays and molecular mechanism studies were performed in HASMCs. Results: Immunohistochemical staining results revealed increased RCN2 expression in the calcified plaques of femoral arteries of patients with CKD and in a high phosphate-induced aortic culture ex vivo model. RCN2 promoted HASMCs osteogenic differentiation and calcification by inducing STAT3 phosphorylation. Furthermore, inhibition of STAT3 activation by cryptotanshinone (CT) promoted miR-155-5p expression in HASMCs. In turn, miR-155-5p inhibited RCN2 mRNA expression, while RCN2 overexpression partially offset the miR-155-5pmediated inhibition of HASMC calcification, acting as a positive feedback loop. Conclusion: These results demonstrate that RCN2 is a crucial regulator of VC under hyperphosphatemic conditions. RCN2/STAT3/miR-155-5p feedback loop is important in VC and targeting each member of this feedback loop could potentially reverse high phosphate-induced VC.	[Zhao, Jian; Liu, Zhaoyu; Chang, Zhihui] China Med Univ, Dept Radiol, Shengjing Hosp, Shenyang, Peoples R China		Chang, ZH (通讯作者)，36 Sanhao St,Heping Area, Shenyang, Peoples R China.	changzh@sj-hospital.org		Chang, Zhihui/0000-0002-7697-6435	Doctoral Start-up Foundation of Liaoning Province [2019-BS-286]; 345 Talent Project in Shengjing Hospital of China Medical University; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2020M670821]	This study was supported by funding from the Doctoral Start-up Foundation of Liaoning Province (No. 2019-BS-286), the 345 Talent Project in Shengjing Hospital of China Medical University and China Postdoctoral Science Foundation (2020M670821).	Amann K, 2008, CLIN J AM SOC NEPHRO, V3, P1599, DOI 10.2215/CJN.02120508; Balogh E, 2019, ARTERIOSCL THROM VAS, V39, P1088, DOI 10.1161/ATVBAHA.119.312509; Brigant B, 2017, CLIN KIDNEY J, V10, P30, DOI 10.1093/ckj/sfw060; Chang ZH, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116746; Chen NX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064558; Chen Q, 2019, THERANOSTICS, V9, P6424, DOI 10.7150/thno.35528; Chistiakov DA, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7463590; Ding D, 2017, ONCOGENE, V36, P6691, DOI 10.1038/onc.2017.230; Dutzmann J, 2015, CARDIOVASC RES, V106, P365, DOI 10.1093/cvr/cvv103; Escobar T, 2013, INVEST OPHTH VIS SCI, V54, P4017, DOI 10.1167/iovs.13-11937; Fakhry M, 2018, J CELL PHYSIOL, V233, P4056, DOI 10.1002/jcp.26121; Fukuyo S, 2014, RHEUMATOLOGY, V53, P1282, DOI 10.1093/rheumatology/ket496; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Kakutani Y, 2015, J CELL BIOCHEM, V116, P1325, DOI 10.1002/jcb.25088; Kong YL, 2018, LAB INVEST, V98, P1320, DOI 10.1038/s41374-018-0076-x; Lee K, 2014, BIOCHEM BIOPH RES CO, V451, P436, DOI 10.1016/j.bbrc.2014.08.007; Li J, 2019, AM J PHYSIOL-RENAL, V316, pF1141, DOI 10.1152/ajprenal.00567.2018; Li P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064678; Liao XB, 2013, ENDOCRINOLOGY, V154, P3344, DOI 10.1210/en.2012-2236; Liu LP, 2018, ARTERIOSCL THROM VAS, V38, P2382, DOI 10.1161/ATVBAHA.118.311546; Manichaikul A, 2011, AM J PHYSIOL-HEART C, V301, pH1056, DOI 10.1152/ajpheart.00366.2011; Meuth VML, 2017, BBA-MOL BASIS DIS, V1863, P337, DOI 10.1016/j.bbadis.2016.10.027; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871; Raitoharju E, 2011, ATHEROSCLEROSIS, V219, P211, DOI 10.1016/j.atherosclerosis.2011.07.020; Schelski N, 2019, PFLUG ARCH EUR J PHY, V471, P889, DOI 10.1007/s00424-019-02256-5; Sikorski K, 2011, CYTOKINE GROWTH F R, V22, P211, DOI 10.1016/j.cytogfr.2011.06.003; Toshima T, 2020, CARDIOVASC RES, V116, P983, DOI 10.1093/cvr/cvz210; Voelkl J, 2019, CELL MOL LIFE SCI, V76, P2077, DOI 10.1007/s00018-019-03054-z; Wang C, 2019, RENAL FAILURE, V41, P220, DOI 10.1080/0886022X.2019.1591997; Wang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09174-1; Wang G, 2017, AM J CANCER RES, V7, P2169; Wei YY, 2013, ARTERIOSCL THROM VAS, V33, P449, DOI 10.1161/ATVBAHA.112.300279; Wu TT, 2012, BONE, V51, P498, DOI 10.1016/j.bone.2012.05.013; Xu S, 2014, LEUKEMIA RES, V38, P1237, DOI 10.1016/j.leukres.2014.07.004; Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180	36	0	1	2	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106821	10.1016/j.vph.2020.106821		JAN 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33221530				2022-04-29	WOS:000613540200004
J	Cau, SB; Bruder-Nascimento, A; Silva, MB; Ramalho, FNZ; Mestriner, F; Alves-Lopes, R; Ferreira, N; Tostes, RC; Bruder-Nascimento, T				Cau, Stefany B.; Bruder-Nascimento, Ariane; Silva, Marcondes B.; Ramalho, Fernanda N. Z.; Mestriner, Fabiola; Alves-Lopes, Rheure; Ferreira, Nathanne; Tostes, Rita C.; Bruder-Nascimento, Thiago			Angiotensin-II activates vascular inflammasome and induces vascular damage	VASCULAR PHARMACOLOGY			English	Article						Angiotensin-II; Inflammasome; Vascular damage	NLRP3 INFLAMMASOME; INDUCED HYPERTENSION; MESENTERIC-ARTERIES; OXIDATIVE STRESS; BLOOD-PRESSURE; DYSFUNCTION; DISEASE; CELLS; HEART; CONTRIBUTES	Angiotensin-II (Ang-II), a major target for treatment of cardiovascular disease, promotes cardiovascular dysfunction by directly modulating structure and function of vascular cells. Inflammasome components are expressed in the vasculature and are activated by specific stimuli. However, whether Ang-II activates the inflammasome in vascular cells or inflammasome activation contributes to Ang-II-induced vascular damage is still not fully elucidated. We tested the hypothesis that Ang-II induces endothelial dysfunction, vascular remodeling, and high blood pressure via inflammasome activation. C57BL6/J wild type (WT) and Caspase-1 knockout (Casp1-/-) mice were infused with vehicle or Ang-II for two weeks (490 ng/Kg/day) to determine whether the inflammasome contributes to vascular damage induced by Ang-II. Rat Aortic Vascular Smooth Muscle cells (RASMC) were used to determine if the interaction between Ang-II and inflammasomes causes migration and proliferation of vascular smooth muscle cells. Ex vivo studies revealed that Ang-II infusion induced vascular oxidative stress, endothelial dysfunction and vascular remodeling in WT mice. Casp1-/- mice were protected against Ang-II-induced vascular injury. In vitro experiments, Ang-II activated the NLRP3 inflammasome in RASMC, i.e. Ang-II increased Caspase-1 (Casp1) activity and cleavage of pro-interleukin (IL)-1 beta. MCC950 (NLRP3 receptor antagonist) prevented Ang-II-induced vascular migration and proliferation, but failed to reduce reactive oxygen species production. In conclusion, Ang-II leads to inflammasome activation in the vasculature contributing to endothelial dysfunction and vascular remodeling. Taken together, we place inflammasomes as a possible therapeutic target in conditions associated with increased Ang-II levels.	[Cau, Stefany B.; Silva, Marcondes B.; Ramalho, Fernanda N. Z.; Mestriner, Fabiola; Alves-Lopes, Rheure; Ferreira, Nathanne; Tostes, Rita C.; Bruder-Nascimento, Thiago] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Sao Paulo, Brazil; [Cau, Stefany B.] Univ Fed Minas Gerais, Inst Biol Sci, Dept Pharmacol, Belo Horizonte, MG, Brazil; [Bruder-Nascimento, Ariane; Bruder-Nascimento, Thiago] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15224 USA; [Bruder-Nascimento, Ariane; Bruder-Nascimento, Thiago] Univ Pittsburgh, Ctr Pediat Res Obes & Metab CPROM, Pittsburgh, PA 15224 USA; [Bruder-Nascimento, Thiago] Univ Pittsburgh, Vasc Med Inst VMI, Pittsburgh, PA 15224 USA		Bruder-Nascimento, T (通讯作者)，Univ Pittsburgh, Dept Pediat, John G Rangos Sr Res Ctr, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	bruder@pitt.edu	Alves-Lopes, Rheure/U-7347-2018	Alves-Lopes, Rheure/0000-0002-4885-6647	Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/12604-2]; Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88,887.092495/2015-00, NIH-R00 (4R00HL14013903)]	This work was supported by grants from Sao Paulo Research Foundation (2011/12604-2 to SBC and to the Center of Research in Inflammatory Diseases 2013/08216-2) , Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (88,887.092495/2015-00 to RCT and TBN) , and NIH-R00 (4R00HL14013903) to TBN.	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; Bruder-Nascimento T, 2014, J MOL CELL CARDIOL, V66, P18, DOI 10.1016/j.yjmcc.2013.10.013; Bruder-Nascimento T, 2016, CIRCULATION, V134, P1866, DOI 10.1161/CIRCULATIONAHA.116.024369; Butts B, 2015, J CARD FAIL, V21, P586, DOI 10.1016/j.cardfail.2015.04.014; Chen Y, 2015, BBA-MOL CELL RES, V1853, P396, DOI 10.1016/j.bbamcr.2014.11.012; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Conforti-Andreoni C, 2011, CELL MOL IMMUNOL, V8, P135, DOI 10.1038/cmi.2010.81; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; De Batista PR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104020; De Mello WC, 2000, HYPERTENSION, V35, P1183, DOI 10.1161/01.HYP.35.6.1183; Ferreira NS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121595; Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067; Gasse P, 2007, J CLIN INVEST, V117, P3786, DOI 10.1172/JCI32285; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; Haque S, 2017, HUM VACC IMMUNOTHER, V13, P1741, DOI 10.1080/21645515.2017.1327107; He J, 2012, INT J CARDIOL, V160, P72, DOI 10.1016/j.ijcard.2012.05.083; Hernanz R, 2015, BRIT J PHARMACOL, V172, P3159, DOI 10.1111/bph.13117; Imai Y, 2013, DIABETES OBES METAB, V15, P117, DOI 10.1111/dom.12161; Itani HA, 2016, CIRC RES, V118, P1233, DOI 10.1161/CIRCRESAHA.115.308111; Kang KT, 2018, TOX RESEARCH, V34, P363, DOI 10.5487/TR.2018.34.4.363; Khaper N, 2001, J AM COLL CARDIOL, V37, P1461, DOI 10.1016/S0735-1097(01)01126-3; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Li WJ, 2016, LIFE SCI, V149, P18, DOI 10.1016/j.lfs.2016.02.037; Li YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076289; Nakashima T, 2015, HYPERTENS RES, V38, P649, DOI 10.1038/hr.2015.55; OKUDA T, 1967, TEX REP BIOL MED, V25, P257; OLSEN F, 1980, ACTA PATH MICRO IM C, V88, P1; Rabkin SW, 2009, NAT CLIN PRACT CARD, V6, P192, DOI 10.1038/ncpcardio1453; Ren XS, 2017, CELL PHYSIOL BIOCHEM, V44, P2269, DOI 10.1159/000486061; Sakaue T, 2017, HYPERTENSION, V70, P780, DOI 10.1161/HYPERTENSIONAHA.117.09512; Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009; Silva MAB, 2015, CLIN SCI, V129, P533, DOI 10.1042/CS20140758; Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029; Sun HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.470; Thang LV, 2015, AM J PHYSIOL-HEART C, V309, pH1186, DOI 10.1152/ajpheart.00283.2015; Tousoulis D, 2008, ATHEROSCLEROSIS, V201, P236, DOI 10.1016/j.atherosclerosis.2008.05.034; Varghese GP, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003031; Wang W, 2013, J IMMUNOL, V190, P1239, DOI 10.4049/jimmunol.1201959; Wen Y, 2016, ONCOTARGET, V7, P54290, DOI 10.18632/oncotarget.11091; WHITE FN, 1964, NEPHRON, V1, P93, DOI 10.1159/000179322; Wu YT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01059; Xi H, 2016, CIRC RES, V118, P1525, DOI 10.1161/CIRCRESAHA.116.308501; YUE TL, 1994, BIOCHEM BIOPH RES CO, V204, P1186, DOI 10.1006/bbrc.1994.2588; Zeng C, 2019, INT J BIOL SCI, V15, P1345, DOI 10.7150/ijbs.33568; Zhang LL, 2016, FREE RADICAL BIO MED, V97, P531, DOI 10.1016/j.freeradbiomed.2016.07.014; Zhao M, 2018, KIDNEY DIS-BASEL, V4, P83, DOI 10.1159/000488242	51	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106881	10.1016/j.vph.2021.106881		JUL 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34098096				2022-04-29	WOS:000674133600008
J	Madonna, R				Madonna, Rosalinda			Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension	VASCULAR PHARMACOLOGY			English	Article						Renine-angiotensin-aldosterone; Heart failure; Pulmonary hypertension; Gliflozines	EMPAGLIFLOZIN; MORTALITY; INHIBITORS; STIFFNESS; OUTCOMES; HEALTH	Although results from two major trials trials have shown a clear benefit of gliflozines in the management of heart failure (HF) irrespective of diabetes status, the mechanism of cardiac benefits remains incompletely understood. Gliflozines have an osmotic diuretic effect that differs from that of other diuretic classes, resulting in greater electrolyte-free water clearance, and clinical studies have shown that intravascular volume depletion is rare and occurs at similar frequency in the gliflozines and placebo groups. As a consequence of the negligible effects on the blood volume and body's fluid balance compared to diuretics, gliflozines may limit the reflex neurohumoral stimulation and activation of renin-angiotensin-aldosterone system (RAAS). Since neurohormonal and RAAS activation in patients with HF reduced or ejection fraction (HFrEF and HFpEF) also leads to systemic and pulmonary arterial stiffening, pulmonary hypertension (PH) and PH-related right ventricular failure, gliflozines may lead to a mitigation of systemic and pulmonary arterial stiffening, which in turn can reduce the degree of PH associated with HFrEF or HFpEF, can improve the ventricular arterial coupling and can reduce the overload of the left and right ventricle, improving their function. The current review discusses the latest findings regarding the effects of SGLT2 inhibitors on heart failure with focus also on pulmonary hypertension, discussing the molecular mechanisms involved.	[Madonna, Rosalinda] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, McGovern Sch Med, Houston, TX 77030 USA; [Madonna, Rosalinda] Univ Pisa, Inst Cardiol, Osped Cisanello Via Paradisa 2, I-56124 Pisa, Italy		Madonna, R (通讯作者)，Univ Pisa, Inst Cardiol, Osped Cisanello Via Paradisa 2, I-56124 Pisa, Italy.	rosalinda.madonna@unipi.it		Madonna, Rosalinda/0000-0001-6455-2777	Incyte; Ministero dell'Istruzione, Universita e Ricerca ScientificaMinistry of Education, Universities and Research (MIUR) [549901_2020_Madonna:Ateneo]	This work was supported by a grant from Incyte to RM and funds from Ministero dell'Istruzione, Universit`a e Ricerca Scientifica to RM (549901_2020_Madonna:Ateneo). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.	Agoston-Coldea L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32784-6; Agrawal Vimal, 2016, Indian Heart J, V68, P856, DOI 10.1016/j.ihj.2016.06.010; Ameri P, 2016, HEART FAIL REV, V21, P539, DOI 10.1007/s10741-016-9566-3; Chen YJ, 2017, STROKE VASC NEUROL, V2, P65, DOI 10.1136/svn-2016-000045; Chowdhury B, 2020, BIOCHEM BIOPH RES CO, V524, P50, DOI 10.1016/j.bbrc.2020.01.015; Di Franco A, 2017, INT J CARDIOL, V243, P86, DOI 10.1016/j.ijcard.2017.05.032; Foglia MJ, 2016, DEVELOPMENT, V143, P729, DOI 10.1242/dev.132910; Forte E, 2020, CELL REP, V30, P3149, DOI 10.1016/j.celrep.2020.02.008; Forte E, 2018, NAT REV CARDIOL, V15, P601, DOI 10.1038/s41569-018-0077-x; Frigerio M, 2005, AM J CARDIOL, V96, p10L, DOI 10.1016/j.amjcard.2005.09.060; Gan CTJ, 2007, CHEST, V132, P1906, DOI 10.1378/chest.07-1246; Grosman-Rimon L, 2020, HEART FAIL REV, V25, P685, DOI 10.1007/s10741-019-09860-8; Humeres C, 2019, JACC-BASIC TRANSL SC, V4, P449, DOI 10.1016/j.jacbts.2019.02.006; Kaplan NM, 2004, J HUM HYPERTENS, V18, pS29, DOI 10.1038/sj.jhh.1001798; Kong P, 2014, CELL MOL LIFE SCI, V71, P549, DOI 10.1007/s00018-013-1349-6; Lu IN, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04618-2; Madonna R., 2020, J CLIN MED, V9; Madonna R, 2020, J CELL MOL MED, V24, P12331, DOI 10.1111/jcmm.15699; Madonna R, 2020, VASC PHARMACOL, V125, DOI 10.1016/j.vph.2020.106648; Madonna R, 2016, CURR DRUG TARGETS, V17, P817, DOI 10.2174/1389450116666150722140424; Mahmud A, 2002, AM J HYPERTENS, V15, P1092, DOI 10.1016/S0895-7061(02)02982-5; Maliha G, 2015, J AM SOC HYPERTENS, V9, P48, DOI 10.1016/j.jash.2014.11.001; Mayourian J, 2018, CIRC RES, V122, P167, DOI 10.1161/CIRCRESAHA.117.311589; McMurray JJV, 2019, EUR J HEART FAIL, V21, P665, DOI 10.1002/ejhf.1432; Mullens W, 2020, ESC HEART FAIL, V7, P2071, DOI 10.1002/ehf2.12850; Obokata M, 2019, EUR HEART J, V40, P3707, DOI 10.1093/eurheartj/ehz626; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Packer M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016270; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Sano M, 2019, CIRCULATION, V139, P1985, DOI 10.1161/CIRCULATIONAHA.118.038881; Schmieder R, 2016, J HYPERTENS, V34, pE76, DOI 10.1097/01.hjh.0000500051.20830.98; SCHRIER RW, 1990, ANN INTERN MED, V113, P155, DOI 10.7326/0003-4819-113-2-155; Smith KJ, 2003, CARDIOVASC RES, V59, P538, DOI 10.1016/S0008-6363(03)00468-1; Steffens S, 2020, CARDIOVASC RES, V116, P1850, DOI 10.1093/cvr/cvaa137; Uthman L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01575; Vrhovac I, 2015, PFLUG ARCH EUR J PHY, V467, P1881, DOI 10.1007/s00424-014-1619-7; Williams DM, 2020, DIABETES THER, V11, P1925, DOI 10.1007/s13300-020-00889-9; Yasui A, 2018, DIABETES THER, V9, P863, DOI 10.1007/s13300-018-0385-5; Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720	39	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106839	10.1016/j.vph.2021.106839		MAY 2021	4	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33524548				2022-04-29	WOS:000652840900013
J	Misuth, S; Uhrinova, M; Klimas, J; Vavrincova-Yaghi, D; Vavrinec, P				Misuth, Svetozar; Uhrinova, Marina; Klimas, Jan; Vavrincova-Yaghi, Diana; Vavrinec, Peter			Vildagliptin improves vascular smooth muscle relaxation and decreases cellular senescence in the aorta of doxorubicin-treated rats	VASCULAR PHARMACOLOGY			English	Article						Doxorubicin; Cellular senescence; Vascular smooth muscle of aorta; Vildagliptin; GLP-1	INDUCED APOPTOSIS; DYSFUNCTION; RECEPTOR; CELLS; ATTENUATION; INHIBITION; ACTIVATION; GLUCOSE; KIDNEY; GLP-1	Introduction: Doxorubicin (DOX) is a chemotherapeutic agent used in cancer treatment. Its use is limited by later toxicity to the cardiovascular system (CVS). Cellular senescence has been proposed as one mechanism of DOX toxicity. It has also been suggested that senescence reduction can improve the condition in many pathologies. We hypothesised that vildagliptin treatment can reduce senescence and thus improve the relaxation of vascular smooth muscle (VSM) in the aorta of a rat DOX model. Methods: The rats received DOX and were treated with vildagliptin for 6 weeks. Thereafter, the rats were sacrificed, and the aorta prepared for measurements of VSM relaxation and RNA isolation to detect the level of senescence markers. To further prove the antisenescence effect of the main vildagliptin effector glucagon-like peptide 1(GLP-1), VSM cells (VSMCs) were incubated with DOX and treated with GLP-1. Subsequently, senescence was detected by senescence-associated beta-galactosidase (SA-beta-gal) and by the presence of senescence markers. Results: DOX in rats caused diminished relaxation of VSM to sodium nitrate and caused an increase in the senescence mRNA markers p16(Ink4a) and p27(Kip1) and the senescence-associated secretory phenotype (SASP) IL-6 and IL-8. Vildagliptin treatment led to improved relaxation and a reduction in senescence and SASP markers. Furthermore, in VSMCs DOX increased SA-beta-gal activity, p16(Ink4a), p27(Kip1), IL-6 and IL-8, and GLP1 treatment led to a decrease of both senescence and SASP markers. Conclusion: In summary we conclude that vildagliptin can reduce senescence and improve relaxation of vascular smooth muscle in the aorta of DOX-treated rats, and GLP-1 can reduce senescence of DOX-treated VSMCs. These data suggest that incretin-based drugs are promising candidates for patients suffering from late doxorubicin cardiovascular toxicity.	[Misuth, Svetozar; Uhrinova, Marina; Klimas, Jan; Vavrincova-Yaghi, Diana; Vavrinec, Peter] Comenius Univ, Fac Pharm, Dept Pharmacol & Toxicol, Odbojarov 10, Bratislava 83232, Slovakia		Vavrinec, P (通讯作者)，Comenius Univ, Fac Pharm, Dept Pharmacol & Toxicol, Odbojarov 10, Bratislava 83232, Slovakia.	vavrinec@fpharm.uniba.sk			Scientific Grant Agency of The Ministry of Education, Science, Research and Sport of the Slovak Republic; Slovak Academy of SciencesSlovak Academy of Sciences [VEGA 1/0027/20]; Slovak Research and Development AgencySlovak Research and Development Agency [APVV-15-0685]	This work was supported by grants of The Scientific Grant Agency of The Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences [VEGA 1/0027/20] and the grant of The Slovak Research and Development Agency [APVV-15-0685].	Altieri P, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002383; Arakawa M, 2010, DIABETES, V59, P1030, DOI 10.2337/db09-1694; Bielak-Zmijewska A, 2014, BIOGERONTOLOGY, V15, P47, DOI 10.1007/s10522-013-9477-9; Campisi J, 2016, ANN AM THORAC SOC, V13, pS402, DOI 10.1513/AnnalsATS.201609-703AW; Cappetta D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1521020; de Magalhaes JP, 2018, MECH AGEING DEV, V170, P2, DOI 10.1016/j.mad.2017.07.001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drucker DJ, 2016, CELL METAB, V24, P15, DOI 10.1016/j.cmet.2016.06.009; Gibson NM, 2013, J CARDIOVASC PHARM, V62, P355, DOI 10.1097/FJC.0b013e31829c9993; Glossmann HH, 2019, GERONTOLOGY, V65, P581, DOI 10.1159/000502257; Hallbrink M, 2001, BBA-PROTEIN STRUCT M, V1546, P79, DOI 10.1016/S0167-4838(00)00270-3; Hayward R, 2013, J PHYSIOL BIOCHEM, V69, P177, DOI 10.1007/s13105-012-0200-0; Holz George G, 2005, Sci STKE, V2005, ppe2; Hydock DS, 2009, J CARDIOVASC PHARM T, V14, P59, DOI 10.1177/1074248408329449; Jo CH, 2018, KIDNEY BLOOD PRESS R, V43, P987, DOI 10.1159/000490688; Joyner DE, 2006, J ORTHOP RES, V24, P1163, DOI 10.1002/jor.20169; Justice JN, 2019, EBIOMEDICINE, V40, P554, DOI 10.1016/j.ebiom.2018.12.052; LARSON DM, 1988, DIABETES, V37, P1380, DOI 10.2337/diabetes.37.10.1380; Li MY, 2001, EXP BIOL MED, V226, P450, DOI 10.1177/153537020122600510; Liao PZ, 2017, CELL PHYSIOL BIOCHEM, V44, P1842, DOI 10.1159/000485820; Liu HB, 2008, J ENDOCRINOL, V196, P57, DOI 10.1677/JOE-07-0387; Nino PKB, 2015, CLIN SCI, V129, P1061, DOI 10.1042/CS20140753; Noyan-Ashraf MH, 2013, CIRCULATION, V127, P74, DOI 10.1161/CIRCULATIONAHA.112.091215; Oeseburg H, 2010, ARTERIOSCL THROM VAS, V30, P1407, DOI 10.1161/ATVBAHA.110.206425; Olukman M, 2009, ANATOL J CARDIOL, V9, P260; Orshal JM, 2004, AM J PHYSIOL-REG I, V286, pR1013, DOI 10.1152/ajpregu.00729.2003; Probin V, 2006, J PHARMACOL EXP THER, V319, P551, DOI 10.1124/jpet.106.107771; Przybylska D, 2016, ONCOTARGET, V7, P66429, DOI 10.18632/oncotarget.12079; Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x; Rao SG, 2016, TRENDS CANCER, V2, P676, DOI 10.1016/j.trecan.2016.10.001; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Steven S, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0465-x; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Tian XL, 2014, J GENET GENOMICS, V41, P485, DOI 10.1016/j.jgg.2014.08.001; Uhm Jae-Sun, 2014, Clin Hypertens, V20, P8, DOI 10.1186/2056-5909-1-2; Ulu N, 2013, J PHARMACOL EXP THER, V345, P393, DOI 10.1124/jpet.113.203497; Vavrinec P, 2014, CURR VASC PHARMACOL, V12, P836, DOI 10.2174/15701611113116660151; VILLASCHI S, 1994, IN VITRO CELL DEV-AN, V30A, P589; Yagmurca M, 2015, BRATISL MED J, V116, P486, DOI 10.4149/BLL_2015_092; Zhao L, 2014, AM J PHYSIOL-CELL PH, V307, pC1130, DOI 10.1152/ajpcell.00151.2014	40	2	2	3	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106855	10.1016/j.vph.2021.106855		MAY 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33744414	hybrid			2022-04-29	WOS:000652840900011
J	Verdoia, M; Negro, F; Kedhi, E; Suryapranata, H; Marcolongo, M; De Luca, G				Verdoia, Monica; Negro, Federica; Kedhi, Elvin; Suryapranata, Harry; Marcolongo, Marco; De Luca, Giuseppe			Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials	VASCULAR PHARMACOLOGY			English	Article						Drug-coated balloons; Coronary artery disease; Peripheral artery disease; Stent; Angioplasty; Meta-analysis	IN-STENT RESTENOSIS; PACLITAXEL-ELUTING BALLOON; BARE-METAL STENT; DUAL ANTIPLATELET THERAPY; LONG-TERM OUTCOMES; 3-YEAR FOLLOW-UP; FEMOROPOPLITEAL LESIONS; STANDARD BALLOON; CLINICAL-TRIAL; ANGIOPLASTY	Background: Drug-coated balloons (DCB) have shown promising results for the percutaneous treatment of de novo and restenotic lesions, involving both the coronary and femoropopliteal district. However, clinical outcomes data associated with the use of this devices are still unclear, with potential warnings on increased mortality being raised from initial studies. We aimed at performing an updated and comprehensive meta-analysis comparing DCB with conventional percutaneous revascularization strategies for the treatment of coronary (CAD) or peripheral artery disease (PAD). Methods: Literature and main scientific session abstracts were searched for studies comparing DCB vs a standard percutaneous revascularization strategy, with or without stenting, for the treatment of CAD and PAD. The primary efficacy endpoint was mortality. Secondary endpoints were recurrent acute ischemic events (myocardial infarction or amputation) or target lesion revascularization (TLR). Results: We included 45 randomized trials, (CAD: 27 studies, PAD: 18 studies) with an overall population of 7718 patients, (56.4%) randomized to a DCB strategy. At a mean follow-up of19.3 +/- 15.2 months, death occurred in 5.8% of the patients, with no significant difference between DCB or conventionally treated patients (5.9% vs 5.7%, OR[95%CI] = 0.89[0.71,1.11], p = 0.31; phet = 0.43). We observed a non-significant reduction in recurrent acute ischemic events, whereas the use of DCB significantly reduced the rate of TLR, with larger benefits observed in patients with PAD and respect to balloon-only angioplasty, while being lower in comparison with stent implantation. No significant interaction was observed with de novo lesions or in-stent restenosis. Conclusions: Based on the current meta-analysis, the use of drug-coated balloons for the percutaneous treatment of CAD and PAD is associated to a comparable risk of mortality and recurrent acute ischemic events as compared to a conventional revascularization strategy, although offering larger benefits in terms of TLR, especially when compared with balloon-only angioplasty and in femoropopliteal disease.	[Verdoia, Monica; Marcolongo, Marco] ASL Biella, Div Cardiol, Ponderano, Italy; [Verdoia, Monica; Negro, Federica; De Luca, Giuseppe] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy; [Kedhi, Elvin] Univ Libre Bruxelles, Erasmus Hosp, Dept Cardiol, Brussels, Belgium; [Suryapranata, Harry] Radboud Univ Nijmegen Med Ctr, Dept Cardiol, Nijmegen, Netherlands		De Luca, G (通讯作者)，Univ Maggiore della Carita, Azienda Osped, Univ Eastern Piedmont, Corso Mazzini 18, I-28100 Novara, Italy.	giuseppe.deluca@maggioreosp.novara.it	Verdoia, Monica/AAS-1779-2021	Verdoia, Monica/0000-0001-6506-8397			Adriaenssens T, 2014, EUROINTERVENTION, V10, P439, DOI 10.4244/EIJV10I4A77; Afilalo J, 2014, J AM COLL CARDIOL, V63, P747, DOI 10.1016/j.jacc.2013.09.070; Albrecht T, 2018, CARDIOVASC INTER RAD, V41, P1008, DOI 10.1007/s00270-018-1940-1; Alfonso F, 2018, JACC-CARDIOVASC INTE, V11, P981, DOI 10.1016/j.jcin.2018.02.037; Alfonso F, 2017, EUROINTERVENTION, V13, P680, DOI 10.4244/EIJ-D-17-00494; Alfonso F, 2016, JACC-CARDIOVASC INTE, V9, P1246, DOI 10.1016/j.jcin.2016.03.037; Ali R.M, 2011, EUROINTERVENTION, P83; Ann SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147057; Baan J, 2018, JACC-CARDIOVASC INTE, V11, P275, DOI 10.1016/j.jcin.2017.10.024; Bailey SR, 2019, J AM COLL CARDIOL, V73, P214, DOI 10.1016/j.jacc.2018.10.002; Bausback Y, 2019, J AM COLL CARDIOL, V73, P667, DOI 10.1016/j.jacc.2018.11.039; Bausback Y, 2017, J ENDOVASC THER, V24, P459, DOI 10.1177/1526602817710770; Belkacemi A, 2012, J AM COLL CARDIOL, V59, P2327, DOI 10.1016/j.jacc.2012.02.027; Bjorkman P, 2019, ANN VASC SURG, V55, P36, DOI 10.1016/j.avsg.2018.04.042; Bortnick AE, 2014, AM J CARDIOL, V113, P573, DOI 10.1016/j.amjcard.2013.10.039; Brodmann M, 2018, JACC-CARDIOVASC INTE, V11, P2357, DOI 10.1016/j.jcin.2018.08.034; Burzotta F, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-55; Cassese S, 2019, EUROINTERVENTION, V15, pE560, DOI 10.4244/EIJ-D-18-00550; de Boer SW, 2017, J ENDOVASC THER, V24, P783, DOI 10.1177/1526602817725062; De Luca G, 2019, EUROINTERVENTION, V15, pE990, DOI 10.4244/EIJ-D-19-00539; De Luca G, 2015, DIABETES VASC DIS RE, V12, P306, DOI 10.1177/1479164115592252; De Luca G, 2013, AM J CARDIOL, V111, P1295, DOI 10.1016/j.amjcard.2013.01.281; Fanelli F, 2014, J CARDIOVASC SURG, V55, P207; Feldman DN, 2018, CATHETER CARDIO INTE, V92, P124, DOI 10.1002/ccd.27635; Funatsu A, 2017, CLIN RES CARDIOL, V106, P824, DOI 10.1007/s00392-017-1126-x; Giacoppo D, 2020, EUR HEART J, V41, P3715, DOI 10.1093/eurheartj/ehz594; Giannini F, 2017, CARDIOVASC REVASCULA, V18, P4, DOI 10.1016/j.carrev.2016.12.008; Gobic D, 2017, AM J MED SCI, V354, P553, DOI 10.1016/j.amjms.2017.07.005; Grenon SM, 2013, VASC MED, V18, P176, DOI 10.1177/1358863X13493825; Habara S, 2011, JACC-CARDIOVASC INTE, V4, P149, DOI 10.1016/j.jcin.2010.10.012; Hokimoto S, 2016, INT J CARDIOL, V222, P185, DOI 10.1016/j.ijcard.2016.07.221; Jeger RV, 2018, LANCET, V392, P849, DOI 10.1016/S0140-6736(18)31719-7; Jensen CJ, 2018, EUROINTERVENTION, V14, P1096, DOI 10.4244/EIJ-D-17-01079; Katsanos K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.011245; Kinstner CM, 2016, JACC-CARDIOVASC INTE, V9, P1386, DOI 10.1016/j.jcin.2016.04.012; Kleber FX, 2016, CLIN RES CARDIOL, V105, P613, DOI 10.1007/s00392-015-0957-6; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Krankenberg H, 2015, CIRCULATION, V132, P2230, DOI 10.1161/CIRCULATIONAHA.115.017364; Kufner S, 2015, JACC-CARDIOVASC INTE, V8, P877, DOI 10.1016/j.jcin.2015.01.031; Laird JR, 2015, J AM COLL CARDIOL, V66, P2329, DOI 10.1016/j.jacc.2015.09.063; Liberati A., 2009, PLOS MED, V339, pB2700, DOI [10.1136/bmj.b2700, DOI 10.1371/JOURNAL.PMED.1000100, DOI 10.7326/0003-4819-151-4-200908180-00136]; Liistro F., AM HEART J, V166; Minguez JRL, 2014, EUROINTERVENTION, V10, P50, DOI 10.4244/EIJV10I1A10; Micari A, 2018, JACC-CARDIOVASC INTE, V11, P945, DOI 10.1016/j.jcin.2018.02.019; Miura K, 2017, AM J CARDIOL, V119, P365, DOI 10.1016/j.amjcard.2016.10.030; Mustapha JA, 2019, J INVASIVE CARDIOL, V31, P205; Nishiyama N, 2016, INT J CARDIOL, V222, P113, DOI 10.1016/j.ijcard.2016.07.156; Ott I, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006321; Ott I, 2017, CIRCULATION, V135, P2218, DOI 10.1161/CIRCULATIONAHA.116.025329; Ouriel K, 2019, JACC-CARDIOVASC INTE, V12, P2515, DOI 10.1016/j.jcin.2019.08.025; Pleva L, 2018, CATHETER CARDIO INTE, V92, pE416, DOI 10.1002/ccd.27688; Rissanen T.T, 2019, LANCET, V394; Rittger H, 2015, JACC-CARDIOVASC INTE, V8, P1695, DOI 10.1016/j.jcin.2015.07.023; Rittger H, 2012, J AM COLL CARDIOL, V59, P1377, DOI 10.1016/j.jacc.2012.01.015; Rosenfield K, 2015, NEW ENGL J MED, V373, P145, DOI 10.1056/NEJMoa1406235; Scheinert D, 2014, JACC-CARDIOVASC INTE, V7, P11, DOI 10.1016/j.jcin.2013.05.022; Scheller B, 2020, EUROINTERVENTION, V15, P1527, DOI 10.4244/EIJ-D-19-00723; Scheller B, 2016, CATHETER CARDIO INTE, V88, P51, DOI 10.1002/ccd.26216; Scheller B, 2012, JACC-CARDIOVASC INTE, V5, P323, DOI 10.1016/j.jcin.2012.01.008; Schneider PA, 2019, J AM COLL CARDIOL, V73, P2550, DOI 10.1016/j.jacc.2019.01.013; Shin ES, 2016, CATHETER CARDIO INTE, V88, P193, DOI 10.1002/ccd.26257; Siablis D, 2014, JACC-CARDIOVASC INTE, V7, P1048, DOI 10.1016/j.jcin.2014.04.015; Silverio A, 2020, JACC-CARDIOVASC INTE, V13, P1380, DOI 10.1016/j.jcin.2020.04.009; Stella PR, 2012, CATHETER CARDIO INTE, V80, P1138, DOI 10.1002/ccd.23499; Tepe G., 2020, J ENDOVASC THER, V27; Tepe G, 2015, JACC-CARDIOVASC INTE, V8, P102, DOI 10.1016/j.jcin.2014.07.023; Tian J, 2020, CATHETER CARDIO INTE, V95, P587, DOI 10.1002/ccd.28705; Unverdorben M, 2009, CIRCULATION, V119, P2986, DOI 10.1161/CIRCULATIONAHA.108.839282; Verdoia M, 2016, J THROMB HAEMOST, V14, P57, DOI 10.1111/jth.13177; Verheye S, 2017, JACC-CARDIOVASC INTE, V10, P2029, DOI 10.1016/j.jcin.2017.06.021; Vos NS, 2019, JACC-CARDIOVASC INTE, V12, P1691, DOI 10.1016/j.jcin.2019.04.016; Werk M, 2012, CIRC-CARDIOVASC INTE, V5, P831, DOI 10.1161/CIRCINTERVENTIONS.112.971630; WHO, 2012, WORLD MALARIA REPORT 2012, P1; Wong YTA, 2018, AM HEART J, V197, P35, DOI 10.1016/j.ahj.2017.11.008; Xia X., 2016, JACC CARDIOVASC INTE, V9; Xu B, 2014, JACC-CARDIOVASC INTE, V7, P204, DOI 10.1016/j.jcin.2013.08.011; Zeller T, 2014, J AM COLL CARDIOL, V64, P1568, DOI 10.1016/j.jacc.2014.06.1198	77	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106859	10.1016/j.vph.2021.106859		MAY 2021	23	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33819672				2022-04-29	WOS:000652840900010
J	Buono, MF; Slenders, L; Wesseling, M; Hartman, RJG; Monaco, C; den Ruijter, HM; Pasterkamp, G; Mokry, M				Buono, Michele F.; Slenders, Lotte; Wesseling, Marian; Hartman, Robin J. G.; Monaco, Claudia; den Ruijter, Hester M.; Pasterkamp, Gerard; Mokry, Michal			The changing landscape of the vulnerable plaque: a call for fine-tuning of preclinical models	VASCULAR PHARMACOLOGY			English	Review						Atherosclerotic plaque; Vulnerable plaque; Phenotypic switch; Plaque cells; Disease modelling	SMOOTH-MUSCLE-CELLS; CORONARY-THROMBOSIS; ATHEROSCLEROSIS; MACROPHAGES; HYPERCHOLESTEROLEMIA; DIFFERENTIATION; CLASSIFICATION; VALIDATION; ACTIVATION; MECHANISMS	For decades, the pathological definition of the vulnerable plaque led to invaluable insights into the mechanisms that underlie myocardial infarction and stroke. Beyond plaque rupture, other mechanisms, such as erosion, may elicit thrombotic events underlining the complexity and diversity of the atherosclerotic disease. Novel insights, based on single-cell transcriptomics and other "omics" methods, provide tremendous opportunities in the ongoing search for cell-specific determinants that will fine-tune the description of the thrombosis prone lesion. It coincides with an increasing awareness that knowledge on lesion characteristics, cell plasticity and clinical presentation of ischemic cardiovascular events have shifted over the past decades. This shift correlates with an observed changes of cell composition towards phenotypical stabilizing of human plaques. These stabilization features and mechanisms are directly mediated by the cells present in plaques and can be mimicked in vitro via primary plaque cells derived from human atherosclerotic tissues. In addition, the rapidly evolving of sequencing technologies identify many candidate genes and molecular mechanisms that may influence the risk of developing an atherosclerotic thrombotic event - which bring the next challenge in sharp focus: how to translate these cell-specific insights into tangible functional and translational discoveries?	[Buono, Michele F.; Hartman, Robin J. G.; den Ruijter, Hester M.; Mokry, Michal] Univ Med Ctr Utrecht, Lab Expt Cardiol, Utrecht, Netherlands; [Slenders, Lotte; Wesseling, Marian; Pasterkamp, Gerard; Mokry, Michal] Univ Med Ctr Utrecht, Cent Diagnost Lab, Utrecht, Netherlands; [Monaco, Claudia] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England		Mokry, M (通讯作者)，UMC Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	M.Mokry@umcutrecht.nl		Slenders, Lotte/0000-0003-3794-7604	Dutch Heart FoundationNetherlands Heart Foundation [T083/2014]; EU Project ERC [866478]; ERA-CVD [2017T099]	This study was funded by the Dutch Heart Foundation (Queen of Hearts T083/2014), EU Project ERC Consolidator Grant 866478 (UCARE), and ERA-CVD 2017T099 ENDLESS.	Ackers-Johnson M, 2015, ARTERIOSCL THROM VAS, V35, P817, DOI 10.1161/ATVBAHA.114.305218; Aday AW, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00016; Aherrahrou R, 2020, CIRC RES, V127, P1552, DOI 10.1161/CIRCRESAHA.120.317415; Alencar GF, 2020, CIRCULATION, V142, P2045, DOI 10.1161/CIRCULATIONAHA.120.046672; Alexander MR, 2012, ANNU REV PHYSIOL, V74, P13, DOI 10.1146/annurev-physiol-012110-142315; Arbab-Zadeh A, 2019, J AM COLL CARDIOL, V74, P1582, DOI 10.1016/j.jacc.2019.07.062; Bennett BJ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005711; Bennett MR, 2016, CIRC RES, V118, P692, DOI 10.1161/CIRCRESAHA.115.306361; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Bonanno E, 2000, CYTOMETRY, V39, P158, DOI 10.1002/(SICI)1097-0320(20000201)39:2<158::AID-CYTO9>3.0.CO;2-8; Butcher MJ, 2016, CIRC RES, V119, P1190, DOI 10.1161/CIRCRESAHA.116.309764; Campbell IC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111785; Chandran S, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005868; Cochain C, 2018, CIRC RES, V122, P1661, DOI 10.1161/CIRCRESAHA.117.312509; DARTSCH PC, 1990, ARTERIOSCLEROSIS, V10, P62, DOI 10.1161/01.ATV.10.1.62; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; Deguchi J, 2006, CIRCULATION, V114, P55, DOI 10.1161/CIRCULATIONAHA.106.619056; Depuydt MAC, 2020, CIRC RES, V127, P1437, DOI 10.1161/CIRCRESAHA.120.316770; FALK E, 1983, BRIT HEART J, V50, P127; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; Feil S, 2014, CIRC RES, V115, P662, DOI 10.1161/CIRCRESAHA.115.304634; Fernandez DM, 2019, NAT MED, V25, P1576, DOI 10.1038/s41591-019-0590-4; Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301; Gomez D, 2013, NAT METHODS, V10, P171, DOI [10.1038/NMETH.2332, 10.1038/nmeth.2332]; Hartman RJG, 2021, CIRCULATION, V143, P713, DOI 10.1161/CIRCULATIONAHA.120.051231; Herring BP, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-21; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kaur Gurvinder, 2012, Spermatogenesis, V2, P1; Kayashima Y., 2020, GENES-BASEL, V11, P1; Kilic ID, 2020, CURR ATHEROSCLER REP, V22, DOI 10.1007/s11883-020-00890-4; Kim K, 2018, CIRC RES, V123, P1127, DOI 10.1161/CIRCRESAHA.118.312804; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; Libby P, 2019, CIRC RES, V124, P150, DOI 10.1161/CIRCRESAHA.118.311098; Libby P, 2015, CIRC RES, V117, P921, DOI 10.1161/CIRCRESAHA.115.307523; Libby P, 2015, EUR HEART J, V36, P472, DOI 10.1093/eurheartj/ehu510; Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317; Madjid M., 2006, J AM COLL CARDIOL, V47; Mantella LE, 2021, ATHEROSCLEROSIS, V319, P42, DOI 10.1016/j.atherosclerosis.2020.12.021; Martinez E, 2019, ADV PHYS-X, V4, DOI 10.1080/23746149.2019.1622451; Martos-Rodriguez CJ, 2021, ARTERIOSCL THROM VAS, V41, pE427, DOI 10.1161/ATVBAHA.120.315627; Matsuura Y, 2019, ARTERIOSCL THROM VAS, V39, pE1, DOI 10.1161/ATVBAHA.118.311999; Monaco C, 2004, P NATL ACAD SCI USA, V101, P5634, DOI 10.1073/pnas.0401060101; Monaco C, 2009, CIRCULATION, V120, P2462, DOI 10.1161/CIRCULATIONAHA.109.851881; Nair A, 2002, CIRCULATION, V106, P2200, DOI 10.1161/01.CIR.0000035654.18341.5E; Neumann JT, 2020, CLIN RES CARDIOL, V109, P1186, DOI 10.1007/s00392-020-01612-1; Newman AAC, 2021, NAT METAB, V3, P166, DOI 10.1038/s42255-020-00338-8; Novikova OA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218892; Pankajakshan D, 2011, EXP MOL PATHOL, V90, P280, DOI 10.1016/j.yexmp.2011.02.005; Park SJ, 2016, J AM COLL CARDIOL, V67, P1772, DOI 10.1016/j.jacc.2016.02.014; Pasterkamp G, 2020, J AM COLL CARDIOL, V76, P2302, DOI 10.1016/j.jacc.2020.09.600; Pasterkamp G, 2017, NAT REV CARDIOL, V14, P21, DOI 10.1038/nrcardio.2016.166; Pasterkamp G, 2016, ARTERIOSCL THROM VAS, V36, P1240, DOI 10.1161/ATVBAHA.115.306958; Pastor DM, 2010, INT J CLIN EXP MED, V3, P69; Pendyal A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017208; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Puri R, 2014, EUR HEART J-CARD IMG, V15, P380, DOI 10.1093/ehjci/jet251; Quillard T, 2015, EUR HEART J, V36, P1394, DOI 10.1093/eurheartj/ehv044; Rensen SSM, 2007, NETH HEART J, V15, P100, DOI 10.1007/BF03085963; Schaar JA, 2004, CIRCULATION, V109, P2716, DOI 10.1161/01.CIR.0000131887.65955.3B; Schrijvers DM, 2005, ARTERIOSCL THROM VAS, V25, P1256, DOI 10.1161/01.ATV.0000166517.18801.a7; Shankman LS, 2015, NAT MED, V21, P628, DOI 10.1038/nm.3866; Siemelink MA, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.002030; Souilhol C, 2018, CARDIOVASC RES, V114, P565, DOI 10.1093/cvr/cvx253; Stone GW, 2020, J AM COLL CARDIOL, V76, P2289, DOI 10.1016/j.jacc.2020.09.547; Stone GW, 2011, NEW ENGL J MED, V364, P226, DOI 10.1056/NEJMoa1002358; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; van Lammeren GW, 2014, CIRCULATION, V129, P2269, DOI 10.1161/CIRCULATIONAHA.113.007603; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Wang XH, 2014, NAT COMMUN, V5, P1, DOI 10.1038/ncomms3957; Wang Y, 2020, P NATL ACAD SCI USA, V117, P15818, DOI 10.1073/pnas.2006348117; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; White SJ, 2016, THROMB HAEMOSTASIS, V115, P509, DOI 10.1160/TH15-09-0765; Winkels H, 2018, CIRC RES, V122, P1675, DOI 10.1161/CIRCRESAHA.117.312513; Wirka RC, 2019, NAT MED, V25, P1280, DOI 10.1038/s41591-019-0512-5; Xie CQ, 2011, ARTERIOSCL THROM VAS, V31, P1485, DOI 10.1161/ATVBAHA.110.221101	78	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106924	10.1016/j.vph.2021.106924		NOV 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34607015	Green Published, hybrid			2022-04-29	WOS:000756079500015
J	Fan, KK; Ruan, XH; Wang, LL; Lu, WL; Shi, QW; Xu, YW				Fan, Kaikai; Ruan, Xinhua; Wang, Leilei; Lu, Wanli; Shi, Qiangwei; Xu, Yawei			Circ_0004872 promotes platelet-derived growth factor-BB-induced proliferation, migration and dedifferentiation in HA-VSMCs via miR-513a-5p/TXNIP axis	VASCULAR PHARMACOLOGY			English	Article						Atherosclerosis; Platelet-derived growth factor-BB; HA-VSMCs; circ_0004872; miR-513a-5p; TXNIP	SMOOTH-MUSCLE-CELL; THIOREDOXIN-INTERACTING PROTEIN; MITOCHONDRIAL-FUNCTION; CIRCULAR RNAS; TXNIP; INFLAMMATION; INHIBITION; EXPRESSION; RECEPTOR; STRESS	The proliferation, migration and dedifferentiation of vascular smooth muscle cells (VSMCs) exert crucial roles in atherosclerosis (AS) progression. The aim of our study was to explore the influences of circular RNA 0004872 (circ_0004872) in platelet-derived growth factor-BB (PDGF-BB)-induced AS cell model and investigate the underlying mechanisms. Real-time quantitative polymerase chain reaction (RT-qPCR) was implemented for the expression detection of circ_0004872, mitogen-activated protein kinase 1 (MAPK1) messenger RNA (mRNA), microRNA-513a-5p (miR-513a-5p) and thioredoxin interacting protein (TXNIP). Cell proliferation was analyzed via Cell Counting Kit 8 (CCK8) assay. Cell migration was assessed via wound healing assay and transwell migration assay. Western blot assay was used to measure the expression of alpha smooth muscle actin (alpha-SMA), osteopontin (OPN), calponin and TXNIP. Dual-luciferase reporter assay and RNA-pull down assay were used for confirmation of interaction between miR-513a-5p and circ_0004872 or TXNIP. Circ_0004872 expression was elevated in PDGF-BB-induced human aortic vascular smooth muscle cells (HA-VSMCs) and carotid plaque tissues. Circ_0004872 silencing alleviated PDGF-BB-induced proliferation, migration and dedifferentiation in HA-VSMCs. MiR-513a-5p bound to circ_0004872, and circ_0004872 knockdown-induced effects in PDGF-BB-treated HAVSMCs were largely attenuated by the silencing of miR-513a-5p. MiR-513a-5p bound to the 3 ' untranslated region (3 ' UTR) of TXNIP, and miR-513a-5p overexpression-mediated effects were counteracted by the transfection of pcDNA-TXNIP in PDGF-BB-induced HA-VSMCs. TXNIP was modulated by circ_0004872/miR-513a-5p signaling cascade in HA-VSMCs. Circ_0004872 accelerated PDGF-BB-induced proliferation, migration and dedifferentiation in HA-VSMCs through enhancing TXNIP level via sponging miR-513a-5p.	[Fan, Kaikai] Zhengzhou Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, 4 Fengqing Rd, Zhengzhou, Henan, Peoples R China; [Ruan, Xinhua] Tianjin Union Med Ctr, Dept Cardiovasc Surg, Tianjin, Peoples R China; [Wang, Leilei] Cangzhou Cent Hosp, Dept Neurosurg, Cangzhou, Hebei, Peoples R China; [Lu, Wanli] TEDA Int Cardiovasc Hosp, Dept Cardiovasc Surg, Tianjin, Peoples R China; [Shi, Qiangwei; Xu, Yawei] Zhengzhou Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Zhengzhou, Henan, Peoples R China		Fan, KK (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, 4 Fengqing Rd, Zhengzhou, Henan, Peoples R China.	puos7eq@163.com					Bennett MR, 2016, CIRC RES, V118, P692, DOI 10.1161/CIRCRESAHA.115.306361; Byon CH, 2015, ATHEROSCLEROSIS, V241, P313, DOI 10.1016/j.atherosclerosis.2015.05.020; Cao T, 2017, BBA-MOL BASIS DIS, V1863, P2772, DOI 10.1016/j.bbadis.2017.07.002; Chen W, 2020, J CELL MOL MED, V24, P4762, DOI 10.1111/jcmm.15150; Chistiakov DA, 2015, ACTA PHYSIOL, V214, P33, DOI 10.1111/apha.12466; Dai Nan, 2018, Oncotarget, V9, P25414, DOI 10.18632/oncotarget.11003; Feng M, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578-018-0203-9; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429; Kim JH, 2005, BIOCHEM PHARMACOL, V69, P1715, DOI 10.1016/j.bcp.2005.04.002; Kim JY, 2015, VASC PHARMACOL, V70, P8, DOI 10.1016/j.vph.2014.12.004; Li JF, 2020, J CELL MOL MED, V24, P6609, DOI 10.1111/jcmm.15308; Liao XH, 2015, J BIOL CHEM, V290, P19641, DOI 10.1074/jbc.M114.630111; Liu C, 2017, THERANOSTICS, V7, P2863, DOI 10.7150/thno.19353; Ma CY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01268-5; Mao YY, 2018, BIOCHEM BIOPH RES CO, V505, P119, DOI 10.1016/j.bbrc.2018.09.069; Meng SJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0663-2; Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87; Panda AC, 2018, ADV EXP MED BIOL, V1087, P67, DOI 10.1007/978-981-13-1426-1_6; Patwari P, 2006, J BIOL CHEM, V281, P21884, DOI 10.1074/jbc.M600427200; Schulze PC, 2004, J BIOL CHEM, V279, P30369, DOI 10.1074/jbc.M400549200; Song TF, 2019, J CELL PHYSIOL, V234, P14296, DOI 10.1002/jcp.28128; Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Yang LD, 2020, DNA CELL BIOL, V39, P69, DOI 10.1089/dna.2019.5063; Yang R, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0933-7; Yang Y, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158779; Yoshioka J, 2014, TRENDS CARDIOVAS MED, V24, P75, DOI 10.1016/j.tcm.2013.06.007; Yoshioka J, 2012, J CLIN INVEST, V122, P267, DOI 10.1172/JCI44927; Yu T, 2018, CANCER SCI, V109, P1393, DOI 10.1111/cas.13583; Zhang CX, 2005, ARTERIOSCL THROM VAS, V25, P533, DOI 10.1161/01.ATV.0000155461.50450.5a; Zhang YJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009108; Zhang ZW, 2017, BIOCHEM BIOPH RES CO, V486, P414, DOI 10.1016/j.bbrc.2017.03.056; Zhu JL, 2017, TRANSL ONCOL, V10, P271, DOI 10.1016/j.tranon.2016.12.006; Zhu LH, 2015, CLIN SCI, V129, P129, DOI 10.1042/CS20140679	35	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106842	10.1016/j.vph.2021.106842		SEP 2021	11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33592319				2022-04-29	WOS:000709412300007
J	Barbosa, LC; Goncalves, TL; de Araujo, LP; Rosario, LVD; Ferrer, VP				Barbosa, Lucas Cunha; Goncalves, Thaynan Lopes; de Araujo, Luanna Prudencio; de Oliveira Rosario, Luciane Vieira; Ferrer, Valeria Pereira			Endothelial cells and SARS-CoV-2: An intimate relationship	VASCULAR PHARMACOLOGY			English	Article						Endothelial cells; SARS-CoV-2; ACE2; Inflammation; Coagulation	CONVERTING ENZYME 2; SARS CORONAVIRUS; EPITHELIAL-CELLS; HEPARAN-SULFATE; ACE2 RECEPTOR; SPIKE PROTEIN; BED REST; COVID-19; CANCER; INFECTION	Angiotensin-converting enzyme 2 (ACE2) is an important player of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II into angiotensin (1-7). While expressed on the surface of human cells, such as lung, heart, kidney, neurons, and endothelial cells (EC), ACE2 is the entry receptor for SARS-CoV-2. Here, we would like to highlight that ACE2 is predominant on the EC membrane. Many of coronavirus disease 2019 (COVID-19) symptoms have been associated with the large recruitment of immune cells, directly affecting EC. Additionally, cytokines, hypoxia, and complement activation can trigger the activation of EC leading to the coagulation cascade. The EC dysfunction plus the inflammation due to SARS-CoV-2 infection may lead to abnormal coagulation, actively participating in thrombo-inflammatory processes resulting in vasculopathy and indicating poor prognosis in patients with COVID-19. Considering the intrinsic relationship between EC and the pathophysiology of SARS-CoV-2, EC-associated therapies such as anticoagulants, fibrinolytic drugs, immunomodulators, and molecular therapies have been proposed. In this review, we will discuss the role of EC in the lung inflammation and edema, in the disseminate coagulation process, ACE2 positive cancer patients, and current and future EC-associated therapies to treat COVID-19.	[Barbosa, Lucas Cunha; Ferrer, Valeria Pereira] Univ Fed Rio de Janeiro, Clementino Fraga Filho Hosp, Grad Program Med Pathol Anat, Rio De Janeiro, Brazil; [Barbosa, Lucas Cunha; Goncalves, Thaynan Lopes; de Araujo, Luanna Prudencio; de Oliveira Rosario, Luciane Vieira] Paulo Niemeyer State Brain Inst, Brains Biomed Lab, Rio De Janeiro, Brazil; [Ferrer, Valeria Pereira] Fluminense Fed Univ, Inst Biol, Dept Cellular & Mol Biol, Niteroi, RJ, Brazil		Ferrer, VP (通讯作者)，Fluminense Fed Univ, Inst Biol, Dept Cellular & Mol Biol, Niteroi, RJ, Brazil.	valeriaferrer@id.uff.br	Ferrer, Valeria Pereira/N-9890-2018	Ferrer, Valeria Pereira/0000-0002-5210-3445	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Associacao Mahatma Gandhi	This study was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Associacao Mahatma Gandhi.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; Al-Zaidan L, 2020, SARS COV 2 S PROTEIN, P43; Allegra A, 2020, CANCERS, V12, DOI 10.3390/cancers12061581; Alquisiras-Burgos I, 2021, MOL NEUROBIOL, V58, P520, DOI 10.1007/s12035-020-02134-7; Barrett CD, 2020, RES PRACT THROMB HAE, V4, P524, DOI 10.1002/rth2.12357; Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Blume C., 2017, RNA, P12; Buzhdygan T.P., 2020, BIORXIV, DOI [10.1101/ 2020.06.15.150912, 2020.06.15.150912, DOI 10.1101/2020.06.15.150912,2020.06.15.150912]; Cameron AC, 2016, CAN J CARDIOL, V32, P852, DOI 10.1016/j.cjca.2015.12.023; Chai PW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00883-5; Chakravarty D, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1088-9; Chauhan AJ, 2020, J THROMB HAEMOST, V18, P2110, DOI 10.1111/jth.14981; Chen B., 2020, J CANCER, V11, P4; Chen Z, 2020, SPATIAL CELL TYPE DI, DOI [10.1101/2020.04.07.030650, DOI 10.1101/2020.04.07.030650]; Chen ZZ, 2021, INNATE IMMUN-LONDON, V27, P109, DOI 10.1177/1753425920954281; Chen ZN, 2005, J INFECT DIS, V191, P755, DOI 10.1086/427811; Chowdhury F, 2010, EXP LUNG RES, V36, P1, DOI 10.3109/01902140903026582; Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422; De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4; Rosario LVD, 2020, ANTICANCER RES, V40, P2725, DOI 10.21873/anticanres.14244; Deliwala S, 2020, CUREUS, V12, DOI 10.7759/cureus.8121; Desai A, 2020, JCO GLOB ONCOL, V6, P557, DOI 10.1200/GO.20.00097; Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014; Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560; Dolgin E, 2020, CANCER DISCOV, V10, P634, DOI 10.1158/2159-8290.CD-ND2020-006; DosSantos MF, 2020, FRONT NEUROANAT, V14, DOI 10.3389/fnana.2020.00037; Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448; Fernig C., 2020, 2019 CORONAVIRUS SAR, P9; Fletcher-Sandersjoo A, 2020, THROMB RES, V194, P36, DOI 10.1016/j.thromres.2020.06.027; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Freeman TL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01518; Froldi G, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110015; Garcia-Ponce A, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1228439; Ged Y, 2020, NAT REV UROL, V17, P425, DOI 10.1038/s41585-020-0345-5; Ghafouri-Fard S, 2020, VASC PHARMACOL, V130, DOI 10.1016/j.vph.2020.106680; Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Gong JM, 2020, PATIENT PREFER ADHER, V14, P1659, DOI 10.2147/PPA.S271481; Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7; Goshua George, 2020, Lancet Haematol, V7, pe575, DOI 10.1016/S2352-3026(20)30216-7; Gray Elaine, 2012, Handb Exp Pharmacol, P43, DOI 10.1007/978-3-642-23056-1_3; Grobler C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145168; Guerrini M., 2020, SARS COV 2 SPIKE S1, P15; Guimond S.E., 2020, SYNTHETIC HEPARAN SU, DOI [10.1101/2020.06.24.169334, DOI 10.1101/2020.06.24.169334]; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hamadeh A, 2020, AM J CARDIOL, V131, P1, DOI 10.1016/j.amjcard.2020.06.063; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Herrmann J, 2016, CIRCULATION, V133, P1272, DOI 10.1161/CIRCULATIONAHA.115.018347; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hua YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02178; Huertas A, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01634-2020; Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116; Iba Toshiaki, 2015, Intensive Care Med Exp, V3, P36, DOI 10.1186/s40635-015-0072-z; Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18; Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005; Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8; Kaur S, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00989; Kewan T, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100418; Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013; Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9; Laforge M, 2020, NAT REV IMMUNOL, V20, P515, DOI 10.1038/s41577-020-0407-1; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Langen UH, 2019, ANNU REV CELL DEV BI, V35, P591, DOI 10.1146/annurev-cellbio-100617-062608; Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Marchetti M, 2020, ANN HEMATOL, V99, P1701, DOI 10.1007/s00277-020-04138-8; Marques Marcos Arêas, 2017, J. vasc. bras., V16, P60, DOI 10.1590/1677-5449.009616; Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117; Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10; McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516; Meneghetti MCZ, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0589; Meng YF, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00907-0; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Milewska A, 2014, J VIROL, V88, P13221, DOI 10.1128/JVI.02078-14; Millar FR, 2016, THORAX, V71, P462, DOI 10.1136/thoraxjnl-2015-207461; Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Mulloy B, 2016, PHARMACOL REV, V68, P76, DOI 10.1124/pr.115.011247; Mycroft-West CJ, 2020, THROMB HAEMOSTASIS, V120, P1700, DOI 10.1055/s-0040-1721319; National Library of Medicine (US) National Center for Biotechnology Information, 2004, PUBCHEM COMPOUND SUM; Navarro AG, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00202; Noris M, 2020, KIDNEY INT, V98, P314, DOI 10.1016/j.kint.2020.05.013; O'Sullivan JM, 2020, LANCET HAEMATOL, V7, pE553, DOI 10.1016/S2352-3026(20)30215-5; Panfoli I, 2020, CLIN MED, V20, pE146, DOI 10.7861/clinmed.2020-0252; Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915; Partsch H, 2002, CURR OPIN PULM MED, V8, P389, DOI 10.1097/00063198-200209000-00008; Pelaia C, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620933508; Pellegrini L., 2020, SARS COV 2 INFECTS B, DOI DOI 10.1101/2020.08.20; Perico L, 2021, NAT REV NEPHROL, V17, P46, DOI 10.1038/s41581-020-00357-4; Perico L, 2020, NEPHRON, V144, P213, DOI 10.1159/000507305; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Pons S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03062-7; Puerta-Guardo H, 2019, CELL REP, V26, P1598, DOI 10.1016/j.celrep.2019.01.036; Qin C, 2020, STROKE, V51, P2219, DOI 10.1161/STROKEAHA.120.030365; Rao ST, 2020, DIABETES CARE, V43, P1416, DOI 10.2337/dc20-0643; Ratajczak MZ, 2021, STEM CELL REV REP, V17, P266, DOI 10.1007/s12015-020-10010-z; Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z; RODRIGUEZPUERTA.R, 2020, NATURE, V92, P1701, DOI DOI 10.1002/JMV.25992; Sardu C., 2020, CLIN BASIC EVID, DOI 10.20944/preprints202004.0204.v1; Sebba A, 2008, AM J HEALTH-SYST PH, V65, P1413, DOI 10.2146/ajhp070449; Sharif-Askari NS, 2020, CTS-CLIN TRANSL SCI, V13, P1048, DOI 10.1111/cts.12862; Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Siegenthaler JA, 2013, CURR OPIN NEUROBIOL, V23, P1057, DOI 10.1016/j.conb.2013.06.006; Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tavassoly O, 2020, MOL PHARMACOL, V98, P612, DOI 10.1124/molpharm.120.000098; Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0; Tiwari Vaibhav, 2020, bioRxiv, DOI 10.1101/2020.10.08.331751; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y; Trouillet-Assant S, 2020, J ALLERGY CLIN IMMUN, V146, P206, DOI 10.1016/j.jaci.2020.04.029; Tsivgoulis G, 2020, STROKE, V51, P1924, DOI 10.1161/STROKEAHA.120.030791; Ueki Y, 2020, EUR HEART J, V41, P2134, DOI 10.1093/eurheartj/ehaa399; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; van Dam PA, 2020, CANCER TREAT REV, V89, DOI 10.1016/j.ctrv.2020.102068; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Walchl T., 2020, HUMAN BRAIN VASCULAT, DOI [10.1101/2020.10.10.334664, 10.10.334664, DOI 10.1101/2020.10.10.334664,10.10.334664]; Walchli T., 2020, BIORXIV, DOI [10.1101/ 2020.10.10.334664, 2020.10.10.334664, DOI 10.1101/2020.10.10.334664,2020.10.10.334664]; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000; Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2; Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828; Wang J, 2020, ADV THER, V37, P3033, DOI 10.1007/s12325-020-01399-7; Wang M, 2018, ARTERIOSCL THROM VAS, V38, pE90, DOI 10.1161/ATVBAHA.118.310367; Wang N, 2020, CELL HOST MICROBE, V28, P455, DOI 10.1016/j.chom.2020.07.005; Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872; Wilkinson AL, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00990; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xia HJ, 2013, CIRC RES, V113, P1087, DOI 10.1161/CIRCRESAHA.113.301811; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-X, 10.1038/s41368-020-0074-x]; Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335; Yaqinuddin A, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109906; Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427; Zhang, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]; Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9; Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5; Zhao Yu, 2020, American Journal of Respiratory and Critical Care Medicine, V202, P756, DOI 10.1164/rccm.202001-0179LE; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu CR, 2019, J TRAUMA ACUTE CARE, V87, P614, DOI 10.1097/TA.0000000000002387; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035; Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065	152	10	11	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106829	10.1016/j.vph.2021.106829		MAR 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33422689	Green Submitted, Green Published, Bronze			2022-04-29	WOS:000629161700007
J	Dela Justina, V; Giachini, FR; Priviero, F; Webb, RC				Dela Justina, Vanessa; Giachini, Fernanda R.; Priviero, Fernanda; Webb, R. Clinton			COVID-19 and hypertension: Is there a role for dsRNA and activation of Toll-like receptor 3?	VASCULAR PHARMACOLOGY			English	Article						COVID-19; dsRNA; TLR3; Hypertension	DOUBLE-STRANDED-RNA; BLOOD-PRESSURE; KINASE; CELLS; ACE2	The virus responsible for the coronavirus disease of 2019 (COVID-19) is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidences suggest that COVID-19 could trigger cardiovascular complications in apparently healthy patients. Coronaviruses are enveloped positive-strand RNA viruses acting as a pathogenassociated molecular pattern (PAMP)/ danger-associated molecular patterns (DAMP). Interestingly, Toll-like receptor (TLR) 3 recognize both PAMPs DAMPs and is activated by viral double-stranded RNA (dsRNA) leading to activation of TIR receptor domain-containing adaptor inducing IFN-beta (TRIF) dependent pathway. New evidence has shown a link between virus dsRNA and increased BP. Hence, we hypothesize that COVID-19 infection may be over activating the TLR3 through dsRNA, evoking further damage to the patients, leading to vascular inflammation and increased blood pressure, favoring the development of several cardiovascular complications, including hypertension.	[Dela Justina, Vanessa; Giachini, Fernanda R.] Univ Fed Goias, Grad Program Biol Sci, Goiania, Go, Brazil; [Giachini, Fernanda R.] Univ Fed Mato Grosso, Inst Hlth Sci & Hlth, Barra Do Garcas, Brazil; [Priviero, Fernanda; Webb, R. Clinton] Univ South Carolina, Sch Med, Cardiovasc Translat Res Ctr, Columbia, SC 29208 USA		Dela Justina, V (通讯作者)，Univ Fed Goias, Av Esperanca S-N, BR-74690900 Goiania, Go, Brazil.	vane_cessa@hotmail.com			NIDDK Diabetic Complications Consortium [DK076169, DK115255]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL-134604]; Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT)Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT) [0324552/2018]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [306166/2019-4]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88881.190484/2018-01]	Financial support for this work was provided by the NIDDK Diabetic Complications Consortium (DK076169 and DK115255 to RCW) ; the National Institutes of Health (HL-134604 to RCW) ; Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT, 0324552/2018 to F.R. G.) ; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, 306166/2019-4 to F.R.G) ; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, 88881.190484/2018-01 Scholarship to V.D.J.) .	Banerjee S, 2014, MBIO, V5, DOI 10.1128/mBio.00856-14; Chae CU, 2001, HYPERTENSION, V38, P399, DOI 10.1161/01.HYP.38.3.399; Chatterjee P, 2015, AM J HYPERTENS, V28, P135, DOI 10.1093/ajh/hpu100; Cheng JL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000427; Cruz JLG, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002090; Daley E, 2008, J EXP MED, V205, P361, DOI 10.1084/jem.20071008; Dela Justina V, 2020, CLIN SCI, V134, P303, DOI 10.1042/CS20190913; Dinh QN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/406960; Fara A, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200160; George PM, 2012, BIOCHEM BIOPH RES CO, V426, P486, DOI 10.1016/j.bbrc.2012.08.106; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jr, 2005, AM J RESP CRIT CARE, V172, P1, DOI [10.1164/rccm.2508005, DOI 10.1164/RCCM.2508005]; Kalra J, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118436; Kalra J, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165606; Khodadadi H, 2020, CANNABIS CANNABINOID, V5, P197, DOI 10.1089/can.2020.0043; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Li Yize, 2020, bioRxiv, DOI 10.1101/2020.09.24.312553; MAIUOLO J, 2020, INT J MOL SCI, V21, P1; Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Singh MV, 2019, AM J PHYSIOL-HEART C, V316, pH1027, DOI 10.1152/ajpheart.00697.2018; South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020; Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029; Stoian AP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78575-w; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Tu WJ, 2020, INTENS CARE MED, V46, P1117, DOI 10.1007/s00134-020-06023-4; Tudoran C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020199; Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001; van Dongen Christel Mp, 2020, Eur J Case Rep Intern Med, V7, P001784, DOI 10.12890/2020_001784; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2; Wong NA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031308; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Zhang LY, 2016, J BIOL CHEM, V291, P15093, DOI 10.1074/jbc.M116.717942; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zimmer S, 2011, CIRC RES, V108, P1358, DOI 10.1161/CIRCRESAHA.111.243246	39	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106861	10.1016/j.vph.2021.106861		SEP 2021	4	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33845201	Green Published, Bronze			2022-04-29	WOS:000709412300001
J	Klingler, P; Niklaus, M; Koessler, J; Weber, K; Koessler, A; Boeck, M; Kobsar, A				Klingler, Philipp; Niklaus, Marius; Koessler, Juergen; Weber, Katja; Koessler, Angela; Boeck, Markus; Kobsar, Anna			Influence of long-term proteasome inhibition on platelet responsiveness mediated by bortezomib	VASCULAR PHARMACOLOGY			English	Article						Platelet; Inhibitory signaling; Bortezomib; Proteasome; Glycoprotein; Aggregation; Adhesion; Purinergic receptor	VASODILATOR-STIMULATED PHOSPHOPROTEIN; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; CGMP; PHOSPHORYLATION; AGGREGATION; EXPRESSION; RECEPTORS; ADHESION; STORAGE	Introduction: Although platelets contain a full proteasome system, its role in platelet function is not completely understood yet. Since the proteasome system may be involved in time-delayed processes, platelet responsiveness was investigated after long-term, bortezomib-mediated proteasome inhibition. Materials and Methods: Citrate-anticoagulated whole blood was stored with 5 nM and 1 mu M bortezomib for 24 h. Consecutively, aggregation was measured by light transmission in platelet-rich-plasma (PRP). Flow cytometry was performed to determine phosphorylation levels of the vasodilator-stimulated phosphoprotein (VASP), fibrinogen binding, PAC1-antibody binding and purinergic receptor expression in PRP, P2Y12 activity or glycoprotein (GP) Ib and IIb expression in whole blood. P2Y1 and P2X1 activities were assessed by calcium fluxinduced fluorescence in washed platelets. Using PRP, adherent platelets on fibrinogen-, collagen- and ristocetincoated surfaces were visualized and quantified by immunostaining. Results: Under bortezomib, VASP phosphorylation was less inducible and nitric oxide-induced inhibition of fibrinogen binding was slightly reduced. Proteasome inhibition did not tamper adenosine diphosphate-mediated aggregation or purinergic receptor expression and activity. Induced expression of activated fibrinogen receptors and fibrinogen binding were not significantly influenced by incubation with bortezomib for 24 h. Aggregation values with threshold agonist concentrations were increased under bortezomib. Despite unchanged GPIb expression, bortezomib-treated platelets showed enhanced adhesion on coated surfaces. Conclusions: In platelets incubated for 24 h, bortezomib mediates a slight attenuation of inhibitory signaling, associated with facilitated platelet aggregation using threshold agonist concentrations and enhanced adhesion on agonist-coated surfaces.	[Klingler, Philipp; Niklaus, Marius; Koessler, Juergen; Weber, Katja; Koessler, Angela; Boeck, Markus; Kobsar, Anna] Univ Wurzburg, Inst Transfus Med & Haemotherapy, Oberduerrbacher Str 6, D-97080 Wurzburg, Germany		Koessler, J (通讯作者)，Univ Wurzburg, Inst Transfus Med & Haemotherapy, Oberduerrbacher Str 6, D-97080 Wurzburg, Germany.	klingler_p@ukw.de; niklaus_m@ukw.de; koessler_j@ukw.de; Weber_K2@ukw.de; koessler_a@ukw.de; boeck_m@ukw.de; kobsar_a@ukw.de			Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Germany)German Research Foundation (DFG) [KO 5256/3-1, KO 5294/2-1]	The study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Germany) project number KO 5256/3-1 (Juergen Koessler) and KO 5294/2-1 (Anna Kobsar) .	Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Borst O, 2021, PHARMACOL THERAPEUT, V217, DOI 10.1016/j.pharmthera.2020.107630; Clemetson KJ, 2012, THROMB RES, V129, P220, DOI 10.1016/j.thromres.2011.11.036; Colberg L, 2020, J THROMB HAEMOST, V18, P771, DOI 10.1111/jth.14730; Duerschmied D, 2014, THROMB HAEMOSTASIS, V112, P678, DOI 10.1160/TH14-02-0146; Gachet C, 2008, THROMB HAEMOSTASIS, V99, P466, DOI 10.1160/TH07-11-0673; Gardiner EE, 2004, BLOOD, V104, P3611, DOI 10.1182/blood-2004-04-1549; Groterhorst K. Grundler, 2019, INT J MOL SCI, V20; Hassan SA, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0702-5; Horii K, 2009, BIOCHEMISTRY-US, V48, P2907, DOI 10.1021/bi801820q; HOYLAERTS MF, 1995, BIOCHEM J, V306, P453, DOI 10.1042/bj3060453; Kanaji S, 2003, J BIOL CHEM, V278, P39452, DOI 10.1074/jbc.M300199200; Keuren JFW, 2006, TRANSFUSION, V46, P204, DOI 10.1111/j.1537-2995.2006.00702.x; Klockenbusch C, 2014, MOL CELL PROTEOMICS, V13, P3308, DOI 10.1074/mcp.M113.031757; Kobsar A., 2014, TRANSFUSION, V54; Kobsar A, 2014, TRANSFUSION, V54, P1008, DOI 10.1111/trf.12360; Koessler J, 2019, CELL SIGNAL, V62, DOI 10.1016/j.cellsig.2019.109351; Koessler J, 2018, THROMB RES, V168, P40, DOI 10.1016/j.thromres.2018.05.029; Koessler J, 2016, BLOOD TRANSFUS-ITALY, V14, P545, DOI 10.2450/2015.0073-15; Koessler J, 2016, EUR J PHARMACOL, V791, P99, DOI 10.1016/j.ejphar.2016.08.031; Koessler J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147370; Lub S, 2016, ONCOTARGET, V7, P6521, DOI 10.18632/oncotarget.6658; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Massberg S, 2004, BLOOD, V103, P136, DOI 10.1182/blood-2002-11-3417; Necchi V, 2013, THROMB HAEMOSTASIS, V109, P263, DOI 10.1160/TH12-07-0497; Nguyen MN, 2020, AM J HEMATOL, V95, pE218, DOI 10.1002/ajh.25832; NOLTE C, 1994, BIOCHEM PHARMACOL, V48, P1569, DOI 10.1016/0006-2952(94)90201-1; Piva R, 2008, BLOOD, V111, P2765, DOI 10.1182/blood-2007-07-100651; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Reininger AJ, 2008, HAEMOPHILIA, V14, P11, DOI 10.1111/j.1365-2516.2008.01848.x; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Rupa-Matysek J, 2014, THROMB RES, V134, P404, DOI 10.1016/j.thromres.2014.05.032; Schwarz UR, 1999, THROMB HAEMOSTASIS, V82, P1145, DOI 10.1055/s-0037-1614344; Scott K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010816.pub2; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Teicher BA, 2015, BIOCHEM PHARMACOL, V96, P1, DOI 10.1016/j.bcp.2015.04.008; Toth-Zsamboki E, 2003, J BIOL CHEM, V278, P46661, DOI 10.1074/jbc.M308452200; Unsworth AJ, 2019, THROMB HAEMOSTASIS, V119, P104, DOI 10.1055/s-0038-1676344; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; Zangari M, 2008, HAEMATOLOGICA, V93, P953, DOI 10.3324/haematol.12522	42	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106830	10.1016/j.vph.2021.106830		MAY 2021	11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33422688				2022-04-29	WOS:000652840900002
J	Gonzalez-Montelongo, MD; Fountain, SJ				Gonzalez-Montelongo, Maria del Carmen; Fountain, Samuel J.			Neuropeptide Y facilitates P2X1 receptor-dependent vasoconstriction via Y1 receptor activation in small mesenteric arteries during sympathetic neurogenic responses	VASCULAR PHARMACOLOGY			English	Article						Neuropeptide Y; P2X receptors; Vasoconstriction; Neurogenic; Calcium channel		ATP, norepinephrine and NPY are co-released by sympathetic nerves innervating arteries. ATP elicits vasoconstriction via activation of smooth muscle P2X receptors. The functional interaction between neuropeptide Y (NPY) and P2X receptors in arteries is not known. In this study we investigate the effect of NPY on P2X1dependent vasoconstriction in mouse mesenteric arteries. Suramin or P2X1 antagonist NF449 abolished alpha,beta-meATP evoked vasoconstrictions. NPY lacked any direct vasoconstrictor effect but facilitated the vasoconstrictive response to alpha,beta-meATP. Mesenteric arteries expressed Y-1 and Y-4 receptors, but not Y-2 or Y-5. Y1 receptor inhibition (BIBO3304) reversed NPY facilitation of the alpha,alpha-meATP-evoked vasoconstriction. L-type Ca2+ channel antagonism (nifedipine) had no effect on alpha,beta-meATP-evoked vasoconstrictions, but completely reversed NPY facilitation. Electrical field stimulation evoked sympathetic neurogenic vasoconstriction. Neurogenic responses were dependent upon dual alpha 1-adrenergic (prazosin) and P2X1 (NF449) receptor activation. Y-1 receptor antagonism partially reduced neurogenic vasoconstriction. Isolation of the P2X1 component by alpha 1-adrenergic blockade allowed faciliatory effects of Y1 receptor activation to be explored. Y-1 receptor antagonism reduced the P2X1 receptor component during neurogenic vasoconstriction. alpha 1-adrenergic and P2X1 receptors are post-junctional receptors during sympathetic neurogenic vasoconstriction in mesenteric arteries. In conclusion, we have identified that NPY lacks a direct vasoconstrictor effect in mesenteric arteries but can facilitate vasoconstriction by enhancing the activity of P2X1, following activation by exogenous agonists or during sympathetic nerve stimulation. The mechanism of P2X1 facilitation by NPY involved activation of the NPY Y-1 receptor and the L-type Ca2+ channel.	[Gonzalez-Montelongo, Maria del Carmen; Fountain, Samuel J.] Univ East Anglia, Sch Biol Sci, Biomed Res Ctr, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England		Fountain, SJ (通讯作者)，Univ East Anglia, Sch Biol Sci, Biomed Res Ctr, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.	s.j.fountain@uea.ac.uk	del Carmen González-Montelongo, María/E-9695-2015	Gonzalez-Montelongo, Maria C./0000-0003-2332-6153	British Heart FoundationBritish Heart Foundation [PG/16/69/32194]	This work was funded by a British Heart Foundation project grant (PG/16/69/32194) awarded to SJF.	ABOUNADER R, 1995, BRIT J PHARMACOL, V116, P2245, DOI 10.1111/j.1476-5381.1995.tb15060.x; Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS1, DOI 10.1111/bph.13882; ANDRIANTSITOHAINA R, 1988, BRIT J PHARMACOL, V95, P419, DOI 10.1111/j.1476-5381.1988.tb11662.x; Bao L, 1997, P NATL ACAD SCI USA, V94, P12661, DOI 10.1073/pnas.94.23.12661; BOYER JL, 1994, J BIOL CHEM, V269, P2814; Brothers SP, 2010, EMBO MOL MED, V2, P429, DOI 10.1002/emmm.201000100; Bryant SM, 1996, BRIT J PHARMACOL, V118, P1455, DOI 10.1111/j.1476-5381.1996.tb15560.x; Burkhoff AM, 1998, MOL BRAIN RES, V53, P311, DOI 10.1016/S0169-328X(97)00302-1; Burnstock G, 2014, PHARMACOL REV, V66, P102, DOI 10.1124/pr.113.008029; Christiansen AT, 2018, J COMP NEUROL, V526, P1877, DOI 10.1002/cne.24455; Crnkovic S, 2014, BRIT J PHARMACOL, V171, P3895, DOI 10.1111/bph.12751; Dumont Y, 2000, BRIT J PHARMACOL, V129, P1075, DOI 10.1038/sj.bjp.0703162; Fountain SJ, 2004, J PHYSIOL-LONDON, V556, P29, DOI 10.1113/jphysiol.2003.058594; Gitterman DP, 2001, BRIT J PHARMACOL, V132, P1201, DOI 10.1038/sj.bjp.0703925; Gradin KA, 2006, EUR J PHARMACOL, V539, P184, DOI 10.1016/j.ejphar.2006.03.080; Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121; Harhun MI, 2014, STROKE, V45, P2444, DOI 10.1161/STROKEAHA.114.005544; Harhun MI, 2010, BRIT J PHARMACOL, V160, P987, DOI 10.1111/j.1476-5381.2010.00714.x; Harrington LS, 2004, BRIT J PHARMACOL, V143, P611, DOI 10.1038/sj.bjp.0706004; Hubers SA, 2018, HYPERTENSION, V72, P712, DOI 10.1161/HYPERTENSIONAHA.118.11498; Hulsmann M, 2003, EUR J PHARMACOL, V470, P1, DOI 10.1016/S0014-2999(03)01761-8; HULTING J, 1990, CARDIOVASC RES, V24, P102, DOI 10.1093/cvr/24.2.102; Inscho EW, 2011, HYPERTENSION, V57, P780, DOI 10.1161/HYPERTENSIONAHA.110.168955; Inscho EW, 2003, J CLIN INVEST, V112, P1895, DOI 10.1172/JCI200318499; Egea-Guerrero JJ, 2015, VASC PHARMACOL, V72, P64, DOI 10.1016/j.vph.2015.04.011; KENNEDY C, 1986, EUR J PHARMACOL, V122, P291, DOI 10.1016/0014-2999(86)90409-7; Kennedy C, 2015, AUTON NEUROSCI-BASIC, V191, P2, DOI 10.1016/j.autneu.2015.04.004; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lamont C, 2006, AM J PHYSIOL-HEART C, V291, pH3106, DOI 10.1152/ajpheart.00466.2006; Li L, 2012, ACTA PHARM SIN B, V2, P459, DOI 10.1016/j.apsb.2012.04.005; LYNCH JW, 1994, J BIOL CHEM, V269, P8226; Malmstrom RE, 1997, BRIT J PHARMACOL, V121, P595, DOI 10.1038/sj.bjp.0701154; MALMSTROM RE, 1995, ACTA PHYSIOL SCAND, V155, P329, DOI 10.1111/j.1748-1716.1995.tb09981.x; McCullough LA, 1998, AM J PHYSIOL-CELL PH, V274, pC1290, DOI 10.1152/ajpcell.1998.274.5.C1290; McQuiston AR, 1996, J NEUROSCI, V16, P1422; MILLAR BC, 1991, AM J PHYSIOL, V261, pH1727, DOI 10.1152/ajpheart.1991.261.6.H1727; NAKAMURA M, 1995, J BIOL CHEM, V270, P30102, DOI 10.1074/jbc.270.50.30102; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pons J, 2008, CAN J PHYSIOL PHARM, V86, P438, DOI [10.1139/Y08-054, 10.1139/y08-054]; Prieto D, 2000, BRIT J PHARMACOL, V129, P1689, DOI 10.1038/sj.bjp.0703256; Rettinger J, 2003, J GEN PHYSIOL, V121, P451, DOI 10.1085/jgp.200208730; SHIGERI Y, 1995, J BIOCHEM, V118, P515, DOI 10.1093/oxfordjournals.jbchem.a124938; SHIGERI Y, 1991, J NEUROCHEM, V56, P852, DOI 10.1111/j.1471-4159.1991.tb02001.x; Silva AP, 2003, NEUROPHARMACOLOGY, V44, P282, DOI 10.1016/S0028-3908(02)00382-9; Tan CMJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01281; Tanaka E, 1997, J AM COLL CARDIOL, V29, P1380, DOI 10.1016/S0735-1097(97)82759-3; Tarasova O, 2003, ACTA PHYSIOL SCAND, V177, P157, DOI 10.1046/j.1365-201X.2003.01057.x; Vial C, 2002, MOL PHARMACOL, V62, P1438, DOI 10.1124/mol.62.6.1438; Wang YC, 2018, MOL PHARMACOL, V94, P973, DOI 10.1124/mol.118.112441; WESTFALL TC, 1990, BRIT J CLIN PHARMACO, V30, pS75, DOI 10.1111/j.1365-2125.1990.tb05472.x; Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084; Wiest R, 2006, J HEPATOL, V44, P512, DOI 10.1016/j.jhep.2005.08.023; WILEY JW, 1990, J NEUROPHYSIOL, V63, P1499, DOI 10.1152/jn.1990.63.6.1499; XIONG ZG, 1993, PFLUG ARCH EUR J PHY, V423, P504, DOI 10.1007/BF00374948	54	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106810	10.1016/j.vph.2020.106810		JAN 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33181321				2022-04-29	WOS:000613540200001
J	Jensen, T; Olesen, KKW; De Caterina, R; Wurtz, M; Kristensen, SD; Maeng, M				Jensen, Thomas; Olesen, Kevin Kris Warnakula; Caterina, Raffaele De; Wurtz, Morten; Kristensen, Steen Dalby; Maeng, Michael			Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation	VASCULAR PHARMACOLOGY			English	Article						Ischemic stroke; CHA2DS2-VASc score; Diabetes mellitus; Thromboembolism; Insulin		Background: Diabetes mellitus (DM) and atrial fibrillation (AF) are known risk factors for ischemic stroke. Recent data, however, suggest that only insulin-treated DM is a risk factor for ischemic stroke among AF patients. Objectives: To evaluate the risk of stroke in patients with insulin and noninsulin treated DM. Methods: We included AF patients undergoing coronary angiography in Western Denmark between 2003 and 2016. Patients were categorized as 1) insulin treated DM, 2) noninsulin treated DM, or 3) nonDM patients. The main outcome was ischemic stroke >30 days after CAG. Results: AF patients (n = 21,223) were included, of whom 17,181 (81%) did not have DM, 2890 (14%) had noninsulin-treated DM and 1152 (5%) had insulin-treated DM. Median follow-up was 5.3 years. Ischemic stroke rates were 0.83 per 100 person-years for nonDM, 1.19 for noninsulin-treated DM and 1.40 for insulin-treated DM. Insulin-treated DM (adjusted hazard ratio (HRadj) 1.48, 95% CI 1.15-1.91) and noninsulin-treated DM patients (HRadj 1.30, 95% CI 1.09-1.54) had higher risks of ischemic stroke than nonDM patients. There was no difference between insulin-treated DM and noninsulin-treated DM (HRadj 1.09, 95% CI 0.82-1.46). Stratification by coronary artery disease yielded comparable risk estimates. Conclusion: In patients with AF, DM increases the risk of ischemic stroke, regardless of treatment.	[Jensen, Thomas; Olesen, Kevin Kris Warnakula; Wurtz, Morten; Kristensen, Steen Dalby; Maeng, Michael] Aarhus Univ Hosp, Dept Cardiol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus, Denmark; [Caterina, Raffaele De] Pisa Univ Hosp, Dept Cardiol, Pisa, Italy; [Wurtz, Morten] Reg Hosp West Jutland, Dept Cardiol, Herning, Denmark		Maeng, M (通讯作者)，Aarhus Univ Hosp, Dept Cardiol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus, Denmark.	michael.maeng@clin.au.dk	Maeng, Michael/AAY-2135-2021	Maeng, Michael/0000-0002-4310-6433; Jensen, Thomas/0000-0002-5054-4108; Olesen, Kevin Kris Warnakula/0000-0002-0560-3615	Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark	Funded by the Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.	Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS73, DOI 10.2337/dc18-S008; Banerjee C, 2012, STROKE, V43, P1212, DOI 10.1161/STROKEAHA.111.641381; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Guzik Amy, 2017, Continuum (Minneap Minn), V23, P15, DOI 10.1212/CON.0000000000000416; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Krarup LH, 2007, NEUROEPIDEMIOLOGY, V28, P150, DOI 10.1159/000102143; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Meschia JF, 2014, STROKE, V45, P3754, DOI 10.1161/STR.0000000000000046; Olesen KKW, 2019, STROKE, V50, P3347, DOI 10.1161/STROKEAHA.119.026099; Overvad TF, 2015, STROKE, V46, P2168, DOI 10.1161/STROKEAHA.115.009371; Patti G, 2017, J AM COLL CARDIOL, V69, P409, DOI 10.1016/j.jacc.2016.10.069; Pottegard A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213; Schmidt M, 2018, J AM COLL CARDIOL, V71, P1259, DOI 10.1016/j.jacc.2017.10.110; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Sorensen R, 2009, LANCET, V374, P1967, DOI 10.1016/S0140-6736(09)61751-7; Steensig K, 2018, THROMB HAEMOSTASIS, V118, P2162, DOI 10.1055/s-0038-1675401; Steensig K, 2018, J AM COLL CARDIOL, V72, P2540, DOI 10.1016/j.jacc.2018.08.1046	18	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106809	10.1016/j.vph.2020.106809		JAN 2021	6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33130017				2022-04-29	WOS:000613540200005
J	Lee, S; Eichelberger, B; Kopp, CW; Panzer, S; Gremmel, T				Lee, Silvia; Eichelberger, Beate; Kopp, Christoph W.; Panzer, Simon; Gremmel, Thomas			Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity	VASCULAR PHARMACOLOGY			English	Article						Obesity; Body weight; Low-dose aspirin; Cardiovascular disease		Background: Recent data suggest a decreased clinical efficacy of low-dose aspirin in patients weighing >= 70 kg. We therefore investigated the impact of body weight and class 1 obesity on thromboxane generation and platelet reactivity to arachidonic acid (AA) in 316 patients on dual antiplatelet therapy following angioplasty and stenting. Methods: Platelet surface expression of P-selectin and activated glycoprotein (GP) IIb/IIIa in response to AA were determined by flow cytometry as sensitive markers of platelet activation. Urinary 11-dehydro-thromboxane B2 (11-dehydro-TXB2) and serum TXB2 were measured by commercially-available immunoassays. On-treatment residual AA-inducible platelet aggregation was assessed by light transmission aggregometry (LTA), the VerifyNow aspirin assay and multiple electrode aggregometry (MEA). Results: Class 1 obesity was independently associated with increased platelet surface expression of P-selectin and activated GPIIb/IIIa, but not with urinary 11-dehydro-TXB2, serum TXB2, and on-treatment platelet aggregation by all assays. Of all measured parameters, only MEA showed a positive albeit very weak correlation with body weight (r = 0.13, p = 0.02). Furthermore, the results of all tests did not differ significantly between patients without and with a body weight >= 70 kg. After adjustment for age and diabetes by multivariate logistic regression analysis, the frequency of high-on treatment residual TXB2 generation and high on-treatment residual AA-inducible platelet reactivity (HRTG/HRPR) did not differ significantly between obese and non-obese patients. Conclusion: Class 1 obesity is associated with enhanced platelet activation in response to AA in patients on dual antiplatelet therapy. This seems to be independent of cyclooxygenase-1 inhibition and does not translate into HRTG/HRPR.	[Lee, Silvia; Kopp, Christoph W.; Gremmel, Thomas] Med Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Eichelberger, Beate; Panzer, Simon] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, Vienna, Austria; [Gremmel, Thomas] Landesklinikum Mistelbach Ganserndorf, Dept Internal Med 1, Mistelbach, Austria		Gremmel, T (通讯作者)，Med Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	thomas.gremmel@meduniwien.ac.at					Ay L, 2010, J THROMB HAEMOST, V8, P759, DOI 10.1111/j.1538-7836.2010.03766.x; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Beijers HJBH, 2012, THROMB RES, V129, P557, DOI 10.1016/j.thromres.2011.07.033; Beijers HJBH, 2010, ARTERIOSCL THROM VAS, V30, P2639, DOI 10.1161/ATVBAHA.110.211946; Bothwell PM, 2018, LANCET, V392, P387, DOI [10.1016/s0140-6736(18)31133-4, 10.1016/S0140-6736(18)31133-4]; Chen WH, 2007, AM J MED, V120, P631, DOI 10.1016/j.amjmed.2006.10.021; Chen WH, 2004, J AM COLL CARDIOL, V43, P1122, DOI 10.1016/j.jacc.2003.12.034; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Eikelboom JW, 2008, CIRCULATION, V118, P1705, DOI 10.1161/CIRCULATIONAHA.108.768283; Eslam RB, 2013, INT J CARDIOL, V168, P403, DOI 10.1016/j.ijcard.2012.09.103; Frelinger AL, 2009, CIRCULATION, V120, P2586, DOI 10.1161/CIRCULATIONAHA.109.900589; Gremmel T., 2011, PLATELETS, V22; Gremmel T, 2018, RES PRACT THROMB HAE, V2, P439, DOI 10.1002/rth2.12115; Gremmel T, 2018, TRANSL RES, V200, P35, DOI 10.1016/j.trsl.2018.05.009; Gremmel T, 2016, SEMIN THROMB HEMOST, V42, P191, DOI 10.1055/s-0035-1564835; Gremmel T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129666; Gremmel T, 2015, THROMB HAEMOSTASIS, V113, P806, DOI 10.1160/TH14-08-0690; Gremmel T, 2014, ATHEROSCLEROSIS, V237, P692, DOI 10.1016/j.atherosclerosis.2014.10.095; Gremmel T, 2013, J ATHEROSCLER THROMB, V20, P630, DOI 10.5551/jat.17665; Gremmel T, 2013, TRANSL RES, V161, P421, DOI 10.1016/j.trsl.2012.12.015; Gremmel T, 2010, PLATELETS, V21, P515, DOI 10.3109/09537104.2010.493587; Gremmel T, 2009, THROMB HAEMOSTASIS, V101, P333, DOI 10.1160/TH08-09-0577; Gum PA, 2003, J AM COLL CARDIOL, V41, P961, DOI 10.1016/S0735-1097(02)03014-0; Lordkipanidze M, 2007, EUR HEART J, V28, P1702, DOI 10.1093/eurheartj/ehm226; Mayer K, 2014, J AM COLL CARDIOL, V64, P863, DOI 10.1016/j.jacc.2014.05.049; Mertens I, 2002, Obes Rev, V3, P85, DOI 10.1046/j.1467-789X.2002.00056.x; Mourikis P, 2020, VASC PHARMACOL, V125, DOI 10.1016/j.vph.2019.106635; Patrono C, 2009, J THROMB HAEMOST, V7, P258, DOI 10.1111/j.1538-7836.2009.03391.x; Patrono C, 2005, NEW ENGL J MED, V353, P2373, DOI 10.1056/NEJMra052717; Petrucci G, 2019, J THROMB HAEMOST, V17, P885, DOI 10.1111/jth.14445; Pultar J, 2019, VASA, V48, P291, DOI 10.1024/0301-1526/a000753; Santilli F, 2012, OBES REV, V13, P27, DOI 10.1111/j.1467-789X.2011.00930.x; Santilli F, 2009, J AM COLL CARDIOL, V53, P667, DOI 10.1016/j.jacc.2008.10.047; Wang ZJ, 2009, HEART, V95, P1587, DOI 10.1136/hrt.2009.172395	34	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106819	10.1016/j.vph.2020.106819		JAN 2021	6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33207279	hybrid			2022-04-29	WOS:000613540200002
J	Verdoia, M; Viglione, F; Boggio, A; Stefani, D; Panarotto, N; Malabaila, A; Rolla, R; Solda, PL; De Luca, G				Verdoia, Monica; Viglione, Filippo; Boggio, Annalisa; Stefani, Daniele; Panarotto, Nicolo; Malabaila, Aurelio; Rolla, Roberta; Solda, Pier Luigi; De Luca, Giuseppe		Novara Atherosclerosis Study Grp N	Vitamin D deficiency is associated with impaired reperfusion in STEMI patients undergoing primary percutaneous coronary intervention	VASCULAR PHARMACOLOGY			English	Article						Vitamin D; Primary angioplasty; ST-segment elevation myocardial infarction; Reperfusion	CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PERFUSION; IMPACT; CHOLECALCIFEROL; MORTALITY; THERAPY	Background and aims: Vitamin D displays a broad spectrum of cardioprotective effects, preventing oxidative stress, inflammation and thrombosis and improving endothelial function. Previous studies have associated vitamin D deficiency with more extended and severe coronary artery disease (CAD) and worse outcome, and especially among patients with ST-segment elevation myocardial infarction (STEMI). However, few data have been reported on the association of vitamin D levels with the angiographic findings and epicardial reperfusion in STEMI patients undergoing primary percutaneous coronary intervention (pPCI), that was therefore the aim of the present study. Methods and results: A consecutive cohort of patients admitted for STEMI and treated with pPCI were included. The levels of 25(OH)D were assessed at admission by chemiluminescence immunoassay kit LIAISON (R) Vitamin D assay (Diasorin Inc). Hypovitaminosis D was defined for 25(OH)D < 10 ng/ml. We included in our study 450 patients, divided according to tertiles values of 25(OH)D. Lower vitamin D was associated to a higher use of diuretics (p = 0.02), higher levels of white blood cells and glycemia (p < 0.001), lower prevalence of lesions on bifurcations (p = 0.03) and smaller diameter of the target coronary vessel (p = 0.03). Procedural characteristics and pre-procedural TIMI flow were not different according to vitamin D levels, but for a higher rate of impaired epicardial reperfusion (12.8% vs 8.1% vs 5.3%, p = 0.03, adjusted OR[95%CI] = 2.6[1.05-6.6], p = 0.04 for I vs III tertile), requiring higher use of adenosine (p = 0.006) and glycoprotein IIbIIIa inhibitors (p = 0.01). Conclusion: The present study shows that among patients with STEMI undergoing pPCI, lower levels of vitamin D are independently associated with impaired reperfusion, Future dedicated studies will shed light on the prognostic implications of hypovitaminosis D in these patients and the potential therapeutic perspectives.	[Verdoia, Monica; Solda, Pier Luigi] ASL Biella, Div Cardiol, Osped Infermi, Biella, Italy; [Viglione, Filippo; Rolla, Roberta; De Luca, Giuseppe] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy; [Boggio, Annalisa; Stefani, Daniele; Panarotto, Nicolo; Malabaila, Aurelio] ASL Biella, Clin Chem, Osped Infermi, Biella, Italy; [Rolla, Roberta] Univ Piemonte Orientale, Azienda Osped Univ Maggiore Carita, Clin Chem, Novara, Italy; [De Luca, Giuseppe] Univ Piemonte Orientale, Azienda Osped Univ Maggiore Carita, Div Cardiol, Novara, Italy		De Luca, G (通讯作者)，Eastern Piedmont Univ, Osped Maggiore Carita, Cso Mazzini 18, I-28100 Novara, Italy.	giuseppe.deluca@maggioreosp.novara.it	Verdoia, Monica/AAS-1779-2021	Verdoia, Monica/0000-0001-6506-8397; Roberta, Rolla/0000-0003-0805-8285			Abdallah AA, 2020, EGYPT HEART J, V72, DOI 10.1186/s43044-020-00118-5; Afifeh AMS, 2021, NUTR METAB CARDIOVAS, V31, P36, DOI 10.1016/j.numecd.2020.09.021; Akkus O, 2018, TURK KARDIYOL DERN A, V46, P268, DOI 10.5543/tkda.2018.49393; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Cerit L, 2019, PROG NUTR, V21, P270, DOI 10.23751/pn.v21i2.7536; Choudry FA, 2020, J AM COLL CARDIOL, V76, P1168, DOI 10.1016/j.jacc.2020.07.022; Correia LCL, 2013, AM J CARDIOL, V111, P324, DOI 10.1016/j.amjcard.2012.10.006; De Luca G, 2012, NUTR METAB CARDIOVAS, V22, P426, DOI 10.1016/j.numecd.2010.08.005; De Luca G., 2005, EUR HEART J, V26; De Luca G, 2020, J AM COLL CARDIOL, V76, P2321, DOI 10.1016/j.jacc.2020.09.546; De Luca G, 2019, EUROINTERVENTION, V15, pE990, DOI 10.4244/EIJ-D-19-00539; De Luca G, 2015, CURR VASC PHARMACOL, V13, P594, DOI 10.2174/1570161113666141229115302; De Luca G, 2013, AM J CARDIOL, V112, P1083, DOI 10.1016/j.amjcard.2013.05.053; De Luca G, 2013, J CARDIOVASC MED, V14, P815, DOI 10.2459/JCM.0b013e32835fcb38; De Luca G, 2012, AM J CARDIOL, V109, P202, DOI 10.1016/j.amjcard.2011.08.027; De Metrio M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000857; Fabris E, 2019, EUR HEART J-ACUTE CA, V8, P208, DOI 10.1177/2048872617727722; Gibson CM, 2004, AM HEART J, V148, P336, DOI 10.1016/j.ahj.2003.12.044; HOLICK MF, 1989, LANCET, V2, P1104; Kendrick J, 2017, CLIN J AM SOC NEPHRO, V12, P1438, DOI 10.2215/CJN.01870217; Khalili H, 2012, CLIN RES CARDIOL, V101, P321, DOI 10.1007/s00392-011-0394-0; KLONER RA, 1980, CIRCULATION, V62, P945, DOI 10.1161/01.CIR.62.5.945; Kunadian V, 2014, AM HEART J, V167, P283, DOI 10.1016/j.ahj.2013.11.012; Lajdova I, 2008, EUR J PHARMACOL, V586, P14, DOI 10.1016/j.ejphar.2008.02.004; Lavie CJ, 2013, CIRCULATION, V128, P2404, DOI 10.1161/CIRCULATIONAHA.113.002902; Lee JH, 2011, AM J CARDIOL, V107, P1636, DOI 10.1016/j.amjcard.2011.01.048; Manson JE, 2019, NEW ENGL J MED, V380, P33, DOI [10.1056/NEJMoa1809944, 10.1056/nejmoa1809944]; Milazzo V, 2017, WORLD J CARDIOL, V9, P14, DOI 10.4330/wjc.v9.i1.14; NELLIS SH, 1980, CARDIOVASC RES, V14, P137, DOI 10.1093/cvr/14.3.137; Ng LL, 2013, INT J CARDIOL, V168, P2341, DOI 10.1016/j.ijcard.2013.01.030; Niccoli G, 2013, J CARDIOVASC TRANSL, V6, P798, DOI 10.1007/s12265-013-9509-5; Norman PE, 2014, CIRC RES, V114, P379, DOI 10.1161/CIRCRESAHA.113.301241; Palacios C, 2014, J STEROID BIOCHEM, V144, P138, DOI 10.1016/j.jsbmb.2013.11.003; Pilz S, 2016, NAT REV CARDIOL, V13, P404, DOI 10.1038/nrcardio.2016.73; Rezkalla SH, 2002, CIRCULATION, V105, P656, DOI 10.1161/hc0502.102867; Safaie N, 2018, IRAN J PHARM RES, V17, P73; Stach K, 2011, CARDIOLOGY, V118, P107, DOI 10.1159/000327547; Taniyama Y, 1997, J AM COLL CARDIOL, V30, P1193, DOI 10.1016/S0735-1097(97)00277-5; Verdoia M, 2021, QJM-INT J MED, V114, P3, DOI 10.1093/qjmed/hcaa234; Verdoia M., EUR J CLIN INVEST, V28; Verdoia M, 2021, CLIN NUTR, V40, P2228, DOI 10.1016/j.clnu.2020.09.054; Verdoia M, 2021, EUR J INTERN MED, V83, P62, DOI 10.1016/j.ejim.2020.08.016; Verdoia M, 2019, VASC PHARMACOL, V120, DOI 10.1016/j.vph.2019.106564; Verdoia M, 2018, CARDIOVASC REVASCULA, V19, P744, DOI 10.1016/j.carrev.2018.03.002; Verdoia M, 2014, EUR J CLIN INVEST, V44, P634, DOI 10.1111/eci.12281; Wang L, 2012, CIRC-CARDIOVASC QUAL, V5, P819, DOI 10.1161/CIRCOUTCOMES.112.967604	46	0	0	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106897	10.1016/j.vph.2021.106897		SEP 2021	6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	UW4KC	34274529				2022-04-29	WOS:000700125900002
J	Alajbegovic, A; Holmberg, J; Daoud, F; Rippe, C; Kalliokoski, G; Ekman, M; Daudi, S; Ragnarsson, S; Sward, K; Albinsson, S				Alajbegovic, Azra; Holmberg, Johan; Daoud, Fatima; Rippe, Catarina; Kalliokoski, Gabriella; Ekman, Mari; Daudi, Sebastien; Ragnarsson, Sigurdur; Sward, Karl; Albinsson, Sebastian			MRTFA overexpression promotes conversion of human coronary artery smooth muscle cells into lipid-laden foam cells	VASCULAR PHARMACOLOGY			English	Article						Atherosclerosis; Transdifferentiation; Myocardin; Pinocytosis; LDL receptor	LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL ACCUMULATION; GENE-EXPRESSION; UP-REGULATION; OXIDIZED LDL; RECEPTOR; MACROPHAGES; ACTIVATION; MACROPINOCYTOSIS; DIFFERENTIATION	Objective: Smooth muscle cells contribute significantly to lipid-laden foam cells in atherosclerotic plaques. However, the underlying mechanisms transforming smooth muscle cells into foam cells are poorly understood. The purpose of this study was to gain insight into the molecular mechanisms regulating smooth muscle foam cell formation. Approach and results: Using human coronary artery smooth muscle cells we found that the transcriptional co activator MRTFA promotes lipid accumulation via several mechanisms, including direct transcriptional control of LDL receptor, enhanced fluid-phase pinocytosis and reduced lipid efflux. Inhibition of MRTF activity with CCG1423 and CCG203971 significantly reduced lipid accumulation. Furthermore, we demonstrate enhanced MRTFA expression in vascular remodeling of human vessels. Conclusions: This study demonstrates a novel role for MRTFA as an important regulator of lipid homeostasis in vascular smooth muscle cells. Thus, MRTFA could potentially be a new therapeutic target for inhibition of vascular lipid accumulation.	[Alajbegovic, Azra; Holmberg, Johan; Daoud, Fatima; Rippe, Catarina; Kalliokoski, Gabriella; Ekman, Mari; Sward, Karl; Albinsson, Sebastian] Lund Univ, Dept Expt Med Sci, BMC D12, SE-22184 Lund, Sweden; [Daudi, Sebastien; Ragnarsson, Sigurdur] Lund Univ, Dept Clin Sci, Lund, Sweden		Alajbegovic, A (通讯作者)，Lund Univ, Dept Expt Med Sci, BMC D12, SE-22184 Lund, Sweden.	azra.alajbegovic@med.lu.se	Albinsson, Sebastian/B-4105-2010	Albinsson, Sebastian/0000-0001-6936-3967; Daoud, Fatima/0000-0002-8567-8296	Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2017-00860]; Swedish Heart and Lung FoundationSwedish Heart-Lung Foundation; Crafoord foundation; Magnus Bergvall foundation; Lars Hierta Memorial Foundation; Royal Physiographic Society	This study was supported by grants from the Novo Nordisk Foundation, the Swedish Research Council (2017-00860), the Swedish Heart and Lung Foundation, the Crafoord foundation, the Magnus Bergvall foundation, Lars Hierta Memorial Foundation and the Royal Physiographic Society.	Ackers-Johnson M, 2015, ARTERIOSCL THROM VAS, V35, P817, DOI 10.1161/ATVBAHA.114.305218; Albinsson S, 2004, J BIOL CHEM, V279, P34849, DOI 10.1074/jbc.M403370200; Allahverdian S, 2014, CIRCULATION, V129, P1551, DOI 10.1161/CIRCULATIONAHA.113.005015; An J, 2019, J MOL CELL CARDIOL, V133, P26, DOI 10.1016/j.yjmcc.2019.05.015; Anzinger JJ, 2010, ARTERIOSCL THROM VAS, V30, P2022, DOI 10.1161/ATVBAHA.110.210849; Bell JL, 2013, BIOORG MED CHEM LETT, V23, P3826, DOI 10.1016/j.bmcl.2013.04.080; Zhao B, 2006, J BIOL CHEM, V281, P15757, DOI 10.1074/jbc.M510714200; Chen PY, 2020, CELL STEM CELL, V26, P542, DOI 10.1016/j.stem.2020.02.013; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; COOKSON FB, 1971, BRIT J EXP PATHOL, V52, P62; Cui YD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7333; Ding LA, 2017, J BIOL CHEM, V292, P9283, DOI 10.1074/jbc.M116.773739; Draude G, 1999, BIOCHEM PHARMACOL, V57, P383, DOI 10.1016/S0006-2952(98)00313-X; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144; Fraley AE, 2006, CURR OPIN LIPIDOL, V17, P502, DOI 10.1097/01.mol.0000245255.40634.b5; Frontini MJ, 2009, CIRC RES, V104, P832, DOI 10.1161/CIRCRESAHA.108.187302; Hayashi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089016; Hinohara K, 2009, HUM GENET, V126, P539, DOI 10.1007/s00439-009-0698-6; Hutchings KM, 2017, BIOORG MED CHEM LETT, V27, P1744, DOI 10.1016/j.bmcl.2017.02.070; Ishigaki Y, 2009, CURR OPIN LIPIDOL, V20, P363, DOI 10.1097/MOL.0b013e32832fa58d; Jones NL, 1999, ANAT REC, V255, P57; Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x; Koivusalo M, 2010, J CELL BIOL, V188, P547, DOI 10.1083/jcb.200908086; Krawczyk KK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133931; Kruth HS, 2002, J BIOL CHEM, V277, P34573, DOI 10.1074/jbc.M205059200; Krysko DV, 2006, CELL DEATH DIFFER, V13, P2011, DOI 10.1038/sj.cdd.4401900; Levitan I, 2010, ANTIOXID REDOX SIGN, V13, P39, DOI 10.1089/ars.2009.2733; Lin SS, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00078; Lisabeth EM, 2019, ACS PHARMACOL TRANSL, V2, P92, DOI 10.1021/acsptsci.8b00048; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Mietus-Snyder M, 2000, J BIOL CHEM, V275, P17661, DOI 10.1074/jbc.275.23.17661; Minami T, 2012, EMBO J, V31, P4428, DOI 10.1038/emboj.2012.296; Montel L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214385; Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pan HZ, 2020, CIRCULATION, V142, P2060, DOI 10.1161/CIRCULATIONAHA.120.048378; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pfisterer SG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14858; PITAS RE, 1990, J BIOL CHEM, V265, P12722; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; Satoh K, 2011, AM J PHYSIOL-HEART C, V301, pH287, DOI 10.1152/ajpheart.00327.2011; SCHROEDER F, 1983, J BIOCHEM BIOPH METH, V8, P15, DOI 10.1016/0165-022X(83)90017-9; Shankman LS, 2015, NAT MED, V21, P628, DOI 10.1038/nm.3866; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Hien TT, 2016, J BIOL CHEM, V291, P3552, DOI 10.1074/jbc.M115.654384; Velasquez LS, 2013, P NATL ACAD SCI USA, V110, P16850, DOI 10.1073/pnas.1316764110; Vengrenyuk Y, 2015, ARTERIOSCL THROM VAS, V35, P535, DOI 10.1161/ATVBAHA.114.304029; Wang Y, 2019, ARTERIOSCL THROM VAS, V39, P876, DOI 10.1161/ATVBAHA.119.312434; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283; Zhao XH, 2007, J CELL SCI, V120, P1801, DOI 10.1242/jcs.001586; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	57	1	1	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106837	10.1016/j.vph.2021.106837		MAY 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33516965	hybrid			2022-04-29	WOS:000652840900012
J	Gelbenegger, G; Erari-Canyurt, U; Grafeneder, J; Jilma, B; Lesiak, M; Komosa, A; de Caterina, R; Postula, M; Siller-Matula, JM				Gelbenegger, Georg; Erari-Canyurt, Ummahan; Grafeneder, Jurgen; Jilma, Bernd; Lesiak, Maciej; Komosa, Anna; de Caterina, Raffaele; Postula, Marek; Siller-Matula, Jolanta M.			Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis	VASCULAR PHARMACOLOGY			English	Article						Dual antiplatelet therapy; Aspirin; P2Y(12) inhibitor; Clopidogrel; Prasugrel; Ticagrelor	ELUTING STENT IMPLANTATION; LONG-TERM; CARDIOVASCULAR EVENTS; CLOPIDOGREL; MONOTHERAPY; INHIBITORS; EFFICACY; 6-MONTH; SAFETY; TRIAL	Introduction: The ideal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) is still unknown. In this meta-analysis, we aimed to compare very short-term (1-3 months), short-term (6 months), standard-term (12 months) and long-term (>12 months) DAPT durations for efficacy and safety. Methods: Overall DAPT comparisons were classified as "any shorter-term"/"any longer-term" DAPT. The primary outcome was a composite of major adverse cardiovascular events (MACE: non-fatal myocardial infarction, nonfatal stroke and cardiovascular death). The primary safety outcome was major bleeding. Results: Twenty-six studies comprising 103.394 patients were included. Compared with standard-term DAPT duration, very short-term DAPT duration with subsequent drop of aspirin (RR 1.06, 95% CI, 0.95-1.18, p = 0.26) or drop of the P2Y(12) inhibitor (RR 0.92, 95% CI, 0.72-1.16, p = 0.47) was not associated with a higher risk of MACE. Any longer-term compared with any shorter-term DAPT durations led to a significantly lower risk of MACE (RR 0.88, 95% CI, 0.81-0.96, p = 0.002), but a significantly higher risk of BARC 3-5 major bleeding events (RR 1.63, 95% CI, 1.22-2.17, p = 0.001). In the ACS subgroup receiving prasugrel or ticagrelor but not clopidogrel, any longer-term DAPT duration was associated with a significantly lower risk of MACE compared to any shorter-term DAPT duration (RR 0.84, 95% CI, 0.77-0.92, p = 0.0001). Conclusion: DAPT may be shortened to 1-3 months in patients with low ischemic but high bleeding risk followed by aspirin or P2Y12 monotherapy. Prasugrel or ticagrelor based DAPT may be extended to >12 months in case of high ischemic and low bleeding risk.	[Gelbenegger, Georg; Jilma, Bernd] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria; [Erari-Canyurt, Ummahan; Siller-Matula, Jolanta M.] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Wahringer Gurtel 18-20, A-1090 Vienna, Austria; [Grafeneder, Jurgen] Med Univ Vienna, Dept Emergency Med, Vienna, Austria; [Lesiak, Maciej; Komosa, Anna] Poznan Univ Med Sci, Dept Cardiol 1, Poznan, Poland; [de Caterina, Raffaele] Univ Pisa, Pisa, Italy; [de Caterina, Raffaele] Fdn Villa Serena Ric, Citta S Angelo, Pescara, Italy; [Postula, Marek; Siller-Matula, Jolanta M.] Med Univ Warsaw, Ctr Preclin Res & Technol CEPT, Dept Expt & Clin Pharmacol, Warsaw, Poland		Siller-Matula, JM (通讯作者)，Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Jolanta.siller-matula@meduniwien.ac.at	; Siller-Matula, Jolanta Maria/J-8992-2015	Jilma, Bernd/0000-0001-5652-7977; Siller-Matula, Jolanta Maria/0000-0001-6041-1635	Austrian Science FundsAustrian Science Fund (FWF) [SFB54-P04]	GG is supported by grant SFB54-P04 from the Austrian Science Funds. The funding had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.016, 10.1016/j.jacc.2014.09.017]; Bandstein N, 2014, J AM COLL CARDIOL, V63, P2569, DOI 10.1016/j.jacc.2014.03.017; Bernardi V, 2007, AM J CARDIOL, V99, P349, DOI 10.1016/j.amjcard.2006.08.034; Bonaca MP, 2015, NEW ENGL J MED, V372, P1791, DOI 10.1056/NEJMoa1500857; Brar SS, 2011, J AM COLL CARDIOL, V58, P1945, DOI 10.1016/j.jacc.2011.06.059; Chiarito M, 2020, LANCET, V395, P1487, DOI 10.1016/S0140-6736(20)30315-9; Collet JP, 2014, LANCET, V384, P1577, DOI 10.1016/S0140-6736(14)60612-7; Colombo A, 2014, J AM COLL CARDIOL, V64, P2086, DOI 10.1016/j.jacc.2014.09.008; Costa F, 2017, LANCET, V389, P1025, DOI 10.1016/S0140-6736(17)30397-5; De Luca G, 2019, EUROINTERVENTION, V15, pE990, DOI 10.4244/EIJ-D-19-00539; Ducroq G, 2015, EUROINTERVENTION, V11, P737, DOI 10.4244/EIJY14M09_11; Feres F, 2013, JAMA-J AM MED ASSOC, V310, P2510, DOI 10.1001/jama.2013.282183; Gilard M, 2015, J AM COLL CARDIOL, V65, P777, DOI 10.1016/j.jacc.2014.11.008; Gwon HC, 2012, CIRCULATION, V125, P505, DOI 10.1161/CIRCULATIONAHA.111.059022; Hahn JY, 2019, JAMA-J AM MED ASSOC, V321, P2428, DOI 10.1001/jama.2019.8146; Hahn JY, 2018, LANCET, V391, P1274, DOI 10.1016/S0140-6736(18)30493-8; Han YL, 2016, CIRC-CARDIOVASC INTE, V9, P1, DOI 10.1161/CIRCINTERVENTIONS.115.003145; Helft G, 2016, EUR HEART J, V37, P365, DOI 10.1093/eurheartj/ehv481; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hong SJ, 2016, JACC-CARDIOVASC INTE, V9, P1438, DOI 10.1016/j.jcin.2016.04.036; Kedhi E, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k3793; Kim BK, 2020, JAMA-J AM MED ASSOC, V323, P2407, DOI 10.1001/jama.2020.7580; Kim BK, 2012, J AM COLL CARDIOL, V60, P1340, DOI 10.1016/j.jacc.2012.06.043; Lee BK, 2018, EUROINTERVENTION, V13, P1923, DOI 10.4244/EIJ-D-17-00792; Lee CW, 2014, CIRCULATION, V129, P304, DOI 10.1161/CIRCULATIONAHA.113.003303; Mauri L, 2014, NEW ENGL J MED, V371, P2155, DOI 10.1056/NEJMoa1409312; Mehran R, 2019, NEW ENGL J MED, V381, P2032, DOI 10.1056/NEJMoa1908419; Miyazaki Y, 2017, NAT REV CARDIOL, V14, P294, DOI 10.1038/nrcardio.2017.12; Nakamura M, 2017, JACC-CARDIOVASC INTE, V10, P1189, DOI 10.1016/j.jcin.2017.04.019; Navarese EP, 2015, JACC-CARDIOVASC INTE, V8, P201, DOI 10.1016/j.jcin.2014.10.003; Palmerini T, 2012, CIRC-CARDIOVASC INTE, V5, P357, DOI 10.1161/CIRCINTERVENTIONS.111.967083; Park SJ, 2010, NEW ENGL J MED, V362, P1374, DOI 10.1056/NEJMoa1001266; Schupke S, 2019, NEW ENGL J MED, V381, P1524, DOI 10.1056/NEJMoa1908973; Schulz-Schupke S, 2015, EUR HEART J, V36, P1252, DOI 10.1093/eurheartj/ehu523; Siller-Matula JM, 2010, J THROMB HAEMOST, V8, P2624, DOI 10.1111/j.1538-7836.2010.04049.x; Siller-Matula JM, 2013, JACC-CARDIOVASC INTE, V6, P1111, DOI 10.1016/j.jcin.2013.06.011; Valgimigli M, 2018, EUR HEART J, V39, P213, DOI 10.1093/eurheartj/ehx419; Valgimigli M, 2013, EUR HEART J, V34, P909, DOI 10.1093/eurheartj/ehs460; Vranckx P, 2018, LANCET, V392, P940, DOI 10.1016/S0140-6736(18)31858-0; Watanabe H, 2019, JAMA-J AM MED ASSOC, V321, P2414, DOI 10.1001/jama.2019.8145; Winter MP, 2017, EUR HEART J-CARD PHA, V3, P221, DOI 10.1093/ehjcvp/pvw044	41	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106858	10.1016/j.vph.2021.106858		MAY 2021	11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33753284	hybrid			2022-04-29	WOS:000652840900005
J	McCarthy, CG; Wilczynski, S; Wenceslau, CF; Webb, RC				McCarthy, Cameron G.; Wilczynski, Stephanie; Wenceslau, Camilla F.; Webb, R. Clinton			A new storm on the horizon in COVID-19: Bradykinin-induced vascular complications	VASCULAR PHARMACOLOGY			English	Editorial Material							KININ; RECEPTOR; ACE2		[McCarthy, Cameron G.; Wenceslau, Camilla F.] Ctr Hypertens & Personalized Med, 3000 Arlington Ave, Toledo, OH 43614 USA; [McCarthy, Cameron G.; Wenceslau, Camilla F.] Univ Toledo, Coll Med & Life Sci, Dept Physiol & Pharmacol, 2801 W Bancroft St, Toledo, OH 43606 USA; [Wilczynski, Stephanie; Webb, R. Clinton] Cardiovasc Translat Res Ctr, 6311 Garners Ferry Rd, Columbia, SC 29209 USA; [Wilczynski, Stephanie; Webb, R. Clinton] Univ South Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29208 USA		McCarthy, CG (通讯作者)，Univ Toledo, Coll Med & Life Sci, Dept Physiol & Pharmacol, Ctr Hypertens & Precis Med, Block Hlth Sci Bldg,3000 Arlington Ave, Toledo, OH 43614 USA.	cameron.mccarthy@utoledo.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K99HL151889, R00GM118885, P01HL134604]	This work was supported by National Institutes of Health (K99HL151889, R00GM118885, and P01HL134604).	Araujo RC, 2001, BIOL CHEM, V382, P91, DOI 10.1515/BC.2001.014; Brunnee T, 1997, CLIN EXP ALLERGY, V27, P653; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; Dutra RC, 2017, AUTOIMMUN REV, V16, P192, DOI 10.1016/j.autrev.2016.12.011; Garvin MR, 2020, ELIFE, V9, DOI 10.7554/eLife.59177; Goncalves ECD, 2021, CELL MOL NEUROBIOL, V41, P63, DOI 10.1007/s10571-020-00832-3; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Libby P, 2020, EUR HEART J, V41, P3038, DOI 10.1093/eurheartj/ehaa623; Motta JD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574862; Oschatz C, 2011, IMMUNITY, V34, P258, DOI 10.1016/j.immuni.2011.02.008; Sidarta-Oliveira D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76488-2; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016; Stuardo M, 2004, J LEUKOCYTE BIOL, V75, P631, DOI 10.1189/jlb.1103546; Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0; van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5	20	5	5	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106826	10.1016/j.vph.2020.106826		MAR 2021	3	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33358968	Green Published, Bronze			2022-04-29	WOS:000629161700005
J	Aradhyula, V; Waigi, E; Bearss, NR; Edwards, JM; Joe, B; McCarthy, CG; Koch, LB; Wenceslau, CF				Aradhyula, Vaishnavi; Waigi, Emily; Bearss, Nicole R.; Edwards, Jonnelle M.; Joe, Bina; McCarthy, Cameron G.; Koch, Lauren B.; Wenceslau, Camilla F.			Intrinsic exercise capacity induces divergent vascular plasticity via arachidonic acid-mediated inflammatory pathways in female rats	VASCULAR PHARMACOLOGY			English	Article						Test	ENDOTHELIAL DYSFUNCTION; HYPERPOLARIZING FACTOR; OXIDATIVE STRESS; AEROBIC CAPACITY; SMALL ARTERIES; LIPOXIN	Metabolic syndrome prevalence has increased among US adults, particularly among non-hispanic white and black women. Sedentary behavior often leads to chronic inflammation, a triggering factor of metabolic syndrome. Given that intrinsic exercise capacity is genetically inherited, we questioned if low-grade chronic inflammation would be present in a female rat model of low intrinsic exercise capacity-induced metabolic syndrome, while beneficial increase of resolution of inflammation would be present in a female rat model of high intrinsic exercise capacity. In the vascular system, two primary markers for inflammation and resolution of inflammation are cyclooxygenase (COX) and lipoxygenase (LOX), respectively. Our study focused on the novel hypothesis that untrained, inherited exercise capacity induces divergent vascular plasticity via changes in the delicate balance between COX and LOX inflammatory mediators. We used divergent rat strains with low (LCR) and high (HCR) aerobic running capacity. By using animals with contrasting intrinsic exercise capacities, it is possible to determine the exact triggers that lead to inherited vascular plasticity in female rats. We observed that female LCR displayed increased periovarian fat pad and body weight, which is congruent with their obesity-presenting phenotype. Furthermore, LCR presented with vascular hypocontractility and increased COX and LOX-derived pro-inflammatory factors. On the other hand, HCR presented with a "shutdown" of COX-induced vasoconstriction and enhanced resolution of inflammation to maintain vascular tone and homeostasis. In conclusion, LCR display low-grade chronic inflammation via increased COX activity. These results provide mechanistic clues as to why lower intrinsic aerobic capacity correlates with a predisposition to risk of vascular disease. Conversely, being born with higher intrinsic aerobic capacity is a significant factor for improved vascular physiology in female rats.	[Aradhyula, Vaishnavi; Waigi, Emily; Bearss, Nicole R.; Edwards, Jonnelle M.; Joe, Bina; McCarthy, Cameron G.; Koch, Lauren B.; Wenceslau, Camilla F.] Univ Toledo, Dept Physiol & Pharmacol, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA		Wenceslau, CF (通讯作者)，Univ Toledo, Dept Physiol & Pharmacol, Coll Med & Life Sci, Lab Vasc Biol LVB, 3000 Transverse Dr, Toledo, OH 43614 USA.	Camilla.Wenceslau@utoledo.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL149762, R00GM118885, K99HL151889, R01HL1430820]; American Heart AssociationAmerican Heart Association [18POST34060003]; NSFNational Science Foundation (NSF) [AGEP1432878]; Office of Research Infrastructure Programs [P40OD021331]; Department of Physiology & Pharmacology, University of Toledo College of Medicine, Toledo, OH	This work was supported by National Institutes of Health (R01HL149762 and R00GM118885 to C.F.W., K99HL151889 to C.G.M., R01HL1430820 to B.J.), American Heart Association (18POST34060003 to C.G.M.) and NSF (AGEP1432878 to J.M.E.). The LCR and HCR rat model system was funded by the Office of Research Infrastructure Programs grant (P40OD021331 to L.G.K.). The rat models for low and high exercise capacity are maintained as an international resource with support from the Department of Physiology & Pharmacology, University of Toledo College of Medicine, Toledo, OH. Contact LGKLauren.Koch2@UToledo.Edu for information on the rat models.	[Anonymous], 2018, WHO REPORT GLOBAL AC; Back M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104593; Battault S, 2018, AM J PHYSIOL-HEART C, V314, pH497, DOI 10.1152/ajpheart.00217.2017; Bishop-Bailey D, 2006, ARTERIOSCL THROM VAS, V26, P956, DOI 10.1161/01.ATV.0000219672.68024.bc; BOONEN HCM, 1993, J CARDIOVASC PHARM, V22, P388, DOI 10.1097/00005344-199309000-00007; Bouchard C, 1998, MED SCI SPORT EXER, V30, P252, DOI 10.1097/00005768-199802000-00013; Boyle JJ, 2003, ARTERIOSCL THROM VAS, V23, P1553, DOI 10.1161/01.ATV.0000086961.44581.B7; Campbell WB, 2010, PFLUG ARCH EUR J PHY, V459, P881, DOI 10.1007/s00424-010-0804-6; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Craft Baine B, 2014, Int J Lib Arts Soc Sci, V2, P65; Davel AP, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007675; de Chantemele EJB, 2012, J MOL CELL CARDIOL, V52, P840, DOI 10.1016/j.yjmcc.2011.08.018; Division of Nutrition, 2019, PHYS ACTIVITY OBESIT; Edwards JM, 2020, CURR PHARM DESIGN, V26, P3723, DOI 10.2174/1381612826666200417150121; Fernandes T, 2011, BRAZ J MED BIOL RES, V44, P836, DOI 10.1590/S0100-879X2011000900003; Fleming I, 2004, PHARMACOL RES, V49, P525, DOI 10.1016/j.phrs.2003.11.016; Hagdorn QAJ, 2019, AM J PHYSIOL-HEART C, V316, pH1552, DOI 10.1152/ajpheart.00182.2019; Hilgers RHP, 2012, AM J PHYSIOL-HEART C, V303, pH513, DOI 10.1152/ajpheart.01175.2011; HWA JJ, 1994, AM J PHYSIOL, V266, pH952, DOI 10.1152/ajpheart.1994.266.3.H952; Koch LG, 2011, CIRC RES, V109, P1162, DOI 10.1161/CIRCRESAHA.111.253807; Koch LG, 2005, INTEGR COMP BIOL, V45, P405, DOI 10.1093/icb/45.3.405; Laufs U, 2005, ARTERIOSCL THROM VAS, V25, P809, DOI 10.1161/01.ATV.0000158311.24443.af; Luksha L, 2009, ATHEROSCLEROSIS, V202, P330, DOI 10.1016/j.atherosclerosis.2008.06.008; Maddipati KR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580117; Moore JX, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160287; Mulvany MJ, 2008, MED BIOL ENG COMPUT, V46, P461, DOI 10.1007/s11517-008-0305-3; Nosova EV, 2014, J SURG RES, V190, P672, DOI 10.1016/j.jss.2014.02.001; Novak CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005869; Pober JS, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016345; Pourageaud F, 1997, AM J PHYSIOL-HEART C, V273, pH1699, DOI 10.1152/ajpheart.1997.273.4.H1699; Reusch JEB, 2018, ENDOCRINOLOGY, V159, P9, DOI 10.1210/en.2017-03019; Romanko OP, 2005, AM J PHYSIOL-HEART C, V289, pH2097, DOI 10.1152/ajpheart.00213.2005; Romero R, 1996, PROSTAG LEUKOTR ESS, V54, P187, DOI 10.1016/S0952-3278(96)90015-0; Roy S., FUNCTION, V2; Scotland RS, 2005, CIRCULATION, V111, P796, DOI 10.1161/01.CIR.0000155238.70797.4E; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Silva JF, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00386; Singh NK, 2019, PROG LIPID RES, V73, P28, DOI 10.1016/j.plipres.2018.11.001; Stapleton Phoebe A, 2008, Pathophysiology, V15, P79, DOI 10.1016/j.pathophys.2008.04.007; Stenholm S, 2008, CURR OPIN CLIN NUTR, V11, P693, DOI 10.1097/MCO.0b013e328312c37d; Tang EHC, 2009, PHARMACOL THERAPEUT, V122, P140, DOI 10.1016/j.pharmthera.2009.02.006; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Vessieres E, 2013, VASC PHARMACOL, V58, P356, DOI 10.1016/j.vph.2013.03.001; Wenceslau CF, 2019, PHARMACOL RES, V141, P276, DOI 10.1016/j.phrs.2019.01.015; Wenceslau CF, 2014, J VASC RES, V51, P407, DOI 10.1159/000371490; Wenceslau CF, 2014, J HYPERTENS, V32, P542, DOI 10.1097/HJH.0000000000000059; Young DR, 2016, CIRCULATION, V134, pE262, DOI 10.1161/CIR.0000000000000440; Zhu SS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221366	48	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106862	10.1016/j.vph.2021.106862		SEP 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33872803				2022-04-29	WOS:000709412300005
J	Yu, Q; Zheng, HD; Zhang, YP				Yu, Qi; Zheng, Huadong; Zhang, Yaping			Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia	VASCULAR PHARMACOLOGY			English	Article						Statins; Inducible degrader of LDLR; Proprotein convertase subtilisin; kexin type 9; LDL receptor	LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL UPTAKE; IDOL; LXR; RECEPTOR; DEGRADATION; PCSK9; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; METABOLISM	Statins are the most effective lipid-lowering drugs ever developed, and numerous patients with cardiovascular disease (CVD) have obtained remarkable benefits from statin therapy. However, issues with statin resistance and intolerance cannot be ignored in clinical practice. Additionally, adverse effects, such as an increased risk of newonset diabetes and muscle symptoms, may limit the utilization of statins. Therefore, the development of new lipid-lowering agents is necessary to reduce CVD risk in patients who are unable to receive statin therapy. Among these new lipid-lowering strategies, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective way to enhance clearance of LDL-C from the circulation by impeding the degradation of LDL receptor (LDLR) in hepatocytes. Interestingly, given that upregulation of LDLR is an effective method for lowering lipid levels, the question arises as to whether other LDLR-mediated genes could serve as potential therapeutic targets for CVD. As an E3-ubiquitin ligase, inducible degrader of LDLR (IDOL) can cause ubiquitination and degradation of LDLR in lysosome and is a novel regulator of LDLR expression similar to PCSK9. Although there are no approved drugs for targeting the IDOL-LDLR pathway, recent studies demonstrate that IDOL could serve as a potential therapeutic target for hyperlipidemia. Herein, we have summarized these novel studies to present the pathological role of IDOL in CVD, further assessing its pharmacological effects for lipid-lowering therapy.	[Yu, Qi; Zheng, Huadong; Zhang, Yaping] Xian Med Univ, Shaanxi Basic & Clin Translat Res Team Atheroscle, Shaanxi Key Lab Ischem Cardiovasc Dis, Inst Basic & Translat Med, Xian 710021, Peoples R China; [Yu, Qi] Xian Med Univ, Dept Histol & Embryol, Xian 710021, Peoples R China		Zhang, YP (通讯作者)，Xian Med Univ, Shaanxi Basic & Clin Translat Res Team Atheroscle, Shaanxi Key Lab Ischem Cardiovasc Dis, Inst Basic & Translat Med, Xian 710021, Peoples R China.	zypxu@yahoo.com	Qi, Yu/ABB-1418-2021		National Natural Science of ChinaNational Natural Science Foundation of China (NSFC) [81400328, 81773795]; Innovation Support Plan and Key Research and Development Program of Shaanxi Province of China [2020PT-003, 2018SF-266]; Research Found of Xi'an Medical University [2018XNRC02, 2018PT23]	The present study was supported by the National Natural Science of China (81400328 and 81773795), Innovation Support Plan and Key Research and Development Program of Shaanxi Province of China (2020PT-003 and 2018SF-266) and Research Found of Xi'an Medical University (2018XNRC02 and 2018PT23).	Adi D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71241-1; Adi D, 2019, ARTERIOSCL THROM VAS, V39, P2468, DOI 10.1161/ATVBAHA.119.312589; Calkin AC, 2014, CIRC RES, V115, P442, DOI 10.1161/CIRCRESAHA.115.304440; Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312; Calkin AC, 2011, P NATL ACAD SCI USA, V108, P20107, DOI 10.1073/pnas.1111589108; Choi J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad1904; Choi YJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76224-w; Fan JL, 2015, PHARMACOL THERAPEUT, V146, P104, DOI 10.1016/j.pharmthera.2014.09.009; Girona J, 2018, J CLIN LIPIDOL, V12, P211, DOI 10.1016/j.jacl.2017.10.003; Goldstein JL, 2015, CELL, V161, P161, DOI 10.1016/j.cell.2015.01.036; Hong C, 2014, CELL METAB, V20, P910, DOI 10.1016/j.cmet.2014.10.001; Hong C, 2010, J BIOL CHEM, V285, P19720, DOI 10.1074/jbc.M110.123729; Ibrahim S, 2016, CARDIOVASC RES, V110, P23, DOI 10.1093/cvr/cvw010; Lagace TA, 2014, CURR OPIN LIPIDOL, V25, P387, DOI 10.1097/MOL.0000000000000114; Lee SD, 2019, NAT METAB, V1, P1089, DOI 10.1038/s42255-019-0127-7; Martinelli L, 2020, J BIOL CHEM, V295, P13570, DOI 10.1074/jbc.RA120.014349; Nelson JK, 2016, CIRC RES, V118, P410, DOI 10.1161/CIRCRESAHA.115.307298; Olsson PA, 1999, J BIOL CHEM, V274, P36288, DOI 10.1074/jbc.274.51.36288; Pattanayak SP, 2018, BIOMED PHARMACOTHER, V108, P297, DOI 10.1016/j.biopha.2018.08.145; Rakipovski G, 2020, CURR OPIN LIPIDOL, V31, P340, DOI 10.1097/MOL.0000000000000718; Rosenson RS, 2018, J AM COLL CARDIOL, V72, P314, DOI 10.1016/j.jacc.2018.04.054; Santos Paulo C J L, 2014, Pharmacogenet Genomics, V24, P548, DOI 10.1097/FPC.0000000000000089; Seidah NG, 2014, CIRC RES, V114, P1022, DOI 10.1161/CIRCRESAHA.114.301621; Sorrentino V, 2013, J LIPID RES, V54, P2174, DOI 10.1194/jlr.M037713; Sorrentino V, 2013, EUR HEART J, V34, P1292, DOI 10.1093/eurheartj/ehs472; Stopsack KH, 2017, CARCINOGENESIS, V38, P806, DOI 10.1093/carcin/bgx058; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; van Loon NM, 2020, ATHEROSCLEROSIS, V315, P1, DOI 10.1016/j.atherosclerosis.2020.10.898; van Loon NM, 2018, AGING-US, V10, P3042, DOI 10.18632/aging.101597; van Loon NM, 2018, ARTERIOSCL THROM VAS, V38, P1785, DOI 10.1161/ATVBAHA.118.311168; Wan Z., INFECT IMMUN, V89; Wang F, 2020, J AGR FOOD CHEM, V68, P12651, DOI 10.1021/acs.jafc.0c05800; Wang JQ, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.015420; Waterworth DM, 2010, ARTERIOSCL THROM VAS, V30, P2264, DOI 10.1161/ATVBAHA.109.201020; Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797; Yang RS, 2020, ONCOGENE, V39, P6340, DOI 10.1038/s41388-020-01439-0; Yu Q, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00372; Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974; Zhang CP, 2016, MED HYPOTHESES, V86, P138, DOI 10.1016/j.mehy.2015.11.010; Zhang L, 2012, ARTERIOSCL THROM VAS, V32, P2541, DOI 10.1161/ATVBAHA.112.250571; Zhang L, 2011, GENE DEV, V25, P1262, DOI 10.1101/gad.2056211	41	0	0	9	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106878	10.1016/j.vph.2021.106878		SEP 2021	5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	UW4KC	34015522				2022-04-29	WOS:000700125900001
J	Verdoia, M; Savonitto, S; Dudek, D; Kedhi, E; De Luca, G				Verdoia, Monica; Savonitto, Stefano; Dudek, Dariusz; Kedhi, Elvin; De Luca, Giuseppe			Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials	VASCULAR PHARMACOLOGY			English	Article						Dual antiplatelet therapy; Ticagrelor; Meta-analysis, acute coronary syndrome; Mortality, bleedings	MYOCARDIAL-INFARCTION; PLATELET REACTIVITY; CLOPIDOGREL; PRASUGREL; EFFICACY; SAFETY; INTERVENTION; REGIMENS; THERAPY; ASPIRIN	Background: Ticagrelor has been shown to offer potential outcome benefits in acute coronary syndromes and for the long-term cardiovascular prevention, reducing mortality and the recurrence of ischemic events. However, data from real-world and recent meta-analyses have suggested that the anti-ischemic benefits of ticagrelor could be lower than expected, potentially outweighed by an increased risk of bleeding complications. Therefore, the aim of the present meta-analysis was to evaluate the prognostic impact of ticagrelor as compared to the conventional antiplatelet agents (ASA and clopidogrel) in patients with coronary artery disease (CAD), enclosing patients with acute coronary syndromes and stable CAD. Methods: Literature and main scientific session abstracts were searched for studies comparing a ticagrelor-based antiplatelet regimen vs different antiplatelet agents in patients with CAD. The primary efficacy endpoint was mortality, and the primary safety endpoint was the occurrence of major bleedings. Secondary endpoints were cardiovascular mortality, myocardial infarction, stroke and intracranial hemorrhage (ICH). Results: We included 15 randomized clinical trials, with a total population of 73,402 patients (55% randomized to ticagrelor). At a mean follow-up of 15 +/- 11.3 months, the ticagrelor based strategy did not significantly reduce mortality as compared to the traditional therapy (OR[95%CI] = 0.88[0.70,1.09], p = 0.24; phet<0.00001), with comparable results and no interaction according to patients' presentation (p interaction = 0.80). A similar result was achieved for cardiovascular mortality, whereas the reduction of recurrent myocardial infarction was significant (OR[95%CI] = 0.84[0.78,0.90], p < 0.00001; phet = 0.76). As for the risk of stroke, the largest reduction was observed in stable patients, while a neutral effect was observed in the ACS subgroup (p int = 0.35). Major bleeding events were increased in ticagrelor-treated patients (OR [95%CI] = 1.40 [1.06, 1.84], p = 0.02; phet<0.00001), especially ICH (OR [95% CI] = 1.45[1.13,1.84], p = 0.003; phet = 0.93), and mainly among non-ACS patient. No interaction for any outcome endpoint was observed according to patients' age. Conclusions: Based on the current meta-analysis, a ticagrelor-based strategy for the treatment of patients with coronary artery disease is associated to a significant increase in major bleeding complications and especially for intracranial hemorrhage, as compared to a strategy based on conventional antiplatelet agents, while resulting in a neutral effect on survival. However, a significant reduction of recurrent myocardial infarction was observed with ticagrelor.	[Verdoia, Monica; De Luca, Giuseppe] Eastern Piedmont Univ, Azienda Osped Univ Maggiore Carita, Div Cardiol, Novara, Italy; [Savonitto, Stefano] Osped Alessandro Manzoni, Cardiovasc Dept, Lecce, Italy; [Dudek, Dariusz] Jagiellonian Univ, Inst Cardiol, Med Coll, Krakow, Poland; [Kedhi, Elvin] ISALA Hosp, Dept Cardiol, Zwolle, Netherlands		De Luca, G (通讯作者)，Eastern Piedmont Univ, Azienda Osped Univ Maggiore Carita, Cardiol, Corso Mazzini 18, I-28100 Novara, Italy.	giuseppe.deluca@maggioreosp.novara.it	Verdoia, Monica/AAS-1779-2021	Verdoia, Monica/0000-0001-6506-8397			Berger JS, 2018, VASC MED, V23, P523, DOI 10.1177/1358863X18775594; Berwanger O, 2019, J AM COLL CARDIOL, V73, P2819, DOI 10.1016/j.jacc.2019.03.011; Birnbaum Yochai, 2019, Cell Physiol Biochem, V53, P961, DOI 10.33594/000000189; Bonaca MP, 2017, J AM COLL CARDIOL, V70, P1368, DOI 10.1016/j.jacc.2017.07.768; Bonello L, 2010, J AM COLL CARDIOL, V56, P919, DOI 10.1016/j.jacc.2010.04.047; Cannon CP, 2007, J AM COLL CARDIOL, V50, P1844, DOI 10.1016/j.jacc.2007.07.053; Cassese S, 2020, AM HEART J, V219, P109, DOI 10.1016/j.ahj.2019.08.020; Cattaneo M, 2014, J AM COLL CARDIOL, V63, P2503, DOI 10.1016/j.jacc.2014.03.031; De Luca G, 2013, DIABETES CARE, V36, P1020, DOI 10.2337/dc12-1507; DELUCA G, 2015, VASC MED, V13, P594; Goto S, 2015, CIRC J, V79, P2452, DOI 10.1253/circj.CJ-15-0112; Guan WJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012978; Hansen CM, 2018, JACC-CARDIOVASC INTE, V11, P369, DOI 10.1016/j.jcin.2017.12.016; Hiatt WR, 2017, NEW ENGL J MED, V376, P32, DOI 10.1056/NEJMoa1611688; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Johnston SC, 2016, NEW ENGL J MED, V375, P35, DOI 10.1056/NEJMoa1603060; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Liu Y, 2017, KARDIOL POL, V75, P850, DOI 10.5603/KP.a2017.0116; Mehran R, 2019, NEW ENGL J MED, V381, P2032, DOI 10.1056/NEJMoa1908419; Misumida N, 2018, CARDIOVASC REVASCULA, V19, P689, DOI 10.1016/j.carrev.2018.01.009; Montalescot G, 2013, NEW ENGL J MED, V369, P999, DOI 10.1056/NEJMoa1308075; Motovska Z, 2016, CIRCULATION, V134, P1603, DOI 10.1161/CIRCULATIONAHA.116.024823; Park DW, 2019, CIRCULATION, V140, P1865, DOI 10.1161/CIRCULATIONAHA.119.041766; Park K, 2019, CIRC-CARDIOVASC INTE, V12, DOI 10.1161/CIRCINTERVENTIONS.119.008105; Qaderdan K, 2015, AM HEART J, V170, P981, DOI 10.1016/j.ahj.2015.07.030; SAW J, 2016, NEW ENGL J MED, V102, P763; Schulz S, 2014, J CARDIOVASC TRANSL, V7, P91, DOI 10.1007/s12265-013-9527-3; Schunkert H, 2019, EUR HEART J, V40, P2432, DOI 10.1093/eurheartj/ehz185; Serebruany VL, 2016, INT J CARDIOL, V215, P372, DOI 10.1016/j.ijcard.2016.04.125; Sibbing D, 2019, JACC-CARDIOVASC INTE, V12, P1521, DOI 10.1016/j.jcin.2019.03.034; STEBLOVNIK K, 2016, KARDIOL POL, V134, P2128; Steg PG, 2019, NEW ENGL J MED, V381, P1309, DOI 10.1056/NEJMoa1908077; Tang XY, 2016, J CARDIOVASC PHARM, V68, P115, DOI 10.1097/FJC.0000000000000390; Turgeon RD, 2020, JAMA INTERN MED, V180, P420, DOI 10.1001/jamainternmed.2019.6447; VERDOIA M, 2019, JACC-CARDIOVASC INTE, V284, P136; Verdoia M, 2019, J THROMB THROMBOLYS, V48, P413, DOI 10.1007/s11239-019-01873-2; Verdoia M, 2015, EXPERT OPIN PHARMACO, V16, P1739, DOI 10.1517/14656566.2015.1056151; Verdoia M, 2014, J CARDIOVASC PHARM, V63, P339, DOI 10.1097/FJC.0000000000000052; Vranckx P, 2018, LANCET, V392, P940, DOI 10.1016/S0140-6736(18)31858-0; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wang XC, 2019, CORONARY ARTERY DIS, V30, P317, DOI 10.1097/MCA.0000000000000707; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Xu F, 2019, J THORAC CARDIOV SUR, V158, P430, DOI 10.1016/j.jtcvs.2018.10.032; You SC, 2020, JAMA-J AM MED ASSOC, V324, P1640, DOI 10.1001/jama.2020.16167; Zhao Q, 2018, JAMA-J AM MED ASSOC, V319, P1677, DOI 10.1001/jama.2018.3197	45	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106828	10.1016/j.vph.2020.106828		MAR 2021	17	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33385541				2022-04-29	WOS:000629161700006
J	Wallace, RG; Rochfort, KD; Barabas, P; Curtis, TM; Uehara, H; Ambati, BK; Cummins, PM				Wallace, Robert G.; Rochfort, Keith D.; Barabas, Peter; Curtis, Timothy M.; Uehara, Hironori; Ambati, Balamurali K.; Cummins, Philip M.			COMP-Ang1: Therapeutic potential of an engineered Angiopoietin-1 variant	VASCULAR PHARMACOLOGY			English	Review						Endothelial; COMP-Ang1; Tie2; Therapeutic; Vascular	IN-VIVO; ENDOTHELIAL PERMEABILITY; COMP-ANGIOPOIETIN-1; ANGIOGENESIS; MOUSE; TIE2; PROTEIN; TARGET; GROWTH; INJURY	The Angiopoietin-1/2 system is an opportune target for therapeutic intervention in a wide range of vascular pathologies, particularly through its association with endothelium. The complex multi-domain structure of native human Angiopoietin-1 has hindered its widespread applicability as a therapeutic agent, prompting the search for alternative approaches to mimicking the Ang1:Tie2 signalling axis; a system with highly complex patterns of regulation involving multiple structurally similar molecules. An engineered variant, Cartilage Oligomeric Matrix Protein - Angiopoietin-1 (COMP-Ang1), has been demonstrated to overcome the limitations of the native molecule and activate the Tie2 pathway with several fold greater potency than Ang1, both in vitro and in vivo. The therapeutic efficacy of COMP-Ang1, at both the vascular and systemic levels, is evident from multiple studies. Beneficial impacts on skeletal muscle regeneration, wound healing and angiogenesis have been reported alongside renoprotective, anti-hypertensive and anti-inflammatory effects. COMP-Ang1 has also demonstrated synergy with other compounds to heighten bone repair, has been leveraged for potential use as a co-therapeutic for enhanced targeted cancer treatment, and has received considerable attention as an anti-leakage agent for microvascular diseases like diabetic retinopathy. This review examines the vascular Angiopoietin:Tie2 signalling mechanism, evaluates the potential therapeutic merits of engineered COMP-Ang1 in both vascular and systemic contexts, and addresses the inherent translational challenges in moving this potential therapeutic from bench-to-bedside.	[Wallace, Robert G.; Rochfort, Keith D.; Cummins, Philip M.] Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; [Wallace, Robert G.; Rochfort, Keith D.; Cummins, Philip M.] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin, Ireland; [Barabas, Peter; Curtis, Timothy M.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, North Ireland; [Uehara, Hironori; Ambati, Balamurali K.] Univ Oregon, Knight Campus, Eugene, OR 97403 USA		Wallace, RG (通讯作者)，Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland.	robert.wallace6@mail.dcu.ie			Science Foundation Ireland US-Ireland R&D Partnership ProgrammeScience Foundation Ireland [14/US/B3116]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1-EY026029]; Northern Ireland Health and Social Care RD Division [STL/4748/13]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_15026]	The authors acknowledge the generous financial support provided through the Science Foundation Ireland US-Ireland R&D Partnership Programme (PMC, 14/US/B3116), National Institute of Health RO1 (BKA, RO1-EY026029), Northern Ireland Health and Social Care R&D Division (TC, STL/4748/13), and the Medical Research Council (TC, MC_PC_15026).	Ahmed A, 2009, CIRC RES, V104, P1333, DOI 10.1161/CIRCRESAHA.109.196154; Akwii RG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050471; Al-awar A, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/9051426; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340; Bhattarai G, 2016, BONE, V92, P168, DOI 10.1016/j.bone.2016.09.002; Byun SJ, 2007, AM J PATHOL, V171, P1682, DOI 10.2353/ajpath.2007.070142; Cahoon JM, 2015, DIABETES, V64, P4247, DOI 10.2337/db14-1030; Carra S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051245; Carroll LS, 2019, INVEST OPHTH VIS SCI, V60, P2494, DOI 10.1167/iovs.18-26182; Cho CH, 2006, P NATL ACAD SCI USA, V103, P4946, DOI 10.1073/pnas.0506352103; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5553, DOI 10.1073/pnas.0307575101; Choi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140502; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; Fang JH, 2018, HEPATOLOGY, V68, P1459, DOI 10.1002/hep.29920; Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Fuxe J, 2011, AM J PATHOL, V178, P2897, DOI 10.1016/j.ajpath.2011.02.008; Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019; Goyal SN, 2016, CHEM-BIOL INTERACT, V244, P49, DOI 10.1016/j.cbi.2015.11.032; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Hwang JA, 2009, MOL CANCER RES, V7, P1920, DOI 10.1158/1541-7786.MCR-09-0041; Hwang JA, 2009, BIOCHEM BIOPH RES CO, V381, P592, DOI 10.1016/j.bbrc.2009.02.096; Hwang SJ, 2008, PROTEIN J, V27, P319, DOI 10.1007/s10930-008-9140-5; Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019; Jian WG, 2014, ANTICANCER RES, V34, P3377; Jiang XY, 2018, PROG NEUROBIOL, V163, P144, DOI 10.1016/j.pneurobio.2017.10.001; Kim KE, 2007, ARTERIOSCL THROM VAS, V27, P564, DOI 10.1161/01.ATV.0000256458.82320.be; Kim MS, 2009, CIRCULATION, V120, P2240, DOI 10.1161/CIRCULATIONAHA.109.856815; Kim SR, 2008, EXP MOL MED, V40, P320, DOI 10.3858/emm.2008.40.3.320; Kim S, 2013, J CELL BIOCHEM, V114, P2513, DOI 10.1002/jcb.24596; Kim SO, 2013, J KOREAN MED SCI, V28, P725, DOI 10.3346/jkms.2013.28.5.725; Kim Won, 2008, Electrolyte Blood Press, V6, P22, DOI 10.5049/EBP.2008.6.1.22; Kook SH, 2018, BIOCHEM BIOPH RES CO, V499, P669, DOI 10.1016/j.bbrc.2018.03.210; Korhonen EA, 2016, J CLIN INVEST, V126, P3495, DOI 10.1172/JCI84923; Lambert NG, 2016, EXP EYE RES, V145, P248, DOI 10.1016/j.exer.2016.01.009; Lee HJ, 2008, J RADIAT RES, V49, P313, DOI 10.1269/jrr.07064; Lee JS, 2008, CARDIOVASC RES, V78, P572, DOI 10.1093/cvr/cvn048; Lee KS, 2007, EXP MOL MED, V39, P733, DOI 10.1038/emm.2007.80; Lee S, 2008, NEPHROL DIAL TRANSPL, V23, P2784, DOI 10.1093/ndt/gfn168; Lee S, 2007, NEPHROL DIAL TRANSPL, V22, P396, DOI 10.1093/ndt/gfl598; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Moon HE, 2015, EXP NEUROBIOL, V24, P55, DOI 10.5607/en.2015.24.1.55; Moss A, 2013, CYTOKINE GROWTH F R, V24, P579, DOI 10.1016/j.cytogfr.2013.05.009; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Oh N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15291; Pan LY, 2017, CELL PHYSIOL BIOCHEM, V44, P2395, DOI 10.1159/000486155; Park KS, 2010, TRANSPL P, V42, P2653, DOI 10.1016/j.transproceed.2010.04.048; Passaro D, 2017, CANCER CELL, V32, P324, DOI 10.1016/j.ccell.2017.08.001; Patel JI, 2005, BRIT J OPHTHALMOL, V89, P480, DOI 10.1136/bjo.2004.049940; Pfister F, 2010, ACTA DIABETOL, V47, P59, DOI 10.1007/s00592-009-0099-2; Pizurki L, 2003, BRIT J PHARMACOL, V139, P329, DOI 10.1038/sj.bjp.0705259; Qiu LH, 2015, ANN BIOMED ENG, V43, P2924, DOI 10.1007/s10439-015-1342-3; Rochfort KD, 2019, INVEST OPHTH VIS SCI, V60, P3547, DOI 10.1167/iovs.19-27644; Saharinen P, 2005, J CELL BIOL, V169, P239, DOI 10.1083/jcb.200411105; Satchell SC, 2002, J AM SOC NEPHROL, V13, P544, DOI 10.1681/ASN.V132544; Seyhan AA., 2019, TRANSL MED COMMUN, V4, P18, DOI [10.1186/s41231-019-0050-7, DOI 10.1186/S41231-019-0050-7]; Sim HJ, 2021, MOL CELLS, V44, P254, DOI 10.14348/molcells.2021.2155; Singh H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029319; Sturk C, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-30; Syrjala SO, 2015, AM J TRANSPLANT, V15, P2075, DOI 10.1111/ajt.13296; Teichert M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16106; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tian M, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2019-000882; Wang CY, 2018, J BIOMED MATER RES A, V106, P2070, DOI 10.1002/jbm.a.36390; Woo KV, 2011, J CLIN INVEST, V121, P1624, DOI 10.1172/JCI42040; Youn SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30513-7; Zhang Y, 2019, ISCIENCE, V20, P497, DOI 10.1016/j.isci.2019.10.006	71	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106919	10.1016/j.vph.2021.106919		NOV 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34583025	hybrid			2022-04-29	WOS:000756079500010
J	Bosmans, LA; Shami, A; Atzler, D; Weber, C; Goncalves, I; Lutgens, E				Bosmans, Laura A.; Shami, Annelie; Atzler, Dorothee; Weber, Christian; Goncalves, Isabel; Lutgens, Esther			Glucocorticoid induced TNF receptor family-related protein (GITR)-A novel driver of atherosclerosis	VASCULAR PHARMACOLOGY			English	Review						GITR; Costimulatory molecule; Immune checkpoint; Atherosclerosis; CVD	NECROSIS-FACTOR-RECEPTOR; REGULATORY T-CELLS; B-CELLS; REDUCES ATHEROSCLEROSIS; DENDRITIC CELLS; CO-STIMULATION; TUMOR-IMMUNITY; GITR ANTIBODY; ACTIVATION; INTERMEDIATE	Atherosclerosis is a lipid-driven, chronic inflammatory disease. In spite of efficient lipid lowering treatments, such as statins and PCSK9 inhibitors, patients, especially those with elevated inflammatory biomarkers, still have a significant residual cardiovascular disease risk. Novel drugs targeting inflammatory mediators are needed to further reduce this residual risk. Agonistic immune checkpoint proteins, including CD86, CD40L and CD40, have been shown to be drivers of atherosclerosis. Recently, glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR), a co-stimulatory immune checkpoint protein, was identified to be pivotal in cardiovascular disease. Cardiovascular patients have elevated soluble GITR plasma levels compared to healthy controls. Furthermore, in human carotid endarterectomy plaques, GITR expression was higher in plaques from symptomatic compared to asymptomatic patients and correlated with features of plaque vulnerability. Moreover, depleting GITR reduced atherosclerotic plaque development in mice. GITR-deficient monocytes and macrophages exhibited less inflammatory potential and reduced migratory capacity. In this review, we discuss GITR's effects on various immune cells, mechanisms, signalling pathways and finally GITR's potential as a novel drug target in atherosclerosis.	[Bosmans, Laura A.; Lutgens, Esther] Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam Cardiovasc Sci ACS, Dept Med Biochem, Amsterdam, Netherlands; [Shami, Annelie; Goncalves, Isabel] Lund Univ, Clin Res Ctr, Dept Clin Sci Malmo, Malmo, Sweden; [Atzler, Dorothee; Weber, Christian; Lutgens, Esther] Ludwig Maximilians Univ LMU Munich, Inst Cardiovasc Prevent IPEK, Munich, Germany; [Atzler, Dorothee; Weber, Christian; Lutgens, Esther] German Ctr Cardiovasc Res DZHK, Partner Site Munich Heart Alliance, Munich, Germany; [Atzler, Dorothee] Ludwig Maximilians Univ LMU Munich, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany; [Weber, Christian] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Weber, Christian] Maastricht Univ, Dept Biochem, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands; [Goncalves, Isabel] Skane Univ Hosp, Dept Cardiol, Malmo, Sweden		Lutgens, E (通讯作者)，Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	e.lutgens@amsterdamumc.nl	Weber, Christian/AAW-2153-2020; Goncalves, Isabel/AAC-6632-2022; Goncalves, Isabel/AAD-4654-2022	Weber, Christian/0000-0003-4610-8714; Goncalves, Isabel/0000-0002-2935-0181; 	Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation [CVON201720]; Dutch Federation of University Medical Centres [CVON201720]; Netherlands Organization for Health Research and DevelopmentNetherlands Organization for Health Research and Development [CVON201720]; Royal Netherlands Academy of Sciences [CVON2017-20]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC 1123]; Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO); European Research Council (ERC)European Research Council (ERC)European Commission; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Heart and Lung FoundationSwedish Heart-Lung Foundation; SUS Foundation; Swedish Foundation for Strategic ResearchSwedish Foundation for Strategic Research [IRC15-0067]	This work was supported by the following grants: We acknowledge the support from the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences for the GENIUS-II project "Generating the best evidencebased pharmaceutical targets for atherosclerosis" [CVON201720 to E.L.,.] , the Deutsche Forschungsgemeinschaft [CRC 1123 to D.A., E.L., C.W.] ; the Netherlands Organization for Scientific Research (NWO) [VICI grant to E.L.] ; the European Research Council (ERC consolidator grant to E.L, ERC advanced grant to C.W.) , the Swedish Research Council (to I.G.) , the Swedish Heart and Lung Foundation (to I.G., A.S.) , the SUS Foundation (to I.G.) and Swedish Foundation for Strategic Research Dnr IRC15-0067 (to I.G.) .	Aday AW, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00016; Alique M, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.29240; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bae E, 2007, CLIN EXP IMMUNOL, V148, P410, DOI 10.1111/j.1365-2249.2007.03363.x; Balmanoukian A.S., 2020, CLIN CANCER RES; Ben-Chetrit E, 1998, SEMIN ARTHRITIS RHEU, V28, P48, DOI 10.1016/S0049-0172(98)80028-0; Bosmans LA, 2021, J CARDIOVASC TRANSL, V14, P13, DOI 10.1007/s12265-020-09994-3; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; Byrne AM, 2012, CLIN EXP ALLERGY, V42, P550, DOI 10.1111/j.1365-2222.2012.03956.x; Byrne Aideen M, 2009, J Invest Dermatol, V129, P2784, DOI 10.1038/jid.2009.163; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chien CH, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0391-3; Chu KL, 2020, J LEUKOCYTE BIOL, V107, P953, DOI 10.1002/JLB.4AB1219-254R; Cuzzocrea S, 2004, J LEUKOCYTE BIOL, V76, P933, DOI 10.1189/jlb.0204110; Cuzzocrea S, 2006, J IMMUNOL, V177, P631, DOI 10.4049/jimmunol.177.1.631; de Boer OJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000779; de Boer OJ, 2007, J HISTOCHEM CYTOCHEM, V55, P891, DOI 10.1369/jhc.6A7119.2007; di Ricca ML, 2020, EUR J IMMUNOL, V50, P972, DOI 10.1002/eji.201948393; Elliott MR, 2017, J IMMUNOL, V198, P1387, DOI 10.4049/jimmunol.1601520; Esparza EM, 2006, J BIOL CHEM, V281, P8559, DOI 10.1074/jbc.M512915200; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Foks Amanda C, 2012, Arterioscler Thromb Vasc Biol, V32, P2862, DOI 10.1161/ATVBAHA.112.300509; Galle-Treger L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08449-x; Galuppo M, 2011, BRIT J PHARMACOL, V162, P1186, DOI 10.1111/j.1476-5381.2010.01123.x; Gistera A, 2017, NAT REV NEPHROL, V13, DOI 10.1038/nrneph.2017.51; Golubovskaya V, 2018, FRONT BIOSCI-LANDMRK, V23, P2245, DOI 10.2741/4703; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Heinhuis KM, 2020, JAMA ONCOL, V6, P100, DOI 10.1001/jamaoncol.2019.3848; Kamimura Y, 2009, J IMMUNOL, V182, P2708, DOI 10.4049/jimmunol.0803704; Kawano M, 2015, ONCOL REP, V34, P1995, DOI 10.3892/or.2015.4161; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Kim WJ, 2006, IMMUNOLOGY, V119, P421, DOI 10.1111/j.1365-2567.2006.02453.x; Knight AM, 2015, EUR J IMMUNOL, V45, P1600, DOI 10.1002/eji.201545684; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kusters PJH, 2018, CARDIOVASC RES, V114, P368, DOI 10.1093/cvr/cvx248; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Lacal PM, 2013, J PHARMACOL EXP THER, V347, P164, DOI 10.1124/jpet.113.207605; Leyland R, 2017, CLIN CANCER RES, V23, P3416, DOI 10.1158/1078-0432.CCR-16-2000; Li BY, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1380142; Liao GX, 2012, GASTROENTEROLOGY, V142, P582, DOI 10.1053/j.gastro.2011.11.031; Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293; Ma J, 2016, AM J PATHOL, V186, P1559, DOI 10.1016/j.ajpath.2016.02.010; Mahmud SA, 2014, NAT IMMUNOL, V15, P473, DOI 10.1038/ni.2849; Mahne AE, 2017, CANCER RES, V77, P1108, DOI 10.1158/0008-5472.CAN-16-0797; Meiler S, 2016, ARTERIOSCL THROM VAS, V36, P1748, DOI 10.1161/ATVBAHA.116.307354; Nagashima H, 2018, J ALLERGY CLIN IMMUN, V141, P1939, DOI 10.1016/j.jaci.2018.01.028; Nidorf SM, 2020, NEW ENGL J MED, V383, P1838, DOI 10.1056/NEJMoa2021372; Nidorf SM, 2013, J AM COLL CARDIOL, V61, P404, DOI 10.1016/j.jacc.2012.10.027; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Nowakowska DJ, 2016, J IMMUNOL, V196, P2145, DOI 10.4049/jimmunol.1501877; Papadopoulos KP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9509; Pascutti MF, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004675; Patel M, 2005, EUR J IMMUNOL, V35, P3581, DOI 10.1002/eji.200535421; Pennock ND, 2013, ADV PHYSIOL EDUC, V37, P273, DOI 10.1152/advan.00066.2013; Potteaux S, 2011, J CLIN INVEST, V121, P2025, DOI 10.1172/JCI43802; Ray A, 2012, J IMMUNOL, V188, P3188, DOI 10.4049/jimmunol.1103354; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2019, NEW ENGL J MED, V380, P752, DOI 10.1056/NEJMoa1809798; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Ronchetti S, 2011, IMMUNOL LETT, V135, P24, DOI 10.1016/j.imlet.2010.09.008; Santucci L, 2007, GUT, V56, P52, DOI 10.1136/gut.2006.091181; Satoguina JS, 2008, EUR J IMMUNOL, V38, P3101, DOI 10.1002/eji.200838193; Schaer DA, 2013, CANCER IMMUNOL RES, V1, P320, DOI 10.1158/2326-6066.CIR-13-0086; Sehested TSG, 2019, JAMA CARDIOL, V4, P128, DOI 10.1001/jamacardio.2018.4566; Seijkens TTP, 2018, J AM COLL CARDIOL, V71, P527, DOI 10.1016/j.jacc.2017.11.055; Shami Annelie, 2020, EUR HEART J, DOI [10.1093/eurheartj, DOI 10.1093/EURHEARTJ]; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shin HH, 2002, FEBS LETT, V514, P275, DOI 10.1016/S0014-5793(02)02379-7; Shin HH, 2002, CYTOKINE, V19, P187, DOI 10.1006/cyto.2002.1962; Suvas S, 2005, J VIROL, V79, P11935, DOI 10.1128/JVI.79.18.11935-11942.2005; Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388; Tran B, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0407-x; van Beek AA, 2019, INT J CANCER, V145, P1111, DOI 10.1002/ijc.32181; Wang J, 2005, J BIOL CHEM, V280, P37725, DOI 10.1074/jbc.M507976200; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Willemsen L, 2020, J PATHOL, V250, P705, DOI 10.1002/path.5392; Winkels H, 2017, EUR HEART J, V38, P3590, DOI 10.1093/eurheartj/ehx517; Wong ND, 2017, CARDIOVASC DIAGN THE, V7, pS11, DOI 10.21037/cdt.2017.03.02; World Health Organisation, 2016, GLOB HLTH EST DEATHS GLOB HLTH EST DEATHS; Yusuf S, 2016, NEW ENGL J MED, V374, P2021, DOI 10.1056/NEJMoa1600176; Zhou PF, 2007, J IMMUNOL, V179, P7365, DOI 10.4049/jimmunol.179.11.7365; Zhou P, 2010, J IMMUNOTHER, V33, P789, DOI 10.1097/CJI.0b013e3181ee6ba9; Zhu LX, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.992237	88	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106884	10.1016/j.vph.2021.106884		JUL 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34102305	hybrid			2022-04-29	WOS:000674133600002
J	Eldahshan, W; Sayed, MA; Awad, ME; Ahmed, HA; Gillis, E; Althomali, W; Pillai, B; Alshammari, A; Jackson, L; Dong, GK; Sullivan, JC; Cooley, MA; Elsalanty, M; Ergul, A; Fagan, SC				Eldahshan, Wael; Sayed, Mohammed A.; Awad, Mohamed E.; Ahmed, Heba A.; Gillis, Ellen; Althomali, Waleed; Pillai, Bindu; Alshammari, Abdulkarim; Jackson, Ladonya; Dong, Guangkuo; Sullivan, Jennifer C.; Cooley, Marion A.; Elsalanty, Mohammed; Ergul, Adviye; Fagan, Susan C.			Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke	VASCULAR PHARMACOLOGY			English	Article						Angiotensin II receptor subtype 2 (AT2R); Female rodents; Spontaneously hypertensive rats (SHRs); Post-stroke cognitive impairment (PSCI); microCT angiography	SPONTANEOUSLY HYPERTENSIVE-RATS; ANXIETY-LIKE BEHAVIOR; MEMORY; BRAIN; INVOLVEMENT; MODULATION; IMPAIRMENT; LOSARTAN; DEFICITS	Angiotensin signaling is known to be sexually dimorphic. Although it is a well-studied target for intervention in stroke and cognitive impairment, female studies are rare. With females suffering a disproportionately greater negative impact of stroke and dementia vs. males, effective interventions are of utmost urgency. The aim of the current study was to determine the impact of activation of the angiotensin II type 2 receptor (AT2R) with the agonist compound 21 (C21) on the development of post-stroke cognitive impairment, after experimental ischemic stroke. Ovariectomized (OVX) spontaneously hypertensive rats (SHRs) were subjected to 1 h of middle cerebral artery occlusion (MCAO). At 24 h, rats with a significant neurologic deficit were randomized to receive either saline or C21 (0.03 mg/kg/day) intraperitoneally (IP) for 5 days, then orally (0.12 mg/kg/day) for a total of 6 weeks. Cognitive function, brain structure by MRI and vascular architecture by microCT angiography were measured. C21 preserved cognitive function, specifically spatial memory, and improved vascular density in the ischemic hemisphere at 6 weeks, reflecting both arteriogenesis and angiogenesis. In conclusion, C21 prevented cognitive impairment after stroke, likely through a mechanism involving vascular protection and restoration.	[Eldahshan, Wael; Sayed, Mohammed A.; Ahmed, Heba A.; Althomali, Waleed; Pillai, Bindu; Alshammari, Abdulkarim; Jackson, Ladonya; Fagan, Susan C.] Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA 30912 USA; [Eldahshan, Wael; Sayed, Mohammed A.; Althomali, Waleed; Pillai, Bindu; Alshammari, Abdulkarim; Jackson, Ladonya; Fagan, Susan C.] Augusta Univ, Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA; [Awad, Mohamed E.; Cooley, Marion A.] Augusta Univ, Dept Oral Biol & Diagnost Sci, Dent Coll Georgia, Augusta, GA 30912 USA; [Gillis, Ellen; Dong, Guangkuo; Sullivan, Jennifer C.] Augusta Univ, Dept Physiol, Med Coll Georgia, Augusta, GA 30912 USA; [Ergul, Adviye] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Ergul, Adviye] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [Elsalanty, Mohammed] Western Univ Med Sci, Coll Osteopath Med Pacif, Dept Med Anat Sci, Pomona, CA USA		Fagan, SC (通讯作者)，Augusta Univ, Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA.; Fagan, SC (通讯作者)，Univ Georgia, Coll Pharm, HM Bldg 914 New Bailie St, Augusta, GA 30901 USA.	sfagan@augusta.edu		Cooley, Marion A./0000-0002-4286-745X; Jackson-Cowan, Ladonya/0000-0002-8723-7240	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS104573]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10 OD025177]; Veterans Affairs (VA) Merit ReviewUS Department of Veterans Affairs [BX000347]; VA Senior Research Career Scientist Award [IK6 BX004471, TL1 TR002382, UL1TR002378];  [RF1 NS083559]	This study was supported by National Institute of Health (NIH) R01 NS104573 to Adviye Ergul and Susan C. Fagan; RF1 NS083559 to Adviye Ergul; (NIH) S10 OD025177 to Mohammed Elsalanty, Veterans Affairs (VA) Merit Review (BX000347), VA Senior Research Career Scientist Award (IK6 BX004471) to Adviye Ergul. TL1 Award TL1 TR002382 and UL1TR002378 to Ladonya Jackson.	Adriani W, 2003, NEUROSCI BIOBEHAV R, V27, P639, DOI 10.1016/j.neubiorev.2003.08.007; Ahmad A, 2017, HYPERTENSION, V70, P19, DOI 10.1161/HYPERTENSIONAHA.117.08317; Ahmed HA, 2019, BEHAV BRAIN RES, V359, P560, DOI 10.1016/j.bbr.2018.10.010; Ahmed HA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1262-x; Ahmed HA, 2018, BEHAV BRAIN RES, V346, P29, DOI 10.1016/j.bbr.2017.12.007; Alhusban A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178867; Alhusban A, 2016, NEURAL REGEN RES, V11, P912, DOI 10.4103/1673-5374.184484; Alhusban A, 2015, J HYPERTENS, V33, P170, DOI 10.1097/HJH.0000000000000364; BARNES JM, 1990, J CARDIOVASC PHARM, V16, P234, DOI 10.1097/00005344-199008000-00009; Bennion DM, 2018, CLIN SCI, V132, P581, DOI 10.1042/CS20180100; Bove R, 2014, NEUROLOGY, V82, P222, DOI 10.1212/WNL.0000000000000033; Buckley RF, 2019, AM J EPIDEMIOL, V188, P1213, DOI 10.1093/aje/kwz048; Burton CAC, 2013, INT J STROKE, V8, P545, DOI 10.1111/j.1747-4949.2012.00906.x; Cammarota M., 2007, NEURAL PLASTICITY ME; Eldahshan W, 2019, AM J PHYSIOL-HEART C, V316, pH1192, DOI 10.1152/ajpheart.00446.2018; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ennaceur A, 1997, EXP BRAIN RES, V113, P509, DOI 10.1007/PL00005603; Fouda AY, 2017, MOL NEUROBIOL, V54, P661, DOI 10.1007/s12035-015-9675-3; Frye CA, 2007, NEUROBIOL LEARN MEM, V88, P208, DOI 10.1016/j.nlm.2007.04.003; Gaugler J, 2019, ALZHEIMERS DEMENT, V15, P321, DOI 10.1016/j.jalz.2019.01.010; Ghosh S, 2015, NAT NEUROSCI, V18, P112, DOI 10.1038/nn.3888; Giovannini MG, 2015, NEUROBIOL LEARN MEM, V119, P18, DOI 10.1016/j.nlm.2014.12.014; Gomes AL, 2018, IUBMB LIFE, V70, P420, DOI 10.1002/iub.1738; Guan WH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024551; Hafez S, 2015, TRANSL STROKE RES, V6, P171, DOI 10.1007/s12975-015-0391-0; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Iadecola C, 2016, HYPERTENSION, V68, pE67, DOI 10.1161/HYP.0000000000000053; Ishrat T, 2019, J CEREBR BLOOD F MET, V39, P1635, DOI 10.1177/0271678X18764773; Iwanami J, 2015, J AM SOC HYPERTENS, V9, P250, DOI 10.1016/j.jash.2015.01.010; Izquierdo LA, 2002, CELL MOL NEUROBIOL, V22, P269, DOI 10.1023/A:1020715800956; Jackson L., 2019, NEUROMOLECULAR MED, V21; Jackson L, 2020, TRANSL STROKE RES, V11, P762, DOI 10.1007/s12975-019-00752-5; Jackson L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030876; Justin B Ng, 2013, Clin Epidemiol, V5, P135, DOI 10.2147/CLEP.S30621; Khan MB, 2018, TRANSL STROKE RES, V9, P51, DOI 10.1007/s12975-017-0555-1; Leys D, 2005, LANCET NEUROL, V4, P752, DOI 10.1016/S1474-4422(05)70221-0; McCarthy CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095762; MCGAUGH JL, 1989, ANNU REV NEUROSCI, V12, P255, DOI 10.1146/annurev.neuro.12.1.255; Menlove L, 2015, J STROKE CEREBROVASC, V24, P1107, DOI 10.1016/j.jstrokecerebrovasdis.2014.12.036; Myskiw JC, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00008; Orduna V, 2017, BEHAV BRAIN RES, V328, P178, DOI 10.1016/j.bbr.2017.04.033; Persky Rebecca W, 2010, Curr Cardiol Rep, V12, P6, DOI 10.1007/s11886-009-0080-2; Ranjbar H, 2018, IRAN J BASIC MED SCI, V21, P856, DOI 10.22038/IJBMS.2018.27113.6632; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; Sanabria F, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-7; Sanz H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187901; Sullivan JC, 2010, HYPERTENSION, V56, P658, DOI 10.1161/HYPERTENSIONAHA.110.153668; Tanaka KZ, 2014, NEURON, V84, P347, DOI 10.1016/j.neuron.2014.09.037; Tashev R, 2018, PHARMACOL REP, V70, P847, DOI 10.1016/j.pharep.2018.03.001; Tipton AJ, 2014, HYPERTENSION, V64, P557, DOI 10.1161/HYPERTENSIONAHA.114.03512; Tota S, 2012, BEHAV BRAIN RES, V226, P317, DOI 10.1016/j.bbr.2011.07.047; Tuscher JJ, 2015, BEHAV BRAIN RES, V285, P140, DOI 10.1016/j.bbr.2014.08.001; Wan YQ, 2004, J MED CHEM, V47, P5995, DOI 10.1021/jm049715t; Winter B, 2005, BIOL PSYCHIAT, V57, P1166, DOI 10.1016/j.biopsych.2005.02.010; Yang LC, 2015, BIOCHEM PHARMACOL, V94, P270, DOI 10.1016/j.bcp.2015.02.012; Yu L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00371; Zhang TL, 2012, CNS NEUROSCI THER, V18, P981, DOI 10.1111/cns.12015	59	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106904	10.1016/j.vph.2021.106904		NOV 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34481068				2022-04-29	WOS:000756079500006
J	Jurisic, A; Jurisic, Z; Lefkou, E; Girardi, G				Jurisic, Aleksandar; Jurisic, Zaklina; Lefkou, Eleftheria; Girardi, Guillermina			Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction	VASCULAR PHARMACOLOGY			English	Article						Doppler studies; Intrauterine growth restriction; L-arginine; Neonatal complications; Placenta; Pravastatin; Preeclampsia; Preterm birth; Pulsatility index; Uterine arteries	UTERINE ARTERY DOPPLER; NITRIC-OXIDE; MOUSE MODEL; PREECLAMPSIA; COMPLICATIONS; IMPROVE; STATINS	Background: Uteroplacental vascular dysfunction, characterized by diminished uterine artery (UtA) blood flow in the second trimester is a clinically useful predictor of the further development of preeclampsia, fetal growth restriction and stillbirth. Efforts to develop effective treatments to protect pregnancies with abnormal UtA Dopplers would be of significant clinical benefit for mothers and their fetuses. Objective: The aim of this pilot non randomized control study was to use pravastatin +L-arginine to improve uteroplacental haemodynamics and prevent adverse maternal and neonatal outcomes in women with abnormal Dopplers and high risk for developing adverse pregnancy outcomes. Study design: This study was performed between 2015 and 2018. All women received primary care at OB/GYN Polyclinic Jurisic and Narodni Front University Hospital, University of Belgrade Medical School, Serbia. Approval for investigational drug use was obtained and all women gave informed consent. 10 pregnant women with a poor obstetric history that developed uteroplacental dysfunction (UtA pulsatility index (PI) above the 95th percentile and notching) at 20.5 weeks IQR [17.7-22] gave consent to be treated daily with pravastatin (40 mg) and L-arginine (1.5 g) to improve placental blood flow and pregnancy outcomes. 5 women remained untreated after diagnosis at 21 weeks [20 22] (control group). Due to presence of risk factors for pregnancy complications, close maternal and fetal monitoring was undertaken in all patients. Doppler examinations were performed to monitor changes in placental vascular resistance and fetal well-being and growth. Results: PRAV+L-arginine improved uteroplacental haemodynamics, increased fetal growth and prevented early onset preeclampsia leading to delivery close to term (delivery date: median 38 weeks, IQR[36.5-39]) and appropriate weight for gestational age compared to controls, in which placental blood flow did not improve and 2 women developed severe early onset preeclampsia. Neonates from the control group were born preterm (25 weeks IQR[23.5-25]), growth restricted and spent several months at NICU. Two neonates died due to prematurity-associated complications. PRAV+L-arginine treatment prolonged pregnancies for 4.1 months, compared to 26 days in the untreated group, preventing neonatal complications associated with prematurity. The infants are now 1-3 years old and show normal growth and development. Conclusion: This study describes the successful management with pravastatin+L-arginine of 10 pregnant patients with uteroplacental vascular dysfunction and high risk of adverse maternal and fetal outcomes. A larger study is being organized to confirm these observations.	[Jurisic, Aleksandar] Univ Belgrade, Narodni Front Univ Hosp, Med Sch, Belgrade, Serbia; [Jurisic, Aleksandar; Jurisic, Zaklina] OB GYN Polyclin Juris, Belgrade, Serbia; [Lefkou, Eleftheria] Inst Obstet Haematol, Perigenesis, Thessaloniki, Greece; [Girardi, Guillermina] Qatar Univ, Coll Med, QU Hlth, Doha, Qatar		Girardi, G (通讯作者)，Qatar Univ, Coll Med, QU Hlth, Doha, Qatar.	guillerminagirardi@gmail.com			Narodni Front University Hospital, University of Belgrade Medical School in Serbia; Qatar National Library	Narodni Front University Hospital, University of Belgrade Medical School in Serbia provided the patients and consumables used for the clinical care and routine exams of the patients. The study was designed, conducted, analysed, and reported entirely by the authors. Open Access funding provided by the Qatar National Library.	Ahmed A, 2019, STAMP TRIAL COLLABOR, DOI [10.1111/1471-0528.16013., DOI 10.1111/1471-0528.16013]; Ahmed A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013663; Barquiel B, 2014, DIABETES METAB, V40, P204, DOI 10.1016/j.diabet.2013.12.011; Bateman BT, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1035; Brownfoot FC, 2015, HYPERTENSION, V66, P687, DOI 10.1161/HYPERTENSIONAHA.115.05445; Pulido EEC, 2016, HYPERTENS PREGNANCY, V35, P217, DOI 10.3109/10641955.2015.1137586; Costantine M, 2016, AM J OBSTET GYNECOL, V214, pS201, DOI 10.1016/j.ajog.2015.10.399; Costantine MM, 2010, OBSTET GYNECOL, V116, P114, DOI 10.1097/AOG.0b013e3181e10ebd; Giordano Rosalba, 2010, J Prenat Med, V4, P59; Girardi G, 2014, J REPROD IMMUNOL, V101, P161, DOI 10.1016/j.jri.2013.07.005; Grandone E, 2006, FERTIL STERIL, V86, P726, DOI 10.1016/j.fertnstert.2006.01.038; HADLOCK FP, 1985, AM J OBSTET GYNECOL, V151, P333, DOI 10.1016/0002-9378(85)90298-4; Harrington K, 2004, ULTRASOUND OBST GYN, V23, P50, DOI 10.1002/uog.932; Ilekis JV, 2016, AM J OBSTET GYNECOL, V215, pS1, DOI 10.1016/j.ajog.2016.03.001; Johal T, 2014, BRIT J CLIN PHARMACO, V78, P244, DOI 10.1111/bcp.12301; Jurisic A, 2018, VASC PHARMACOL, V110, P64, DOI 10.1016/j.vph.2018.06.001; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; Krause BJ, 2011, PLACENTA, V32, P797, DOI 10.1016/j.placenta.2011.06.025; Kumasawa K, 2011, P NATL ACAD SCI USA, V108, P1451, DOI 10.1073/pnas.1011293108; Lamminpaa R, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-47; Lefkou E., 2016, J CLIN INVEST, V26, P2933; Lefkou E, 2014, HYPERTENSION, V63, pE118, DOI 10.1161/HYPERTENSIONAHA.114.03115; Mannisto T, 2013, J CLIN ENDOCR METAB, V98, P2725, DOI 10.1210/jc.2012-4233; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Ostlund I, 2004, EUR J OBSTET GYN R B, V113, P12, DOI 10.1016/j.ejogrb.2003.07.001; Panczel Z., 2020, PRAVASTATIN INDUCES; Papageorghiou AT, 2004, BEST PRACT RES CL OB, V18, P383, DOI 10.1016/j.bpobgyn.2004.02.003; Redecha P, 2008, J CLIN INVEST, V118, P3453, DOI 10.1172/JCI36089; Schneider S, 2011, J PERINAT MED, V39, P257, DOI 10.1515/jpm.2011.010; Singh J, 2011, HYPERTENSION, V58, P716, DOI 10.1161/HYPERTENSIONAHA.111.175919; Staff AC, 2014, J REPROD IMMUNOL, V101, P120, DOI 10.1016/j.jri.2013.09.001; Vadillo-Ortega F, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2901	32	1	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106824	10.1016/j.vph.2020.106824		MAR 2021	6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33249273	hybrid			2022-04-29	WOS:000629161700003
J	Roscigno, RF; Vaughn, T; Parsley, E; Hunt, T; Eldon, MA; Rubin, LJ				Roscigno, Robert F.; Vaughn, Toby; Parsley, Ed; Hunt, Thomas; Eldon, Michael A.; Rubin, Lewis J.			Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso (R) in healthy subjects	VASCULAR PHARMACOLOGY			English	Article						Bioavailability; Inhaled treprostinil; Pharmacokinetic; Pulmonary arterial hypertension	PULMONARY ARTERIAL-HYPERTENSION; THERAPIES	Introduction: Treprostinil is a synthetic prostacyclin analogue approved for inhalation administration to patients with pulmonary arterial hypertension (PAH) via nebulized Tyvaso (R) inhalation solution. LIQ861 is an inhaled, dry-powder formulation of treprostinil produced using Print (R) (Particle Replication in Nonwetting Templates) technology, a proprietary process for designing and producing highly uniform drug particles. Methods: We conducted comparative bioavailability analyses of treprostinil exposure from LIQ861 (79.5 mu g capsule [approximate delivered dose of 58.1 mu g treprostinil]) compared with Tyvaso (R) (9 breaths [approximate delivered dose of 54 mu g treprostinil]). Results: Treprostinil exposure parameters had least squares geometric mean ratios (LIQ861: Tyvaso (R)) between 0.9 and 1.0 with 90% confidence intervals contained within 0.8 to 1.25. LIQ861 and Tyvaso (R) were both well tolerated. Discussion: Results showed comparable bioavailability of treprostinil and similar tolerability for LIQ861 and Tyvaso (R) administered to healthy adults. Conclusions: Given the comparable treprostinil bioavailability and similar safety profiles of LIQ861 and Tyvaso (R), LIQ861 fulfills a significant unmet need for PAH patients by maximizing the therapeutic benefits of treprostinil by safely delivering doses to the lungs in 1 to 2 breaths using a discreet, convenient, easy-to-use inhaler.	[Roscigno, Robert F.] Clin Dev, Melbourne Beach, FL USA; [Vaughn, Toby] Clin Dev, Rolesville, NC USA; [Parsley, Ed] Med Monitor, San Diego, CA USA; [Hunt, Thomas] PPD Dev LLC, Austin, TX USA; [Eldon, Michael A.] Clin Pharmacol, San Francisco, CA USA; [Rubin, Lewis J.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA		Parsley, E (通讯作者)，3972 Albatross,Suite 303, San Diego, CA 92103 USA.	eparsley@att.net			Liquidia Technologies; thepharmaceutical company developing [LIQ861]	This work was supported by Liquidia Technologies, thepharmaceutical company developing LIQ861.	Barnes H, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012785.pub2; Channick RN, 2012, DRUG DES DEV THER, V6, DOI 10.2147/DDDT.S19281; Chen H, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-31; Delcroix M, 2015, EUR RESPIR REV, V24, P621, DOI 10.1183/16000617.0063-2015; Farber HW, 2016, EUR RESPIR REV, V25, P418, DOI 10.1183/16000617.0083-2016; Galie N, 2016, REV ESP CARDIOL, V69, P177, DOI 10.1016/j.rec.2016.01.002; Hill NS, 2019, J HEART LUNG TRANSPL, V38, pS11, DOI 10.1016/j.healun.2019.01.011; Hill NS, 2015, RESP CARE, V60, P794, DOI 10.4187/respcare.03927; Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818; Kumar P, 2016, CLIN PHARMACOKINET, V55, P1495, DOI 10.1007/s40262-016-0409-0; Nelsen AC, 2010, AM J RESP CRIT CARE, V181; Roscigno R, 2020, PULM CIRC, V10, DOI 10.1177/2045894020971509; United Therapeutics Corp, 2017, TYV PACK INS	13	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106840	10.1016/j.vph.2021.106840		MAY 2021	5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33545364				2022-04-29	WOS:000652840900001
J	Akgol, S; Kalkan, BM; Yucel, D; Kocabas, F				Akgol, Sezer; Kalkan, Batuhan Mert; Yucel, Dogacan; Kocabas, Fatih			SC1 limits tube formation, branching, migration, expansion and induce apoptosis of endothelial cells	VASCULAR PHARMACOLOGY			English	Article						Tumor angiogenesis; Endothelial growth; SC1; Antiangiogenic; Anticancer; Apoptosis	INDOLEAMINE 2,3-DIOXYGENASE; TUMOR ANGIOGENESIS; VASCULAR NICHE; SELF-RENEWAL; PHASE-II; CANCER; GROWTH; MODEL; PYROPTOSIS; CARCINOMA	Endothelial cells (ECs) are essential in the growth and progression of the tumor cells by supplying nutrition and angiogenesis factors. Targeting ECs emerged as a major strategy to prevent the growth of tumors. Studies suggest that ERK1/2 signaling is important for endothelial cells, which could be specifically targeted by small molecule SC1. We aimed to study the effects of SC1 treatments on endothelial cell proliferation, angiogenesis, and death. To this end, we performed viability, apoptosis, cell cycle, gene expression, wound closure, tube formation, and western blot analysis in endothelial cells post SC1 treatments. Intriguingly, we found that SC1 has an antiangiogenic effect on endothelial cells, which limits the endothelial cell expansion, tube formation, branching, and migration. The proliferation is especially limited in dose dependent manner by SC1. In addition, we found that SC1 elevates the apoptosis of endothelial cells and associated pathways including BAK1, Stat1, Sox4, and Caspase1. We believe that these findings could contribute to the development of improved therapies based on the SC1 as an attractive candidate for anticancer clinical studies targeted to tumor angiogenesis.	[Akgol, Sezer; Kocabas, Fatih] Yeditepe Univ, Dept Genet & Bioengn, Fac Engn, Istanbul, Turkey; [Kalkan, Batuhan Mert] Koc Univ, Istanbul, Turkey; [Yucel, Dogacan] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA		Kocabas, F (通讯作者)，Yeditepe Univ, Dept Genet & Bioengn, Fac Engn, Istanbul, Turkey.	fatih.kocabas@yeditepe.edu.tr	Kalkan, Batuhan M/P-6129-2017	Kalkan, Batuhan Mert/0000-0002-3288-0968	EU CommissionEuropean CommissionEuropean Commission Joint Research Centre; TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [115C039]	FK was funded by EU Commission and TUB.ITAK (grant #115C039).	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429; Akiyama K, 2015, AM J PATHOL, V185, P572, DOI 10.1016/j.ajpath.2014.10.017; Aksoz M, 2019, CURR CANCER DRUG TAR, V19, P479, DOI 10.2174/1568009618666180905100608; Al-Habib M, 2013, STEM CELLS DEV, V22, P2402, DOI 10.1089/scd.2012.0426; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Aprile G, 2014, ONCOTARGETS THER, V7, P1997, DOI 10.2147/OTT.S61132; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Bagley RG, 2003, CANCER RES, V63, P5866; Barton M, 2012, BRIT J PHARMACOL, V165, P591, DOI 10.1111/j.1476-5381.2011.01472.x; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Brinkman CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12021; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Broz P, 2010, CELL HOST MICROBE, V8, P471, DOI 10.1016/j.chom.2010.11.007; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Cao ZW, 2017, CANCER CELL, V31, P110, DOI 10.1016/j.ccell.2016.11.010; Cao ZW, 2014, CANCER CELL, V25, P350, DOI 10.1016/j.ccr.2014.02.005; Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103; Chouaib S, 2010, CRIT REV IMMUNOL, V30, P529, DOI 10.1615/CritRevImmunol.v30.i6.30; Daniels BP, 2013, J NEUROSCI METH, V212, P173, DOI 10.1016/j.jneumeth.2012.10.001; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; Du J, 2014, CELL PHYSIOL BIOCHEM, V33, P501, DOI 10.1159/000358630; Duan HY, 2012, EXP EYE RES, V100, P52, DOI 10.1016/j.exer.2012.04.012; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fra AM, 2003, J IMMUNOL, V170, P2279, DOI 10.4049/jimmunol.170.5.2279; Gao DC, 2009, BBA-REV CANCER, V1796, P33, DOI 10.1016/j.bbcan.2009.05.001; Girgin B, 2020, TURK J BIOL, V44, P328, DOI 10.3906/biy-2006-25; He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Johnson FM, 2004, CANCER-AM CANCER SOC, V100, P991, DOI 10.1002/cncr.20079; Kalkan BM, 2020, MICROVASC RES, V130, DOI 10.1016/j.mvr.2020.104001; Katz JB, 2008, IMMUNOL REV, V222, P206, DOI 10.1111/j.1600-065X.2008.00610.x; Keedy VL, 2007, CANCER SCI, V98, P1825, DOI 10.1111/j.1349-7006.2007.00620.x; Keith RobertsPW., 2018, MOL BIOL CELL; Kocherova I, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101602; Li X, 2016, EXP CELL RES, V347, P212, DOI 10.1016/j.yexcr.2016.08.007; Liu H, 2006, FASEB J, V20, P2384, DOI 10.1096/fj.06-6228fje; Liu HZ, 2006, AM J RESP CRIT CARE, V173, P566, DOI 10.1164/rccm.200509-1413OC; Liu YX, 2018, ACTA BIOCH BIOPH SIN, V50, P793, DOI 10.1093/abbs/gmy069; Luscher TF, 1997, CLIN CARDIOL, V20, P3; Ma Y, 2007, ONCOGENE, V26, P3532, DOI 10.1038/sj.onc.1210143; Maishi N, 2016, SCI REP-UK, V6, DOI 10.1038/srep28039; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; McKimmie CS, 2013, BLOOD, V121, P3768, DOI 10.1182/blood-2012-04-425314; Mertins SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057099; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; PAKU S, 1991, LAB INVEST, V65, P334; Pantsulaia I, 2016, AGEING RES REV, V29, P13, DOI 10.1016/j.arr.2016.05.011; Pieters T, 2012, STEM CELL REV REP, V8, P768, DOI 10.1007/s12015-011-9323-x; Poller B, 2008, J NEUROCHEM, V107, P1358, DOI 10.1111/j.1471-4159.2008.05730.x; Ricard N, 2019, J EXP MED, V216, P1874, DOI 10.1084/jem.20182151; Sobierajska K, 2020, ADV EXP MED BIOL, V1234, P71, DOI 10.1007/978-3-030-37184-5_6; Srinivasan R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008283; Tashiro E, 2012, BIOORGAN MED CHEM, V20, P1910, DOI 10.1016/j.bmc.2011.10.081; Tu HY, 2009, BIOORGAN MED CHEM, V17, P7265, DOI 10.1016/j.bmc.2009.08.046; Turan RD, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64888-3; Vander Lugt B, 2013, J IMMUNOL, V191, P3119, DOI 10.4049/jimmunol.1200938; Versieren K, 2012, STEM CELL REV REP, V8, P1088, DOI 10.1007/s12015-012-9382-7; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Xie J., 2020, FRONT CELL NEUROSCI, V14; Xiong YQ, 2009, CLIN CANCER RES, V15, P4838, DOI 10.1158/1078-0432.CCR-08-2780; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang W, 2009, STEM CELLS, V27, P383, DOI 10.1634/stemcells.2008-0974; Zhang RM, 2020, INT J MOL MED, V46, P2161, DOI 10.3892/ijmm.2020.4751; Zhang XS, 2017, ONCOTARGET, V8, P59086, DOI 10.18632/oncotarget.19175; Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269; Ziyad Safiyyah, 2011, Genes Cancer, V2, P1085, DOI 10.1177/1947601911432334	72	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106903	10.1016/j.vph.2021.106903		NOV 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34481979				2022-04-29	WOS:000756079500005
J	Sun, XY; Deng, KY; Zang, YH; Zhang, ZY; Zhao, BX; Fan, JY; Huang, LJ				Sun, Xueyuan; Deng, Kaiyuan; Zang, Yunhui; Zhang, Zhiyong; Zhao, Boxin; Fan, Jingyao; Huang, Lijuan			Exploring the regulatory roles of circular RNAs in the pathogenesis of atherosclerosis	VASCULAR PHARMACOLOGY			English	Review						Circular RNAs; Biogenesis; Atherosclerosis; Transcription	SMOOTH-MUSCLE-CELL; VASCULAR ENDOTHELIAL-CELLS; TOLL-LIKE RECEPTORS; OXIDATIVE STRESS; NITRIC-OXIDE; LOW-DENSITY; CHOLESTEROL ACCUMULATION; INFLAMMATORY RESPONSE; CIRCRNA BIOGENESIS; SIGNALING PATHWAY	Circular RNAs (circRNAs) are a class of noncoding RNAs with a covalently closed loop structure. Recent evidence has shown that circRNAs can regulate gene transcription, alternative splicing, microRNA (miRNA) "molecular sponges", RNA-binding proteins and protein translation. Atherosclerosis is one of the leading causes of death worldwide, and more studies have indicated that circRNAs are related to atherosclerosis pathogenesis, including vascular endothelial cells, vascular smooth muscle cells, inflammation and lipid metabolism. In this review, we systematically summarize the biogenesis, characteristics and functions of circRNAs with a focus on their roles in the pathogenesis of atherosclerosis.	[Sun, Xueyuan; Deng, Kaiyuan; Zang, Yunhui; Zhang, Zhiyong; Zhao, Boxin; Fan, Jingyao; Huang, Lijuan] Harbin Med Univ, Dept Clin Lab, Affiliated Hosp 2, Harbin 150086, Peoples R China		Huang, LJ (通讯作者)，Harbin Med Univ, Dept Clin Lab, Affiliated Hosp 2, Harbin 150086, Peoples R China.	hebhlj@sina.com					Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Akkoca M, 2017, CLIN HEMORHEOL MICRO, V65, P151, DOI 10.3233/CH-16143; Allahverdian S, 2014, CIRCULATION, V129, P1551, DOI 10.1161/CIRCULATIONAHA.113.005015; ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Aubart FC, 2009, MOL THER, V17, P455, DOI 10.1038/mt.2008.291; Badimon L, 2014, J INTERN MED, V276, P618, DOI 10.1111/joim.12296; Balzan S, 2018, LIFE SCI, V198, P79, DOI 10.1016/j.lfs.2018.02.024; Baumer Y, 2017, ATHEROSCLEROSIS, V256, P105, DOI 10.1016/j.atherosclerosis.2016.11.017; Bazan HA, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.117.001720; Begum S, 2018, ONCOGENE, V37, P4055, DOI 10.1038/s41388-018-0230-3; Boeckel JN, 2015, CIRC RES, V117, P884, DOI 10.1161/CIRCRESAHA.115.306319; Borran S, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153217; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Buttery LDK, 1996, LAB INVEST, V75, P77; Cao Y, 2018, BIOCHEM BIOPH RES CO, V507, P362, DOI 10.1016/j.bbrc.2018.11.041; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Chen JJ, 2017, BIOCHEM BIOPH RES CO, V494, P126, DOI 10.1016/j.bbrc.2017.10.068; Chen YH, 2016, J MED GENET, V53, P359, DOI 10.1136/jmedgenet-2016-103758; Cheng J, 2019, GENE, V709, P1, DOI 10.1016/j.gene.2019.05.012; Choromanska B, 2017, ADV CLIN EXP MED, V26, P717, DOI 10.17219/acem/62325; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Cui M, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22468; Cui YM, 2018, BIOMED PHARMACOTHER, V108, P1081, DOI 10.1016/j.biopha.2018.09.095; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Danan M, 2012, NUCLEIC ACIDS RES, V40, P3131, DOI 10.1093/nar/gkr1009; Dang RY, 2017, BIOCHEM BIOPH RES CO, V490, P104, DOI 10.1016/j.bbrc.2017.05.164; Deng T, 2017, MOL MED REP, V16, P9367, DOI 10.3892/mmr.2017.7779; Dong YZ, 2017, DIABETES VASC DIS RE, V14, P14, DOI 10.1177/1479164116666762; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Eriksson EE, 2001, J EXP MED, V194, P205, DOI 10.1084/jem.194.2.205; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Feinberg MW, 2016, CIRC RES, V118, P703, DOI 10.1161/CIRCRESAHA.115.306300; Fernandez S, 2001, CELL IMMUNOL, V209, P140, DOI 10.1006/cimm.2001.1795; Firouzi SS, 2018, NEUROL RES, V40, P624, DOI 10.1080/01616412.2018.1458813; Forstermann U, 2017, CIRC RES, V120, P713, DOI 10.1161/CIRCRESAHA.116.309326; Frostegard J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-117; GBD Risk Factors C., 2016, LANCET, V388, p1659?1724, DOI [10.1016/S0140-6736(16)31679-8, DOI 10.1016/S0140-6736(16)31679-8]; Gharavi NM, 2007, J BIOL CHEM, V282, P31460, DOI 10.1074/jbc.M704267200; Giannotti KC, 2019, MOLECULES, V24, DOI 10.3390/molecules24183244; Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301; Goedeke L, 2015, NAT MED, V21, P1280, DOI 10.1038/nm.3949; Gorenne I, 2013, CIRCULATION, V127, P386, DOI 10.1161/CIRCULATIONAHA.112.124404; Grote K, 2005, VASC PHARMACOL, V43, P357, DOI 10.1016/j.vph.2005.08.021; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Guo RW, 2012, CARDIOVASC RES, V93, P360, DOI 10.1093/cvr/cvr307; Guo XY, 2018, WORLD J GASTROENTERO, V24, P323, DOI 10.3748/wjg.v24.i3.323; Guo XY, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3960197; Gwon WG, 2017, INT IMMUNOPHARMACOL, V42, P81, DOI 10.1016/j.intimp.2016.11.014; Hall IF, 2019, CIRC RES, V124, P498, DOI 10.1161/CIRCRESAHA.118.314240; Hanefeld M, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-65; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hashemian SM, 2020, MOL THER-NUCL ACIDS, V21, P51, DOI 10.1016/j.omtn.2020.05.012; Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429; Huang AQ, 2020, THERANOSTICS, V10, P3503, DOI 10.7150/thno.42174; Huang C, 2015, TRANSCR-AUSTIN, V6, P61, DOI 10.1080/21541264.2015.1071301; Huang HS, 2020, BIOCHEM BIOPH RES CO, V525, P512, DOI 10.1016/j.bbrc.2020.02.109; Indolfi C, 2019, VASC PHARMACOL, V114, P49, DOI 10.1016/j.vph.2018.10.006; Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Kassi E, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-48; Khan MA, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02305-z; Khan MAF, 2016, CIRC RES, V119, P996, DOI 10.1161/CIRCRESAHA.116.309568; Kim NY, 2020, INT J MOL MED, V46, P449, DOI 10.3892/ijmm.2020.4582; Kong P, 2019, NUCLEIC ACIDS RES, V47, P3580, DOI 10.1093/nar/gkz141; Lacolley P, 2012, CARDIOVASC RES, V95, P194, DOI 10.1093/cvr/cvs135; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Lemmens K, 2007, CIRCULATION, V116, P954, DOI 10.1161/CIRCULATIONAHA.107.690487; Li A, 2018, CELL PHYSIOL BIOCHEM, V47, P2458, DOI 10.1159/000491619; Li CY, 2017, BIOMED PHARMACOTHER, V95, P1514, DOI 10.1016/j.biopha.2017.09.064; Li H, 2020, ECOTOX ENVIRON SAFE, V192, DOI 10.1016/j.ecoenv.2020.110267; Li HM, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1538; Li MY, 2018, FEBS J, V285, P220, DOI 10.1111/febs.14191; Li QD, 2019, CELL METAB, V30, P157, DOI 10.1016/j.cmet.2019.05.009; Li QG, 2020, CELL CYCLE, V19, P1466, DOI 10.1080/15384101.2020.1754561; Li R, 2020, CELL MOL LIFE SCI, V77, P1661, DOI 10.1007/s00018-019-03345-5; Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032; Li YS, 2017, EBIOMEDICINE, V24, P137, DOI 10.1016/j.ebiom.2017.09.015; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Lin HJ, 2016, SEMIN OPHTHALMOL, V31, P1, DOI 10.3109/08820538.2015.1114865; Lin S., 2019, SILENCING HSA CIRC 0; Liu C, 2017, THERANOSTICS, V7, P2863, DOI 10.7150/thno.19353; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mao YY, 2018, BIOCHEM BIOPH RES CO, V505, P119, DOI 10.1016/j.bbrc.2018.09.069; Marszalek RJ, 2019, PFLUG ARCH EUR J PHY, V471, P769, DOI 10.1007/s00424-018-2224-y; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6; Mirzaei H, 2020, MOL THER-ONCOLYTICS, V19, P218, DOI 10.1016/j.omto.2020.10.003; Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520; Morton DJ, 2018, RNA, V24, P127, DOI 10.1261/rna.064626.117; Naeli P, 2020, CRIT REV ONCOL HEMAT, V145, DOI 10.1016/j.critrevonc.2019.102854; Nahand JS, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01853; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; Ng WL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12550-w; Ng WL, 2016, RNA BIOL, V13, P861, DOI 10.1080/15476286.2016.1207036; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Pan L, 2018, INT J MOL MED, V42, P597, DOI 10.3892/ijmm.2018.3625; Pentikainen MO, 2000, J INTERN MED, V247, P359, DOI 10.1046/j.1365-2796.2000.00655.x; Ping SN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.213; Ping SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141375; Pirillo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/152786; Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qiu JH, 2011, ANN BIOMED ENG, V39, P2869, DOI 10.1007/s10439-011-0382-6; Qu SB, 2017, RNA BIOL, V14, P992, DOI 10.1080/15476286.2016.1220473; Rahman S, 2007, DIABETES OBES METAB, V9, P767, DOI 10.1111/j.1463-1326.2006.00655.x; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rong ZH, 2019, MOL THER-NUCL ACIDS, V18, P999, DOI 10.1016/j.omtn.2019.10.023; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Seo HH, 2017, BIOL RES, V50, DOI 10.1186/s40659-016-0106-3; Shabaninejad Z, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0558-5; Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004; Shang LL, 2019, GENE, V711, DOI 10.1016/j.gene.2019.143948; Shankman LS, 2015, NAT MED, V21, P628, DOI 10.1038/nm.3866; Shen L, 2019, MOL MED REP, V19, P3923, DOI 10.3892/mmr.2019.10011; Solly EL, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122199; Song CL, 2017, CELL PHYSIOL BIOCHEM, V42, P1202, DOI 10.1159/000478918; STEPANOV SS, 1985, TSITOLOGIYA+, V27, P1235; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Sun JG, 2019, BIOCHEM CELL BIOL, V97, P709, DOI 10.1139/bcb-2019-0031; Sun XH, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0372-2; Sun Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1590-5; Sun Y, 2017, CIRC RES, V121, P628, DOI 10.1161/CIRCRESAHA.117.311441; Suzuki H, 2014, INT J MOL SCI, V15, P9331, DOI 10.3390/ijms15069331; Tan WLW, 2017, CARDIOVASC RES, V113, P298, DOI 10.1093/cvr/cvw250; Tang Q, 2020, ONCOTARGETS THER, V13, P2067, DOI 10.2147/OTT.S233672; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tousoulis D, 2016, EUR HEART J, V37, P1723, DOI 10.1093/eurheartj/ehv759; Vausort M, 2016, J AM COLL CARDIOL, V68, P1247, DOI 10.1016/j.jacc.2016.06.040; Vilades D, 2020, FASEB J, V34, P4403, DOI 10.1096/fj.201902507R; Violi F, 2017, ANTIOXID REDOX SIGN, V27, P1083, DOI 10.1089/ars.2016.6963; Wang HH, 2009, GLIA, V57, P24, DOI 10.1002/glia.20732; Wang LY, 2019, ATHEROSCLEROSIS, V286, P88, DOI 10.1016/j.atherosclerosis.2019.05.006; Wang LB, 2019, DNA CELL BIOL, V38, P1499, DOI 10.1089/dna.2019.4865; Wang PL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090859; Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep36790; Wang Y, 2020, EUR REV MED PHARMACO, V24, P3476, DOI 10.26355/eurrev_202004_20806; Wang Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7954657; Weinert S, 2013, CARDIOVASC RES, V97, P544, DOI 10.1093/cvr/cvs367; Weiser-Evans MCM, 2017, CIRC RES, V121, P591, DOI 10.1161/CIRCRESAHA.117.311722; Werfel S, 2016, J MOL CELL CARDIOL, V98, P103, DOI 10.1016/j.yjmcc.2016.07.007; Williams JW, 2019, IMMUNITY, V50, P941, DOI 10.1016/j.immuni.2019.03.007; Wilusz JE, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1478; Xia X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1056-5; Xiang Q, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102679; Xiao ZP, 2018, CELL PHYSIOL BIOCHEM, V46, P1779, DOI 10.1159/000489364; Xu G, 2009, CIRC RES, V105, P500, DOI 10.1161/CIRCRESAHA.109.193870; Xu JY, 2019, FASEB J, V33, P2659, DOI 10.1096/fj.201800243RRR; Xu S, 2018, PEERJ, V6, DOI 10.7717/peerj.5503; Yan XD, 2018, CELL PHYSIOL BIOCHEM, V48, P1245, DOI 10.1159/000492010; Yang L, 2019, MOL THER-NUCL ACIDS, V16, P434, DOI 10.1016/j.omtn.2019.02.028; Yang MH, 2014, J LIPID RES, V55, P226, DOI 10.1194/jlr.M041335; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yao QP, 2020, J CELL PHYSIOL, V235, P6831, DOI 10.1002/jcp.29577; Yousefi F, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00555-4; Yvan-Charvet L, 2008, CIRCULATION, V118, P1837, DOI 10.1161/CIRCULATIONAHA.108.793869; Zaiou Mohamed, 2018, Diseases, V6, DOI 10.3390/diseases6020034; Zaphiropoulos PG, 1996, P NATL ACAD SCI USA, V93, P6536, DOI 10.1073/pnas.93.13.6536; Zhang CZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0105-2; Zhang F, 2018, AGING-US, V10, P2266, DOI 10.18632/aging.101541; Zhang J, 2018, EXP THER MED, V16, P265, DOI 10.3892/etm.2018.6170; Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2; Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9; Zhang SC, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0595-9; Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115; Zhang XS, 2016, NUTR RES, V36, P964, DOI 10.1016/j.nutres.2016.06.004; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zhao ZZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep39918; Zheng CF, 2015, MOL MED REP, V12, P6656, DOI 10.3892/mmr.2015.4264; Zhou P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00464; Zhou WP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121823; Zhu K, 2019, EBIOMEDICINE, V49, P341, DOI 10.1016/j.ebiom.2019.10.004; Zhu YY, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111753	185	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106898	10.1016/j.vph.2021.106898		NOV 2021	16	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34302990				2022-04-29	WOS:000756079500001
J	Sethy, C; Goutam, K; Das, B; Dash, SR; Kundu, CN				Sethy, Chinmayee; Goutam, Kunal; Das, Biswajit; Dash, Somya Ranjan; Kundu, Chanakya Nath			Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis	VASCULAR PHARMACOLOGY			English	Article						Nectin-4; Lymphangiogenesis; CXCR4-CXCL12; Axillary lymph node; CTCs	CELLS; ANGIOGENESIS; MIGRATION; EP4	Tumor-induced lymphangiogenesis promotes tumor progression by generating new lymphatic vessels that helps in tumor dissemination to regional lymph nodes and distant sites. Recently, the role of Nectin-4 in cancer metastasis and angiogenesis has been studied, but its role in lymphangiogenesis is unknown. Here, we systematically delineated the role of Nectin-4 in lymphangiogenesis and its regulation in invasive duct carcinoma (IDC). Nectin-4 expression positively correlated with occurrence risk factors associated with breast cancer (alcohol, smoke, lifestyle habit, etc), CXCR4 expression, and LYVE-1-lymphatic vessel density (LVD). LVD was significantly higher in axillary lymph node (ALN) than primary tumor. Depleting Nectin-4, VEGF-C or both attenuated the important lymphangiogenic marker LYVE-1 expression, tube formation, and migration of ALN derived primary cells. Nectin-4 stimulated the expressions of CXCR4 and CXCL12 under hypoxic conditions in ALN derived primary cells. Further, Nectin-4 augmented expressions of lymphatic metastatic markers (e.g. eNOS, TGF-beta, CD 105) and MMPs. Induced expressions of Nectin-4 along with other representative metastatic markers were noted in lymph and blood circulating tumor cells (LCTCs and BCTCs) of local and distant metastatic samples. Thus, Nectin-4 displayed a predominant role in promoting tumor-induced lymphangiogenesis and lymphatic metastasis by modulating CXCR4/CXCL12-LYVE-1-axis.	[Sethy, Chinmayee; Das, Biswajit; Dash, Somya Ranjan; Kundu, Chanakya Nath] Kalinga Inst Ind Technol, KIIT Sch Biotechnol, Canc Biol Div, Campus 11, Bhubaneswar 751024, Odisha, India; [Goutam, Kunal] Acharya Harihar Reg Canc Ctr, Dept Surg Oncol, Cuttack 753007, Odisha, India		Kundu, CN (通讯作者)，Kalinga Inst Ind Technol, KIIT Sch Biotechnol, Canc Biol Div, Campus 11, Bhubaneswar 751024, Odisha, India.	cnkundu@gmail.com	SETHY, CHINMAYEE/AGJ-2326-2022	SETHY, CHINMAYEE/0000-0002-0092-097X; Kundu, Chanakya/0000-0003-0297-1030	Rajiv Gandhi National fellowship (RGNF)University Grants Commission, India	Authors thankfully acknowledge a Rajiv Gandhi National fellowship (RGNF) to CS.	Abe Noriko, 2016, Fukushima J Med Sci, V62, P57, DOI 10.5387/fms.2015-10; Bono P, 2004, CLIN CANCER RES, V10, P7144, DOI 10.1158/1078-0432.CCR-03-0826; Carey RN, 2020, J MED SCREEN, V27, P77, DOI 10.1177/0969141319878747; Chatterjee S, 2021, CELL SIGNAL, V80, DOI 10.1016/j.cellsig.2020.109902; Chatterjee S, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173308; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Detry B, 2012, BLOOD, V119, P5048, DOI 10.1182/blood-2011-12-400267; Fei XF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117572; Huang Yu-Wen, 2019, Cell Physiol Biochem, V52, P1, DOI 10.33594/000000001; Jones D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030762; Karlsen TV, 2017, ARTERIOSCL THROM VAS, V37, P2128, DOI 10.1161/ATVBAHA.117.309883; Karnezis T, 2019, CANCER RES, V79, P1558, DOI 10.1158/0008-5472.CAN-18-1858; Kinashi H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092487; Ko KP, 2018, INT J CANCER, V142, P2263, DOI 10.1002/ijc.31257; Krishnapriya S, 2019, ANGIOGENESIS, V22, P441, DOI 10.1007/s10456-019-09669-x; Lahdenranta J, 2009, CANCER RES, V69, P2801, DOI 10.1158/0008-5472.CAN-08-4051; Ma J, 2016, ONCOTARGETS THER, V9, P183, DOI 10.2147/OTT.S96999; Majumder M, 2014, CANCER SCI, V105, P1142, DOI 10.1111/cas.12475; Mohammed SI, 2019, MOL ONCOL, V13, P1400, DOI 10.1002/1878-0261.12494; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nandi P, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3018-2; Nayak A, 2019, CELL ONCOL, V42, P157, DOI 10.1007/s13402-018-0417-1; Nishiwada S, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0144-7; Paduch R, 2016, CELL ONCOL, V39, P397, DOI 10.1007/s13402-016-0281-9; Pak KH, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5972-y; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Ran Sophia, 2010, Pathophysiology, V17, P229, DOI 10.1016/j.pathophys.2009.11.003; Rofstad EK, 2016, ONCOTARGET, V7, P56986, DOI 10.18632/oncotarget.10931; Sethy C, 2020, J CANCER RES CLIN, V146, P245, DOI 10.1007/s00432-019-03055-2; Shields JD, 2007, CANCER CELL, V11, P526, DOI 10.1016/j.ccr.2007.04.020; Siddharth S, 2018, INT J BIOCHEM CELL B, V102, P151, DOI 10.1016/j.biocel.2018.07.011; Siddharth S, 2017, INT J BIOCHEM CELL B, V89, P85, DOI 10.1016/j.biocel.2017.06.007; Sopik V, 2018, BREAST CANCER RES TR, V170, P647, DOI 10.1007/s10549-018-4796-9; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Tai HC, 2019, MAR DRUGS, V17, DOI 10.3390/md17040215; Tutunea-Fatan E, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-5152; Viner B, 2019, CANCER CAUSE CONTROL, V30, P1313, DOI 10.1007/s10552-019-01226-7; Wang QS, 2018, CANCER LETT, V420, P116, DOI 10.1016/j.canlet.2018.01.069; Wong HLX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10824; Wu LZ, 2014, ASIAN PAC J CANCER P, V15, P2727, DOI 10.7314/APJCP.2014.15.6.2727; Xin XP, 2012, LAB INVEST, V92, P1115, DOI 10.1038/labinvest.2012.90; Xiong Y, 2017, INT J ONCOL, V51, P75, DOI 10.3892/ijo.2017.4003; Yamauchi H, 2018, INT J CLIN ONCOL, V23, P45, DOI 10.1007/s10147-017-1208-9; Youn Hyun Jo, 2020, Asian Pac J Cancer Prev, V21, P867, DOI 10.31557/APJCP.2020.21.4.867; Zhang S, 2017, SCI REP-UK, V7, DOI 10.1038/srep40364; Zhang YJ, 2016, CANCER LETT, V375, P179, DOI 10.1016/j.canlet.2016.02.049; Zhuo W, 2012, CLIN CANCER RES, V18, P5387, DOI 10.1158/1078-0432.CCR-12-0708	47	2	2	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106865	10.1016/j.vph.2021.106865		SEP 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33945869				2022-04-29	WOS:000709412300003
J	Mattisson, IY; Rattik, S; Bjorkbacka, H; Ljungcrantz, I; Terrinoni, M; Lebens, M; Holmgren, J; Fredrikson, GN; Gullstrand, B; Bengtsson, AA; Nilsson, J; Wigren, M				Mattisson, Ingrid Yao; Rattik, Sara; Bjorkbacka, Harry; Ljungcrantz, Irena; Terrinoni, Manuela; Lebens, Michael; Holmgren, Jan; Fredrikson, Gunilla Nordin; Gullstrand, Birgitta; Bengtsson, Anders A.; Nilsson, Jan; Wigren, Maria			Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus	VASCULAR PHARMACOLOGY			English	Article						Atherosclerosis; Autoimmunity; Systemic lupus erythematosus; oxLDL; Vaccine	REGULATORY T-CELLS; ACCELERATED ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; INCREASED RISK; IMMUNIZATION; MECHANISMS; MICE; ANTIBODIES; INNATE	Patients suffering from systemic lupus erythematosus (SLE) are at increased risk of developing cardiovascular disease (CVD) and traditional therapies including statins provide insufficient protection. Impaired removal of apoptotic material is a common pathogenic mechanism in both SLE and atherosclerosis and is considered to be a key factor in the development of autoimmunity. Since oxidized LDL and apoptotic material bind to the same receptors, we aimed to investigate if targeting the oxidized LDL autoimmunity can affect atherosclerosis in SLE. To investigate the possible role of oxidized LDL autoimmunity in the accelerated atherosclerosis associated with SLE we used a hypercholesterolemic SLE mouse model (B6.lpr.ApoE- /- mice). Promoting LDL tolerance through mucosal immunization with an apolipoprotein B-100 peptide p45 (amino acids 661-680) and cholera toxin Bsubunit fusion protein increased regulatory T cells and B cells in mesenteric lymph nodes and reduced plaque development in the aorta by 33%. Treatment with the oxidized LDL-specific antibody Orticumab reduced aortic atherosclerosis by 43%, subvalvular plaque area by 50% and the macrophage content by 31%. The present study provides support for oxLDL as a possible target for prevention of cardiovascular complications in SLE.	[Mattisson, Ingrid Yao; Rattik, Sara; Bjorkbacka, Harry; Ljungcrantz, Irena; Fredrikson, Gunilla Nordin; Nilsson, Jan; Wigren, Maria] Lund Univ, Skane Univ Hosp, Dept Clin Sci Malmo, Malmo, Sweden; [Terrinoni, Manuela; Lebens, Michael; Holmgren, Jan] Gothenburg Univ, Dept Microbiol & Immunol, Gothenburg, Sweden; [Gullstrand, Birgitta; Bengtsson, Anders A.] Lund Univ, Dept Clin Sci Lund, Lund, Sweden		Mattisson, IY (通讯作者)，Lund Univ, Skane Univ Hosp, Dept Clin Sci Malmo, Malmo, Sweden.; Mattisson, IY (通讯作者)，Lund Univ, Clin Res Ctr, Expt Cardiovasc Res Unit, Jan Waldenstroms Gata 35, SE-21428 Malmo, Sweden.	Ingrid.yao_mattisson@med.lu.se		Bjorkbacka, Harry/0000-0003-3918-0857	Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study was supported by grants from the Swedish Heart-Lung Foundation and the Swedish Research Council.	Ait-Oufella H, 2006, NAT MED, V12, P178, DOI 10.1038/nm1343; Ait-Oufella H, 2007, CIRCULATION, V115, P2168, DOI 10.1161/CIRCULATIONAHA.106.662080; Aprahamian T, 2004, J EXP MED, V199, P1121, DOI 10.1084/jem.20031557; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Binder CJ, 2016, NAT REV IMMUNOL, V16, P485, DOI 10.1038/nri.2016.63; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Bjorkbacka H, 2016, ARTERIOSCL THROM VAS, V36, P765, DOI 10.1161/ATVBAHA.115.306938; Chyu KY, 2004, ATHEROSCLEROSIS, V176, P27, DOI 10.1016/j.atherosclerosis.2004.04.016; Colonna L, 2014, CURR OPIN RHEUMATOL, V26, P459, DOI 10.1097/BOR.0000000000000083; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; Feng XB, 2007, J LIPID RES, V48, P794, DOI 10.1194/jlr.M600512-JLR200; Fredrikson GN, 2003, ARTERIOSCL THROM VAS, V23, P879, DOI 10.1161/01.ATV.0000067937.93716.DB; Gharavi AE, 2002, ARTHRITIS RHEUM, V46, P545, DOI 10.1002/art.10130; Gladman DD, 2002, J RHEUMATOL, V29, P288; Gladman DD, 2000, J RHEUMATOL, V27, P373; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gurevitz Samuel L, 2013, Consult Pharm, V28, P110, DOI 10.4140/TCP.n.2013.110; Hansson GK, 2008, J INTERN MED, V263, P462, DOI 10.1111/j.1365-2796.2008.01959.x; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Herbin O, 2012, ARTERIOSCL THROM VAS, V32, P605, DOI 10.1161/ATVBAHA.111.242800; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Kahlenberg JM, 2013, ANNU REV MED, V64, P249, DOI 10.1146/annurev-med-060911-090007; Klingenberg R, 2010, ARTERIOSCL THROM VAS, V30, P946, DOI 10.1161/ATVBAHA.109.202671; Lehrer-Graiwer J, 2015, JACC-CARDIOVASC IMAG, V8, P493, DOI 10.1016/j.jcmg.2014.06.021; Li SJ, 2013, MOL METAB, V2, P256, DOI 10.1016/j.molmet.2013.06.001; Libby P, 2013, IMMUNITY, V38, P1092, DOI 10.1016/j.immuni.2013.06.009; Libby P, 2013, NEW ENGL J MED, V368, P2004, DOI 10.1056/NEJMra1216063; Lichtman AH, 2013, J CLIN INVEST, V123, P27, DOI 10.1172/JCI63108; Liu YD, 2018, CURR OPIN RHEUMATOL, V30, P441, DOI 10.1097/BOR.0000000000000528; Lu XJ, 2010, ATHEROSCLEROSIS, V212, P472, DOI 10.1016/j.atherosclerosis.2010.06.007; Ma ZJ, 2008, CLIN IMMUNOL, V127, P168, DOI 10.1016/j.clim.2008.01.002; Mallat Z, 2007, TRENDS CARDIOVAS MED, V17, P113, DOI 10.1016/j.tcm.2007.03.001; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Nilsson J, 2015, J INTERN MED, V278, P507, DOI 10.1111/joim.12353; Park JK, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1204-x; Schiopu A, 2004, CIRCULATION, V110, P2047, DOI 10.1161/01.CIR.0000143162.56057.B5; Schiopu A, 2007, J AM COLL CARDIOL, V50, P2313, DOI 10.1016/j.jacc.2007.07.081; Shao WH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3206; Stanford M, 2004, CLIN EXP IMMUNOL, V137, P201, DOI 10.1111/j.1365-2249.2004.02520.x; Steinberg D, 1997, CIRCULATION, V95, P1062; Strom A, 2007, ATHEROSCLEROSIS, V190, P298, DOI 10.1016/j.atherosclerosis.2006.03.032; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Svenungsson E, 2015, CLIN EXP IMMUNOL, V181, P417, DOI 10.1111/cei.12651; Tas SW, 2006, ANN RHEUM DIS, V65, P216, DOI 10.1136/ard.2005.037143; Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003; Tse K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00493; van Puijvelde GHM, 2006, CIRCULATION, V114, P1968, DOI 10.1161/CIRCULATIONAHA.106.615609; Wigren M, 2015, J INTERN MED, V278, P494, DOI 10.1111/joim.12357; Wigren M, 2018, ATHEROSCLEROSIS, V270, P1, DOI 10.1016/j.atherosclerosis.2018.01.022; Wigren M, 2012, ARTERIOSCL THROM VAS, V32, P2000, DOI 10.1161/ATVBAHA.112.251579; Wu R, 1999, LUPUS, V8, P142, DOI 10.1191/096120399678847434	52	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106863	10.1016/j.vph.2021.106863		SEP 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33857652	hybrid			2022-04-29	WOS:000709412300004
J	Suzuki, YJ; Nikolaienko, SI; Dibrova, VA; Dibrova, YV; Vasylyk, VM; Novikov, MY; Shults, NV; Gychka, SG				Suzuki, Yuichiro J.; Nikolaienko, Sofia, I; Dibrova, Vyacheslav A.; Dibrova, Yulia, V; Vasylyk, Volodymyr M.; Novikov, Mykhailo Y.; Shults, Nataliia, V; Gychka, Sergiy G.			SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells	VASCULAR PHARMACOLOGY			English	Article						Cell signaling; Coronavirus; COVID-19; SARS-CoV-2; Vascular	ACUTE RESPIRATORY SYNDROME; PATHOLOGY; SARS	Currently, the world is suffering from the pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter the host cells. So far, 60 million people have been infected with SARS-CoV-2, and 1.4 million people have died because of COVID-19 worldwide, causing serious health, economical, and sociological problems. However, the mechanism of the effect of SARS-CoV-2 on human host cells has not been defined. The present study reports that the SARS-CoV-2 spike protein alone without the rest of the viral components is sufficient to elicit cell signaling in lung vascular cells. The treatment of human pulmonary artery smooth muscle cells or human pulmonary artery endothelial cells with recombinant SARS-CoV-2 spike protein S1 subunit (Val16 - Gln690) at 10 ng/ml (0.13 nM) caused an activation of MEK phosphorylation. The activation kinetics was transient with a peak at 10 min. The recombinant protein that contains only the ACE2 receptor-binding domain of the SARS-CoV-2 spike protein S1 subunit (Arg319 - Phe541), on the other hand, did not cause this activation. Consistent with the activation of cell growth signaling in lung vascular cells by the SARS-CoV-2 spike protein, pulmonary vascular walls were found to be thickened in COVID-19 patients. Thus, SARS-CoV-2 spike protein-mediated cell growth signaling may participate in adverse cardiovascular/pulmonary outcomes, and this mechanism may provide new therapeutic targets to combat COVID-19.	[Suzuki, Yuichiro J.; Shults, Nataliia, V] Georgetown Univ, Dept Pharmacol & Physiol, Med Ctr, 3900 Reservoir Rd NW, Washington, DC 20007 USA; [Nikolaienko, Sofia, I; Dibrova, Vyacheslav A.; Dibrova, Yulia, V; Gychka, Sergiy G.] Bogomolets Natl Med Univ, Dept Pathol Anat N2, UA-01601 Kiev, Ukraine; [Vasylyk, Volodymyr M.] Ivano Frankivsk Dist Clin Hosp, Centralized Dept Pathol Anat, UA-76000 Ivano Frankivsk, Ukraine; [Novikov, Mykhailo Y.] Reg Municipal Inst, Sumy Dist Forens Med Examinat Bur, UA-40050 Sumy, Ukraine		Suzuki, YJ (通讯作者)，Georgetown Univ, Dept Pharmacol & Physiol, Med Ctr, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	ys82@georgetown.edu	Vasylyk, Volodymyr/ABE-6777-2021	Hychka, Sergiy/0000-0002-6821-0085; Dibrova, Ulia/0000-0002-7268-8073; Nikolaienko, Sofiia/0000-0002-0655-5344	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AI142649, R03AG059554, R03AA026516]	This work was supported in part by the National Institutes of Health [grant numbers R21AI142649, R03AG059554, R03AA026516] to Y.J.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Bonjardim CA, 2017, VIROLOGY, V507, P267, DOI 10.1016/j.virol.2016.12.011; Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440; Huang L., LANCET RESPIR MED 8; Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247; Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9; Satija N, 2007, ANN NY ACAD SCI, V1102, P26, DOI 10.1196/annals.1408.002; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shults NV, 2018, CELL SIGNAL, V52, P147, DOI 10.1016/j.cellsig.2018.09.005; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wong CM, 2008, CIRC RES, V102, P310, DOI 10.1161/CIRCRESAHA.107.159814; Wortzel Inbal, 2011, Genes Cancer, V2, P195, DOI 10.1177/1947601911407328; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	19	16	16	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106823	10.1016/j.vph.2020.106823		MAR 2021	6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33232769	hybrid, Green Published, Green Submitted			2022-04-29	WOS:000629161700002
J	Strohbach, A; Bohm, A; Mahajan-Thakur, S; Wirtz, C; Wetzel, H; Busch, MC; Felix, SB; Rauch, BH; Busch, R				Strohbach, Anne; Boehm, Andreas; Mahajan-Thakur, Shailaja; Wirtz, Christopher; Wetzel, Hanno; Busch, Mathias C.; Felix, Stephan B.; Rauch, Bernhard H.; Busch, Raila			Platelet apelin receptor expression is reduced in patients with acute myocardial infarction	VASCULAR PHARMACOLOGY			English	Article						Apelin receptor; Apelin-17; Platelets; Platelet aggregation; Acute myocardial infarction		Background: The G-protein-coupled apelin receptor and its apelin ligand are an emerging regulatory system of the vascular homeostasis. To date, the implications of the apelin/apelin receptor system in athero-thrombosis are not completely clarified yet. This study determines the expression of the apelin receptor on human platelets, the effect of different apelin isoforms on platelet aggregation and the potential role of the apelin/apelin receptor system in acute myocardial infarction. Methods: We applied immunofluorescence staining, Western Blot analysis, aggregometry, and flow cytometry to elucidate the role of the apelin receptor in activated platelets. Furthermore, in an observational pilot study, we assessed platelet apelin recpetor expression and apelin-17 plasma levels in patients with acute myocardial infarction (AMI, n = 27). Results: Immunofluorescence staining indicates that the apelin receptor is located at the cell membrane in resting platelets and diminishes upon activation with a selective thrombin receptor-activating peptide (AP1, 3 to 100 mu M). Western Blot analyses of AP1-activated platelets and their supernatants suggest that the apelin receptor is not predominantly internalized but is released from activated platelets. The isoform apelin-17 attenuated AP-1induced platelet activation in-vitro, presumably via a NO-dependent mechanism. Furthermore, platelet apelin receptor expression was significantly reduced in patients with AMI (n = 27) compared to age-matched controls (n = 14; p < 0.05) and inversely correlated with troponin I plasma levels (r =-0.46; p = 0.03). Besides that, circulating apelin-17 was significantly reduced in MI patients compared to the control group. Conclusion: Taken together, our data support a crucial role of the platelet apelinergic system assuming an antithrombotic effect and therefore holding a potential diagnostic and therapeutic impact.	[Strohbach, Anne; Boehm, Andreas; Wetzel, Hanno; Busch, Mathias C.; Felix, Stephan B.; Busch, Raila] Univ Med Greifswald, Dept Internal Med Cardiol 2, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany; [Strohbach, Anne; Boehm, Andreas; Busch, Mathias C.; Felix, Stephan B.; Rauch, Bernhard H.; Busch, Raila] DZHK German Ctr Cardiovasc Res, Partner Site, Greifswald, Germany; [Boehm, Andreas; Mahajan-Thakur, Shailaja; Wirtz, Christopher; Rauch, Bernhard H.] Ernst Moritz Arndt Univ Greifswald, Ctr Drug Absorpt & Transport C DAT, Inst Pharmacol, Felix Hausdorff Str 3, D-17487 Greifswald, Germany		Busch, R (通讯作者)，Univ Med Greifswald, Dept Internal Med Cardiol 2, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany.	anne.strohbach@med.uni-greifswald.de; buschr@uni-greifswald.de	Strohbach, Anne/ABE-6695-2020	Strohbach, Anne/0000-0002-5508-1771; Rauch, Bernhard/0000-0002-6003-4662	German Federal Ministry of Research and Technology (BMBF) within RESPONSE "Partnerschaft fur Innovation in der Implantattechnologie"Federal Ministry of Education & Research (BMBF) [FKZ: 03ZZ0927E]	This research was funded by the German Federal Ministry of Research and Technology (BMBF) within RESPONSE "Partnerschaft fur Innovation in der Implantattechnologie" (FKZ: 03ZZ0927E).	Adam F, 2016, BLOOD, V127, P908, DOI 10.1182/blood-2014-05-578781; Alpert J.S, MYOCARDIAL INFARCTIO; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Angiolillo DJ, 2007, J AM COLL CARDIOL, V50, P1541, DOI 10.1016/j.jacc.2007.05.049; [Anonymous], COLL CARDIOLOGY COMM; Ault KA, 1999, J AM COLL CARDIOL, V33, P634, DOI 10.1016/S0735-1097(98)00635-4; Baj-Krzyworzeka M, 2002, EXP HEMATOL, V30, P450, DOI 10.1016/S0301-472X(02)00791-9; Barnes G, 2010, HEART, V96, P1011, DOI 10.1136/hrt.2009.191122; Bohmer A, 2015, PLATELETS, V26, P583, DOI 10.3109/09537104.2014.974024; BROEKMAN MJ, 1991, BLOOD, V78, P1033, DOI 10.1182/blood.V78.4.1033.bloodjournal7841033; Busch R, 2015, CELL SIGNAL, V27, P1286, DOI 10.1016/j.cellsig.2015.03.011; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Galanth C, 2012, CURR PHARM DESIGN, V18, P789, DOI 10.2174/138161212799277770; Gambaryan S, 2015, AMINO ACIDS, V47, P1779, DOI 10.1007/s00726-015-1986-1; Japp AG, 2008, BIOCHEM PHARMACOL, V75, P1882, DOI 10.1016/j.bcp.2007.12.015; Jedlitschky G, 2004, BLOOD, V104, P3603, DOI 10.1182/blood-2003-12-4330; Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192; Jia Yue Xia, 2007, Peptides, V28, P2023, DOI 10.1016/j.peptides.2007.07.016; Kabbani SS, 2003, AM J CARDIOL, V91, P876, DOI 10.1016/S0002-9149(03)00025-0; Kadoglou NPE, 2010, TRANSL RES, V155, P238, DOI 10.1016/j.trsl.2010.01.004; Kizer JR, 2003, EUR HEART J, V24, P1314, DOI 10.1016/S0195-668X(03)00258-6; Kleinz MJ, 2005, REGUL PEPTIDES, V126, P233, DOI 10.1016/j.regpep.2004.10.019; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001; Korff S, 2006, HEART, V92, P987, DOI 10.1136/hrt.2005.071282; Kuklinska AM, 2010, HEART VESSELS, V25, P363, DOI 10.1007/s00380-009-1217-3; Langelaan DN, 2009, BIOCHEMISTRY-US, V48, P537, DOI 10.1021/bi801864b; Li Z, 2008, INTERNAL MED, V47, P1951, DOI 10.2169/internalmedicine.47.1287; Lievens D, 2011, THROMB HAEMOSTASIS, V106, P827, DOI 10.1160/TH11-08-0592; Michelson AD, 1996, AM J PHYSIOL-HEART C, V270, pH1640, DOI 10.1152/ajpheart.1996.270.5.H1640; Mulvihill NT, 2002, HEART, V87, P201, DOI 10.1136/heart.87.3.201; Natarajan A, 2008, DIABETES VASC DIS RE, V5, P138, DOI 10.3132/dvdr.2008.023; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Offermanns S, 2006, CIRC RES, V99, P1293, DOI 10.1161/01.RES.0000251742.71301.16; Okamatsu K, 2004, CIRCULATION, V109, P465, DOI 10.1161/01.CIR.0000109696.92474.92; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Rumbaut RE, 2005, MICROCIRCULATION, V12, P259, DOI 10.1080/10739680590925664; STAMLER J, 1989, CIRC RES, V65, P789, DOI 10.1161/01.RES.65.3.789; Strohbach A, 2018, J CELL PHYSIOL, V233, P6250, DOI 10.1002/jcp.26496; Tantry US, 2010, PLATELETS, V21, P360, DOI 10.3109/09537100903548903; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; Tycinska AM, 2012, CLIN CHIM ACTA, V413, P406, DOI 10.1016/j.cca.2011.11.021; Tycinska AM, 2010, CLIN CHIM ACTA, V411, P2014, DOI 10.1016/j.cca.2010.08.024; Ulrych T, 2011, J THROMB HAEMOST, V9, P790, DOI 10.1111/j.1538-7836.2011.04194.x; Ulrych T., RELEASE SPACING DIAE; Weir RAP, 2009, EUR J HEART FAIL, V11, P551, DOI 10.1093/eurjhf/hfp043; Yang PR, 2017, CIRCULATION, V135, P1160, DOI 10.1161/CIRCULATIONAHA.116.023218; Zaldivia MTK, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00074; Zhen EY, 2013, ANAL BIOCHEM, V442, P1, DOI 10.1016/j.ab.2013.07.006	53	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	FEB	2021	136								106808	10.1016/j.vph.2020.106808		JAN 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QA6FT	33130016				2022-04-29	WOS:000613540200007
J	Ahmad, A; Raish, M; Alkharfy, KM				Ahmad, Ajaz; Raish, Mohammad; Alkharfy, Khalid M.			The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19	VASCULAR PHARMACOLOGY			English	Article						COVID-19; SARS-CoV; Cardiovascular complications; ACE-2; Thymoquinone	OXIDATIVE STRESS; THERAPEUTIC TARGET; INHIBITOR T-20; ANGIOTENSIN; HYPERTENSION; CORONAVIRUS; RECEPTOR; HEART; RISK; OIL	A new virus strain detected in late 2019 and not previously described in humans is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes corona virus disease (COVID-19). While potential therapeutic approaches for COVID-19 are being investigated, significant initiatives are being made to create protective drugs and study various antiviral agents to cure the infection. However, an effective treatment strategy against COVID-19 is worrisome inadequate. The objective of the present manuscript is to discuss the potential role of thymoquinone (TQ) in preventing the cardiovascular complications of COVID-19, focusing on viral inhibition, antioxidant potential, vascular effect, and cardiac protection. The multifunctional properties of TQ could potentially synergize with the activity of current therapeutic interventions and offer a basis for managing COVID-19 disease more effectively. Even though the experimental evidence is positive, a translational application of TQ in COVID-19 is timely warranted.	[Ahmad, Ajaz; Alkharfy, Khalid M.] King Saud Univ, Dept Clin Pharm, Coll Pharm, Riyadh 11451, Saudi Arabia; [Raish, Mohammad] King Saud Univ, Dept Pharmaceut, Coll Pharm, Riyadh 11451, Saudi Arabia		Alkharfy, KM (通讯作者)，King Saud Univ, Dept Clin Pharm, Coll Pharm, Riyadh 11451, Saudi Arabia.	alkharfy@ksu.edu.sa			Deanship of Scientific Research at King Saud UniversityKing Saud University [RG-1441-337]	The authors extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this work through research group no. RG-1441-337.	Ahmad A, 2020, EUR REV MED PHARMACO, V24, P4030, DOI 10.26355/eurrev_202004_20873; Ahmad A, 2020, PHYTOTHER RES, V34, P2786, DOI 10.1002/ptr.6793; Ahmad A, 2020, EXP LUNG RES, V46, P53, DOI 10.1080/01902148.2020.1726529; Ahmad A, 2013, J CARDIOVASC PHARM, V62, P111, DOI 10.1097/FJC.0b013e3182927e47; Alkharfy K.M., 2014, US Patent, Patent No. [8,895,625, 8895625]; Alkharfy KM, 2020, FARMACIA, V68, P966, DOI 10.31925/farmacia.2020.6.2; Alkharfy KM, 2018, BIOMED PHARMACOTHER, V98, P801, DOI 10.1016/j.biopha.2018.01.028; Alkharfy KM, 2015, LIFE SCI, V143, P131, DOI 10.1016/j.lfs.2015.08.007; Atta MS, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7845681; Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282; Bouchentouf S., 2020, IDENTIFICATION COMPO, DOI [10.26434/chemrxiv.12055716.v1, DOI 10.26434/CHEMRXIV.12055716.V1]; Butt MS, 2010, CRIT REV FOOD SCI, V50, P654, DOI 10.1080/10408390902768797; Chen QS, 2018, BRIT J PHARMACOL, V175, P1279, DOI 10.1111/bph.13828; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Djemel, 2020, IN SILICO IDENTIFICA, P1, DOI DOI 10.26434/CHEMRXIV.12181404.V1; Enayatfard Lili, 2019, Journal of Basic and Clinical Physiology and Pharmacology, V30, P51, DOI 10.1515/jbcpp-2018-0074; Goto K, 2004, CLIN EXP PHARMACOL P, V31, P650, DOI 10.1111/j.1440-1681.2004.04054.x; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hartt JK, 2000, BIOCHEM BIOPH RES CO, V272, P699, DOI 10.1006/bbrc.2000.2846; Hassanien MFR, 2015, J FOOD SCI TECH MYS, V52, P6136, DOI 10.1007/s13197-015-1785-4; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Idris-Khodja N, 2012, N-S ARCH PHARMACOL, V385, P749, DOI 10.1007/s00210-012-0749-8; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Jaarin K, 2015, CLINICS, V70, P751, DOI 10.6061/clinics/2015(11)07; Khattab MM, 2007, PHYTOTHER RES, V21, P410, DOI 10.1002/ptr.2083; Kouhpayeh S., 2020, MOLECULAR STORY COVI; Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090; Kytomaa S, 2019, JAMA CARDIOL, V4, P363, DOI 10.1001/jamacardio.2019.0549; Maack C, 2011, J AM COLL CARDIOL, V58, P83, DOI 10.1016/j.jacc.2011.01.032; Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035; Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286; Madjid M, 2019, AM J CARDIOL, V124, P44, DOI 10.1016/j.amjcard.2019.04.011; Mahboubi M, 2018, INTEGR MED RES, V7, P27, DOI 10.1016/j.imr.2018.01.005; Mollnau H, 2005, ARTERIOSCL THROM VAS, V25, P2554, DOI 10.1161/01.ATV.0000190673.41925.9b; Munzel T, 2017, J AM COLL CARDIOL, V70, P212, DOI 10.1016/j.jacc.2017.05.035; Munzel T, 2010, EUR HEART J, V31, P2741, DOI 10.1093/eurheartj/ehq396; Munzel T, 2001, CIRCULATION, V104, P1571, DOI 10.1161/hc3801.095585; Pei X, 2016, DNA CELL BIOL, V35, P426, DOI 10.1089/dna.2016.3262; Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231; Ragheb A, 2008, INT J ANGIOL, V17, P186, DOI 10.1055/s-0031-1278307; Rahman MT, 2020, J HERB MED, V23, DOI 10.1016/j.hermed.2020.100382; Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010; Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016/j.intimp.2005.06.008; Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f; Silva ACSE, 2012, PEDIATR NEPHROL, V27, P1835, DOI 10.1007/s00467-011-2002-y; South AM, 2019, CLIN SCI, V133, P55, DOI 10.1042/CS20171550; Suddek GM, 2010, J ETHNOPHARMACOL, V127, P210, DOI 10.1016/j.jep.2009.11.019; Tan WY, 2020, INT J CARDIOL, V309, P70, DOI 10.1016/j.ijcard.2020.03.063; Tesarova H, 2011, NAT PROD COMMUN, V6, P213; Ulasli M, 2014, MOL BIOL REP, V41, P1703, DOI 10.1007/s11033-014-3019-7; Umar S, 2016, POULTRY SCI, V95, P1513, DOI 10.3382/ps/pew069; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Xiao JH, 2018, J CELL BIOCHEM, V119, DOI 10.1002/jcb.26878; Xu H, 2021, INFECT DIS THER, V10, P483, DOI 10.1007/s40121-021-00400-2; Yousif MHM, 2017, PEPTIDES, V90, P10, DOI 10.1016/j.peptides.2017.02.001; Yuan X, 2014, EXP THER MED, V8, P973, DOI 10.3892/etm.2014.1820; Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5; Zhou YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/374963	61	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106899	10.1016/j.vph.2021.106899		NOV 2021	5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34311073	Bronze, Green Published			2022-04-29	WOS:000756079500002
J	Tong, Y; Ye, C; Zheng, F; Bo, JH; Wu, LL; Han, Y; Zhou, YB; Xiong, XQ; Chen, Q; Li, YH; Kang, YM; Zhu, GQ				Tong, Ying; Ye, Chao; Zheng, Fen; Bo, Jin-Hua; Wu, Lu -Lu; Han, Ying; Zhou, Ye-Bo; Xiong, Xiao-Qing; Chen, Qi; Li, Yue-Hua; Kang, Yu-Ming; Zhu, Guo-Qing			Extracellular vesicle-mediated miR135a-5p transfer in hypertensive rat contributes to vascular smooth muscle cell proliferation via targeting FNDC5	VASCULAR PHARMACOLOGY			English	Article						microRNA; FNDC5; Hypertension; Exosome; Vascular smooth muscle cell; Proliferation	ANGIOTENSIN-II; ADVENTITIAL FIBROBLASTS; REGULATOR	Background Extracellular vesicles (EVs) from vascular adventitial fibroblasts (AFs) contribute to the proliferation of vascular smooth muscle cells (VSMCs) and vascular remodeling in spontaneously hypertensive rat (SHR). This study shows the crucial roles of EVs-mediated miR135a-5p transfer in VSMC proliferation and the underlying mechanisms in hypertension. Methods AFs and VSMCs were obtained from the aorta of Wistar-Kyoto rat (WKY) and SHR. EVs were isolated from the culture of AFs with ultracentrifugation method. Results MiR135a-5p level in SHR-EVs was significantly increased. MiR135a-5p inhibitor prevented the SHR-EVsinduced VSMC proliferation. Fibronectin type III domain containing 5 (FNDC5) was a target gene of miR135a5p. FNDC5 level was lower in VSMCs of SHR. MiR135a-5p inhibitor not only increased FNDC5 expression, but reversed the SHR-EVs-induced FNDC5 downregulation in VSMCs of SHR. MiR135a-5p mimic inhibited FNDC5 expression, but failed to promote the SHR-EVs-induced FNDC5 downregulation in VSMCs of SHR. Exogenous FNDC5 prevented the SHR-EVs-induced VSMC proliferation of both WKY and SHR. Knockdown of miR135a-5p in fibroblasts completely prevented the upregulation of miR135a-5p in the EVs. The SHR-EVs from the miR135a-5p knockdown-treated fibroblasts lost their roles in inhibiting FNDC5 expression and promoting proliferation in VSMCs of both WKY and SHR. Conclusions Increased miR135a-5p in the SHR-EVs promoted VSMC proliferation of WKY and SHR via inhibiting FNDC5 expression. MiR135a-5p and FNDC5 are crucial targets for intervention of VSMC proliferation in hypertension.	[Tong, Ying; Ye, Chao; Zheng, Fen; Bo, Jin-Hua; Wu, Lu -Lu; Han, Ying; Zhou, Ye-Bo; Xiong, Xiao-Qing; Zhu, Guo-Qing] Nanjing Med Univ, Dept Physiol, Collaborat Innovat Ctr Translat Med Cardiovasc Di, Key Lab Targeted Intervent Cardiovasc Dis, Nanjing 211166, Peoples R China; [Chen, Qi; Li, Yue-Hua; Zhu, Guo-Qing] Nanjing Med Univ, Dept Pathophysiol, Nanjing 211166, Jiangsu, Peoples R China; [Kang, Yu-Ming] Xi An Jiao Tong Univ, Sch Med, Cardiovasc Res Ctr, Dept Physiol & Pathophysiol, Xian 710061, Peoples R China; [Bo, Jin-Hua] Nanjing Med Univ, Clin Coll, Nanjing Drum Tower Hosp, Dept Anesthesiol, Nanjing 210008, Peoples R China		Zhu, GQ (通讯作者)，Nanjing Med Univ, Dept Physiol, Key Lab Cardiovasc Dis & Mol Intervent, 101 Longmian Ave, Nanjing 211166, Peoples R China.	gqzhucn@njmu.edu.cn		wu, lulu/0000-0003-0529-3722; Zheng, Fen/0000-0002-0783-7802; Han, Ying/0000-0001-8591-7894	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32071106, 91639105, 31871148, 81770426]	This work was supported by the National Natural Science Foundation of China [32071106, 91639105, 31871148 & 81770426] .	Ayers L, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1593755; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; Catalano M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1703244; Femmino S, 2020, VASC PHARMACOL, V135, DOI 10.1016/j.vph.2020.106790; Gao SY, 2018, INT J CLIN EXP PATHO, V11, P1347; Guo LM, 2018, CANCER BIOL THER, V19, P973, DOI 10.1080/15384047.2018.1450112; Kumar S, 2019, VASC PHARMACOL, V114, P76, DOI 10.1016/j.vph.2018.10.001; Ling L, 2018, J HYPERTENS, V36, P1104, DOI 10.1097/HJH.0000000000001654; Liu HM, 2019, ACTA PHARMACOL SIN, V40, P477, DOI 10.1038/s41401-018-0076-9; Liu TY, 2016, DIABETES, V65, P3262, DOI 10.2337/db16-0356; Liu TY, 2015, CLIN SCI, V129, P839, DOI 10.1042/CS20150009; Rabiee F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00413-3; Ragni E, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040347; Ren XS, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1698795; Ren XS, 2017, CELL PHYSIOL BIOCHEM, V44, P2269, DOI 10.1159/000486061; Samanta S, 2018, ACTA PHARMACOL SIN, V39, P501, DOI 10.1038/aps.2017.162; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Schiffrin EL, 2012, HYPERTENSION, V59, P367, DOI 10.1161/HYPERTENSIONAHA.111.187021; Stenmark KR, 2013, ANNU REV PHYSIOL, V75, P23, DOI 10.1146/annurev-physiol-030212-183802; Stenmark KR, 2011, COMPR PHYSIOL, V1, P141, DOI 10.1002/cphy.c090017; Sun HJ, 2017, EUR REV MED PHARMACO, V21, P5197, DOI 10.26355/eurrev_201711_13840; Sun HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.470; Sun HJ, 2016, ANTIOXID REDOX SIGN, V24, P1045, DOI 10.1089/ars.2015.6475; Tinajero MG, 2020, AM J PATHOL, V190, P520, DOI 10.1016/j.ajpath.2019.10.021; Tong Y, 2018, HYPERTENSION, V72, P881, DOI 10.1161/HYPERTENSIONAHA.118.11375; Vacante F, 2019, VASC PHARMACOL, V112, P24, DOI 10.1016/j.vph.2018.11.006; Wang D, 2018, ACTA PHARMACOL SIN, V39, P124, DOI 10.1038/aps.2017.89; Wang DD, 2018, BIOTECHNOL ADV, V36, P1586, DOI 10.1016/j.biotechadv.2018.04.006; Xiong XQ, 2018, METABOLISM, V83, P31, DOI 10.1016/j.metabol.2018.01.013; Xiong XQ, 2015, BBA-MOL BASIS DIS, V1852, P1867, DOI 10.1016/j.bbadis.2015.06.017; Xu JY, 2017, J CELL BIOCHEM, V118, P1921, DOI 10.1002/jcb.25941; Yuen CY, 2012, CIRC RES, V111, pE55, DOI 10.1161/CIRCRESAHA.112.271361; Zang YH, 2019, VASC PHARMACOL, V121, DOI 10.1016/j.vph.2019.106579; Zhang JR, 2021, HYPERTENS RES, V44, P129, DOI 10.1038/s41440-020-00553-6; Zhang KL, 2019, ACTA PHARMACOL SIN, V40, P1587, DOI 10.1038/s41401-019-0248-2; Zhang SH, 2021, VASC PHARMACOL, V136, DOI 10.1016/j.vph.2020.106820; Zhang Y, 2019, J CELL PHYSIOL, V234, P18679, DOI 10.1002/jcp.28508; Zhao X, 2017, CANCER BIOMARK, V20, P207, DOI 10.3233/CBM-170566; Zhou B, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6384803	39	3	3	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	OCT	2021	140								106864	10.1016/j.vph.2021.106864		SEP 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK0GC	33865997				2022-04-29	WOS:000709412300006
J	Maiti, S; Banerjee, A; Kanwar, M				Maiti, Smarajit; Banerjee, Amrita; Kanwar, Mehak			In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity	VASCULAR PHARMACOLOGY			English	Article						Angiotensin receptors; Spike glycoproteins; Nigellidine; Inhibitory constant; COVID 19 treatment	SMOOTH-MUSCLE; RECEPTOR; INHIBITION; APOPTOSIS; SEPSIS	COVID-19, a global-pandemic binds human-lung-ACE2. ACE2 causes vasodilatation. ACE2 works in balance with ACE1. The vaso-status maintains blood-pressure/vascular-health which is demolished in Covid-19 manifesting aldosterone/salt-deregulations/inflammations/endothelial-dysfunctions/hyper-hypo- tension, sepsis/ hypovolemic-shock and vessel-thrombosis/coagulations. Here, nigellidine, an indazole-alkaloid was analyzed by molecular-docking for binding to different Angiotensin-binding-proteins (enzymes, ACE1(6en5)/ACE2 (4aph)/receptors, AT1(6os1)/AT2(5xjm)) and COVID-19 spike-glycoprotein(6vsb). Nigellidine strongly binds to the spike-protein at the hinge-region/active-site-opening which may hamper proper-binding of nCoV2-ACE2 surface. Nigellidine effectively binds in the Angiotensin- II binding-site/entry-pocket (-7.54 kcal/mol, -211.76, Atomic-Contact-Energy; ACE-value) of ACE2 (Ki 8.68 and 8.3 Irmol) in comparison to known-binder EGCG (-4.53) and Theaflavin-di-gallate (-2.85). Nigellidine showed strong-binding (Ki, 50.93 Irmol/bindingenergy -5.48 kcal/mol) to mono/multi-meric ACE1. Moreover, it binds Angiotensin-receptors, AT1/AT2 (Ki, 42.79/14.22 Irmol, binding-energy, -5.96/-6.61 kcal/mol) at active-sites, respectively. This article reports the novel binding of nigellidine and subsequent blockage of angiotensin-binding proteins. The ACEs-blocking could restore Angiotensin-level, restrict vaso-turbulence in Covid patients and receptor-blocking might stop inflammatory/vascular impairment. Nigellidine may slowdown the vaso-fluctuations due to Angiotensin-deregulations in Covid patients. Angiotensin II-ACE2 binding (ACE-value -294.81) is more favorable than nigellidine-ACE2. Conversely, nigellidine-ACE1 binding-energy/Ki is lower than nigellidine-ACE2 values indicating a balancedstate between constriction-dilatation. Moreover, nigellidine binds to the viral-spike, closer-proximity to its ACE2 binding-domain. Taken together, Covid patients/elderly-patients, comorbid-patients (with hypertensive/ diabetic/cardiac/renal-impairment, counting >80% of non-survivors) could be greatly benefited.	[Maiti, Smarajit; Banerjee, Amrita; Kanwar, Mehak] Oriental Inst Sci & Technol, Cell & Mol Therapeut Lab, Dept Biochem & Biotechnol, Midnapore, India; [Maiti, Smarajit] Agricure Biotech Res Soc, Epidemiol & Human Hlth Div, Midnapore 721101, India		Maiti, S (通讯作者)，Oriental Inst Sci & Technol, Cell & Mol Therapeut Lab, Dept Biochem & Biotechnol, Midnapore, India.	maitism@rediffmail.com; bamrita.bioinfo@gmail.com					Ahmed OG, 2013, J PHYSIOL BIOCHEM, V69, P1, DOI 10.1007/s13105-012-0182-y; Martinez-Rojas MA, 2020, AM J PHYSIOL-RENAL, V318, pF1454, DOI 10.1152/ajprenal.00160.2020; [Anonymous], 2013, ELECT MAGNETISM; Boskabady Mohammad H., 2004, BMC Pharmacology, V4, P3, DOI 10.1186/1471-2210-4-3; Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471; Chinn IK, 2012, SEMIN IMMUNOL, V24, P309, DOI 10.1016/j.smim.2012.04.005; DeLano W.L., 2002, CCP4 NEWSL PROTEIN C, V40, P82; Gracia-Ramos AE, 2020, ARCH MED RES, V51, P345, DOI 10.1016/j.arcmed.2020.03.011; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Faria-Costa G, 2014, REV PORT CARDIOL, V33, P439, DOI 10.1016/j.repc.2014.02.011; Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461; Gris JC, 2020, ANAESTH CRIT CARE PA, V39, P381, DOI 10.1016/j.accpm.2020.04.013; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Guan W., 2020, N. Engl. J. Med., V382, P1708, DOI 10.1056/; Guo F, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-158; Halliday D., 1997, FUNDAMENTALS PHYS; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Hyndman RJ, 2006, INT J FORECASTING, V22, P679, DOI 10.1016/j.ijforecast.2006.03.001; Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388; Ishikawa M, 2007, AM J PHYSIOL-HEART C, V292, pH2306, DOI 10.1152/ajpheart.00601.2006; Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997; Li YX, 2006, AM J PHYSIOL-HEART C, V290, pH2116, DOI 10.1152/ajpheart.00551.2005; Liu J., 2020, J MED VIROL, V55, P102763, DOI [DOI 10.1016/J.EBIOM.2020.102763, 10.1101/2020.02.16.20023671]; Liu Z, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21932; Maiti S, 2021, DRUG DEVELOP RES, V82, P86, DOI 10.1002/ddr.21730; Mareev YV, 2020, KARDIOLOGIYA, V60, P4, DOI 10.18087/cardio.2020.4.n1122; Martiniuc C, 2012, MED-SURG J, V116, P1016; Park S, 2020, CLIN HYPERTENS, V26, DOI 10.1186/s40885-020-00144-0; Poblotzki A, 2017, J PHYS CHEM LETT, V8, P5656, DOI 10.1021/acs.jpclett.7b02337; Schneidman-Duhovny D, 2003, PROTEINS, V52, P107, DOI 10.1002/prot.10397; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sturrock BRH, 2020, CLIN MED, V20, pE72, DOI 10.7861/clinmed.2020-0146; Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]; Tan NY, 2009, CIRC RES, V105, P422, DOI 10.1161/CIRCRESAHA.109.203323; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Tsutsumi Y, 1999, J CLIN INVEST, V104, P925, DOI 10.1172/JCI7886; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang P.-H., 2020, BIORXIV, DOI [10.1101/2020.02.24.963348, DOI 10.1101/2020.02.24.963348]; Xu J., 2020, LANCET, V395, P1517, DOI [10.1016/S0140-6736(20)30920-X, DOI 10.1016/S0140-6736(20)30920-X]; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	46	2	2	4	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106856	10.1016/j.vph.2021.106856		MAY 2021	10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33746069	Green Published, Bronze, Green Submitted			2022-04-29	WOS:000652840900009
J	Chang, TT; Liao, LY; Chen, JW				Chang, Ting-Ting; Liao, Ling-Yu; Chen, Jaw-Wen			Inhibition on CXCL5 reduces aortic matrix metalloproteinase 9 expression and protects against acute aortic dissection	VASCULAR PHARMACOLOGY			English	Article						Acute aortic dissection; Angiotensin II; CXCL5; CXC-motif chemokine 5; Matrix metalloproteinase 9; Neutrophil	NEUTROPHIL RECRUITMENT; PEPTIDE ENA-78; INFLAMMATION; PROMOTES; METALLOPROTEINASES; ANEURYSMS	Acute aortic dissection (AAD) is an acute inflammatory vascular condition associated with significant morbidity and mortality. Depletion of neutrophils can attenuate the development of AAD. The CXC-motif chemokine 5 (CXCL5) can attract and activate neutrophils. This study aimed to investigate whether direct inhibition of CXCL5 could protect against AAD formation. A set of AAD animal models was designed using an angiotensin II infusion for 3 days after treatment with the lysyl oxidase inhibitor beta-aminopropionitrile for 4 weeks in 4-week-old male BALB/c mice. While AAD developed successfully in all the animals, approximately 31% of the mice died before sacrifice. The morphological changes at different time points during the experimental period indicated that angiotensin II could trigger AAD formation in this model. CXCL5 protein expression in the aorta tissue was increased after treatment with angiotensin II. Moreover, the ex vivo and in vitro study showed that vascular smooth muscle cells and monocytes isolated from the animals could generate CXCL5. CXCL5 inhibition by a specific monoclonal antibody significantly decreased the severity of AAD evaluated by ultrasound, aorta wet weight, and en face assay. The immunohistochemical analysis showed that the aortic tissues from AAD mice had higher expressions of matrix metalloproteinase (MMP) 9 and neutrophil-positive areas in the medial layer compared to control mice. Treatment with a CXCL5 antibody reduced MMP9 and neutrophil expressions as well as neutrophil and CXCL5 double-positive areas compared to untreated AAD mice. In conclusion, direct inhibition on CXCL5 reduced aortic MMP9 expression as well as neutrophil infiltration and attenuated the development of AAD, suggesting the mechanistic role of CXCL5 in neutrophil-triggered AAD. CXCL5 may be a potential therapeutic target for AAD.	[Chang, Ting-Ting; Liao, Ling-Yu; Chen, Jaw-Wen] Natl Yang Ming Univ, Sch Med, Dept & Inst Pharmacol, Taipei, Taiwan; [Chang, Ting-Ting; Chen, Jaw-Wen] Natl Yang Ming Chiao Tung Univ, Dept & Inst Pharmacol, Taipei, Taiwan; [Chang, Ting-Ting; Chen, Jaw-Wen] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan; [Chen, Jaw-Wen] Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan; [Chen, Jaw-Wen] Taipei Vet Gen Hosp, Div Cardiol, Dept Med, Taipei, Taiwan; [Chen, Jaw-Wen] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Taipei, Taiwan		Chen, JW (通讯作者)，Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan.	tf0619@yahoo.com.tw; ifcolorful@gmail.com; jwchen@vghtpe.gov.tw			National Scientific Council, Taiwan, R.O.NSC101-2314-B-010058-MY3 from National Scientific Council, Taiwan, R.O.C. and the project V105D18-004-MY3 from Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C that were given to Jaw-Wen Chen. [NSC101-2314-B-010058-MY3]; Taipei Veterans General Hospital, Taipei, Taiwan, R.O.CTaipei Veterans General Hospital [V105D18-004-MY3]	This work was supported partly by the project NSC101-2314-B-010058-MY3 from National Scientific Council, Taiwan, R.O center dot C. and the project V105D18-004-MY3 from Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C that were given to Jaw-Wen Chen.	Anzai A, 2015, CIRC RES, V116, P612, DOI 10.1161/CIRCRESAHA.116.304918; Begley LA, 2008, NEOPLASIA, V10, P244, DOI 10.1593/neo.07976; Beitelshees AL, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-9; Braverman AC, 2010, CIRCULATION, V122, P184, DOI 10.1161/CIRCULATIONAHA.110.958975; CHANG MS, 1994, J BIOL CHEM, V269, P25277; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Goldfinger JZ, 2014, J AM COLL CARDIOL, V64, P1725, DOI 10.1016/j.jacc.2014.08.025; Imaizumi TA, 1997, AM J RESP CELL MOL, V17, P181, DOI 10.1165/ajrcmb.17.2.2818; Izawa-Ishizawa Y, 2019, J HYPERTENS, V37, P73, DOI 10.1097/HJH.0000000000001898; Kanematsu Y, 2010, HYPERTENSION, V55, P1267, DOI 10.1161/HYPERTENSIONAHA.109.140558; Khan IA, 2002, CHEST, V122, P311, DOI 10.1378/chest.122.1.311; Kuo PL, 2014, INT J CANCER, V135, P96, DOI 10.1002/ijc.28673; Kurihara T, 2012, CIRCULATION, V126, P3070, DOI 10.1161/CIRCULATIONAHA.112.097097; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; Mizutani N, 2014, J IMMUNOL, V192, P1372, DOI 10.4049/jimmunol.1301538; Nagashima H, 2002, J VASC SURG, V36, P818, DOI 10.1067/mva.2002.126091; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Newby AC, 2007, TRENDS CARDIOVAS MED, V17, P253, DOI 10.1016/j.tcm.2007.09.001; Persson T, 2003, CLIN EXP ALLERGY, V33, P531, DOI 10.1046/j.1365-2222.2003.01609.x; Pinard A, 2019, CIRC RES, V124, P588, DOI 10.1161/CIRCRESAHA.118.312436; Ren WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28149; Stachon P, 2014, ARTERIOSCL THROM VAS, V34, P2237, DOI 10.1161/ATVBAHA.114.303585; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; Wong DR, 2008, AM SURGEON, V74, P364; Yoshimura K, 2015, INT J MOL SCI, V16, P11213, DOI 10.3390/ijms160511213; Zhang L, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/689142; Zhang S, 2014, INFECT IMMUN, V82, P3275, DOI 10.1128/IAI.01569-14; Zhang XM, 2009, VASCULAR, V17, P147, DOI 10.2310/6670.2008.00087; Zhou SL, 2012, HEPATOLOGY, V56, P2242, DOI 10.1002/hep.25907	30	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106926	10.1016/j.vph.2021.106926		NOV 2021	13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34653642				2022-04-29	WOS:000756079500017
J	Figueroa, EG; Gonzalez-Candia, A; Villanueva, CA; Ebensperger, G; Reyes, RV; Llanos, AJ; Herrera, EA				Figueroa, Esteban G.; Gonzalez-Candia, Alejandro; Villanueva, Cristian A.; Ebensperger, German; Reyes, Roberto V.; Llanos, Anibal J.; Herrera, Emilio A.			Beneficial effects of melatonin on prostanoids pathways in pulmonary hypertensive neonates	VASCULAR PHARMACOLOGY			English	Article						Prostanoids; Chronic hypoxia; Vascular reactivity; Vascular remodeling; Prostacyclin; Thromboxane; Lambs	REDUCES OXIDATIVE STRESS; THROMBOXANE RECEPTOR; HIGH-ALTITUDE; PROSTACYCLIN; EXPRESSION; HYPOXIA; STABILIZATION; DYSFUNCTION; ACTIVATION; INCREASE	Pulmonary arterial hypertension of the newborn (PAHN) is a syndrome caused by chronic hypoxia, characterized by decreased vasodilator function, a marked vasoconstrictor activity, proliferation of smooth muscle cells (SMC) and thickening of the extracellular matrix in the pulmonary circulation, among other characteristics. Prostaglandins are derived from the arachidonic acid (AA) metabolism and are important regulators of pulmonary vascular tone. Since hypoxia induces oxidative stress and has been related to PAHN, a postnatal treatment with melatonin has been proposed due to its antioxidant properties. Here, we determined the effects of melatonin on pulmonary vascular homeostasis given by prostanoids. Ten PAHN newborn lambs were divided in two groups and treated either with vehicle or melatonin. After 1 week of treatment, we assessed pulmonary vascular prostanoids function and expression by wire myography, RT-PCR, Western Blot and immunohistochemistry. Melatonin improved in vivo and ex vivo pulmonary vasodilation. This was associated with an increased function and expression of vasodilator prostanoids at the expense of vasoconstrictor prostanoids. Our study demonstrates for the first time that melatonin may enhance the vasodilator prostanoid pathway in PAHN.	[Figueroa, Esteban G.; Gonzalez-Candia, Alejandro; Villanueva, Cristian A.; Herrera, Emilio A.] Univ Chile, Fac Med, ICBM, Pathophysiol Program,Lab Vasc Funct & React, Ave Salvador 486, Santiago 7500922, Chile; [Gonzalez-Candia, Alejandro] Univ OHiggins, Inst Hlth Sci, Rancagua, Chile; [Ebensperger, German; Reyes, Roberto V.; Llanos, Anibal J.; Herrera, Emilio A.] Univ Chile, ICBM, Fac Med, Pathophysiol Program, Santiago, Chile; [Llanos, Anibal J.; Herrera, Emilio A.] Univ Chile, Int Ctr Andean Studies INCAS, Santiago, Chile		Herrera, EA (通讯作者)，Univ Chile, Fac Med, ICBM, Pathophysiol Program,Lab Vasc Funct & React, Ave Salvador 486, Santiago 7500922, Chile.	eaherrera@uchile.cl	Ebensperger, Germán/I-1093-2013; Herrera, Emilio A/H-5992-2018	Gonzalez-Candia, Alejandro/0000-0001-8429-367X; Figueroa Becerra, Esteban Gabriel/0000-0003-1316-738X; Herrera, Emilio A/0000-0002-6342-085X	FONDECYTComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [1151119, 1201283]; Proyectos Puente ICBM, Facultad de Medicina, Universidad de Chile [570182, 570235]	This work was funded by FONDECYT grants 1151119 & 1201283, and by Proyectos Puente ICBM, Facultad de Medicina, Universidad de Chile grants 570182 & 570235.	Astorga CR, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00185; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006; Brain KL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.2006552; Cecon E, 2018, BRIT J PHARMACOL, V175, P3263, DOI 10.1111/bph.13950; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Clanton TL, 2007, J APPL PHYSIOL, V102, P2379, DOI 10.1152/japplphysiol.01298.2006; CLAYPOOL LE, 1989, ENDOCRINOLOGY, V124, P2135, DOI 10.1210/endo-124-5-2135; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Durgin BG, 2018, LAB INVEST, V98, P1254, DOI 10.1038/s41374-018-0032-9; Feletou M, 2010, PFLUG ARCH EUR J PHY, V459, P941, DOI 10.1007/s00424-010-0812-6; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Funk CD, 2007, J CARDIOVASC PHARM, V50, P470, DOI 10.1097/FJC.0b013e318157f72d; Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128; Gitto E, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/980374; Gonzalez-Candia A, 2020, J DEV ORIG HLTH DIS, V11, P452, DOI 10.1017/S2040174420000616; Gonzalez-Candia A, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12613; Gonzalez-Candia A, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101128; Herrera EA, 2015, PHARMACOL RES, V101, P94, DOI 10.1016/j.phrs.2015.07.011; Herrera EA, 2007, AM J PHYSIOL-REG I, V292, pR2234, DOI 10.1152/ajpregu.00909.2006; Herrera EA, 2014, J PINEAL RES, V57, P33, DOI 10.1111/jpi.12141; Herrera EA, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00149; Herrera EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009250; Hristovska AM, 2007, HYPERTENSION, V50, P525, DOI 10.1161/HYPERTENSIONAHA.107.088948; Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jacc.2004.02.029; Humbert M, 2004, NEW ENGL J MED, V351, P1425, DOI 10.1056/NEJMra040291; Ichikawa A, 1996, J LIPID MEDIAT CELL, V14, P83, DOI 10.1016/0929-7855(96)00512-3; KATUSIC ZS, 1989, AM J PHYSIOL, V257, pH33, DOI 10.1152/ajpheart.1989.257.1.H33; Keyes LE, 2003, PEDIATR RES, V54, P20, DOI 10.1203/01.PDR.0000069846.64389.DC; Kirkby NS, 2012, P NATL ACAD SCI USA, V109, P17597, DOI 10.1073/pnas.1209192109; Konukoglu D, 2017, ADV EXP MED BIOL, V956, P511, DOI 10.1007/5584_2016_90; Lakshminrusimha S, 2016, J PERINATOL, V36, pS12, DOI 10.1038/jp.2016.44; Majed BH, 2012, PHARMACOL REV, V64, P540, DOI 10.1124/pr.111.004770; Masana M I, 2001, Sci STKE, V2001, ppe39; Masterson LR, 2011, J MOL BIOL, V412, P155, DOI 10.1016/j.jmb.2011.06.041; Mitchell JA, 2019, BRIT J PHARMACOL, V176, P1038, DOI 10.1111/bph.14167; Nabavi SM, 2019, CRIT REV FOOD SCI, V59, pS4, DOI 10.1080/10408398.2018.1487927; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; Penaloza D, 2007, CIRCULATION, V115, P1132, DOI 10.1161/CIRCULATIONAHA.106.624544; POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x; Poggi C, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/721043; Ross AW, 1996, MOL CELL ENDOCRINOL, V123, P71, DOI 10.1016/0303-7207(96)03897-X; Seron-Ferre M, 2001, SEMIN PERINATOL, V25, P363, DOI 10.1053/sper.2001.29037; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Sylvester JT, 2012, PHYSIOL REV, V92, P367, DOI 10.1152/physrev.00041.2010; Szymczyk G, 2005, Rocz Akad Med Bialymst, V50, P322; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tang EHC, 2007, BRIT J PHARMACOL, V151, P15, DOI 10.1038/sj.bjp.0707190; Teixeira-Mendonca C, 2013, REV PORT CARDIOL, V32, P1005, DOI 10.1016/j.repc.2013.06.010; Thakor AS, 2010, J PINEAL RES, V49, P399, DOI 10.1111/j.1600-079X.2010.00813.x; Torres F, 2015, J PINEAL RES, V58, P362, DOI 10.1111/jpi.12222; Urade Y, 2011, SLEEP MED REV, V15, P411, DOI 10.1016/j.smrv.2011.08.003; Urata Y, 1999, FREE RADICAL BIO MED, V27, P838, DOI 10.1016/S0891-5849(99)00131-8; Valentin FO, 2004, J BIOL CHEM, V279, P8316, DOI 10.1074/jbc.M306761200; WATABE A, 1993, J BIOL CHEM, V268, P20175; Wilson SJ, 2009, J LIPID RES, V50, P1047, DOI 10.1194/jlr.M800447-JLR200; Yaekashiwa M, 2003, DNA CELL BIOL, V22, P479, DOI 10.1089/10445490360708883; Yang D, 2002, BRIT J PHARMACOL, V136, P104, DOI 10.1038/sj.bjp.0704669	58	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106853	10.1016/j.vph.2021.106853		MAY 2021	11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33766627				2022-04-29	WOS:000652840900003
J	Zhu, JT; Liu, XM; Deng, YT; Li, DY; Yu, TT; Zhu, D				Zhu, Jingtan; Liu, Xiaomei; Deng, Yating; Li, Dongyu; Yu, Tingting; Zhu, Dan			Tissue optical clearing for 3D visualization of vascular networks: A review	VASCULAR PHARMACOLOGY			English	Review						Tissue optical clearing; Vessel labeling; Optical imaging	SINGLE-CELL RESOLUTION; LIGHT-SHEET MICROSCOPY; WHOLE-BODY; IN-VIVO; GLOMERULAR NUMBER; BLOOD-VESSELS; BRAIN; CLARITY; LECTIN; AGENT	Reconstruction of the vasculature of intact tissues/organs down to the capillary level is essential for understanding the development and remodeling of vascular networks under physiological and pathological conditions. Optical imaging techniques can provide sufficient resolution to distinguish small vessels with several microns, but the imaging depth is somewhat limited due to the high light scattering of opaque tissue. Recently, various tissue optical clearing methods have been developed to overcome light attenuation and improve the imaging depth both for ex-vivo and in-vivo visualizations. Tissue clearing combined with vessel labeling techniques and advanced optical tomography enables successful mapping of the vasculature of different tissues/organs, as well as dynamically monitoring vessel function under normal and pathological conditions. Here, we briefly introduce the commonly-used labeling strategies for entire vascular networks, the current tissue optical clearing techniques available for various tissues, as well as the advanced optical imaging techniques for fast, high-resolution structural and functional imaging for blood vessels. We also discuss the applications of these techniques in the 3D visualization of vascular networks in normal tissues, and the vascular remodeling in several typical pathological models in clinical research. This review is expected to provide valuable insights for researchers to study the potential mechanisms of various vessel-associated diseases using tissue optical clearing pipeline.	[Zhu, Jingtan; Liu, Xiaomei; Deng, Yating; Li, Dongyu; Yu, Tingting; Zhu, Dan] Huazhong Univ Sci & Technol, Wuhan Natl Lab Optoelect, Britton Chance Ctr Biomed Photon, Wuhan 430074, Hubei, Peoples R China; [Zhu, Jingtan; Liu, Xiaomei; Deng, Yating; Li, Dongyu; Yu, Tingting; Zhu, Dan] Huazhong Univ Sci & Technol, Sch Engn Sci, MoE Key Lab Biomed Photon, Wuhan 430074, Hubei, Peoples R China		Yu, TT (通讯作者)，Huazhong Univ Sci & Technol, Wuhan Natl Lab Optoelect, Britton Chance Ctr Biomed Photon, Wuhan 430074, Hubei, Peoples R China.; Yu, TT (通讯作者)，Huazhong Univ Sci & Technol, Sch Engn Sci, MoE Key Lab Biomed Photon, Wuhan 430074, Hubei, Peoples R China.	yutingting@hust.edu.cn			National Key Research and Development Program of China [2017YFA0700501]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61860206009, 81870934, 91749209, 81961138015]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [BX20200138, 2021M691145]; Innovation Fund of WNLO	This study was supported by the National Key Research and Development Program of China (Grant No. 2017YFA0700501), the National Natural Science Foundation of China (Grant Nos. 61860206009, 81870934, 91749209, 81961138015), China Postdoctoral Science Foundation funded project (Grant Nos. BX20200138, 2021M691145), and the Innovation Fund of WNLO.	Abe T, 2013, DEV GROWTH DIFFER, V55, P390, DOI 10.1111/dgd.12062; Alander JT, 2012, INT J BIOMED IMAGING, V2012, DOI 10.1155/2012/940585; Alford R, 2009, MOL IMAGING, V8, P341, DOI 10.2310/7290.2009.00031; Aoyagi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116280; Azaripour A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19685-4; Baldelomar EJ, 2016, KIDNEY INT, V89, P498, DOI 10.1038/ki.2015.316; Baluk P, 2008, ANN NY ACAD SCI, V1131, P1, DOI 10.1196/annals.1413.001; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; Bayguinov Peter O, 2018, Curr Protoc Cytom, V85, pe39, DOI 10.1002/cpcy.39; Becher T, 2020, CIRC RES, V126, P619, DOI 10.1161/CIRCRESAHA.119.315804; Belle M, 2017, CELL, V169, DOI 10.1016/j.cell.2017.03.008; Blinder P, 2013, NAT NEUROSCI, V16, P889, DOI 10.1038/nn.3426; Cai RY, 2019, NAT NEUROSCI, V22, P317, DOI 10.1038/s41593-018-0301-3; Cao Y, 2018, MOL METAB, V14, P71, DOI 10.1016/j.molmet.2018.06.004; Carrillo M, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012392; Chakraborty T, 2019, NAT METHODS, V16, P1109, DOI 10.1038/s41592-019-0615-4; Chen F, 2015, SCIENCE, V347, P543, DOI 10.1126/science.1260088; Chen LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12484-3; Chhetri RK, 2015, NAT METHODS, V12, P1171, DOI 10.1038/nmeth.3632; Chi J, 2018, JOVE-J VIS EXP, DOI 10.3791/58271; Choi B, 2005, LASER SURG MED, V36, P72, DOI 10.1002/lsm.20116; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Costantini I, 2019, BIOMED OPT EXPRESS, V10, P5251, DOI 10.1364/BOE.10.005251; Da Mesquita S, 2018, NATURE, V560, P185, DOI 10.1038/s41586-018-0368-8; Debbage PL, 1998, J HISTOCHEM CYTOCHEM, V46, P627, DOI 10.1177/002215549804600508; Deegan AJ, 2019, PHYS MED BIOL, V64, DOI 10.1088/1361-6560/ab03f1; Di Giovanna AP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30533-3; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Edwards-Richards A, 2014, CLIN KIDNEY J, V7, P569, DOI 10.1093/ckj/sfu106; Ergul Adviye, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P148; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Erturk A, 2012, NAT MED, V18, P166, DOI 10.1038/nm.2600; Fang CY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20329-3; Feng W, 2021, IEEE J SEL TOP QUANT, V27, DOI 10.1109/JSTQE.2021.3062595; Feng W, 2019, THERANOSTICS, V9, P5854, DOI 10.7150/thno.33738; Feng W, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.3.031003; Feng W, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.8.081207; FINA L, 1990, BLOOD, V75, P2417; Fu YY, 2010, MICROVASC RES, V80, P512, DOI 10.1016/j.mvr.2010.06.003; Galanzha EI, 2003, J PHYS D APPL PHYS, V36, P1739, DOI 10.1088/0022-3727/36/14/313; Genina EA, 2006, QUANTUM ELECTRON+, V36, P1119, DOI 10.1070/QE2006v036n12ABEH013337; Genina E.A., 2014, SAR FALL M 2013 OPT; Gomez-Gaviro MV, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101432; Greenbaum A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6518; Guo L, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.8.081202; Hahn C, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800368; Hama H, 2011, NAT NEUROSCI, V14, P1481, DOI 10.1038/nn.2928; Harrison CH, 2018, J ANAT, V232, P1025, DOI 10.1111/joa.12805; Hasegawa S, 2020, KIDNEY INT, V97, P934, DOI 10.1016/j.kint.2019.12.007; Hasegawa S, 2019, KIDNEY INT, V96, P129, DOI 10.1016/j.kint.2019.02.011; Henning Y, 2019, EXP EYE RES, V180, P137, DOI 10.1016/j.exer.2018.12.001; Hirshburg J, 2007, LASER SURG MED, V39, P140, DOI 10.1002/lsm.20417; HOLTHOFER H, 1982, LAB INVEST, V47, P60; Honeycutt SE, 2021, BIOTECHNIQUES, V70, P181, DOI 10.2144/btn-2020-0152; Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/nphoton.2014.166, 10.1038/NPHOTON.2014.166]; Hou B, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00019; Huisken J, 2007, OPT LETT, V32, P2608, DOI 10.1364/OL.32.002608; Jensen KHR, 2016, SCI REP-UK, V6, DOI 10.1038/srep32674; Jing D, 2018, CELL RES, V28, P803, DOI 10.1038/s41422-018-0049-z; Ke MT, 2016, CELL REP, V14, P2718, DOI 10.1016/j.celrep.2016.02.057; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; Kelly-Goss MR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08982-z; Kim SY, 2015, P NATL ACAD SCI USA, V112, pE6274, DOI 10.1073/pnas.1510133112; Kirst C, 2020, CELL, V180, P780, DOI 10.1016/j.cell.2020.01.028; Klingberg A, 2017, J AM SOC NEPHROL, V28, P452, DOI 10.1681/ASN.2016020232; Kolesova H, 2018, DEV DYNAM, V247, P1018, DOI [10.1002/DVDY.24637, 10.1002/dvdy.24637]; Kong K, 2015, ADV DRUG DELIVER REV, V89, P121, DOI 10.1016/j.addr.2015.03.009; Koo DJ, 2020, BIOCONJUGATE CHEM, V31, P1784, DOI 10.1021/acs.bioconjchem.0c00263; Krafft C, 2017, ANGEW CHEM INT EDIT, V56, P4392, DOI 10.1002/anie.201607604; Krolewski DM, 2018, BRAIN STRUCT FUNCT, V223, P987, DOI 10.1007/s00429-017-1583-z; Ku T, 2016, NAT BIOTECHNOL, V34, P973, DOI 10.1038/nbt.3641; Kubota SI, 2017, CELL REP, V20, P236, DOI 10.1016/j.celrep.2017.06.010; Kuwajima T, 2013, DEVELOPMENT, V140, P1364, DOI 10.1242/dev.091844; Lai HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03359-w; Lai HM, 2017, CELL CHEM BIOL, V24, P659, DOI 10.1016/j.chembiol.2017.05.015; LAITINEN L, 1987, HISTOCHEM J, V19, P225, DOI 10.1007/BF01680633; Larin KV, 2019, BIOMED OPT EXPRESS, V10, P5159, DOI 10.1364/BOE.10.005159; Lee E, 2016, SCI REP-UK, V6, DOI 10.1038/srep18631; Lee SSY, 2019, MOL CANCER THER, V18, P213, DOI 10.1158/1535-7163.MCT-18-0554; Li DY, 2020, J BIOPHOTONICS, V13, DOI 10.1002/jbio.202000142; Li J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10640; Li T, 2013, BRAIN, V136, P3578, DOI 10.1093/brain/awt287; Li WZ, 2017, P NATL ACAD SCI USA, V114, pE7321, DOI 10.1073/pnas.1708981114; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Liang XH, 2021, THERANOSTICS, V11, P3035, DOI 10.7150/thno.53979; Liebmann T, 2016, CELL REP, V16, P1138, DOI 10.1016/j.celrep.2016.06.060; Liu YC, 2003, METHODS, V30, P86, DOI 10.1016/S1046-2023(03)00010-0; Liu YD, 2020, PHOTODIAGN PHOTODYN, V30, DOI 10.1016/j.pdpdt.2020.101734; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lo P, 2016, MICROVASC RES, V105, P109, DOI 10.1016/j.mvr.2016.02.002; Lokmic Z, 2011, HISTOL HISTOPATHOL, V26, P781, DOI 10.14670/HH-26.781; Lugo-Hernandez E, 2017, J CEREBR BLOOD F MET, V37, P3355, DOI 10.1177/0271678X17698970; Ma J, 2018, LASER MED SCI, V33, P1295, DOI 10.1007/s10103-018-2481-1; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Mao ZZ, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2892684; Merz G, 2018, JOVE-J VIS EXP, DOI 10.3791/57099; Miyawaki T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14786-z; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Murakami TC, 2018, NAT NEUROSCI, V21, P625, DOI 10.1038/s41593-018-0109-1; Murray E, 2015, CELL, V163, P1500, DOI 10.1016/j.cell.2015.11.025; Na M, 2021, BRAIN STRUCT FUNCT, V226, P297, DOI 10.1007/s00429-020-02160-0; Nehrhoff I, 2017, BIOMED OPT EXPRESS, V8, P3110, DOI 10.1364/BOE.8.003110; Nie J, 2020, ADV SCI, V7, DOI 10.1002/advs.201901891; Novoselova MV, 2020, PHOTOACOUSTICS, V20, DOI 10.1016/j.pacs.2020.100186; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Olianti C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71174-9; Oren R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19663-w; Pan CC, 2016, NAT METHODS, V13, P859, DOI 10.1038/nmeth.3964; Park YG, 2019, NAT BIOTECHNOL, V37, P73, DOI 10.1038/nbt.4281; Phillips MR, 2017, J SURG RES, V207, P115, DOI 10.1016/j.jss.2016.08.074; Pires L, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.8.081210; Piri R, 2020, EUR J NUCL MED MOL I, V47, P2016, DOI 10.1007/s00259-019-04622-y; Power RM, 2017, NAT METHODS, V14, P360, DOI 10.1038/nmeth.4224; Proskurin SG, 2007, LASER PHYS LETT, V4, P824, DOI 10.1002/lapl.200710056; Puelles VG, 2019, KIDNEY INT, V96, P505, DOI 10.1016/j.kint.2019.02.034; Qi YS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau8355; Reeson P, 2015, J NEUROSCI, V35, P5128, DOI 10.1523/JNEUROSCI.2810-14.2015; Renier N, 2016, CELL, V165, P1789, DOI 10.1016/j.cell.2016.05.007; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Richardson DS, 2015, CELL, V162, P246, DOI 10.1016/j.cell.2015.06.067; Robertson RT, 2015, HISTOCHEM CELL BIOL, V143, P225, DOI 10.1007/s00418-014-1301-3; Sang X, 2021, LASER MED SCI, V36, P387, DOI 10.1007/s10103-020-03059-2; Schwarz MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124650; Sdobnov AY, 2019, BIOCHEMISTRY-MOSCOW+, V84, P144, DOI 10.1134/S0006297919140098; Sdobnov AY, 2018, SPECTROCHIM ACTA A, V197, P216, DOI 10.1016/j.saa.2018.01.085; Seo J, 2016, MOL CELLS, V39, P439, DOI 10.14348/molcells.2016.0088; Shi R, 2017, J BIOPHOTONICS, V10, P1647, DOI 10.1002/jbio.201700052; Shi R, 2015, BIOMED OPT EXPRESS, V6, P1977, DOI 10.1364/BOE.6.001977; Song E, 2015, BIOMED OPT EXPRESS, V6, P4154, DOI 10.1364/BOE.6.004154; Susaki EA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15906-5; Susaki EA, 2016, CELL CHEM BIOL, V23, P137, DOI 10.1016/j.chembiol.2015.11.009; Susaki EA, 2014, CELL, V157, P726, DOI 10.1016/j.cell.2014.03.042; Tainaka K, 2018, CELL REP, V24, P2196, DOI 10.1016/j.celrep.2018.07.056; Tainaka K, 2016, ANNU REV CELL DEV BI, V32, P713, DOI 10.1146/annurev-cellbio-111315-125001; Tainaka K, 2014, CELL, V159, P911, DOI 10.1016/j.cell.2014.10.034; Tanaka N, 2017, NAT BIOMED ENG, V1, P796, DOI 10.1038/s41551-017-0139-0; Tian T, 2021, J ANAT, V238, P489, DOI 10.1111/joa.13309; Todorov MI, 2020, NAT METHODS, V17, P442, DOI 10.1038/s41592-020-0792-1; Tomer R, 2015, CELL, V163, P1796, DOI 10.1016/j.cell.2015.11.061; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Toth P, 2017, AM J PHYSIOL-HEART C, V312, pH1, DOI 10.1152/ajpheart.00581.2016; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Tuchin V V, 1997, J Biomed Opt, V2, P401, DOI 10.1117/12.281502; Ueda HR, 2020, NEURON, V106, P369, DOI 10.1016/j.neuron.2020.03.004; Ueda HR, 2020, NAT REV NEUROSCI, V21, P61, DOI 10.1038/s41583-019-0250-1; Voigt FF, 2019, NAT METHODS, V16, P1105, DOI 10.1038/s41592-019-0554-0; Wang J, 2012, LASER PHYS LETT, V9, P469, DOI 10.7452/lapl.201210017; Wang J, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.6.061209; Weissman TA, 2015, GENETICS, V199, P293, DOI 10.1534/genetics.114.172510; Wen X, 2010, J BIOPHOTONICS, V3, P44, DOI 10.1002/jbio.200910080; Wu YC, 2013, NAT BIOTECHNOL, V31, P1032, DOI 10.1038/nbt.2713; Xie WG, 2021, BIOMATER SCI-UK, V9, P2658, DOI 10.1039/d0bm01817a; Xu JY, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800134; Xue SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088067; Yang B, 2014, CELL, V158, P945, DOI 10.1016/j.cell.2014.07.017; Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043; Yu TT, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102178; Yu TT, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700187; Yu TT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20306-3; Zhan YJ, 2021, J BIOPHOTONICS, V14, DOI 10.1002/jbio.202000413; Zhang C, 2018, THERANOSTICS, V8, P2696, DOI 10.7150/thno.23686; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210; Zhang LY, 2018, AGING DIS, V9, P262, DOI 10.14336/AD.2017.0613; Zhang WL, 2018, CELL J, V20, P132, DOI 10.22074/cellj.2018.5266; Zhao F, 2020, BIOMED OPT EXPRESS, V11, P7273, DOI 10.1364/BOE.409732; Zhao F, 2020, J BIOPHOTONICS, V13, DOI 10.1002/jbio.201960243; Zhao JJ, 2021, ACS CHEM NEUROSCI, V12, P5, DOI 10.1021/acschemneuro.0c00563; Zhao S, 2020, CELL, V180, P796, DOI 10.1016/j.cell.2020.01.030; Zhao YJ, 2018, LIGHT-SCI APPL, V7, DOI 10.1038/lsa.2017.153; Zhu D, 2013, LASER PHOTONICS REV, V7, P732, DOI 10.1002/lpor.201200056; Zhu D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3369739; Zhu D, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2907169; Zhu JT, 2021, BIOMED OPT EXPRESS, V12, P5499, DOI 10.1364/BOE.431397; Zhu JT, 2020, ADV SCI, V7, DOI 10.1002/advs.201903185; Zhu XP, 2019, P NATL ACAD SCI USA, V116, P11480, DOI 10.1073/pnas.1819583116	175	0	0	5	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106905	10.1016/j.vph.2021.106905		NOV 2021	15	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34506969				2022-04-29	WOS:000756079500007
J	de Oliveira, AA; Nunes, KP				de Oliveira, Amanda Almeida; Nunes, Kenia Pedrosa			Crosstalk of TLR4, vascular NADPH oxidase, and COVID-19 in diabetes: What are the potential implications?	VASCULAR PHARMACOLOGY			English	Review						TLR4; NADPH oxidase; ROS; Diabetes; COVID-19	NF-KAPPA-B; RECEPTOR 4 CONTRIBUTES; ANGIOTENSIN-II; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR HSP70; OXIDATIVE STRESS; NITRIC-OXIDE; ACTIVATION; LIPOPOLYSACCHARIDE; INHIBITION	Toll-like receptor 4 (TLR4) contributes to the pathophysiology of diabetes. This happens, at least in part, because TLR4 modulates the enzyme NADPH oxidase, a primary source of ROS in vascular structures. Increased oxidative stress disrupts key vascular signaling mechanisms and drives the progression of diabetes, elevating the likelihood of cardiovascular diseases. Recently, it has been shown that patients with diabetes are also at a higher risk of developing severe coronavirus disease 2019 (COVID-19). Given the importance of the interaction between TLR4 and NADPH oxidase to the disrupted diabetic vascular system, we put forward the hypothesis that TLR4mediated NADPH oxidase-derived ROS might be a critical mechanism to help explain why this disparity appears in diabetic patients, but unfortunately, conclusive experimental evidence still lacks in the literature. Herein, we focus on discussing the pathological implications of this signaling communication in the diabetic vasculature and exploring this crosstalk in the context of diabetes-associated severe COVID-19.	[de Oliveira, Amanda Almeida; Nunes, Kenia Pedrosa] Florida Inst Technol, Dept Biomed & Chem Engn & Sci, Lab Vasc Biol, Melbourne, FL 32901 USA		Nunes, KP (通讯作者)，Florida Inst Technol, Dept Biomed & Chem Engn & Sci, 150 W Univ Blvd, Melbourne, FL 32901 USA.	knunes@fit.edu					Abdul Y, 2019, MOL NEUROBIOL, V56, P1607, DOI 10.1007/s12035-018-1184-8; Aboudounya MM, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/8874339; Arauz-Pacheco Carlos, 2003, Diabetes Care, V26 Suppl 1, pS80; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Barbosa LC, 2021, VASC PHARMACOL, V137, DOI 10.1016/j.vph.2021.106829; Barrera FJ, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvaa102; Becker RC, 2020, J THROMB THROMBOLYS, V50, P499, DOI 10.1007/s11239-020-02230-4; Biancardi VC, 2017, PHARMACOL RES, V120, P88, DOI 10.1016/j.phrs.2017.03.017; Bomfim GF, 2015, LIFE SCI, V122, P1, DOI 10.1016/j.lfs.2014.12.001; Bomfim GF, 2012, CLIN SCI, V122, P535, DOI 10.1042/CS20110523; Brandao SCS, 2021, CYTOKINE GROWTH F R, V58, P102, DOI 10.1016/j.cytogfr.2020.09.002; Carrillo-Sepulveda MA, 2015, J MOL MED, V93, P1341, DOI 10.1007/s00109-015-1318-7; Cat AND, 2013, ANTIOXID REDOX SIGN, V19, P1110, DOI 10.1089/ars.2012.4641; Cecchini R, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110102; Chandra S, 2019, EUR J PHARMACOL, V844, P26, DOI 10.1016/j.ejphar.2018.11.027; Chee YJ, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108166; Chen KJ, 2008, ANTIOXID REDOX SIGN, V10, P1185, DOI 10.1089/ars.2007.1959; Chen XP, 2008, CURR HYPERTENS REV, V4, P245, DOI 10.2174/157340208786241336; Choudhury A, 2020, J MED VIROL, V92, P2105, DOI 10.1002/jmv.25987; Damiano S, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.608435; de Oliveira AA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-80966-6; de Oliveira AA, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.666696; de Oliveira AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68919-x; de Oliveira AA, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117986; de Oliveira AA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133121; de Oliveira AA, 2019, CURR DRUG TARGETS, V20, P51, DOI 10.2174/1389450119666180821105544; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fraga-Silva RA, 2013, HYPERTENSION, V61, P1233, DOI 10.1161/HYPERTENSIONAHA.111.00627; Fraser Douglas D, 2020, Crit Care Explor, V2, pe0144, DOI 10.1097/CCE.0000000000000144; Gomes JMG, 2017, METABOLISM, V68, P133, DOI 10.1016/j.metabol.2016.12.009; Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015; Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545; Goulopoulou S, 2014, HYPERTENSION, V63, pE33, DOI 10.1161/HYPERTENSIONAHA.113.02444; Guihur A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.564170; Han J, 2017, BASIC RES CARDIOL, V112, DOI 10.1007/s00395-016-0599-5; Hassett CE, 2020, CLEV CLIN J MED, V87, P729, DOI 10.3949/ccjm.87a.ccc058; Hernanz R, 2015, BRIT J PHARMACOL, V172, P3159, DOI 10.1111/bph.13117; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Jayashree B, 2014, MOL CELL BIOCHEM, V388, P203, DOI 10.1007/s11010-013-1911-4; Joutel A, 2014, STROKE, V45, P1215, DOI 10.1161/STROKEAHA.113.002878; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kayama Y, 2015, INT J MOL SCI, V16, P25234, DOI 10.3390/ijms161025234; Kim Mi Young, 2012, Cells, V1, P646, DOI 10.3390/cells1030646; Konior A, 2014, ANTIOXID REDOX SIGN, V20, P2794, DOI 10.1089/ars.2013.5607; Kramer B, 2018, AM J PHYSIOL-HEART C, V315, pH1735, DOI 10.1152/ajpheart.00218.2018; Krause M, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00572-w; Krause M, 2015, CLIN SCI, V128, P789, DOI 10.1042/CS20140695; Krause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/249205; Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057; Li Y, 2017, FREE RADICAL BIO MED, V109, P33, DOI 10.1016/j.freeradbiomed.2017.02.049; Liang CF, 2013, ARTERIOSCL THROM VAS, V33, P777, DOI 10.1161/ATVBAHA.112.301087; Libby P, 2020, EUR HEART J, V41, P3038, DOI 10.1093/eurheartj/ehaa623; Liu S, 2020, NEW ONSET COVID 19 R; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8; Lovren F, 2008, AM J PHYSIOL-HEART C, V295, pH1377, DOI 10.1152/ajpheart.00331.2008; Lu ZY, 2012, ARTERIOSCL THROM VAS, V32, P1696, DOI 10.1161/ATVBAHA.112.251181; Maloney E, 2009, ARTERIOSCL THROM VAS, V29, P1370, DOI 10.1161/ATVBAHA.109.188813; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Michael J Morgan, 2011, Cell Research, V21, P103; Molteni M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6978936; Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020; Nunes KP, 2017, LIFE SCI, V191, P219, DOI 10.1016/j.lfs.2017.10.014; Nunes KP, 2011, J SEX MED, V8, P3335, DOI 10.1111/j.1743-6109.2011.02499.x; Nunes KP, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00655; Nunes KP, 2018, J SEX MED, V15, P1235, DOI 10.1016/j.jsxm.2018.07.005; Nunes KP, 2019, BRIT J PHARMACOL, V176, P1864, DOI 10.1111/bph.14438; Olejnik J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007390; Pahwa R, 2016, J DIABETES COMPLICAT, V30, P563, DOI 10.1016/j.jdiacomp.2016.01.014; Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Park HS, 2006, CARDIOVASC RES, V72, P447, DOI 10.1016/j.cardiores.2006.09.012; Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708; Patel VB, 2014, HYPERTENSION, V64, P157, DOI 10.1161/HYPERTENSIONAHA.114.03388; Patel VB, 2014, CLIN SCI, V126, P471, DOI 10.1042/CS20130344; Patel VB, 2014, J MOL CELL CARDIOL, V66, P167, DOI 10.1016/j.yjmcc.2013.11.017; Pincemail J, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020257; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2021832, 10.1056/NEJMc2018688]; Sena CM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01668; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shin JJ, 2015, AGEING RES REV, V24, P66, DOI 10.1016/j.arr.2015.06.004; Shirato K, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06187; Siddiqi HK, 2021, TRENDS CARDIOVAS MED, V31, P1, DOI 10.1016/j.tcm.2020.10.005; Sohn KM, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e343; Toque HA, 2013, J SEX MED, V10, P1502, DOI 10.1111/jsm.12134; Troseid M, 2013, DIABETES CARE, V36, P3627, DOI 10.2337/dc13-0451; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Violi F, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101655; Viveiros A, 2021, AM J PHYSIOL-HEART C, V320, pH296, DOI 10.1152/ajpheart.00755.2020; Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15978-3; Wang Y, 2019, BRIT J PHARMACOL, V176, P2642, DOI 10.1111/bph.14687; Wysocki J, 2014, PHYSIOL REP, V2, DOI 10.1002/phy2.264; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Xu Z, 2017, SCI REP-UK, V7, DOI 10.1038/srep44911; Yang JC, 2021, IEEE T INTELL TRANSP, V22, P3742, DOI 10.1109/TITS.2020.3023788; Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4; Zhu ZW, 2020, FASEB J, V34, P8641, DOI 10.1096/fj.202000242R; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	102	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106879	10.1016/j.vph.2021.106879		JUL 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34051372	Green Published, Bronze			2022-04-29	WOS:000674133600007
J	Kumar, RK; Kaiser, LM; Rockwell, CE; Watts, SW				Kumar, R. K.; Kaiser, L. M.; Rockwell, C. E.; Watts, S. W.			Interleukin-10 does not contribute to the anti-contractile nature of PVAT in health	VASCULAR PHARMACOLOGY			English	Article						IL-10; Vascular tone; Vasorelaxation; Anti-contractile; Perivascular adipose tissue	PERIVASCULAR ADIPOSE-TISSUE; T-CELLS; TONE	Perivascular adipose tissue (PVAT) is protective and reduces contraction of blood vessels in health. PVAT is composed of adipocytes, multiple types of immune cells and stromal cells. Interleukin (IL)-10, an antiinflammatory cytokine usually produced by T cells, B cells and macrophages, was identified as one of the highly expressed (mRNA) cytokines in the mesenteric PVAT of healthy rats. One report suggested that exogenous IL-10 causes relaxation of mouse mesenteric arteries, also suggesting that IL-10 maybe a potential anti-contractile factor. Hence, we hypothesized that PVAT-derived IL-10 causes vasorelaxation and/or reduces vasoconstriction, thus contributing to the anti-contractile nature of PVAT in health. Mesenteric arteries from rats and mice expressed the receptor for IL-10 (in tunica intima and media) as determined by immunohistochemistry. Mesenteric resistance arteries for rats and superior mesenteric artery for mice were used for isometric contractility studies. Increasing concentrations [0.4-100 ng/mL] of recombinant rat/mouse (rr/mr) IL-10 or vehicle was directly added to half-maximally constricted (phenylephrine, PE) vessels (without PVAT, with endothelium). IL-10 did not cause a direct vasorelaxation. Further, the ability of rrIL-10 to cause a rightward or downward shift of a vasoconstriction-response curve was tested in the rat. The vessels were incubated with rrIL10 [100 ng/mL or 10 ng/mL] or vehicle for 1.5 h in the tissue bath followed by a cumulative PE [10-8-10-4 M] or U46619 [10- 10-10- 5 M] response curve. The maximal contractions and EC50 values were similar in IL-10 incubated vessels vs vehicle. Thus, acute exposure of exogenous IL-10 did not reduce local vasoconstriction. To further test if endogenous IL-10 from PVAT was anti-contractile, superior mesenteric arteries from IL-10 WT and KO mice, with and without PVAT, were subjected to increasing concentrations of PE. The anti-contractile nature of PVAT was preserved with both short-term and prolonged depletion (using younger and older mice, respectively) of endogenous IL-10 in males and females. Contrary to our hypothesis, PVAT-derived IL-10 neither caused vasorelaxation nor reduced local vasoconstriction directly/indirectly. Therefore, IL-10 does not contribute to the anti-contractile nature of PVAT in healthy rodents.	[Kumar, R. K.; Kaiser, L. M.; Rockwell, C. E.; Watts, S. W.] Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St,Rm B445, E Lansing, MI 48824 USA		Kumar, RK (通讯作者)，Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St,Rm B445, E Lansing, MI 48824 USA.	kalyanak@msu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HL70687]	We would like to thank Dr. Nathan Tykocki from Michigan State University for generously sharing organs from their WT mice. This work was funded by the National Institutes of Health P01 HL70687.	Almabrouk TAM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00051; Chen QS, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/434010, 10.1155/2013/928315]; Farias-Itao DS, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013793; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Giachini FRC, 2009, AM J PHYSIOL-HEART C, V296, pH489, DOI 10.1152/ajpheart.00251.2008; Guilbault C, 2002, IMMUNOLOGY, V107, P297, DOI 10.1046/j.1365-2567.2002.01508.x; Gunnett CA, 2002, DIABETES, V51, P1931, DOI 10.2337/diabetes.51.6.1931; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; Juge-Aubry CE, 2005, CYTOKINE, V29, P270, DOI 10.1016/j.cyto.2004.10.017; Kassan M, 2011, ARTERIOSCL THROM VAS, V31, P2534, DOI 10.1161/ATVBAHA.111.233262; Kessler B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42791; Kumar RK, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00058; Lima VV, 2016, LIFE SCI, V145, P137, DOI 10.1016/j.lfs.2015.12.009; Lohn M, 2002, FASEB J, V16, P1057, DOI 10.1096/fj.02-0024com; Ohkawa F, 1995, CARDIOVASC RES, V30, P711, DOI 10.1016/0008-6363(95)00101-8; Rajbhandari P, 2018, CELL, V172, P218, DOI 10.1016/j.cell.2017.11.019; Sagan A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01979; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sikka G, 2013, EXP GERONTOL, V48, P128, DOI 10.1016/j.exger.2012.11.001; SOLTIS EE, 1991, CLIN EXP HYPERTENS A, V13, P277, DOI 10.3109/10641969109042063; Szasz T, 2013, VASC HEALTH RISK MAN, V9, P105, DOI 10.2147/VHRM.S33760; Tan BB, 2001, J SURG RES, V100, P110, DOI 10.1006/jsre.2001.6105; Verlohren S, 2004, HYPERTENSION, V44, P271, DOI 10.1161/01.HYP.0000140058.28994.ec; Verma R, 2016, J CELL COMMUN SIGNAL, V10, P61, DOI 10.1007/s12079-015-0302-x; Virdis A, 2015, EUR HEART J, V36, P784, DOI 10.1093/eurheartj/ehu072; Westbrook RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186811; Withers SB, 2017, SCI REP-UK, V7, DOI 10.1038/srep44571	27	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106838	10.1016/j.vph.2021.106838		MAY 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33540122				2022-04-29	WOS:000652840900006
J	Totoson, P; Santini, C; Prigent-Tessier, A; Marie, C; Demougeot, C				Totoson, P.; Santini, C.; Prigent-Tessier, A.; Marie, C.; Demougeot, C.			Endothelial TrkB receptor activation controls vascular tone of rat middle cerebral artery	VASCULAR PHARMACOLOGY			English	Article						BDNF; TrkB receptor; Middle cerebral artery; Vasodilation; Endothelium	NEUROTROPHIC FACTOR; NITRIC-OXIDE; BLOOD-FLOW; BRAIN; POLYMORPHISM; RESISTANCE; CELLS; NEUROPROTECTION; CIRCULATION; DYSFUNCTION	Little is known on the cerebrovascular BDNF (brain-derived neurotrophic factor)/TrkB (tropomyosin related kinase B) pathway. This study investigated the contribution of endogenous endothelial BDNF to the control of vascular tone of rat middle cerebral artery (MCA) and the capacity of exogenous agonist of TrkB receptors to induce their relaxation. Endothelial cells constitutively expressed both BDNF and activated TrkB receptors. Supporting endothelial BDNF as an autocrine regulator of basal myogenic tone, incubation of MCA with the TrkB antagonist cyclotraxin B induced contraction as observed with incubation in the presence of inhibitors of nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF) production. Exposure of MCA with the TrkB agonist LM22A-4 that increased expression of TrkB receptors phosphorylated at tyrosine 816 induced relaxation of preconstricted MCA (EC50 6.7 x 10(-8) mol/L) as efficiently than acetylcholine (EC50 5.3 x 10(-8) mol/L). Finally, endothelium removal, exposure to a TrkB antagonist or to inhibitors of NO and EDHF production prevented the relaxant effect of LM22A-4. In conclusion, our study identified endothelial BDNF as a new autocrine regulator of vascular tone of MCA, thus making the endothelial BDNF/TrkB pathway an attractive target for strategies aiming to improve blood supply to the brain.	[Totoson, P.; Demougeot, C.] Univ Bourgogne Franche Comte, PEPITE EA4267, FHU INCREASE, F-25030 Besancon, France; [Santini, C.; Prigent-Tessier, A.; Marie, C.] Univ Bourgogne Franche Comte, INSERM, F-21000 Dijon, France		Marie, C (通讯作者)，UFR Sci Sante, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	chmarie@u-bourgogne.fr		demougeot, celine/0000-0003-0639-9756; Santini, Clelia/0000-0002-8219-1677	French Ministry for Higher Education and Research	This work was supported by funding from the French Ministry for Higher Education and Research.	Alomari MA, 2015, VASC MED, V20, P518, DOI 10.1177/1358863X15598390; Amadio P, 2017, EUR HEART J, V38, P1426, DOI 10.1093/eurheartj/ehv655; Bathina S, 2015, ARCH MED SCI, V11, P1164, DOI 10.5114/aoms.2015.56342; Bayas A, 2002, CYTOKINE, V19, P55, DOI 10.1006/cyto.2002.0892; Bordy R, 2020, TRANSL STROKE RES, V11, P4, DOI 10.1007/s12975-019-00699-7; Chen SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018024; Chumbley J, 2014, NEUROSCIENCE, V280, P130, DOI 10.1016/j.neuroscience.2014.09.014; Davis CM, 2011, WOMENS HEALTH, V7, P293, DOI [10.2217/whe.11.26, 10.2217/WHE.11.26]; Di Marco LY, 2015, NEUROBIOL DIS, V82, P593, DOI 10.1016/j.nbd.2015.08.014; Drouin A, 2009, STROKE, V40, P1827, DOI 10.1161/STROKEAHA.108.536805; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; Foulquier S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110766; Guo SZ, 2008, P NATL ACAD SCI USA, V105, P7582, DOI 10.1073/pnas.0801105105; HARPER SL, 1984, AM J PHYSIOL, V246, pH17, DOI 10.1152/ajpheart.1984.246.1.H17; Hashimoto T, 2009, J PHARMACOL SCI, V109, P546, DOI 10.1254/jphs.08310FP; Jansen-Olesen I, 2005, EUR J PHARMACOL, V523, P109, DOI 10.1016/j.ejphar.2005.08.028; Klein AB, 2011, INT J NEUROPSYCHOPH, V14, P347, DOI 10.1017/S1461145710000738; Lagaud GJL, 1999, J PHARMACOL EXP THER, V290, P832; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Lindholm JSO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00143; Lu B, 2014, Handb Exp Pharmacol, V220, P223, DOI 10.1007/978-3-642-45106-5_9; Marie C, 2018, J CEREBR BLOOD F MET, V38, P935, DOI 10.1177/0271678X18766772; MCPHERSON GA, 1992, BRIT J PHARMACOL, V105, P51, DOI 10.1111/j.1476-5381.1992.tb14209.x; Monnier A, 2017, ACTA PHYSIOL, V219, P790, DOI 10.1111/apha.12743; Nagata K, 2016, AGEING RES REV, V30, P49, DOI 10.1016/j.arr.2016.06.001; Navaratna D, 2011, DIABETES, V60, P1789, DOI 10.2337/db10-1371; Pedard M, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01125; Prigent-Tessier A, 2013, CARDIOVASC RES, V100, P374, DOI 10.1093/cvr/cvt219; Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0; Sandrini L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080875; Santhanam AVR, 2010, STROKE, V41, P350, DOI 10.1161/STROKEAHA.109.564492; Schildmeyer LA, 2002, AM J PHYSIOL-HEART C, V282, pH734, DOI 10.1152/ajpheart.00583.2001; Schuh-Hofer S, 2001, NEUROSCI LETT, V306, P61, DOI 10.1016/S0304-3940(01)01878-X; Smith AJ, 2015, J HUM HYPERTENS, V29, P33, DOI 10.1038/jhh.2014.39; Toda N, 2009, PHARMACOL REV, V61, P62, DOI 10.1124/pr.108.000547; Toth P, 2017, AM J PHYSIOL-HEART C, V312, pH1, DOI 10.1152/ajpheart.00581.2016; Totoson P, 2018, VASC PHARMACOL, V106, P46, DOI 10.1016/j.vph.2018.02.005; Triggle CR, 1999, CLIN EXP PHARMACOL P, V26, P176, DOI 10.1046/j.1440-1681.1999.03007.x; Wei SM, 2017, CEREB CORTEX, V27, P2175, DOI 10.1093/cercor/bhw072; Wei SM, 2012, J NEUROSCI, V32, P7074, DOI 10.1523/JNEUROSCI.5375-11.2012	40	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106930	10.1016/j.vph.2021.106930		NOV 2021	7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34728386				2022-04-29	WOS:000756079500020
J	Zvintzou, E; Karampela, DS; Vakka, A; Xepapadaki, E; Karavia, EA; Hatziri, A; Giannopoulou, PC; Kypreos, KE				Zvintzou, Evangelia; Karampela, Dimitra Sotiria; Vakka, Aggeliki; Xepapadaki, Eva; Karavia, Eleni A.; Hatziri, Aikaterini; Giannopoulou, Panagiota C.; Kypreos, Kyriakos E.			High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?	VASCULAR PHARMACOLOGY			English	Review						Atherosclerosis; Coronary heart disease; High density lipoprotein; Structure; Function	APOLIPOPROTEIN-A-I; REVERSE CHOLESTEROL TRANSPORT; LOW HDL-CHOLESTEROL; ELEVATED OXIDATIVE STRESS; HIGH-RISK; CARDIOVASCULAR-DISEASE; ARTERY-DISEASE; HEALTHY-VOLUNTEERS; LDL CHOLESTEROL; SERUM	Epidemiological studies during the last five years suggest that a relation between high density lipoprotein cholesterol (HDL-C) levels and the risk for cardiovascular disease (CVD) does exist but follows rather a "U-shaped" curve with an optimal range of HDL-C concentration between 40 and 70 mg/dl for men and 50-70 mg/dl for women. Moreover, as research in the field of lipoproteins progresses it becomes increasingly apparent that HDL particles possess different attributes and depending on their structural and functional characteristics, they may be "antiatherogenic" or "proatherogenic". In light of this information, it is highly doubtful that the choice of experimental drugs and the design of respective clinical trials that put the HDL-C raising hypothesis at test, were the most suitable. Here, we compile the existing literature on HDL, providing a critical up-to-date view that focuses on key data from the biochemistry, epidemiology and pharmacology of HDL, including data from clinical trials. We also discuss the most up-to-date information on the contribution of HDL structure and function to the prevention of atherosclerosis. We conclude by summarizing important differences between mouse models and humans, that may explain why pharmacological successes in mice turn out to be failures in humans.	[Zvintzou, Evangelia; Karampela, Dimitra Sotiria; Vakka, Aggeliki; Xepapadaki, Eva; Karavia, Eleni A.; Hatziri, Aikaterini; Giannopoulou, Panagiota C.; Kypreos, Kyriakos E.] Univ Patras, Sch Med, Dept Pharmacol, Rio Achaias 26500, Greece; [Kypreos, Kyriakos E.] European Univ Cyprus, Sch Sci, Dept Life Sci, Nicosia, Cyprus		Kypreos, KE (通讯作者)，Univ Patras, Sch Med, Dept Med, Pharmacol Lab, Panepistimioupolis, Rion 26500, Greece.	kkypreos@med.upatras.gr			European Union (European Social Fund-ESF) through the Operational Programme <<Human Resources Development, Education and Lifelong Learning >> [MIS-5033021]	This research is co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme << Human Resources Development, Education and Lifelong Learning >> in the context of the project "Reinforcement of Postdoctoral Researchers 2nd Cycle" (MIS-5033021), implemented by the State Scholarships Foundation (...).	Argraves KM, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-70; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Barbaras R, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00220; BARR DP, 1951, AM J MED, V11, P480, DOI 10.1016/0002-9343(51)90183-0; Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056/NEJMoa064278; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; Bhatt DL, 2019, J AM COLL CARDIOL, V73, P2791, DOI 10.1016/j.jacc.2019.02.032; Boden WE, 2011, NEW ENGL J MED, V365, P2255, DOI 10.1056/NEJMoa1107579; Bowe B, 2016, CLIN J AM SOC NEPHRO, V11, P1784, DOI 10.2215/CJN.00730116; Caslake MJ, 2003, CURR OPIN LIPIDOL, V14, P347, DOI 10.1097/00041433-200308000-00002; Catapano AL, 2014, CARDIOVASC RES, V103, P372, DOI 10.1093/cvr/cvu150; D'Souza W, 2010, CIRC RES, V107, P217, DOI 10.1161/CIRCRESAHA.110.216507; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; de Beer MC, 2001, J LIPID RES, V42, P309; Despres JP, 2000, ATHEROSCLEROSIS, V153, P263, DOI 10.1016/S0021-9150(00)00603-1; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Diditchenko S, 2013, ARTERIOSCL THROM VAS, V33, P2202, DOI 10.1161/ATVBAHA.113.301981; Dunbar RL, 2017, CTS-CLIN TRANSL SCI, V10, P455, DOI 10.1111/cts.12487; Ertek S, 2018, CURR VASC PHARMACOL, V16, P490, DOI 10.2174/1570161115666171116164612; Filou S, 2016, BIOCHEMISTRY-US, V55, P3752, DOI 10.1021/acs.biochem.6b00389; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; Gibson CM, 2016, CIRCULATION, V134, P1918, DOI 10.1161/CIRCULATIONAHA.116.025687; GOFMAN JW, 1954, PHYSIOL REV, V34, P589, DOI 10.1152/physrev.1954.34.3.589; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON DJ, 1986, CIRCULATION, V74, P1217, DOI 10.1161/01.CIR.74.6.1217; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Haase CL, 2012, J CLIN ENDOCR METAB, V97, pE248, DOI 10.1210/jc.2011-1846; Hansel B, 2004, J CLIN ENDOCR METAB, V89, P4963, DOI 10.1210/jc.2004-0305; Hewing B, 2014, ARTERIOSCL THROM VAS, V34, P779, DOI 10.1161/ATVBAHA.113.303044; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444; Huang JS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030739; Huang Y, 2013, J CLIN INVEST, V123, P3815, DOI 10.1172/JCI67478; Jahangiri A, 2010, CURR OPIN ENDOCRINOL, V17, P156, DOI 10.1097/MED.0b013e328337278b; Janmey PA, 2006, TRENDS CELL BIOL, V16, P538, DOI 10.1016/j.tcb.2006.08.009; JENKINS PJ, 1978, BMJ-BRIT MED J, V2, P388, DOI 10.1136/bmj.2.6134.388; Jeppesen J, 1997, ARTERIOSCL THROM VAS, V17, P1114, DOI 10.1161/01.ATV.17.6.1114; Kallend DG, 2016, EUR HEART J-CARD PHA, V2, P23, DOI 10.1093/ehjcvp/pvv041; Karavia EA, 2014, EXPERT REV CARDIOVAS, V12, P521, DOI 10.1586/14779072.2014.896741; Karjalainen MK, 2020, ATHEROSCLEROSIS, V299, P56, DOI 10.1016/j.atherosclerosis.2020.02.002; Kavo AE, 2012, ATHEROSCLEROSIS, V220, P257, DOI 10.1016/j.atherosclerosis.2011.10.017; Kempen HJ, 2016, ARTERIOSCL THROM VAS, V36, P736, DOI 10.1161/ATVBAHA.115.307052; Kempen HJ, 2014, J LIPIDS, V2014, DOI 10.1155/2014/923903; Kempen HJ, 2013, J LIPID RES, V54, P2341, DOI 10.1194/jlr.M033779; Ko DT, 2016, J AM COLL CARDIOL, V68, P2073, DOI 10.1016/j.jacc.2016.08.038; Kontush A, 2005, ATHEROSCLEROSIS, V182, P277, DOI 10.1016/j.atherosclerosis.2005.03.001; Kontush A, 2007, ARTERIOSCL THROM VAS, V27, P1843, DOI 10.1161/ATVBAHA.107.145672; Kontush A, 2015, HANDB EXP PHARMACOL, V224, P3, DOI 10.1007/978-3-319-09665-0_1; Kontush A, 2013, J LIPID RES, V54, P2950, DOI 10.1194/jlr.R036095; Kontush A, 2010, CURR OPIN LIPIDOL, V21, P312, DOI 10.1097/MOL.0b013e32833bcdc1; Kypreos KE, 2019, ANGIOLOGY, V70, P197, DOI 10.1177/0003319718779533; Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955; Lincoff AM, 2017, NEW ENGL J MED, V376, P1933, DOI 10.1056/NEJMoa1609581; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Madsen CM, 2017, EUR HEART J, V38, P2478, DOI 10.1093/eurheartj/ehx163; MARCEL YL, 1984, EUR J BIOCHEM, V143, P467, DOI 10.1111/j.1432-1033.1984.tb08394.x; Maulucci G, 2016, FREE RADICAL RES, V50, pS40, DOI 10.1080/10715762.2016.1231403; MILLER GJ, 1975, LANCET, V1, P16; MILLER M, 1992, CIRCULATION, V86, P1165, DOI 10.1161/01.CIR.86.4.1165; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; Moerland M, 2007, J LIPID RES, V48, P2622, DOI 10.1194/jlr.M700020-JLR200; Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87; Nicholls SJ, 2018, JAMA CARDIOL, V3, P806, DOI 10.1001/jamacardio.2018.2112; Nicholls SJ, 2018, JAMA CARDIOL, V3, P815, DOI 10.1001/jamacardio.2018.2121; Nicholls SJ, 2011, EXPERT OPIN BIOL TH, V11, P387, DOI 10.1517/14712598.2011.557061; Nicholls SJ, 2009, J LIPID RES, V50, pS346, DOI 10.1194/jlr.R800086-JLR200; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Ohashi R, 2005, QJM-INT J MED, V98, P845, DOI 10.1093/qjmed/hci136; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; Peterson BE, 2021, CIRCULATION, V143, P33, DOI 10.1161/CIRCULATIONAHA.120.050276; Pradhan AD, 2018, AM HEART J, V206, P80, DOI 10.1016/j.ahj.2018.09.011; Prufer N, 2015, BIOL CHEM, V396, P573, DOI 10.1515/hsz-2014-0192; Reina SA, 2015, ATHEROSCLEROSIS, V243, P314, DOI 10.1016/j.atherosclerosis.2015.09.031; Richart AL, 2020, CIRC RES, V127, P1422, DOI 10.1161/CIRCRESAHA.120.316848; Rosenblat M, 2006, ATHEROSCLEROSIS, V187, P74, DOI 10.1016/j.athersclerosis.2005.08.026; Rousset X, 2009, CURR OPIN ENDOCRINOL, V16, P163, DOI 10.1097/MED.0b013e328329233b; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Sato Koichi, 2010, World J Biol Chem, V1, P327, DOI 10.4331/wjbc.v1.i11.327; Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797; Shao BH, 2006, CURR OPIN CARDIOL, V21, P322, DOI 10.1097/01.hco.0000231402.87232.aa; Shaw JA, 2008, CIRC RES, V103, P1084, DOI 10.1161/CIRCRESAHA.108.182063; Simes RJ, 2002, CIRCULATION, V105, P1162, DOI 10.1161/hc1002.105136; Sutter I, 2016, ATHEROSCLEROSIS, V246, P130, DOI 10.1016/j.atherosclerosis.2016.01.003; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; Tardif JC, 2007, JAMA-J AM MED ASSOC, V297, P1675, DOI 10.1001/jama.297.15.jpc70004; Tardy C, 2014, ATHEROSCLEROSIS, V232, P110, DOI 10.1016/j.atherosclerosis.2013.10.018; Tsompanidi EM, 2010, ATHEROSCLEROSIS, V208, P3, DOI 10.1016/j.atherosclerosis.2009.05.034; Tsun JGS, 2013, ATHEROSCLEROSIS, V231, P405, DOI 10.1016/j.atherosclerosis.2013.10.008; Undurti A, 2009, J BIOL CHEM, V284, P30825, DOI 10.1074/jbc.M109.047605; Van Lenten BJ, 2008, J LIPID RES, V49, P2302, DOI 10.1194/jlr.M800075-JLR200; Van Lenten BJ, 2007, J LIPID RES, V48, P2344, DOI 10.1194/jlr.M700138-JLR200; Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2; Westerterp M, 2006, ARTERIOSCL THROM VAS, V26, P2552, DOI 10.1161/01.ATV.0000243925.65265.3c; Wiktorowska-Owczarek A, 2015, ADV CLIN EXP MED, V24, P931, DOI 10.17219/acem/31243; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; Xepapadaki E, 2019, BBA-MOL BASIS DIS, V1865, P1351, DOI 10.1016/j.bbadis.2019.02.003; Zeman M, 2015, MED SCI MONITOR, V21, P2156, DOI 10.12659/MSM.893619; Zerrad-Saadi A, 2009, ARTERIOSCL THROM VAS, V29, P2169, DOI 10.1161/ATVBAHA.109.194555; Zewinger S, 2015, EUR HEART J, V36, P3007, DOI 10.1093/eurheartj/ehv352; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v; Zvintzou E, 2020, J BIOMED RES, V34, P14, DOI 10.7555/JBR.33.20190048; Zvintzou E, 2017, J LIPID RES, V58, P1869, DOI 10.1194/jlr.M077925	106	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106928	10.1016/j.vph.2021.106928		NOV 2021	8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34695591				2022-04-29	WOS:000756079500019
J	Cimmino, G; Conte, S; Morello, A; Pellegrino, G; Marra, L; Cali, G; Golino, P; Cirillo, P				Cimmino, Giovanni; Conte, Stefano; Morello, Andrea; Pellegrino, Grazia; Marra, Laura; Cali, Gaetano; Golino, Paolo; Cirillo, Plinio			Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells	VASCULAR PHARMACOLOGY			English	Article						Colchicine; Thrombosis; Tissue factor	TISSUE FACTOR EXPRESSION; ACUTE CORONARY SYNDROMES; ADHESION MOLECULES; UP-REGULATION; OXIDIZED-LDL; FACTOR GENE; OX-LDL; LOX-1; RECEPTOR; ATHEROSCLEROSIS	Background: Tissue Factor (TF) plays a pivotal role in coronary thrombosis. Oxidized low-density lipoproteins (oxLDL) are crucial in development of atherosclerosclerosis. Moreover, oxLDL are known to induce TF expression on several cell types including endothelial cells. The lectin-type oxidized LDL receptor 1 (LOX-1) represent the oxLDL receptor. Colchicine is an anti-mitotic drug recently proven to have beneficial effects in cardiovascular disease via unknown mechanisms. Thus, we aim at investigating colchicine effects on TF expression in oxLDL stimulated human vascular endothelial cells (HUVEC). Some molecular mechanism(s) potentially involved were investigated. Methods: HUVEC were pre-incubated with colchicine 10 mu M for 1 h and then stimulated with oxLDL (50 mu g/mL). TF gene (RT-PCR), protein (western blot), surface expression (FACS) and procoagulant activity (FXa generation assay) were measured. TF translocation to cell surface was investigated by immunofluorescence. NF-kappa B/I kappa B axis was examined by western blot analysis and translocation assay. Finally, LOX-1 expression was also investigated. Results: Colchicine significantly reduced TF gene and protein expression as well as its procoagulant activity in oxLDL-treated HUVEC. These effects seem to be related mainly to action of colchicine on microtubules that, in turn, modulate TF trafficking in the cytoplasm, NF-kappa B/I kappa B pathway and LOX-1 expression. Conclusions: Data of the present study, although in vitro, indicate that one of the hypothetical mechanisms by which colchicine exert protective cardiovascular effects might be its ability to inhibit the pro-thrombotic activity of oxLDL.	[Cimmino, Giovanni; Golino, Paolo] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Sect Cardiol, Naples, Italy; [Conte, Stefano; Morello, Andrea; Pellegrino, Grazia; Cirillo, Plinio] Univ Naples Federico II, Dept Adv Biomed Sci, Div Cardiol, Via Sergio Pansini 5, I-80131 Naples, Italy; [Morello, Andrea] Azienda Sanit Reg Molise, UOC Lab Anal, PO Antonio Cardarelli, Campobasso, Italy; [Marra, Laura] Fdn G Pascale, Ist Nazl Tumori IRCCS, SC Cell Biol & Biotherapy, Naples, Italy; [Cali, Gaetano] CNR, Endocrinol & Expt Oncol Inst, Naples, Italy		Cirillo, P (通讯作者)，Univ Naples Federico II, Dept Adv Biomed Sci, Div Cardiol, Via Sergio Pansini 5, I-80131 Naples, Italy.	pcirillo@unina.it		MARRA, LAURA/0000-0003-3051-5366	University of Campania "Luigi Vanvitelli"; Ordine Italiano dei Biologi	This work was partially founded by University of Campania "Luigi Vanvitelli", grant MultiOMICS approach to ACS - V:ALERE Program 2019. SC is supported by a frant from Ordine Italiano dei Biologi.	Adler Y, 2015, REV ESP CARDIOL, V68, P1126, DOI 10.1016/j.rec.2015.10.008; Aggarwal Bharat B., 2004, Indian Journal of Experimental Biology, V42, P341; Badimon JJ, 2009, CEREBROVASC DIS, V27, P38, DOI 10.1159/000200440; Balzan S, 2018, LIFE SCI, V198, P79, DOI 10.1016/j.lfs.2018.02.024; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Bode M, 2014, VASC PHARMACOL, V62, P57, DOI 10.1016/j.vph.2014.05.005; Chaldakov GN, 2018, CELL BIOL INT, V42, P1079, DOI 10.1002/cbin.10988; Chen K, 2017, AM J CARDIOVASC DRUG, V17, P347, DOI 10.1007/s40256-017-0226-3; Cimmino G, 2020, CARDIOVASC RES, V116, P1125, DOI 10.1093/cvr/cvz230; Cimmino G, 2018, CARDIOVASC DIAGN THE, V8, P581, DOI 10.21037/cdt.2018.10.14; Cimmino G, 2018, VASC PHARMACOL, V111, P62, DOI 10.1016/j.vph.2018.09.004; Cimmino G, 2017, CURR CARDIOL REV, V13, P110, DOI 10.2174/1573403X12666161014093812; Cimmino G, 2013, INT J CARDIOL, V168, P981, DOI 10.1016/j.ijcard.2012.10.040; Cimmino G, 2011, INTERN EMERG MED, V6, P29, DOI 10.1007/s11739-010-0423-4; Cimmino G, 2009, J CELL MOL MED, V13, P3226, DOI 10.1111/j.1582-4934.2008.00614.x; Cirillo P, 2005, CARDIOVASC RES, V68, P47, DOI 10.1016/j.cardiores.2005.05.010; Cirillo P, 2020, J THROMB THROMBOLYS, V50, P468, DOI 10.1007/s11239-020-02121-8; Cirillo P, 2017, BIOCHEM PHARMACOL, V128, P26, DOI 10.1016/j.bcp.2016.12.016; Cirillo P, 2015, THROMB HAEMOSTASIS, V113, P363, DOI 10.1160/TH14-05-0451; Crea F, 2017, CIRCULATION, V136, P1155, DOI 10.1161/CIRCULATIONAHA.117.029870; De Palma R, 2016, INT J CARDIOL, V218, P188, DOI 10.1016/j.ijcard.2016.04.177; de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87; Di Pietro N, 2016, VASC PHARMACOL, V84, P1, DOI 10.1016/j.vph.2016.05.013; Ford TJ, 2018, HEART, V104, P284, DOI 10.1136/heartjnl-2017-311446; Galkina E, 2007, ARTERIOSCL THROM VAS, V27, P2292, DOI 10.1161/ATVBAHA.107.149179; Hermonat PL, 2011, CARDIOVASC DRUG THER, V25, P393, DOI 10.1007/s10557-011-6322-8; Holzer G, 2007, THROMB RES, V120, P71, DOI 10.1016/j.thromres.2006.07.007; Insull W, 2009, AM J MED, V122, pS3, DOI 10.1016/j.amjmed.2008.10.013; Jackman RW, 2009, EXP CELL RES, V315, P3242, DOI 10.1016/j.yexcr.2009.08.020; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; Kesselheim AS, 2010, NEW ENGL J MED, V362, P2045, DOI 10.1056/NEJMp1003126; Kottoor SJ, 2018, J CARDIOVASC PHARM T, V23, P483, DOI 10.1177/1074248418778548; Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013; Li DY, 2000, ARTERIOSCL THROM VAS, V20, P1116, DOI 10.1161/01.ATV.20.4.1116; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; Mandal SK, 2007, BLOOD, V110, P161, DOI 10.1182/blood-2006-10-050476; Martinez GJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002128; Mehta JL, 2004, CARDIOVASC RES, V64, P243, DOI 10.1016/j.cardiores.2004.07.002; Mehta JL, 2006, CARDIOVASC RES, V69, P36, DOI 10.1016/j.cardiores.2005.09.006; Mehta JL, 1998, BIOCHEM BIOPH RES CO, V248, P511, DOI 10.1006/bbrc.1998.9004; Morawietz H, 2007, CIRC RES, V100, P1534, DOI 10.1161/CIRCRESAHA.107.101105; Nidorf SM, 2013, J AM COLL CARDIOL, V61, P404, DOI 10.1016/j.jacc.2012.10.027; Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365; Pirillo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/152786; Price DT, 1999, AM J MED, V107, P85, DOI 10.1016/S0002-9343(99)00153-9; Simionescu M, 2007, ARTERIOSCL THROM VAS, V27, P266, DOI 10.1161/01.ATV.0000253884.13901.e4; Slobodnick A, 2015, AM J MED, V128, P461, DOI 10.1016/j.amjmed.2014.12.010; Stack J, 2015, AM J THER, V22, pe151, DOI 10.1097/01.mjt.0000433937.07244.e1; Stojkovic S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25171; Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003	51	4	4	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106822	10.1016/j.vph.2020.106822		MAR 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QX2EV	33232770				2022-04-29	WOS:000629161700001
J	Savira, F; Kompa, AR; Kelly, DJ; Magaye, R; Xiong, X; Huang, L; Liew, D; Reid, C; Kaye, D; Scullino, CV; Pitson, SM; Flynn, BL; Wang, BH				Savira, Feby; Kompa, Andrew R.; Kelly, Darren J.; Magaye, Ruth; Xiong, Xin; Huang, Li; Liew, Danny; Reid, Christopher; Kaye, David; Scullino, Carmen V.; Pitson, Stuart M.; Flynn, Bernard L.; Wang, Bing H.			The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate	VASCULAR PHARMACOLOGY			English	Article						Dihydroceramide desaturase 1; Endothelium; Vasorelaxation; Wound healing; Indoxyl sulfate	TO-MESENCHYMAL TRANSITION; UREMIC TOXIN; CARDIORENAL SYNDROME; CERAMIDE; PROLIFERATION; DYSFUNCTION; MIGRATION; CELLS; ACCUMULATION; SURVIVAL	Protein-bound uremic toxins (PBUTs) have adverse effects on vascular function, which is imperative in the progression of cardiovascular and renal diseases. The role of sphingolipids in PBUT-mediated vasculo-endothelial pathophysiology is unclear. This study assessed the therapeutic potential of dihydroceramide desaturase 1 (Des1) inhibition, the last enzyme involved in de novo ceramide synthesis, to mitigate the vascular effects of the PBUT indoxyl sulfate (IS). Rat aortic rings were isolated and vascular reactivity was assessed in organ bath experiments followed by immunohistochemical analyses. Furthermore, cultured human aortic endothelial cells were assessed for phenotypic and mechanistic changes. Inhibition of Des1 by a selective inhibitor CIN038 (0.1 to 0.3 mu M) improved IS-induced impairment of vasorelaxation and modulated immunoreactivity of oxidative stress markers. Des1 inhibition also reversed IS-induced reduction in endothelial cell migration (1.0 mu M) by promoting the expression of angiogenic cytokines and reducing inflammatory and oxidative stress markers. These effects were associated with a reduction of TIMP1 and the restoration of Akt phosphorylation. In conclusion, Des1 inhibition improved vascular relaxation and endothelial cell migration impaired by IS overload. Therefore, Des1 may be a suitable intracellular target to mitigate PBUT-induced adverse vascular effects.	[Savira, Feby; Magaye, Ruth; Xiong, Xin; Huang, Li; Wang, Bing H.] Baker Heart & Diabet Res Inst, Biomarker Discovery Lab, Melbourne, Australia; [Savira, Feby; Kompa, Andrew R.; Magaye, Ruth; Xiong, Xin; Huang, Li; Liew, Danny; Reid, Christopher; Wang, Bing H.] Monash Univ, Sch Publ Hlth & Prevent Med, Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Australia; [Kompa, Andrew R.; Kelly, Darren J.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia; [Reid, Christopher] Curtin Univ, Sch Publ Hlth, Perth, Australia; [Scullino, Carmen V.] Baker Heart & Diabet Inst, Heart Failure Res Grp, Melbourne, Australia; [Scullino, Carmen V.; Flynn, Bernard L.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia; [Pitson, Stuart M.] Univ South Australia, Mol Signalling Lab, Ctr Canc Biol, Adelaide, SA, Australia		Wang, BH (通讯作者)，Baker Heart & Diabet Inst, 75 Commercial Rd, Melbourne, Vic 3004, Australia.	bing.wang@baker.edu.au	Savira, Feby/AFU-5538-2022	Kompa, Andrew/0000-0003-1002-2302; Savira, Feby/0000-0002-0383-812X	National Health and Medical Research Grant of Australia [1092642, 1087355]	The work described here was funded by a National Health and Medical Research Grant of Australia (program grant ID #1092642 and project grant ID #1087355).	Adelibieke Y, 2013, CIRC J, V77, P1326, DOI 10.1253/circj.CJ-12-0884; Ahmed MSE, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-244; Ahmed MSE, 2013, KIDNEY BLOOD PRESS R, V37, P158, DOI 10.1159/000350141; Akahane T, 2004, EXP CELL RES, V301, P158, DOI 10.1016/j.yexcr.2004.08.002; Akwii RG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050471; Apostolov EO, 2010, J AM SOC NEPHROL, V21, P1852, DOI 10.1681/ASN.2010040365; Asanuma H, 2019, CARDIOVASC DRUG THER, V33, P277, DOI 10.1007/s10557-019-06875-z; Aurelio L, 2016, J MED CHEM, V59, P965, DOI 10.1021/acs.jmedchem.5b01439; Bharath LP, 2015, DIABETES, V64, P3914, DOI 10.2337/db15-0244; Bischoff J, 2019, CIRC RES, V124, P1163, DOI 10.1161/CIRCRESAHA.119.314813; Carmona A, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00666; Chaurasia B, 2019, SCIENCE, V365, P386, DOI 10.1126/science.aav3722; Cogolludo A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020411; Dou L, 2004, KIDNEY INT, V65, P442, DOI 10.1111/j.1523-1755.2004.00399.x; Flynn B.L, 2015, ARYLAZOLES SPHINGOSI; Fu MH, 2015, AM J PHYSIOL-HEART C, V308, pH11, DOI 10.1152/ajpheart.00503.2014; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326; Hung SC, 2016, KIDNEY INT, V89, P574, DOI 10.1016/j.kint.2015.11.020; Huwiler A, 2004, BBA-MOL CELL BIOL L, V1636, P159, DOI 10.1016/j.bbalip.2003.08.010; Ito S, 2010, J BIOL CHEM, V285, P38869, DOI 10.1074/jbc.M110.166686; Konukoglu D, 2017, ADV EXP MED BIOL, V956, P511, DOI 10.1007/5584_2016_90; Kovacic JC, 2019, J AM COLL CARDIOL, V73, P190, DOI 10.1016/j.jacc.2018.09.089; Lekawanvijit S, 2012, CIRC RES, V111, P1470, DOI 10.1161/CIRCRESAHA.112.278457; Lekawanvijit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041281; Lekawanvijit S, 2010, EUR HEART J, V31, P1771, DOI 10.1093/eurheartj/ehp574; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Liu S, 2013, INT J CARDIOL, V168, P1866, DOI 10.1016/j.ijcard.2012.12.065; London GM, 1997, NEFROLOGIA, V17, P17; Magaye RR, 2019, CELL MOL LIFE SCI, V76, P1107, DOI 10.1007/s00018-018-2984-8; Matsumoto T, 2019, BIOL PHARM BULL, V42, P1236, DOI 10.1248/bpb.b19-00177; NIWA T, 1988, CLIN CHEM, V34, P2264; Niwa T, 2013, BLOOD PURIFICAT, V35, P20, DOI 10.1159/000350843; Oosterhoff LA, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00101; Pateinakis P, 2011, INT J NEPHROL, V2011, DOI 10.4061/2011/938651; Savira F, 2019, TOXICOL LETT, V308, P34, DOI 10.1016/j.toxlet.2019.03.002; Shea Barry S, 2012, Open Rheumatol J, V6, P123, DOI 10.2174/1874312901206010123; Siddique MM, 2013, MOL CELL BIOL, V33, P2353, DOI 10.1128/MCB.00226-13; Sinha SK, 2014, AM J TRANSL RES, V6, P155; Spijkers LJA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021817; Wang ZJ, 2018, ANN TRANSPL, V23, P1, DOI 10.12659/AOT.906700; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yamada Y, 2019, GLYCOCONJUGATE J, V36, P1, DOI 10.1007/s10719-018-9850-7; Yamane T, 2016, FEBS OPEN BIO, V6, P317, DOI 10.1002/2211-5463.12039; Yao JHS, 2006, BIOCHEM BIOPH RES CO, V342, P1396, DOI 10.1016/j.bbrc.2006.02.100; Zhang QJ, 2012, DIABETES, V61, P1848, DOI 10.2337/db11-1399; Zhao WQ, 1998, J CELL SCI, V111, P1147	47	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106923	10.1016/j.vph.2021.106923		NOV 2021	9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34600152				2022-04-29	WOS:000756079500014
J	Bertoletti, L; Bikdeli, B; Zuily, S; Blondon, M; Mismetti, P				Bertoletti, Laurent; Bikdeli, Behnood; Zuily, Stephane; Blondon, Marc; Mismetti, Patrick			Thromboprophylaxis strategies to improve the prognosis of COVID-19	VASCULAR PHARMACOLOGY			English	Article						COVID-19; Anticoagulant; Thromboprophylaxis; Coagulation; Pulmonary embolism; Deep venous thrombosis	CRITICALLY-ILL PATIENTS; VENOUS THROMBOEMBOLISM; PROPHYLACTIC ANTICOAGULATION; HOSPITALIZATION; COMPLICATIONS; COAGULOPATHY; METAANALYSIS; HEPARIN	The outbreak of 2019 novel coronavirus disease (Covid-19) has deeply challenged the world population, but also our medical knowledge. Special attention has been paid early to an activation of coagulation, then to an elevated rate of venous thromboembolism (VTE) in patients hospitalized with severe COVID-19. These data suggested that anticoagulant drugs should be evaluated in the treatment of patients with COVID-19. The publication of unexpected high rates of VTE in patients hospitalized with COVID-19, despite receiving thromboprophylaxis, open the way to dedicated trials, evaluating modified regimens of thromboprophylaxis. Moreover, the further improvement in our comprehension of the disease, particularly the pulmonary endothelial dysfunction increased the hope that anticoagulant drugs may also protect patients from pulmonary thrombosis. In this comprehensive review, we cover the different situations where thromboprophylaxis standard may be modified (medically-ill inpatients, ICU inpatients, outpatients), and describe some of the current randomized controls trials evaluating new regimens of thromboprophylaxis in patients with COVID-19, including the preliminary available results. We also discuss the potential of anticoagulant drugs to target the thromboinflammation described in patients with severe COVID-19.	[Bertoletti, Laurent; Mismetti, Patrick] CHU St Etienne, Serv Med Vasc & Therapeut, F-42055 St Etienne, France; [Bertoletti, Laurent; Mismetti, Patrick] Univ Jean Monnet, Equipe Dysfonct Vasc & Hernostase, INSERM, UMR1059, F-42055 St Etienne, France; [Bertoletti, Laurent; Mismetti, Patrick] CHU St Etienne, INSERM, CIC 1408, F-42055 St Etienne, France; [Bertoletti, Laurent; Mismetti, Patrick] F CRIN INNOVTE Network, St Etienne, France; [Bikdeli, Behnood] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA; [Bikdeli, Behnood] Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Bikdeli, Behnood] Cardiovasc Res Fdn, New York, NY USA; [Zuily, Stephane] Univ Lorraine, INSERM, UMR S 1116, DCAC, Nancy, France; [Zuily, Stephane] CHRU Nancy, Vasc Med Div, Nancy Acad Hosp, F-54000 Nancy, France; [Blondon, Marc] Geneva Univ Hosp, Geneva, Switzerland; [Blondon, Marc] Fac Med, Geneva, Switzerland		Bertoletti, L (通讯作者)，CHU St Etienne, Serv Med Vasc & Therapeut, F-42055 St Etienne, France.	laurent.bertoletti@gmail.com					Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Allingstrup M, 2016, INTENS CARE MED, V42, P505, DOI 10.1007/s00134-016-4225-7; ATTACC, 2021, ACTIV 4A REMAP CAP M; Barco S, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04678-4; Benzakoun J, 2020, EUR J HEART FAIL, V22, P1046, DOI 10.1002/ejhf.1916; Lemos ACB, 2020, THROMB RES, V196, P359, DOI 10.1016/j.thromres.2020.09.026; Bertoletti L, 2020, RESPIR MED RES-FRANC, V78, DOI 10.1016/j.resmer.2020.100759; Bertoletti L, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.03092-2020; Bikdeli B, 2022, THROMB HAEMOSTASIS, V122, P131, DOI 10.1055/a-1485-2372; Bikdeli B, 2020, THROMB RES, V196, P638, DOI 10.1016/j.thromres.2020.09.033; Bikdeli B, 2020, THROMB RES, V196, P382, DOI 10.1016/j.thromres.2020.09.027; Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Birocchi S, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13433; Bochenek ML, 2017, THROMB HAEMOSTASIS, V117, P769, DOI 10.1160/TH16-10-0790; Bonnefoy PB, 2019, THROMB RES, V184, P67, DOI 10.1016/j.thromres.2019.09.038; Buijsers B, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102969; Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830; Cuker A, 2021, BLOOD ADV, V5, P872, DOI 10.1182/bloodadvances.2020003763; Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254; Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844; Doyle AJ, 2020, THROMB RES, V196, P454, DOI 10.1016/j.thromres.2020.10.007; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Evans PC, 2020, CARDIOVASC RES, V116, P2177, DOI 10.1093/cvr/cvaa230; Fernandez-Capitan C, 2021, SEMIN THROMB HEMOST, V47, P351, DOI 10.1055/s-0040-1718402; Flahault A, 2020, LANCET, V395, P1037, DOI 10.1016/S0140-6736(20)30491-8; Gerotziafas GT, 2020, THROMB HAEMOSTASIS, V120, P1597, DOI 10.1055/s-0040-1715798; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W.J., 2020, NEW ENGL J MED, V382, P1708, DOI [10.21037/apm-20-887, DOI 10.1056/NEJMOA2002032, 10.1056/NEJMoa2002032]; Hill JB, 2020, BLOOD ADV, V4, P5373, DOI 10.1182/bloodadvances.2020003083; Hofstra JJ, 2010, J AEROSOL MED PULM D, V23, P105, DOI 10.1089/jamp.2009.0779; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Ionescu F, 2021, EUR J HAEMATOL, V106, P165, DOI 10.1111/ejh.13533; Jimenez D, 2021, CHEST, V159, P1182, DOI 10.1016/j.chest.2020.11.005; Jin YF, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00454-7; Karolyi M, 2021, EUR J CLIN MICROBIOL, V40, P633, DOI 10.1007/s10096-020-04044-x; Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013; Lang IM, 2013, EUR RESPIR J, V41, P462, DOI 10.1183/09031936.00049312; Laporte S, 2011, J THROMB HAEMOST, V9, P464, DOI 10.1111/j.1538-7836.2011.04182.x; Levi M, 2020, RES PRACT THROMB HAE, V4, P744, DOI 10.1002/rth2.12400; Libby P, 2020, EUR HEART J, V41, P3038, DOI 10.1093/eurheartj/ehaa623; Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869; Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024; Maley JH, 2020, RES PRACT THROMB HAE, V4, P674, DOI 10.1002/rth2.12398; Martinelli I, 2021, INTERN EMERG MED, V16, P1223, DOI 10.1007/s11739-020-02585-9; McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1; [梅恒 Mei Heng], 2020, [中华血液学杂志, Chinese Journal of Hematology], V41, P185; Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020; Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559; Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850; Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001; Patell R, 2020, BLOOD, V136, DOI 10.1182/blood-2020-143185; Piazza G, 2020, J AM COLL CARDIOL, V76, P2060, DOI 10.1016/j.jacc.2020.08.070; Pierre F, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20301; Porfidia A, 2020, THROMB RES, V196, P67, DOI 10.1016/j.thromres.2020.08.020; Poulakou G, 2021, IN VIVO, V35, P653, DOI 10.21873/invivo.12305; Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854; Rashidi F, 2021, THROMB RES, V198, P135, DOI 10.1016/j.thromres.2020.12.001; Roberts LN, 2020, BLOOD, V136, P1347, DOI 10.1182/blood.2020008086; Rokkam Venkata Ram Pradeep, 2020, Obes Med, V19, P100284, DOI 10.1016/j.obmed.2020.100284; Roncon L, 2020, EUR J INTERN MED, V82, P29, DOI 10.1016/j.ejim.2020.09.006; Roubinian NH, 2021, JAMA INTERN MED, V181, P997, DOI 10.1001/jamainternmed.2021.0488; Ruggeri, 2020, CRIT CARE RESUSC, P2; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Santoliquido A, 2020, J THROMB HAEMOST, V18, P2358, DOI 10.1111/jth.14992; Shi C, 2021, CARBOHYD POLYM, V254, DOI 10.1016/j.carbpol.2020.117232; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Spyropoulos AC, 2018, NEW ENGL J MED, V379, P1118, DOI 10.1056/NEJMoa1805090; Talasaz AH, 2021, J AM COLL CARDIOL, V77, P1903, DOI 10.1016/j.jacc.2021.02.035; Tan BK, 2021, THORAX, V76, P970, DOI 10.1136/thoraxjnl-2020-215383; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Thachil J, 2020, J THROMB HAEMOST, V18, P1795, DOI 10.1111/jth.14841; Tritschler T, 2020, J THROMB HAEMOST, V18, P2958, DOI 10.1111/jth.15094; Trunfio M, 2020, THROMB RES, V196, P432, DOI 10.1016/j.thromres.2020.09.039; Tuinman PR, 2012, CRIT CARE, V16, DOI 10.1186/cc11325; Vechi HT, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062063, 10.1590/s1678-9946202062063]; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wynants M, 2012, EUR RESPIR J, V40, P886, DOI 10.1183/09031936.00197511; Yin SY, 2021, J THROMB THROMBOLYS, V51, P1107, DOI 10.1007/s11239-020-02105-8; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	80	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106883	10.1016/j.vph.2021.106883		JUL 2021	6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34091065	Bronze, Green Published			2022-04-29	WOS:000674133600006
J	Madonna, R; Fabiani, S; Morganti, R; Forniti, A; Mazzola, M; Menichetti, F; De Caterina, R				Madonna, Rosalinda; Fabiani, Silvia; Morganti, Riccardo; Forniti, Arianna; Mazzola, Matteo; Menichetti, Francesco; De Caterina, Raffaele			Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status	VASCULAR PHARMACOLOGY			English	Article						Human immunodeficiency virus; Acquired immunodeficiency syndrome; Exercise-induced pulmonary hypertension; Stress echocardiography	HUMAN-IMMUNODEFICIENCY-VIRUS; ARTERIAL-HYPERTENSION; ECHOCARDIOGRAPHIC-ASSESSMENT; STRESS ECHOCARDIOGRAPHY; ANTIRETROVIRAL THERAPY; EUROPEAN ASSOCIATION; PROGNOSTIC-FACTORS; REGISTERED BRANCH; PREVALENCE; SURVIVAL	Background and aim: Exercise-induced pulmonary hypertension (Ex-PH) may represent the earliest sign of pulmonary arterial hypertension (PAH) in human immunodeficiency virus (HIV) patients. We investigated its association with clinical and immunological status, virologic control, and response to antiviral therapy. Methods: In 32 consecutive HIV patients with either low (n = 29) or intermediate probability (n = 3) of PH at rest, we evaluated the association of isolated ExPH with: time to HIV diagnosis; CD4+ T-cell count; clinical progression to acquired immunodeficiency syndrome (AIDS); development of resistance to antiretroviral therapy (ART); HIV RNA levels; time to beginning of ART; current use of protease inhibitors; combination of ART with boosters (ritonavir or cobicistat); immuno-virologic response to ART; and ART discontinuation. Isolated ExPH at stress echocardiography (ESE) was defined as absence of PH at rest and systolic pulmonary arterial pressure (sPAP) >45 mmHg or a >20 mmHg increase during low-intensity exercise cardiac output (<10 L/min). Results: In our cohort, 22% (n = 7) of the enrolled population developed ExPH which was inversely related to CD4+ T-cell count (p = 0.047), time to HIV diagnosis (p = 0.014) and time to onset of ART (p = 0.041). Patients with ExPH had a worse functional class than patients without ExPH (p < 0.001). ExPH and AIDS showed a trend (p = 0.093) to a direct relationship. AIDS patients had a higher pulmonary vascular resistance compared to patients without ExPH (p = 0.020) at rest echocardiography. Conclusions: The presence of isolated ExPH associates with a worse clinical status and poor immunological control in HIV patients. Assessment of ExPH by ESE may help identify subgroups of HIV patients with a propensity to develop subclinical impairment of pulmonary circulation following poor control of HIV infection.	[Madonna, Rosalinda; Mazzola, Matteo; De Caterina, Raffaele] Univ Pisa, Azienda Osped Univ Pisana, Dept Pathol, Cardiol Div, Pisa, Italy; [Fabiani, Silvia; Forniti, Arianna; Menichetti, Francesco] Univ Pisa, Azienda Osped Univ Pisana, Dept Clin & Expt Med, Infect Dis Unit, Pisa, Italy; [Morganti, Riccardo] Univ Pisa, Inst Epidemiol, Pisa, Italy		De Caterina, R (通讯作者)，Univ Pisa, Azienda Osped Univ Pisana, Dept Pathol, Cardiol Div, Pisa, Italy.	raffaele.decaterina@unipi.it		Fabiani, Silvia/0000-0002-9158-5491; Madonna, Rosalinda/0000-0001-6455-2777			Alkotob ML, 2006, CHEST, V130, P176, DOI 10.1378/chest.130.1.176; Almodovar S, 2012, AIDS RES HUM RETROV, V28, P607, DOI [10.1089/aid.2011.0021, 10.1089/AID.2011.0021]; Anthi A, 2007, AM J RESP CRIT CARE, V175, P1272, DOI 10.1164/rccm.200610-1498OC; Argiento P, 2010, EUR RESPIR J, V35, P1273, DOI 10.1183/09031936.00076009; Atkinson C, 2002, CIRCULATION, V105, P1672, DOI 10.1161/01.CIR.0000012754.72951.3D; Badesch DB, 2009, J AM COLL CARDIOL, V54, pS55, DOI 10.1016/j.jacc.2009.04.011; Baumgartner H, 2009, J AM SOC ECHOCARDIOG, V22, P1, DOI 10.1016/j.echo.2008.11.029; Bigna JJR, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0078-3; Bo J, 2006, JAIDS-J ACQ IMM DEF, V42, P391, DOI 10.1097/01.qai.0000228790.40235.0c; Borlaug BA, 2010, CIRC-HEART FAIL, V3, P588, DOI 10.1161/CIRCHEARTFAILURE.109.930701; Cagnina A, 2021, Rev Med Liege, V76, P208; Caldwell RL, 2006, J LEUKOCYTE BIOL, V79, P192, DOI 10.1189/jlb.0405194; Callejas JL, 2007, CHEST, V131, P1267, DOI 10.1378/chest.06-2430; Cool CD, 2003, NEW ENGL J MED, V349, P1113, DOI 10.1056/NEJMoa035115; Degano B, 2010, AIDS, V24, P67, DOI 10.1097/QAD.0b013e328331c65e; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI200112805; Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317; Harter ZJ, 2018, AIDS, V32, P2651, DOI [10.1097/QAD.0000000000002030, 10.1097/qad.0000000000002030]; Hebert Valeria Y, 2004, Cardiovasc Toxicol, V4, P117, DOI 10.1385/CT:4:2:117; HIMELMAN RB, 1989, CIRCULATION, V79, P863, DOI 10.1161/01.CIR.79.4.863; Kanmogne GD, 2005, CURR OPIN PULM MED, V11, P208, DOI 10.1097/01.mcp.0000159833.28271.00; Kim J, 1998, REGUL PEPTIDES, V75-6, P201, DOI 10.1016/S0167-0115(98)00069-X; Madonna R., 2020, J CLIN MED, V9; Madonna R, 2020, VASC PHARMACOL, V125, DOI 10.1016/j.vph.2020.106648; Mehta NJ, 2000, CHEST, V118, P1133, DOI 10.1378/chest.118.4.1133; Mondy KE, 2011, CLIN INFECT DIS, V52, P378, DOI 10.1093/cid/ciq066; Nagel C, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0673-7; Nunes H, 2003, AM J RESP CRIT CARE, V167, P1433, DOI 10.1164/rccm.200204-330OC; Ojima Satoko, 2019, Circ Rep, V1, P610, DOI 10.1253/circrep.CR-19-0087; Parikh RV, 2014, AIDS, V28, P511, DOI 10.1097/QAD.0000000000000124; Pellicelli AM, 1998, ANGIOLOGY, V49, P1005, DOI 10.1177/000331979804901206; Pugliese A, 2000, J INFECTION, V40, P282, DOI 10.1053/jinf.2000.0672; Quezada M, 2012, AIDS, V26, P1387, DOI 10.1097/QAD.0b013e328354f5a1; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Sicari R, 2008, EUR J ECHOCARDIOGR, V9, P415, DOI 10.1093/ejechocard/jen175; Sitbon O, 2008, AM J RESP CRIT CARE, V177, P108, DOI 10.1164/rccm.200704-541OC; Trembath RC, 2001, NEW ENGL J MED, V345, P325, DOI 10.1056/NEJM200108023450503; Zuber JP, 2004, CLIN INFECT DIS, V38, P1178, DOI 10.1086/383037	39	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106888	10.1016/j.vph.2021.106888		JUL 2021	7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34182165				2022-04-29	WOS:000674133600005
J	Zhao, CT; Zong, ZH; Zhu, Q; Wang, YH; Li, XX; Zhang, CH; Ma, CY; Xue, YX				Zhao, Cuiting; Zong, Zhihong; Zhu, Qing; Wang, Yonghuai; Li, Xinxin; Zhang, Chenghong; Ma, Chunyan; Xue, Yixue			The lncRNA MALAT1 participates in regulating coronary slow flow endothelial dysfunction through the miR-181b-5p-MEF2A-ET-1 axis	VASCULAR PHARMACOLOGY			English	Article						Coronary slow flow; Endothelial dysfunction; lncRNA; MALAT1; miR-181b-5p	LONG NONCODING RNA; GENE; INFLAMMATION; ASSOCIATION; EXPRESSION; PROFILES; ARTERIES	Background: Coronary slow flow (CSF) refers to coronary arteries with no obvious stenosis but have slow coronary flow without effective treatment. The main cause of CSF is endothelial dysfunction. The long non-coding RNA (lncRNA) MALAT1 is involved in regulating endothelial dysfunction, but its role in CSF endothelial dysfunction is still unclear. Methods: We included 41 CSF patients and 37 controls in the study, who all underwent coronary angiography, echocardiography, and brachial artery flow-mediated dilatation (FMD) examination. Human umbilical vein endothelial cells (HUVECs) stimulated by oxygen-glucose deprivation were used as CSF-induced HUVECs. Plasma endothelin-1 (ET-1) concentrations were determined by enzyme-linked immunosorbent assay (ELISA). The expression levels of MALAT1, miR-181b-5p, myocyte enhancer factor 2A (MEF2A), and ET-1 were measured by qRT-PCR or western blotting. Cell proliferation was determined by 5-ethynyl-2 '-deoxyuridine (EdU) and Cell Counting Kit-8 (CCK-8) assays. Apoptosis was examined by flow cytometry. The relationship between miR-181b5p and MALAT1 or MEF2A was verified by dual-luciferase reporter assay. MEF2A binding directly to the ET-1 promoter region was verified via chromatin immunoprecipitation (ChIP) assay. Results: MALAT1 and ET-1 were increased, and miR-181b-5p was decreased in the peripheral blood of the CSF patients, and could be used as predictors of CSF. In the CSF-induced HUVECs, MALAT1 was highly expressed, and MALAT1 knockdown improved endothelial function. In contrast, miR-181b-5p was downregulated in the CSFinduced HUVECs, and miR-181b-5p overexpression improved endothelial function. While MEF2A was highly enriched in CSF-induced HUVECs, MEF2A knockdown reduced ET-1 and increased the endothelial function of CSF-induced HUVECs as a transcriptional regulator of ET-1. MALAT1 modulated MEF2A expression positively by sponging miR-181b-5p. Conclusions: Endothelial function is reduced in CSF. MALAT1 participates in regulating CSF endothelial dysfunction through the miR-181b-5p-MEF2A-ET-1 axis, and could provide a new target for CSF treatment.	[Zhao, Cuiting; Zhu, Qing; Wang, Yonghuai; Li, Xinxin; Ma, Chunyan] China Med Univ, Hosp 1, Dept Cardiovasc Ultrasound, 155 Nanjingbei St, Shenyang 110001, Liaoning, Peoples R China; [Zong, Zhihong; Zhang, Chenghong] China Med Univ, Teaching Ctr Basic Med Expt, Shenyang, Peoples R China; [Xue, Yixue] China Med Univ, Sch Life Sci, Dept Neurobiol, Shenyang, Peoples R China; [Xue, Yixue] China Med Univ, Minist Publ Hlth China, Key Lab Cell Biol, Shenyang, Peoples R China; [Xue, Yixue] China Med Univ, Minist Educ China, Key Lab Med Cell Biol, Shenyang, Peoples R China		Ma, CY (通讯作者)，China Med Univ, Hosp 1, Dept Cardiovasc Ultrasound, 155 Nanjingbei St, Shenyang 110001, Liaoning, Peoples R China.	cmu1h_mcy@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871373, 81901766]; Youth Project of Basic Scientific Research for Colleges and Universities in Liaoning Province [LQNK201701]; Natural Science Foundation of Liaoning ProvinceNatural Science Foundation of Liaoning Province [20180530052]	This work was supported by the National Natural Science Foundation of China [Project number 81871373 and 81901766] ; the Youth Project of Basic Scientific Research for Colleges and Universities in Liaoning Province [Project number LQNK201701] , and the Natural Science Foundation of Liaoning Province [Project number 20180530052] .	Bar C, 2016, CIRCULATION, V134, P1484, DOI 10.1161/CIRCULATIONAHA.116.023686; Caglar IM, 2016, ARCH MED SCI, V12, P31, DOI 10.5114/aoms.2015.51412; Chen XY, 2016, ONCOTARGET, V7, P31053, DOI 10.18632/oncotarget.8842; Chen ZY, 2015, CORONARY ARTERY DIS, V26, P114, DOI 10.1097/MCA.0000000000000179; Condorelli G, 2014, J AM COLL CARDIOL, V63, P2177, DOI 10.1016/j.jacc.2014.01.050; Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6; Elhawari S, 2010, ATHEROSCLEROSIS, V209, P152, DOI 10.1016/j.atherosclerosis.2009.09.005; Fragasso G, 2009, INT J CARDIOL, V137, P137, DOI 10.1016/j.ijcard.2008.06.070; Gazi E, 2014, CARDIOVASC J AFR, V25, P9, DOI 10.5830/CVJA-2013-083; Hartmann D, 2011, VASC PHARMACOL, V55, P92, DOI 10.1016/j.vph.2011.07.005; Jae N, 2019, VASC PHARMACOL, V114, P13, DOI 10.1016/j.vph.2018.03.003; Jankowich M, 2020, TRENDS CARDIOVAS MED, V30, P1, DOI 10.1016/j.tcm.2019.01.007; Kazenwadel J, 2010, BLOOD, V116, P2395, DOI 10.1182/blood-2009-12-256297; Kumarswamy R, 2014, CIRC RES, V114, P1569, DOI 10.1161/CIRCRESAHA.114.303915; Lieb W, 2008, CIRCULATION, V117, P185, DOI 10.1161/CIRCULATIONAHA.107.728485; Liu CY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02280-y; Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265; Mitchell C, 2019, J AM SOC ECHOCARDIOG, V32, P1, DOI 10.1016/j.echo.2018.06.004; Niu HM, 2018, EXP THER MED, V15, P904, DOI 10.3892/etm.2017.5484; Novakova V, 2016, VASC PHARMACOL, V76, P1, DOI 10.1016/j.vph.2015.08.005; Saya S, 2008, CLIN CARDIOL, V31, P352, DOI 10.1002/clc.20266; Su Q, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/6345284; Sun P, 2019, EUR REV MED PHARMACO, V23, P3051, DOI 10.26355/eurrev_201904_17587; Sun XH, 2016, CIRC RES, V118, P810, DOI 10.1161/CIRCRESAHA.115.308166; TAMBE AA, 1972, AM HEART J, V84, P66, DOI 10.1016/0002-8703(72)90307-9; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Wang GP, 2018, ARTIF CELL NANOMED B, V46, pS798, DOI 10.1080/21691401.2018.1436065; Wang YH, 2016, ECHOCARDIOGR-J CARD, V33, P871, DOI 10.1111/echo.13197; Wang YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117979; Xiong YJ, 2019, BMC MOL BIOL, V20, DOI 10.1186/s12867-019-0125-z; Yalta K, 2017, INT J CARDIOL, V242, P31, DOI 10.1016/j.ijcard.2017.03.082; Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510; Yao GH, 2015, J AM SOC ECHOCARDIOG, V28, P570, DOI 10.1016/j.echo.2015.01.022; Yue QX, 2018, MOL MED REP, V18, P5742, DOI 10.3892/mmr.2018.9593; Zhang XJ, 2017, RNA BIOL, V14, P1705, DOI 10.1080/15476286.2017.1358347; Zhang Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12449; Zhao HY, 2020, TOXICOL APPL PHARM, V386, DOI 10.1016/j.taap.2019.114827; Zhuo XZ, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116745	38	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JUN	2021	138								106841	10.1016/j.vph.2021.106841		MAY 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	SF6CJ	33545365				2022-04-29	WOS:000652840900008
J	Wagsater, D; Ramilo, AB; Nasstrom, M; Kunath, A; Agic, MB; Mani, K; Wanhainen, A; Petri, MH				Wagsater, Dick; Ramilo, Amanda Balboa; Nasstrom, Mikaela; Kunath, Anne; Agic, Mediha Becirovic; Mani, Kevin; Wanhainen, Anders; Petri, Marcelo Heron			miR-10b promotes aortic aneurysm formation and aortic rupture in angiotensin II-induced ApoE-deficient mice	VASCULAR PHARMACOLOGY			English	Letter						Aorta; Aneurysm; microRNA; miR-10b; Treatment	MICRORNA-B-10; PATHOGENESIS	Abdominal aortic aneurysm (AAA) is associated with increased plasma levels of microRNA (miR)-10b. 5 nmols of miR-10b or miR control was administrated to Apolipoprotein E-deficient mice three days prior implantation of osmotic mini-pumps containing angiotensin II, and for three additional times once a week, which increased expression of miR-10b in plasma. Animals receiving miR-10b had a mortality rate due to aortic rupture of 61% compared to 11% in the miR controls (p < 0.05). Further, miR-10b resulted in an increased aneurysm formation and growth (p < 0.05), which was accompanied by increased elastin degradation, neutrophil and mast cell markers (p < 0.05). In conclusion, miR-10b is functionally affecting aneurysm development and rupture and not only a marker of AAA. More mechanistic studies are required to better understand miR-10b's role in AAA formation.	[Wagsater, Dick; Ramilo, Amanda Balboa; Nasstrom, Mikaela; Kunath, Anne; Agic, Mediha Becirovic; Petri, Marcelo Heron] Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden; [Mani, Kevin; Wanhainen, Anders] Uppsala Univ, Vasc Surg Sect, Dept Surg Sci, Uppsala, Sweden		Petri, MH (通讯作者)，BMC, Husargatan 3, S-75123 Uppsala, Sweden.	marcelomedicina@yahoo.com			Swedish Research CouncilSwedish Research CouncilEuropean Commission [2019-01673]; Swedish Heart and Lung FoundationSwedish Heart-Lung Foundation [2019-0556]; Lions Research Foundation	This work was supported by grants from the Swedish Research Council (2019-01673 DW), the Swedish Heart and Lung Foundation (2019-0556 DW) and the Lions Research Foundation (AK). The funding organizations had no role in the design, management, analysis, interpretation of the data, preparation, review, or approval of the manuscript.	Lin C.C., ONCOL REP, V46; Maegdefessel L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6214; Michel JB, 2011, CARDIOVASC RES, V90, P18, DOI 10.1093/cvr/cvq337; Petri MH, 2018, JACC-BASIC TRANSL SC, V3, P719, DOI 10.1016/j.jacbts.2018.08.005; Shen Y, 2021, J CANCER, V12, P4011, DOI 10.7150/jca.51303; Sun J, 2007, J CLIN INVEST, V117, P3359, DOI 10.1172/JCI31311; Wang DL, 2012, CIRC RES, V111, P967, DOI [10.1161/CIRCRESAHA.112.266502, 10.1161/circresaha.112.266502]; Wang Y, 2012, TRENDS CARDIOVAS MED, V22, P150, DOI 10.1016/j.tcm.2012.07.012; Wanhainen A, 2017, ATHEROSCLEROSIS, V256, P82, DOI 10.1016/j.atherosclerosis.2016.11.007; Yu X, 2015, CURR VASC PHARMACOL, V13, P679, DOI 10.2174/1570161113666150123112751	10	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	DEC	2021	141								106927	10.1016/j.vph.2021.106927		NOV 2021	3	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	ZA3PJ	34715373	Green Published, hybrid			2022-04-29	WOS:000756079500018
J	Hu, FD; Chen, X; Gao, J; Shen, YY; Yang, JH				Hu, Fudong; Chen, Xi; Gao, Juan; Shen, Yangyang; Yang, Jinhua			CircDIP2C ameliorates oxidized low-density lipoprotein-induced cell dysfunction by binding to miR-556-5p to induce TET2 in human umbilical vein endothelial cells	VASCULAR PHARMACOLOGY			English	Article						AS; CircDIP2C; MiR-556-5p; TET2; HUVECs	CIRCULAR RNA; ATHEROSCLEROSIS; INJURY; MICRORNAS; ROLES; DNA	Circular RNAs (circRNAs) are a group of conserved noncoding RNAs. Recent reports reveal that circRNAs play vital parts in cardiovascular system, including atherosclerosis (AS). The present study is designed to reveal the role of circRNA DIP2C-disco interacting protein 2 homolog C (circDIP2C) in oxidized low-density lipoprotein (oxLDL)-triggered damage of human umbilical vein endothelial cells (HUVECs). The expression levels of circDIP2C, microRNA-556-5p (miR-556-5p) and tet methylcytosine dioxygenase 2 (TET2) were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Protein expression was determined by western blot analysis. Cell viability and angiogenesis were demonstrated by cell counting kit-8 and tube formation assays, respectively. The levels of reactive oxygen species (ROS) and malondialdehyde (MDA) were checked by ROS and MDA determination assays. Superoxide dismutase (SOD) and lactate dehydrogenase (LDH) activity assays were performed to detect the activity of SOD and LDH. The binding sites of miR-556-5p in circDIP2C or TET2 were predicted by online databases, and identified by dual-luciferase reporter, RNA immunoprecipitation and RNA pull-down assays. CircDIP2C and TET2 expression were obviously decreased, while miR-556-5p expression was increased in ox-LDL-induced HUVECs in comparison with untreated HUVECs. Ox-LDL treatment inhibited cell viability and angiogenesis, promoted oxidative stress, enhanced cytotoxicity and activated NLR family pyrin domain containing 3 (NLRP3) inflammasome pathway. CircDIP2C upregulation protected HUVECs from ox-LDL-induced injury. Additionally, circDIP2C directly bound to miR-556-5p, which was further found to target TET2. MiR556-5p mimics or TET2 silencing could attenuate the effect of circDIP2C overexpression on ox-LDL-induced cell disorder. Thus, we came a conclusion that circDIP2C protected against ox-LDL-induced HUVEC damage by upregulating TET2 expression through sponging miR-556-5p, which provided a strategy for the therapy of AS.	[Hu, Fudong; Chen, Xi; Shen, Yangyang; Yang, Jinhua] Zhengzhou Univ, Dept Cardiol, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China; [Gao, Juan] Henan Tech Inst, Sch Nursing, Zhengzhou, Peoples R China		Hu, FD (通讯作者)，Zhengzhou Univ, Dept Cardiol, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.	fcchufd@zzu.edu.cn			Scientific and Technological Project of Henan Province [182102310476, 212102310799]; Youth Foundation of the First Affiliated Hospital of Zhengzhou University [YNQN2017109]	Scientific and Technological Project of Henan Province (No. 182102310476 and 212102310799) , and Youth Foundation of the First Affiliated Hospital of Zhengzhou University (No. YNQN2017109) .	Altesha MA, 2019, J CELL PHYSIOL, V234, P5588, DOI 10.1002/jcp.27384; Badimon L, 2014, J INTERN MED, V276, P618, DOI 10.1111/joim.12296; Bazan HA, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.117.001720; Cao WJ, 2015, ARTERIOSCL THROM VAS, V35, P2401, DOI 10.1161/ATVBAHA.115.306506; Chen G, 2021, J CARDIOVASC PHARM, V77, P349, DOI 10.1097/FJC.0000000000000964; Chen J, 2016, ARTERIOSCL THROM VAS, V36, P2381, DOI 10.1161/ATVBAHA.116.308120; de Yebenes VG, 2020, ARTERIOSCL THROM VAS, V40, P2408, DOI 10.1161/ATVBAHA.120.314333; Di Pietro N, 2016, VASC PHARMACOL, V84, P1, DOI 10.1016/j.vph.2016.05.013; Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381; Garikipati VNS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11777-7; Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7; Han YN, 2017, ONCOTARGET, V8, P64551, DOI 10.18632/oncotarget.18350; Holdt LM, 2018, CELL MOL LIFE SCI, V75, P1071, DOI 10.1007/s00018-017-2688-5; Kumar S, 2014, ARTERIOSCL THROM VAS, V34, P2206, DOI 10.1161/ATVBAHA.114.303425; Li M, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.04.066; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Lu Y, 2018, ARTERIOSCL THROM VAS, V38, pE159, DOI 10.1161/ATVBAHA.118.310227; Lu Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00703; Mannarino E, 2008, ANGIOLOGY, V59, p69S, DOI 10.1177/0003319708320761; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Neth P, 2013, CARDIOVASC RES, V99, P294, DOI 10.1093/cvr/cvt096; Newman PE, 1999, MED HYPOTHESES, V53, P421, DOI 10.1054/mehy.1998.0794; Peng J, 2016, ONCOTARGET, V7, P76423, DOI 10.18632/oncotarget.13121; Qin MM, 2020, GENE, V755, DOI 10.1016/j.gene.2020.144900; Rafieian-Kopaei M, 2014, INT J PREVENTIVE MED, V5, P927; Remmerie A, 2018, CELL IMMUNOL, V330, P27, DOI 10.1016/j.cellimm.2018.01.020; Shao X, 2021, MOL CELL BIOCHEM, V476, P1783, DOI 10.1007/s11010-020-04035-8; Su G, 2018, HEART VESSELS, V33, P1185, DOI 10.1007/s00380-018-1169-6; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep40342; Tang F, 2018, BIOCHEM BIOPH RES CO, V495, P1482, DOI 10.1016/j.bbrc.2017.12.001; Tang Q, 2020, ONCOTARGETS THER, V13, P2067, DOI 10.2147/OTT.S233672; Tang Y, 2021, J CELL MOL MED, V25, P1817, DOI 10.1111/jcmm.16203; Zeng ZL, 2019, J CELL PHYSIOL, V234, P7475, DOI 10.1002/jcp.27509; Zeng Z, 2021, CIRCULATION, V143, P354, DOI 10.1161/CIRCULATIONAHA.120.049715; Zhang YB, 2020, J CELL BIOCHEM, V121, P1880, DOI 10.1002/jcb.29423; Zhang ZH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63686-1; Zhao W, 2015, BIOMED PHARMACOTHER, V75, P142, DOI 10.1016/j.biopha.2015.07.015; Zhong ZX, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23099; Zhou YH, 2020, AM J TRANSL RES, V12, P6220	40	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	AUG	2021	139								106887	10.1016/j.vph.2021.106887		JUL 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TK4ME	34147657				2022-04-29	WOS:000674133600010
J	Bhatia, P; Kaur, G; Singh, N				Bhatia, Pankaj; Kaur, Gagandeep; Singh, Nirmal			Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia	VASCULAR PHARMACOLOGY			English	Article						Thromboxane-A2; Ozagrel; Oxidative stress; Memory; Vascular dementia		The present study investigates the potential of ozagrel, a thromboxane A2 (TXA2) synthase inhibitor, in bilateral common carotid artery occlusion (BCCAo) induced vascular dementia (VaD). Wistar rats were subjected to BCCAo procedure under anesthesia to induce VaD. Morris water maze (MWM) test was employed on 7th day post-surgery to determine learning and memory. Endothelial dysfunction was assessed in isolated aorta by observing endothelial dependent vasorelaxation and levels of serum nitrite. A battery of biochemical and histopathological estimations was performed. Expression analysis of inflammatory cytokines TNF-? and IL-6 was carried out by RT-PCR. BCCAo produced significant impairment in endothelium dependent vasorelaxation and decrease in serum nitrite levels indicating endothelial dysfunction along with poor performance on MWM represents impairment of learning and memory. There was a significant rise in brain oxidative stress level (indicated by increase in brain thiobarbituric acid reactive species and decrease in reduced glutathione levels); increase in brain acetylcholinesterase activity; brain myeloperoxidase activity; brain TNF-? & IL-6 levels, brain TNF-? & IL-6 mRNA expression and brain neutrophil infiltration (as marker of inflammation) were also observed. Treatment of ozagrel (10 & 20 mg/kg, p. o.)/donepezil (0. 5 mg/kg, i.p., serving as standard) ameliorated BCCAo induced endothelial dysfunction; memory deficits; biochemical and histopathological changes in a significant manner. It may be concluded that ozagrel markedly improved endothelial dysfunction; learning and memory; biochemical and histopathological alteration associated with BCCAo induced VaD and that TXA2 can be considered as an important therapeutic target for the treatment of VaD.	[Bhatia, Pankaj; Kaur, Gagandeep] Punjabi Univ, Fac Med, Dept Pharmaceut Sci & Drug Res, CNS Res Lab,Pharmacol Div, Patiala 147002, Punjab, India; [Singh, Nirmal] Punjabi Univ, Fac Med, Dept Pharmaceut Sci & Drug Res, Div Pharmacol, Patiala 147002, Punjab, India		Singh, N (通讯作者)，Punjabi Univ, Fac Med, Dept Pharmaceut Sci & Drug Res, Div Pharmacol, Patiala 147002, Punjab, India.	nirmal_puru@rediffmail.com					Appleton JP, 2017, CLIN SCI, V131, P1561, DOI 10.1042/CS20160382; Atri A, 2011, AM J MANAG CARE, V17, P346; Banchroft A.S., 1996, THEORY PRACTICE HIST; Belhassen L, 2003, J AM COLL CARDIOL, V41, P1198, DOI 10.1016/S0735-1097(03)00048-2; Belkhelfa M, 2018, J NEUROIMMUNOL, V320, P48, DOI 10.1016/j.jneuroim.2018.04.004; Bhatia P, 2019, CURR NEUROVASC RES, V16, P27, DOI 10.2174/1567202616666190130153954; BOYNE AF, 1972, ANAL BIOCHEM, V46, P639, DOI 10.1016/0003-2697(72)90335-1; Camarasa J, 2010, PHARMACOL RES, V62, P450, DOI 10.1016/j.phrs.2010.05.004; Davi Giovanni, 2012, Handb Exp Pharmacol, P261, DOI 10.1007/978-3-642-29423-5_11; Dogne Jean-Michel, 2002, Am J Respir Med, V1, P11; Dogne JM, 2002, EXPERT OPIN INV DRUG, V11, P275, DOI 10.1517/13543784.11.2.275; Dovizio M, 2012, J PHARMACOL EXP THER, V341, P242, DOI 10.1124/jpet.111.190785; Ellinsworth DC, 2014, CARDIOVASC RES, V102, P9, DOI 10.1093/cvr/cvu015; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Emdin CA, 2016, STROKE, V47, P1429, DOI 10.1161/STROKEAHA.116.012658; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; FISHER M, 1993, STROKE, V24, P912, DOI 10.1161/01.STR.24.6.912; Fujimura M, 1995, PULM PHARMACOL, V8, P251, DOI 10.1006/pulp.1995.1034; GRISHAM MB, 1990, METHOD ENZYMOL, V186, P729; Gudala K, 2013, J DIABETES INVEST, V4, P640, DOI 10.1111/jdi.12087; Hennerici MG, 2009, CEREBROVASC DIS, V27, P1, DOI [10.1159/000191512, 10.1159/000209263]; Herholz K, 2008, NEUROPSYCHOLOGIA, V46, P1642, DOI 10.1016/j.neuropsychologia.2007.11.024; HORA K, 1990, NEPHRON, V56, P297, DOI 10.1159/000186157; Huang RY, 2014, J CANCER RES CLIN, V140, P375, DOI 10.1007/s00432-013-1573-3; Ishizuka T, 1996, EUR J PHARMACOL, V312, P367, DOI 10.1016/0014-2999(96)00478-5; IWASAKI Y, 1989, J NEUROL SCI, V90, P155, DOI 10.1016/0022-510X(89)90098-1; Jian WX, 2020, ACTA PHARMACOL SIN, V41, P588, DOI 10.1038/s41401-019-0334-5; Kaur J, 2016, INFLAMMOPHARMACOLOGY, V24, P133, DOI 10.1007/s10787-016-0271-6; Kawada N, 2004, AM J PHYSIOL-RENAL, V287, pF753, DOI 10.1152/ajprenal.00423.2003; Kim SR, 2010, BIOCHEM BIOPH RES CO, V397, P413, DOI 10.1016/j.bbrc.2010.05.106; KLAUSNER JM, 1989, CIRC RES, V64, P1178, DOI 10.1161/01.RES.64.6.1178; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; Koladiya Rajeshkumar U., 2008, BMC Pharmacology, V8, P14, DOI 10.1186/1471-2210-8-14; Koladiya RU, 2009, J HEALTH SCI, V55, P215, DOI 10.1248/jhs.55.215; Lapi D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00032; Lesault PF, 2011, BRIT J CLIN PHARMACO, V71, P844, DOI 10.1111/j.1365-2125.2010.03858.x; Li Yuanyuan, 2018, Oncotarget, V9, P26586, DOI 10.18632/oncotarget.25005; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; LOO MH, 1987, J UROLOGY, V137, P571, DOI 10.1016/S0022-5347(17)44108-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; Milne GL, 2008, J BIOL CHEM, V283, P15533, DOI 10.1074/jbc.R700047200; Moreira AS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49855-x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nagata T, 1997, Respirology, V2, P283, DOI 10.1111/j.1440-1843.1997.tb00090.x; Nakano Y, 2019, HYPERTENS RES, V42, P450, DOI 10.1038/s41440-018-0162-x; Nandagopal M., 2010, ANN BIOL RES, V1, P208; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; O'Brien JT, 2015, LANCET, V386, P1698, DOI 10.1016/S0140-6736(15)00463-8; Obara Y, 2005, MOL PHARMACOL, V68, P670, DOI 10.1124/mol.105.012922; Ogiso T, 1997, J PHARM SCI, V86, P1111, DOI 10.1021/js970013j; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Parle M, 2007, YAKUGAKU ZASSHI, V127, P1125, DOI 10.1248/yakushi.127.1125; Pieper GM, 1997, CARDIOVASC RES, V34, P145, DOI 10.1016/S0008-6363(96)00237-4; Price BR, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00350; Sastry KVH, 2002, ANAL BIOCHEM, V306, P79, DOI 10.1006/abio.2002.5676; Saxena A, 2003, EUR J BIOCHEM, V270, P4447, DOI 10.1046/j.1432-1033.2003.03837.x; Sharma B, 2011, PSYCHOPHARMACOLOGY, V215, P677, DOI 10.1007/s00213-011-2164-0; Sharma B, 2010, CURR NEUROVASC RES, V7, P180, DOI 10.2174/156720210792231831; Singh-Manoux A, 2018, ALZHEIMERS DEMENT, V14, P178, DOI 10.1016/j.jalz.2017.06.2637; STIER CT, 1988, STROKE, V19, P1145, DOI 10.1161/01.STR.19.9.1145; Tiwari N, 2018, FUND CLIN PHARMACOL, V32, P516, DOI 10.1111/fcp.12376; Tomimoto H, 2005, DEMENT GERIATR COGN, V19, P282, DOI 10.1159/000084553; Tomishima Y, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-21; Vijayan M, 2016, J ALZHEIMERS DIS, V54, P427, DOI 10.3233/JAD-160527; WALINSKY P, 1984, AM HEART J, V108, P868, DOI 10.1016/0002-8703(84)90447-2; Wang FX, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00376; Wang H, 2014, EXP THER MED, V8, P1599, DOI 10.3892/etm.2014.1926; Wolters FJ, 2019, ARTERIOSCL THROM VAS, V39, P1542, DOI 10.1161/ATVBAHA.119.311908; Xu BL, 2014, NEUROL SCI, V35, P1821, DOI 10.1007/s10072-014-1849-7; Yan AJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35885; Yang LJ, 2015, THROMB RES, V136, P1310, DOI 10.1016/j.thromres.2015.10.039; Yang WL, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00008; Yao ZH, 2018, NEUROCHEM RES, V43, P806, DOI 10.1007/s11064-018-2482-2; Zhang YQ, 2019, MOL MED REP, V20, P4587, DOI 10.3892/mmr.2019.10723; Zhu YY, 2006, NEUROSCI LETT, V393, P122, DOI 10.1016/j.neulet.2005.08.072	76	3	3	4	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	APR	2021	137								106827	10.1016/j.vph.2020.106827		MAR 2021	12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	QW8GU	33346090				2022-04-29	WOS:000628886800001
